





Studies on polyunsaturated fatty acid content and lipid 













A thesis submitted in partial fulfilment of the requirements of  










This copy of the thesis has been supplied on condition that anyone who consults it is 
understood to recognise that its copyright rests with its author and due 
acknowledgement must always be made of the use of any material contained in, or 
derived from, this thesis. 
  
  III 
Abstract 
Long-chain polyunsaturated fatty acids (LCPUFAs) are essential for infants’ health and 
development. Preterm infants have particularly high requirements for LCPUFAs, due to 
premature interruption of the maternal-foetal transfer. Research suggests that current 
feeding practices are insufficient to meet preterm infants’ LCPUFA requirements. 
Furthermore, LCPUFAs are highly susceptible to lipid peroxidation, giving rise to 
potentially harmful lipid peroxidation products (LPPs), which are related to major 
preterm morbidities. Donor human milk (DHM) and preterm formula milk (FM) are used 
when maternal breast milk is not available, sufficient, or suitable. Therefore, the first 
objective of this research was to quantify the LCPUFA intake of preterm infants from 
DHM and preterm FM and to explore how to increase these levels. The main focus of 
this thesis lies on LCPUFAs, however, other fatty acids, such as linoleic acid, were also 
considered. The second objective was to investigate the extent and nature of LPP 
formation in these non-maternal sources.  
LCPUFA levels available to preterm infants from the non-maternal sources DHM and 
FM were measured, for the first time in the U.K., since this data is scarce in the U.K 
and Europe. DHM provided LCPUFAs below European Society for Paediatric 
Gastroenterology, Hepatology and Nutrition recommendations. Although, with 
fortification, recommended levels of docosahexaenoic acid (DHA 22:6n-3; 11.5 ± 2.3 
vs. 8 mg/100 mL) but not arachidonic acid (ARA 20:4n-6; 8.3 ± 2.9 vs. 12 mg/100 mL) 
could be reached. Preterm FM provided LCPUFA levels in agreement with these 
recommendations. Results further suggest that preterm FM and DHM provided ARA 
and DHA levels of less than 27 and 67% of estimated in utero accretion rates, 
respectively. Current hospital storage conditions of preterm FM did not influence 
LCPUFA levels. Both DHM and preterm FM were found to be sources of LPPs 
(malondialdehyde, 4-hydroxy-2-nonenal HNE, hexanal), with the highest levels seen in 
DHM (23.5 ± 6.3 µM TBARS; 60.0 ± 75.1 µg/mL HNE). No detrimental effects of LPPs 
at levels expected in FM were detected in a preliminary in vitro model. However, as 
DHM and preterm FM may be the only nutritional source for an extended period, this 
may lead to a chronic intake of LPPs, which might contribute to the development of 
necrotising enterocolitis, bronchopulmonary dysplasia or retinopathy of prematurity.  
Human milk banking practices that might alter LCPUFA and LPP content of DHM were 
identified through a nationwide survey of human milk banks; and recommendations for 
human milk banking, to improve quality and quantity of LCPUFAs in DHM, were 
provided. Some of the suggested improvements only require small changes in practice 
and could be implemented immediately. Recommendations should be translated into 
IV 
(inter)national guidance, which generally need to be more specific to protect DHM 
nutritional quality.  
Overall, LCPUFA quality and quantity in non-maternal nutritional sources in the U.K. 
can be improved. Especially exclusive, unfortified DHM feeding might not be suitable 
long-term and might contribute to the development of major preterm neonatal 
morbidities. Further research is needed to facilitate improvements in LCPUFA levels 
and the nutritional quality of DHM. Every effort should be made to promote and enable 
breast feeding.  
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1 General introduction 
The essential role of omega-3 fatty acids (n-3 FAs) in the health and development of 
infants has been recognised for several years (Crawford 1993). Docosahexaenoic acid 
(22:6n-3, DHA), a long-chain polyunsaturated fatty acid (LCPUFA), is the most 
abundant n-3 FA in the brain and retina where it is needed for optimal development 
and function (Crawford et al. 1976b; Clandinin et al. 1980; Makrides et al. 1994; Birch 
et al. 2007). The quantitatively most important omega-6 (n-6) LCPUFA in the brain is 
arachidonic acid (20:4n-6, ARA) (Clandinin et al. 1980), which also plays an important 
role in regulating the inflammatory response (Bennett and Gilroy 2016). Other n-6 
LCPUFAs in the brain are dihomo- γ-linolenic acid (20:3n-6), precursor for 
prostaglandin E1, which is regulating blood flow by dilating blood vessels and inhibiting 
platelet aggregation, and adrenic acid (22:4n-6), which is a major LCPUFA in myelin 
and also highly enriched in the adrenal gland (Kirtland 1988; Martínez and Mougan 
1998; Wijendran et al. 2002). ARA is also a major component (around 20%) in the 
inner membranes of endothelial cells (Crawford et al. 1997). 
The maternal-foetal DHA transfer has been interrupted prematurely in preterm infants. 
Amongst other things, like low adipose tissue levels and inefficient absorption rate of 
DHA, this contributes to the so termed “DHA gap of prematurity” (Harris and Baack 
2015), which describes the DHA deficit after preterm birth. However, as described in 
more detail in Chapter 1.1.6, similar mechanisms also lead to an ARA deficit after 
preterm birth. Therefore, the concept has been broadened and termed “LCPUFA gap 
of prematurity”. Consequently, dietary LCPUFAs are of great importance for preterm 
infants. Supplementing preterm infants with DHA (0.5-1.7% of total FAs) is associated 
with improved neurological outcomes at 18 months to two years, with higher problem-
solving scores, better recognition memory, better sustained attention, higher mental 
development index scores and less mental development index scores below 70 
(Lapillonne and Moltu 2016). These and other effects of LCPUFAs are mediated 
through their incorporation into cell membranes, where they can influence membrane 
fluidity, and cellular function, as well as being precursors for bioactive lipid mediators, 
which is described in more detail in Chapter 1.1.3 (Pike 2003; Dyall 2015; Bennett and 
Gilroy 2016). Furthermore, feeding infants FM without ARA and DHA resulted in 
significantly lower verbal IQ scores compared to infants receiving BM, whereas no 
difference was detected when a FM containing DHA and ARA was used (Birch et al. 
2007). Despite their importance, research suggests that current postnatal preterm 
infant intake of LCPUFAs is inadequate, based on estimated in utero accretion rates 
(Lapillonne et al. 2010; De Rooy et al. 2017).  
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Survival rates of preterm infants are increasing due to improvements in care (Cooke 
2006; Glass et al. 2015). Nevertheless, the percentage prevalence of preterm infants 
with severe disabilities, such as cognitive disabilities, has not changed over 10 years 
(Moore et al. 2012), potentially due to the low levels of LCPUFA intake. Other common 
co-morbidities of preterm infants, such as respiratory distress syndrome and 
intraventricular haemorrhage, are also associated with lower LCPUFA levels in red 
blood cells (Fares et al. 2017). The following chapter provides a general literature 
review of the metabolism and physiological functions of LCPUFAs, the relationship of 
LCPUFAs and co-morbidities of prematurity, and the implications of preterm delivery on 
(dietary) LCPUFA needs (Chapter 1.1).  
The first 1000 days of life are of outmost importance for the development, and 
environmental factors like nutrition can have life-long consequences on morbidity and 
mortality later in life (Agosti et al. 2017). Therefore, it is essential to provide preterm 
infants with sufficient levels of LCPUFAs, and to ensure that LCPUFA levels are 
optimised in nutritional sources. For the first months of life, the main nutritional sources 
include parenteral nutrition, maternal breast milk (BM), donor human milk (DHM), and 
preterm formula milk (FM). The research presented in this thesis aims to investigate 
preterm infant LCPUFA intake in the perinatal period, and explore how these levels can 
be increased. Methods to increase BM LCPUFA levels have been researched 
extensively (Makrides et al. 1996; Jensen et al. 2000; Urwin et al. 2012). Therefore, 
this research will focus on the optimisation of LCPUFA provision from the non-maternal 
sources DHM and preterm FM.  
Due to the presence of several double bonds in their chemical structure, LCPUFAs are 
particularly susceptible to oxidative damage and subsequent degradation (Cosgrove et 
al. 1987). This results in the formation of lipid peroxidation products (LPPs), which can 
amongst other things bind to proteins and DNA. This can lead to cell and tissue 
damage and has the potential to increase inflammation (Yadav and Ramana 2013). 
Increased LPPs in parenteral lipid emulsions due to light exposure for example 
increased the incidence of bronchopulmonary dysplasia in preterm infants (+32% vs. 
light protected lipid emulsion) (Chessex et al. 2007). Therefore, the second aim of this 
thesis is to investigate the extent and nature of LPP formation in preterm infant 
nutrition. Chapter 1.2 provides a general overview of LPPs, their role in comorbidities of 
prematurity, and their presence in non-maternal dietary sources of preterm infants. 
LPPs have been measured in BM and FM, with higher concentrations found in the 
latter (e.g. 19.35 vs. 55.33 µg MDA/100 mL) (Martysiak-Zurowska and Stolyhwo 2006; 
Michalski et al. 2008; Almansa et al. 2013), and LPP levels increase in FM following 
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storage (e.g. 40% increase in MDA after 12 months storage at room temperature) 
(Almansa et al. 2013; Cesa et al. 2015). However, the influence of current storage 
conditions of preterm FM in neonatal units in the U.K. has thus far not been 
investigated. Therefore, the first specific objective of this research was to investigate 
the effect of different storage conditions on the LCPUFA and LPP content of preterm 
FM in the U.K. (Chapter 2). 
In addition to identifying whether LPPs have the potential to increase in FM and DHM 
due to storage, it is important to establish the nature of their toxicity, especially 
considering that the average dietary 4-hydroxyalkenal intake can be up to ten times 
higher in infants than in adults (Surh and Kwon 2005). Ingested LPPs can be absorbed 
and act directly on intestinal tissue or elsewhere in the body (Awada et al. 2012). 
Preterm infants, in general, are more prone to inflammation, due to a decreased 
antioxidant defence system (Huertas et al. 1998) and their gastrointestinal tract is 
especially vulnerable to inflammation (Hackam and Sodhi 2018). The second specific 
objective of this research was to investigate the effects of LPPs on an in vitro model of 
the inflammation-sensitive intestine (Chapter 3).  
Several studies have suggested that some milk banking practices may have negative 
effects on DHM LCPUFA levels (Wardell et al. 1981; Bertino et al. 2013; Garcia-Lara et 
al. 2013; Nessel et al. 2019). In the U.K., guidance for human milk banking can be 
found in the Clinical Guideline 93 “Donor Breast Milk Banks: The Operation of Donor 
Breast Milk Bank Services” issued by the National Institute for Health and Care 
Excellence (NICE). The guideline is mainly concerned with the safe operation of human 
milk banks (HMBs), not with the nutritional quality of DHM. Also, some of the guidance 
is vague and leaves room for interpretation; therefore, practices in the 16 HMBs may 
be very different. In order to gain a better understanding of current human milk banking 
practices, it was necessary to conduct a nationwide survey of U.K. milk banking 
practices, the first of its kind in the U.K. Therefore, the third specific objective of this 
research was to ascertain the current human milk banking practices in the U.K., with 
special interest in practices that may impact on LCPUFA levels (Chapter 4). Since 
there is no clear consensus in the literature as to the effects of human milk banking 
practices on the quantity and quality of LCPUFAs in DHM, Chapter 5 provides a 
detailed narrative review of the effects of storage conditions on LCPUFAs, lipid 
mediators, and antioxidants in DHM (Nessel et al. 2019). 
During the literature search for this review, it was identified that LCPUFA levels of DHM 
had only been reported in the U.S.A. (0.40% ARA and 0.14% DHA) (Valentine et al. 
2010; Baack et al. 2012) and in Sweden (0.30 % ARA and 0.19% DHA) (Ntoumani et 
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al. 2013), and only as percentage of total FAs, but not as absolute values. HMBs in 
America pool DHM from several donors (O'Hare et al. 2013), which is in contrast to 
HMBs in the U.K. (National Institute for Health and Clinical Excellence 2010). 
Furthermore, most studies investigating the effects of storage or processing on 
LCPUFA or LPP levels use BM or tried mimicking the milk banking process in the 
laboratory but did not analyse DHM that would be administered in a neonatal unit 
(Elisia and Kitts 2011; Garcia-Lara et al. 2013). Therefore, the fourth specific objective 
of this research was to quantify for the first time the absolute and relative levels of 
LCPUFAs in DHM provided by HMBs in the U.K. and measure LPP levels (Chapter 6). 
Due to the extremely low absolute LCPUFA levels in DHM, the enteral LCPUFA intake, 
as well as the LCPUFA levels available for accretion were also calculated and 
compared to levels provided by preterm BM, enteral intake recommendations from the 
European Society for Paediatric Gastroenterology, Hepatology and Nutrition 
(ESPGHAN) (Agostoni et al. 2010), and published in utero accretion rates (Lapillonne 
and Jensen 2009) (Nessel et al. 2020). The thesis concludes with a General 
Discussion and Conclusion (Chapter 7).  
This thesis is in the format of an integrated thesis, with Chapters 5 and 6 published in 
peer-reviewed academic journals, and the results of Chapter 4 form part of a 
publication on international human milk banking practices. This thesis format provided 
the opportunity to practice the specific writing style for publications, the major research 
output in the STEM field. Furthermore, preparing these chapters as publication and 
going through the submission process, as well as the peer-review process has 
provided a great learning experience for a future career in research.  
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1.1 Preterm infants and LCPUFAs 
1.1.1 Preterm birth: Definition, prevalence, and impact 
Preterm birth is defined as live birth before the completion of 37 weeks gestation 
(March of Dimes PMNCH Save the Children WHO 2012). Subcategories of preterm 
birth are defined by gestational age (Table 1-1).  
Table 1-1: Sub-categories of preterm birth and their distribution 
Subcategory Gestational age Proportion of preterm births1 
Extremely preterm < 28 weeks 5.2% 
Very preterm 28 to < 32 weeks 10.4% 
Moderate to late preterm 32 to < 37 weeks 84.3% 
 
1 
(Blencowe et al. 2013) 
Preterm infants are also often classified by their birth weight. Infants below 1000 g are 
classified as extremely low birth weight, very low birth weight ranges from 1000 to less 
than 1500 g and low birth weight infants weigh between 1500 and less than 2500 g.  
Preterm birth remains a leading cause of neonatal mortality (GBD 2015 Mortality and 
Causes of Death Collaborators 2016), thus it is a major public health concern 
(Blencowe et al. 2012). In England and Wales, approximately 53,887 infants (7.9% of 
all live births) are born preterm every year, and the distribution in subcategories is very 
similar to worldwide numbers (84% moderate to late preterm, 10% very preterm, and 
6% extremely preterm) (Office for National Statistics 2019).  
Complications of preterm birth are the leading cause of neonatal deaths worldwide (Liu 
et al. 2012). Globally, 29.2% (765,900 of 2,621,500) of neonates below 1 months of 
age died due to preterm birth complications in 2015. In England and Wales, 50% (1.4 
per 1000 live births) of neonatal deaths in 2018 were caused by conditions related to 
prematurity, including respiratory and cardiovascular disorders (Office for National 
Statistics 2020). Neonatal mortality within the first 28 days of life is inversely related to 
gestational age. 66.6% of infants born below 24 weeks gestation died on the day of 
delivery, and 80% of them died in the neonatal period. In infants weighting less than 
2500 g, mortality was 32.5 deaths per 1000 live births, whereas it was close to 0 in 
normal birth weight babies. Stratified for preterm birth categories, 33.1% of extremely 
preterm infants, 3.6% of very preterm infants, and 2.6% of moderate to late preterm 
infants died in England and Wales in 2012 (Office for National Statistics 2014). These 
complications are mostly due to immaturity of the related organ systems, which are not 
prepared yet for extra-uterine life (Institute of Medicine (US) Committee on 
Understanding Premature Birth and Assuring Healthy Outcomes; Behrman RE 2007). 
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Common co-morbidities of prematurity include necrotising enterocolitis (NEC, 1.1%), 
bronchopulmonary dysplasia (5.8%), intraventricular haemorrhage (5.6%), and 
retinopathy of prematurity (19.2%) (Hakeem et al. 2012; Black et al. 2015). These 
conditions are classified as oxygen radical associated diseases (Saugstad 2005), 
which are caused by oxidative stress and inflammation, two common conditions in 
preterm infants, and mediated by free radicals. Therefore, it is believed that the 
diseases are manifestations of free radical damage in the respective affected organs. 
Surviving infants, particularly extremely preterm infants, often face lifelong health 
consequences such as impaired neurodevelopment, leading to cognitive and learning 
impairments; cerebral palsy; visual and hearing impairments; chronic lung disease of 
prematurity; an increased risk of non-communicable diseases; and behavioural sequels 
(Blencowe et al. 2013; Platt 2014). The number of very and extremely preterm infants 
suffering from cognitive disabilities has not changed in in England between 1995 (13%) 
and 2006 (12%) (Moore et al. 2012). Similarly, a meta-analysis found no improvement 
in cognitive outcomes in preterm infants between 1990 and 2008, while their outcome 
was worse than in control infants (Twilhaar et al. 2018). Between 2011 and 2015, 19% 
of extremely preterm infants born in the U.S.A. suffered from severe 
neurodevelopmental impairment (Adams-Chapman et al. 2018). The total costs of 
preterm births to the public sector (health, social, and educational services) in England 
and Wales are estimated to be £2.9 billion for one birth cohort up to their 18th birthdays 
(Mangham et al. 2009). Therefore, preterm birth does not only affect the infant and 
their family, but also the health care system (National Health Service (NHS) in the U.K.) 
and the society (Petrou et al. 2011). 
1.1.2 LCPUFAs and their metabolism 
Polyunsaturated fatty acids (PUFAs) contain two or more double bonds in their 
structure. The omega nomenclature, introduced by Holman in 1964, classifies PUFAs 
depending on the position of the first double bond in relation to the methyl end of the 
FA. The schematic structures of ARA (n-6) and DHA (n-3) are shown in Figure 1-1.  
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Figure 1-1: Schematic structure of ARA and DHA 
 
LCPUFAs need to be provided through the diet, since humans are incapable of 
introducing double bonds beyond the carbon-9 position of FAs. Therefore, the LCPUFA 
precursor FAs linoleic acid (18:2n-6, LA) and α-linolenic acid (18:3n-3, ALA) are 
considered dietary essential. They can be converted into the LCPUFAs ARA and DHA 
via a series of desaturation and elongation processes (Figure 1-2) (Sprecher et al. 
1995; Park et al. 2009; Gibson et al. 2011; Park et al. 2015). The conversion rates, 
however, are extremely limited. Although the conversion efficiency was observed to be 
higher in preterm infants than in term infants (Uauy et al. 2000), the absolute synthesis 
of endogenous ARA and DHA was estimated to be only 27 mg and 13 mg per kg 
bodyweight per day, respectively at 1 month in preterm infants, declining significantly 
over time to 12 mg and 2 mg per kg bodyweight per day, respectively at 7 months 
(Carnielli et al. 2007). Furthermore, it is to note that the Δ6 desaturase step is rate 
limiting in the conversion of precursor FAs to LCPUFAs, therefore, high levels of LA 
and ALA will reduce the conversion to DHA, which depends twice on the Δ6 
desaturase activity (Nakamura and Nara 2004; Das 2006; Gibson et al. 2013). 
Although the Δ6 desaturase has a higher preference for n-3 FAs than for n-6 FAs (Das 
2006), Western diets usually provide much higher levels of n-6 FAs (n-6 to n-3 FA ratio 
of 16:1) (Simopoulos 2002), limiting the ALA conversion. High levels of dietary LA can 
also reduce the incorporation of preformed n-3 LCPUFAs into tissue. Feeding 
marmosets with a diet containing preformed eicosapentaenoic acid, and either 7% or 
33% LA, resulted in significantly lower eicosapentaenoic acid incorporation into 
erythrocyte phospholipids in the latter (McMurchie et al. 1990). 
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Figure 1-2: Conversion of precursor FAs into LCPUFAs 
Adapted from (Dyall and Michael-Titus 2008; Park et al. 2009; Gibson et al. 2011) 
The figure displays the Sprecher (black) and Δ4 (grey) LCPUFA biosynthesis pathways  
 
1.1.3 Physiological functions of LCPUFAs 
ARA in cell membranes contributes to membrane order. 15 - 25% of the phospholipid 
FAs in platelets, mononuclear cells, neutrophils, liver, and muscle cell are ARA (Calder 
2007). LCPUFA incorporation into membrane phospholipids can influence membrane 
fluidity and cellular function (Niu et al. 2004), and ensures the correct environment for 
membrane proteins. DHA also influences the formation of lipid rafts and can therefore 
influence cell signalling (Pike 2003). Membrane LCPUFAs are precursors for a range of 
bioactive lipid mediators, which can influence various systems in the body, are 
neuroprotective, and regulate the inflammatory response (Serhan et al. 2008; Crean 
and Godson 2015; Bennett and Gilroy 2016; Jun et al. 2017). These include 
eicosanoids (prostaglandins, thromboxanes, leukotrienes) and specialised pro-
resolving mediators (SPMs; lipoxins, resolvins, (neuro-)protectins, maresins, and 
elovanoids). Furthermore, LCPUFAs influence the immune function in preterm infants 
(Gottrand 2008), and LCPUFA derived endocannabinoids have an important role in 
neurodevelopment and neuroprotection in early life (Fride 2004; Dyall et al. 2016). 
The brain consists of approximately 60% lipids, and of these 8-11% are ARA and 12-
15% are DHA, thus they are the most abundant n-6 and n-3 PUFAs in the brain (Sastry 
1985; Calder 2016). However, quantitatively, n-6 LCPUFAs are more important in the 
brain than n-3 LCPUFAs (25.5 vs 14.4%; phosphatidylethanolamine: 20:3n-6: 1.6%; 
20:4n-6: 12.72%; 22:4n-6: 8.44%; 22:5n-6: 2.74%; 22:5n-3: 0.34%; 22:6n-3: 14.07%) 
(Martínez and Mougan 1998). During the last trimester, brain weight increases by five 
times and at the same time approximately 80% of the brain ARA and DHA accretion 
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occurs (Clandinin et al. 1980), which continues throughout the first two years of life, 
albeit at a slower rate, and levels are maintained throughout life (Makrides et al. 1994; 
Lauritzen et al. 2016). This rapid brain growth needs to be accompanied by an 
appropriate development of the vascular system to provide energy and nutrients 
(Crawford et al. 2003). Low LCPUFA provision can lead to functional abnormal cell 
membranes due to incorporation of other FAs such as mead acid (20:3n-9). 
Incorporation of mead acid and docosapentaenoic acid (22:5n-6) in cell membranes 
are signs of essential FA and DHA deficits (Rump et al. 2001). Mead acid incorporation 
could lead to cell membrane integrity loss and increased risk of membrane rupture. In 
the brain, 5-16% of ARA are converted into adrenic acid , the third most abundant 
PUFA in the brain (around 8%) (Martínez and Mougan 1998; Wijendran et al. 2002). 
Adrenic acid rapidly accumulates in the brain postnatally (Martínez and Mougan 1998), 
as part of myelin lipids, which facilitate faster signal transmission. Within the brain, 
LCPUFAs have a structural function, and DHA is highly enriched in synaptic 
membranes (Cotman et al. 1969). DHA promotes neurogenesis, neuronal 
differentiation, neurotransmission and synaptic function (Chalon et al. 1998; Cao et al. 
2009; Katakura et al. 2009).  
DHA is also the most abundant PUFA in the retina, contributing 50% of FAs in the rod 
outer segments (Anderson 1970). Besides the structural role, DHA also plays a role in 
photoreceptor differentiation during development (Garelli et al. 2006). Activation of the 
visual pigment rhodopsin by conformation change is possible due to the DHA 
molecules in the surrounding phospholipids (Mitchell et al. 2003), and rhodopsin 
regeneration is also affected by DHA content in the retina (Bush et al. 1994). In the 
DIAMOND study, term FM fed infants received either 0%, 0.32%, 0.64%, or 0.96% 
DHA and 0.64% ARA, and visual acuity was measured at 12 months. In the control 
group (0% DHA), infants had significantly poorer visual acuity than infants receiving 
DHA (Birch et al. 2010), demonstrating that DHA is essential for visual acuity. Similar 
results were obtained by other groups (Makrides et al. 1995a); and confirmed in meta 
analyses (SanGiovanni et al. 2000). Results persists into childhood (4 years) with DHA 
and ARA receiving term infants having better visual acuity than the control group, and 
similar visual acuity to breast fed infants (Birch et al. 2007). 
1.1.4 Nutrition in the first 1000 days of life 
The first 1000 days of life cover the period from conception to two years of life (Agosti 
et al. 2017). This is a sensible phase in life, in which stimuli, such as nutrition, can have 
life-long consequences for health outcomes, by affecting the development of important 
endocrine, metabolic, and immunological pathways. The underlying hypothesis was 
formed by the British epidemiologist David Barker in 1939, who postulated that 
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nutritional programming of organs in early life can determine the physiological and 
metabolic response later in life, and adverse nutrition early in life can lead to non-
communicable diseases, including obesity, hypertension, coronary heart disease and 
stroke (Edwards 2017).  
In the neonatal unit, it is aimed to provide preterm infants with nutrients similar to what 
would have been provided in-utero (Agostoni et al. 2010), aiming to achieve growth 
rates similar to intrauterine growth. Growth is an important measurement for clinicians. 
Improved infant growth during hospitalisation is significantly correlated to 
neurodevelopment and growth outcomes at 18-22 months corrected age (Ehrenkranz 
et al. 2006). This effect is long lasting, increased growth of preterm infants between 
birth and discharge was also associated with a reduced risk for abnormal neurological 
examination and impaired mobility at 5 years of age (Franz et al. 2009). Nevertheless, 
extrauterine growth retardation is common in, especially extremely, preterm infants 
(Poindexter 2014). Improved growth is achieved by better nutritional support, for 
example with higher amino acid and protein intake, as well as early lipid supply 
(Stephens et al. 2009; dit Trolli et al. 2012; Cormack and Bloomfield 2013), and a 
standardised feeding regime (McCallie et al. 2011).  
Body growth mainly requires protein and preterm infants need high protein levels to 
achieve intrauterine growth rates (Hay and Thureen 2010). However, in utero, the 
foetus uses up to 70% of the energy for brain growth and development in the last 
trimester (Crawford 2000), the time in which the main LCPUFA accretion occurs 
(described in Chapter 1.1.5). The LCPUFAs ARA and DHA are the most abundant 
PUFAs in the brain (Sastry 1985; Calder 2016). Therefore, it is important to provide 
these building blocks to the developing preterm infants after birth (Makrides and Uauy 
2014). 
1.1.5 In utero accretion of LCPUFAs 
In utero, FAs are transferred from the mother to the developing foetus. The placenta 
contains almost twice the amount of ARA and DHA than maternal plasma (Crawford et 
al. 1976b). Furthermore, DHA is selectively favoured for the transport to the foetal 
circulation during the last trimester (28 weeks gestation until birth), however, the 
selectivity for ARA increased with increasing maternal ARA concentrations (Haggarty 
et al. 1999). For example, an eight times increase of maternal DHA resulted in a 13 
times increase in DHA in the foetal circulation, but a two times increase in maternal 
ARA resulted in an eight times increase in the foetal circulation. Data from midterm 
abortions also showed 1.9 times more ARA in cord blood than in maternal plasma in 
choline phosphoglycerides, while there was only 1.5 times more DHA (Crawford et al. 
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1976b). This was accompanied by a decrease in LA and ALA from maternal plasma to 
foetal cord blood. Similarly, at term, cord plasma ARA levels are 1.8 times higher than 
maternal plasma levels and cord plasma DHA levels are 1.3 times higher than maternal 
plasma levels (Olegard and Svennerholm 1970). Overall, this results in a bio-
magnification of LCPUFAs in the foetus, with higher ARA and DHA levels in cord blood 
than maternal blood, providing it with building blocks for the developing brain (Crawford 
et al. 1976b; Kilari et al. 2009; Ogundipe et al. 2016).  
Based on autopsy tissue analyses, the intrauterine accretion rates for LCPUFAs during 
the last trimester were calculated to be 212 mg ARA per kg bodyweight per day and 
43 mg DHA per kg bodyweight per day (Lapillonne and Jensen 2009) (Table 1-2). The 
total accumulated n-3 FAs during the last trimester are distributed 65% to the adipose 
tissue, 30% into lean mass, 3.9% to the brain and 0.7% to the liver (Lapillonne and 
Jensen 2009). However, the calculations are based on estimations and animal studies 
due to limited available data for FA content and composition of organs at different 
gestational ages. Another study resulted in lower daily accretion rates (Kuipers et al. 
2012), arguing that the previous study overestimates the LCPUFA content in adipose 
tissue and that there is too much uncertainty in the LCPUFA composition of lean body 
mass. However, accretion per kg bodyweight is not provided.  
Table 1-2: Estimated n-3 and n-6 FA accretion rates during the last trimester 
 per day per kg bodyweight per day1 
LA 184 mg 106 mg 
ALA 7 mg 4 mg 
ARA 368 mg 212 mg 
DHA 75 mg 43 mg 
 1 
(Lapillonne and Jensen 2009) 
1.1.6 LCPUFA gap of prematurity 
If an infant is born preterm, the maternal-foetal LCPUFA transfer is interrupted 
prematurely and the infant misses out on the in utero accretion, which is highest in the 
last trimester and leads to a biomagnification of ARA and DHA in term infants 
(Crawford et al. 1976b). Therefore, preterm infants have higher (par)enteral LCPUFA 
requirements than term infants. Indeed, preterm infants have significantly lower 
LCPUFA blood levels than term infants, and LCPUFA blood levels are positively 
correlated with gestational age (Baack et al. 2015). As mentioned above, the majority 
of DHA is deposited in adipose tissue, however the white adipose tissue accretion of 
ARA is 4.7 times the DHA accretion during the last trimester (Clandinin et al. 1981). 
DHA stores will be exhausted within two months in term infants if dietary DHA levels 
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are insufficient (Farquharson et al. 1993), and both DHA and ARA will decline 
significantly after birth in preterm infants, even when fed maternal BM (Leaf et al. 
1992a). In contrast, preterm infants have very little adipose tissue stores, which only 
provide negligible DHA and ARA levels. Part of the enterally provided DHA will also be 
β-oxidised for energy production and will therefore not be available for accretion 
(Cunnane et al. 2000; Lapillonne et al. 2013). The inefficient conversion rates, low 
levels of LCPUFAs in preterm nutrition (as further discussed in Chapter 1.1.8), the high 
levels of LA in preterm nutritional sources, an enteral absorption rate of only 80% 
(Carnielli et al. 1998), and that it might take several days until full enteral feeding is 
achieved, further limits the LCPUFA availability for preterm infants.  
Harris and Baack have mentioned most of these points before, however, they have 
only focused on DHA and concluded in 2015 that taken together, these factors lead to 
what they called the “DHA gap of prematurity” (Harris and Baack 2015). However, as 
described above, most of these factors also contribute to lower ARA levels in preterm 
infants, which as described in Chapter 1.1.3, can also have detrimental effects on 
preterm infant development. Furthermore, it should be considered, that total n-6 
LCPUFAs (20:3n-6, 20:4n-6, 22:4n-6, 22:5n-6) exceed total n-3 LCPUFAs (22:5n-3, 
22:6n-3) in the brain (Martínez and Mougan 1998), and that ARA is an important 
precursor for adrenic acid (Wijendran et al. 2002). Often, studies focus solely on n-3 
LCPUFAs and their role in brain development, however, n-6 LCPUFAs are as 
important. ARA is needed for the construction and function of the brain and its blood 
vessels, since it is a major component of endothelial cells (Crawford et al. 1997). 
Considering all this evidence, it is therefore proposed to broaden the concept of Harris 
and Baack, by considering ARA as well, and to rename the concept as the “LCPUFA 
gap of prematurity”.  
For the same reason, it has been recommended before that both LCPUFAs should be 
considered as conditionally essential in the first year of life (Cunnane 2003; Makrides 
and Uauy 2014), although they can be produced from the dietary essential precursor 
FAs LA and ALA. The LCPUFA gap of prematurity and low LCPUFA levels can have 
several health implications for preterm infants, as further detailed in the next section. 
1.1.7 LCPUFAs and health outcomes of preterm infants 
Neurodevelopmental outcomes 
It is known that the developmental quotient of very preterm infants at school age (8 
years) is lower than the one of term infants, with very preterm infants displaying 
cognitive, educational and behavioural impairments (Anderson et al. 2003). LCPUFA 
supplementation of BM (32 mg DHA and 31 mg ARA per 100 mL, resulting in a 
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combined intake of 59 mg/kg/day DHA and 47 mg/kg/day ARA) received by very low 
birth weight infants resulted in higher plasma LCPUFA levels (DHA: 70.1 ± 22.4 vs. 
64.2 ± 23.5 mg/mL at baseline; ARA: 191.2 ± 58.9 vs. 205.6 ± 52.8 mg/mL at baseline; 
control group: 56.3 6 ± 15.3 mg/mL DHA and 155.9 6 ± 33.8 mg/mL ARA after 
intervention) and was positively correlated with cognitive development (Westerberg et 
al. 2011). Other studies found similar improvements in cognitive development of very 
low birth weight preterm infants receiving LCPUFA supplemented BM (0.86 vs. 0.35% 
DHA) (Henriksen et al. 2008). Recent research suggests better neurological outcomes 
for preterm infants at 18 month and 2 years when higher than routinely used amounts 
of DHA (e.g. BM supplementation to 1% vs. 0.35%; BM supplementation to 0.86% vs. 
0.35%; or supplementation of FM to 0.5% vs. 0%, provided in conjunction with BM, 
resulting in intake levels of 0.5-1.7% DHA) are provided (Lapillonne and Moltu 2016). 
The DINO trial compared the neurodevelopmental outcome at 18 months corrected 
age of preterm infants (< 33 weeks gestational age) which were supplemented with 
DHA (1% of total FAs) to a control group receiving 0.3% DHA, resulting in less children 
with delayed cognitive development in the intervention group (Makrides et al. 2009). 
Girls in the intervention group also had a higher mean mental/cognitive development. 
Neurological improvements have also been seen in term infants receiving 
supplementary LCPUFAs. Receiving FM supplemented with ARA (0.72%) and DHA 
(0.36%) resulted in a mean increase of seven points on the mental development index 
of term infants at 18 months (Birch et al. 2010). 
Oxidative stress 
Evidence suggests that DHA and its metabolites can reduce oxidative stress (Fink et 
al. 2016). For example, preterm infants given a parenteral lipid emulsion containing n-3 
LCPUFAs had reduced oxidative stress, indicated by a significantly increased total 
antioxidant potential (0.71 ± 0.18 mM uric acid at baseline vs. 1.09 ± 0.29 mM uric acid 
at 14 days), which was also significantly higher than in the control group receiving 
standard lipids (0.79 ± 0.16 mM uric acid) (Skouroliakou et al. 2010). Positive effects 
on oxidative stress and lipid peroxidation were also seen in very preterm infants given 
the SMOFlipid emulsion containing n-3 LCPUFAs compared to a lipid emulsion 
containing soy and olive oils (ClinOleic®) (Deshpande et al. 2014). In an animal model, 
Green and colleagues report a 58% reduction in lipid peroxidation compared to controls 
after intra amniotic injection of DHA to near term rat foetuses, and the authors 
speculate that DHA may actually be functioning as an antioxidant (2001).  
Immunomodulation 
Infections are common in preterm infants. Field and colleagues isolated peripheral 
blood lymphocytes from preterm infants fed with BM, FM, or FM containing LCPUFAs 
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(2000). FM with LCPUFAs resulted in lymphocyte populations, cytokine production and 
antigen maturity that was more closely related to that of BM fed infants, indicating that 
LCPUFAs status can affect the ability of the preterm infants to respond to immune 
challenges.  
Blood pressure 
Follow up of FM, FM with LCPUFA, and BM fed control infants at 6 years of life 
demonstrated beneficial effects of LCPUFA supplementation on blood pressure, with 
lower mean and diastolic blood pressure (-3.0 and -3.6 mm Hg, respectively) (Forsyth 
et al. 2003). No difference in diastolic pressure between BM fed and FM with LCPUFA 
fed infants could be detected (57.5 vs. 57.3 mm Hg). This indicates that LCPUFA 
provision during infancy can have long lasting effects on blood pressure and may 
reduce cardiovascular risk later on.  
Co-morbidities of preterm infants 
A Cochrane review concluded that preterm birth is reduced in women who increased 
their n-3 LCPUFA intake from supplementation or food during pregnancy (11.9% vs. 
13.4% without n-3 LCPUFAs, risk ratio 0.89) (Middleton et al. 2018). After birth, low red 
blood cell ARA and DHA levels are associated with an increased risk of neonatal 
morbidities and mortality. Very low birth weight preterm infants with respiratory distress 
syndrome, sepsis, intraventricular haemorrhage and perinatal death had significantly 
lower DHA levels, and ARA was significantly lower in infants with respiratory distress 
syndrome, intraventricular haemorrhage, and perinatal death (Fares et al. 2017). 
Furthermore, the n6:n3 ratio was significantly higher in infants with respiratory distress 
syndrome, and perinatal death. Another study found postnatally decreased DHA and 
ARA levels in extremely and very preterm infants associated with an increased risk of 
chronic lung disease (OR 2.5) and late-onset sepsis (hazard ratio 1.4), respectively 
(Martin et al. 2011). Crawford and colleagues proposed that low ARA and DHA levels 
in preterm infants results in reduced vascular and endothelial integrity, predisposing 
them to the complications of prematurity (1997).  
Feeding preterm infants with preterm FM containing egg phospholipids (containing 
choline, ARA and DHA), resulted in 16.5% less NEC stage II and III (Carlson et al. 
1998), and the results of a systematic review indicate that DHA has a protective effect 
on NEC in extremely and very preterm infants (Zhang et al. 2014).  
Retinopathy of prematurity is the main cause of visual impairment in preterm infants 
due to a disruption in the vascular development of the retina. Very low birth weight 
infants receiving intravenous fish oil emulsion required significantly less laser therapy 
for retinopathy of prematurity than infants receiving soybean oil emulsion (risk ratio 
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0.48) (Pawlik et al. 2014). Very low birthweight infants also had a significantly lower risk 
of stage 3 retinopathy of prematurity (risk ratio 0.66) after receiving 75 mg/kg/d DHA 
orally for 14 days (Bernabe-Garcia et al. 2019). 
Makrides and colleagues increased maternal BM DHA from 0.3% to 1% using 
supplements. Less preterm infants (< 33 weeks gestational age) in this group required 
oxygen treatment at 36 weeks compared to the placebo group (Makrides et al. 2009). 
In preterm infants (< 33 weeks gestational age) boys and all infants < 1250 g birth 
weight also had a reduction in bronchopulmonary dysplasia (Manley et al. 2011). The 
results of a systematic review also indicate that DHA has a protective effect on 
bronchopulmonary dysplasia in extremely and very preterm infants (Zhang et al. 2014). 
The N3RO trial was conducted as fully powered study to determine the effect of enteral 
DHA supplementation on the incidence of bronchopulmonary dysplasia in preterm 
infants born < 29 weeks gestational age (Collins et al. 2017). Using a physiological 
disease definition, the risk of bronchopulmonary dysplasia was higher than in the 
control group, whereas no differences were seen when a clinical definition was used. It 
is noteworthy that the enteral emulsion in this trial only contained DHA, and no ARA.  
Critique on the current evidence 
Studies investigating the effect of DHA on neonatal outcomes vary extremely in the 
study design (Lapillonne et al. 2013). The dose, timing and duration as well as the 
source of LCPUFAs differ greatly between the studies. Furthermore, most trials have 
been performed on relatively healthy and mature preterm infants and had a small 
sample size. The outcome measures and the age of testing varied as well. And some 
of the tests might not be the most appropriate. The Bayley Scale of Infant Development 
is the most used general assessment of cognitive development (Georgieff 2007). 
However, it might be that specific neurobehavioral morbidities are not picked up with 
this tool, and therefore improvements will also not be noticed. Therefore, more specific 
and precise tests of e.g. memory or problem solving might be needed to capture small 
but clinical relevant changes after an increased LCPUFA intake (Cheatham et al. 
2006). Therefore, it is not surprising that the authors of a Cochrane review analysing 
benefits of FM LCPUFA supplementation for preterm infants concluded that no 
differences exist in visual acuity, neurodevelopment and physical growth (Moon et al. 
2016). The quality of the evidence was rated low and overall, as mentioned above, the 
included infants were relatively mature and healthy. Clearly there is the need for more 
studies with standardised doses and outcome measurements at similar time-points. 
Studies investigating the effects of LCPUFAs (DHA as well as ARA) on preterm infants’ 
health and development should also include very and extremely preterm infants, since 
they most likely have the greatest benefit of an increased LCPUFA intake.  
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Overall, there are much more trials that have used DHA supplementation instead of 
LCPUFA supplementation with ARA and DHA. However, a recent study provided 
evidence that preterm infants have a much greater deficit in ARA intake than in DHA 
(De Rooy et al. 2017). Experts in the field recommend that preformed ARA should be 
provided to preterm infants, although more data are needed to know which amount 
would be beneficial (Lapillonne et al. 2013). Furthermore, in all the common 
comorbidities of preterm infants, inflammation plays a critical role and ARA and DHA 
are both needed for an appropriate inflammatory response. Future studies should 
therefore investigate the combined effect of ARA and DHA supplementation on 
common comorbidities of preterm infants.  
1.1.8 Preterm nutrition and LCPUFAs 
Based on the available evidence reviewed in the previous sections, it can be concluded 
that preterm infants should receive sufficient amounts of LCPUFAs from their diet to 
facilitate optimal health and development. Nutritional sources for preterm infants 
include parenteral nutrition and enteral nutrition. 
Parenteral nutrition  
Most extremely and very preterm infants will receive parenteral nutrition in the first days 
of life, which might further increase the LCPUFA gap. Parenteral nutrition is 
recommended for preterm infants (born before 30 weeks gestational age, or weighing 
less than 1250 g at birth, for infants who have failed to establish enteral nutrition with 
more than 100 ml per kg bodyweight per day by day 5 of life, or infants who fail to 
tolerate enteral nutrition) until the establishment of enteral feeding (British Association 
of Perinatal Medicine 2016a). Intravenous lipids (20% lipid emulsion, continuous 
infusion over 24 hours) should be provided within 24 hours of birth, since LA and ARA 
deficiencies in preterm infants have been reported as early as 2 days after birth, when 
feeding a fat free diet (Friedman et al. 1976). On the first day of life, 2 g/kg/day of 
intravenous lipids should be provided with a daily increase to a maximum of 3.5 – 
4 g/kg/day. 
In the U.K., two different intravenous lipid preparations are available for the use in 
neonates, Intralipid and SMOFlipid. Both provide LA and ALA through soybean oil 
(Intralipid 20%: 200 g/L soybean oil; SMOFlipid 20%: 60 g/L soy bean oil) (Tomsits et 
al. 2010). However, only SMOFlipid contains fish oil (30 g/L), and therefore provides 
eicosapentaenoic acid (20:5n-3, EPA) (4.8 g/L) and DHA (3.5 g/L). SMOFlipid can 
therefore significantly increase ALA and EPA, and the n-3 to n-6 ratio in red blood cells 
of preterm infants, compared to Intralipid (Tomsits et al. 2010). Nevertheless, 
SMOFlipid is more expensive and less used. None of the lipid emulsions provide 
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preformed ARA. Considering the above described inefficiency in the conversion of LA 
and ALA into ARA and DHA (Pawlosky et al. 2001; Plourde and Cunnane 2007), it is 
likely that preterm infants receiving parenteral nutrition do not meet their requirements 
based on in utero accretion rates (Lapillonne and Jensen 2009). Therefore, it is even 
more important to provide preterm infants with optimal enteral nutrition after the use of 
parenteral nutrition, to avoid deficiencies.  
Enteral Nutrition 
Mother’s own BM is the accepted best practice and advisable way for feeding neonates 
(ESPGHAN Committee on Nutrition et al. 2009). Exclusive breast feeding for the first 
six months of life is recommended (WHO 2003). Extremely and very preterm infants 
often require feeding via a nasogastric tube, since the ability to suck, swallow and 
breathe only develops around 32 weeks gestation (Lau et al. 2003). In this case, 
expressed BM can be used. However, mothers of preterm infants often cannot express 
any or sufficient BM (Hill et al. 2005). Reasons include incomplete development of the 
mammary glands, or poor hormonal response, as well as psychological problems 
(Jones and Spencer 2005). If maternal BM is not available, DHM or FM can be used. 
Intake and LCPUFA levels of these are further discussed in Chapter 2.1,4.1.3 and 6.3.  
The worldwide mean (± standard deviation, SD) LCPUFA concentrations in mature BM 
from mothers of term infants were reported to be 0.37 ± 0.11% for DHA (by weight 
percentage of total FAs) and 0.55 ± 0.1% for ARA (Fu et al. 2016). U.K. levels are 
below worldwide average (Table 1-3) (Yuhas et al. 2006). A meta-analysis of preterm 
and term BM revealed higher fat content in preterm BM during the first 2 weeks 
(Gidrewicz and Fenton 2014). A systematic review showed that relative DHA levels are 
higher in preterm BM, whereas data for ARA are inconclusive (Bokor et al. 2007).  
Table 1-3: LCPUFA levels in term mature BM in the U.K. and worldwide  
% of total FA United Kingdom1 Worldwide2 
LA 10.45 ± 0.41  
ALA 1.22 ± 0.06  
ARA 0.36 ± 0.01 0.55 ± 0.14 
DHA 0.24 ± 0.01 0.37 ± 0.11 
1
(Yuhas et al. 2006); 
2
(Fu et al. 2016) 
BM FA composition has also changed in the last decades. For example, in 1976, n-6 
LCPUFAs (20:2n-6 – 22:5n-6) made up 1.1% of BM FAs (average of four countries), 
and n-3 LCPUFAs 1.4% (20:3n-3 – 22:6n-3) (Crawford et al. 1976a). In 2006, this 
changed to 0.9% n-6 LCPUFAs in BM from nine different countries, and 0.85% n-3 
LCPUFAs (Yuhas et al. 2006). It is noteworthy that in the same time, LA levels rose 
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from 9.97% to 12.95% (Crawford et al. 1976a; Yuhas et al. 2006), most likely due to a 
change in diet (Sanders 2000). Others similarly reported an increase of LA from 7-10% 
to 14% of FAs in human BM in the U.K. from 1977 to 1992 (Ghebremeskel et al. 1992). 
This might have affected the conversion of dietary ALA to n-3 LCPUFAs (Nakamura 
and Nara 2004), and therefore the n-3 LCPUFA levels in BM.For preterm babies born 
before 33 weeks gestation, fortification of maternal BM or DHM with BM fortifiers is 
recommended and most neonatal intensive care units in the U.K. use BM fortifiers 
(Klingenberg et al. 2012). In the U.K., Gow&Gate (Nutricia Ltd) and SMA (Nestlé UK 
Ltd) provide bovine BM fortifiers. Nutriprem Human Milk Fortifier contains no fat, 
whereas SMA BM Fortifier contains 0.18 g/g fat from rapeseed oil and fish oil (Danone 
Nutricia Early Life Nutrition 2019; SMA Nutrition 2019). Therefore, only SMA provides a 
BM fortifier in the U.K. that contains LCPUFA (LA 9.6 mg/g; ALA 4.2 mg/g; DHA 
1.6 mg/g) for preterm infants. Prolacta Biosciences provides a human milk derived BM 
fortifier, containing DHA and ARA. However, information about the LCPUFA 
concentration is not available and they claim that levels may vary (Prolacta Bioscience 
Inc 2017).  
1.1.9 Dietary LCPUFA guidelines 
Lapillonne and Jensen defined the LCPUFA requirement of preterm infants as the 
amount of FAs that is needed to maintain an optimal LCPUFA composition of all 
tissues, as well as normal growth, and normal short- and long-term outcomes 
(Lapillonne and Jensen 2009). One straightforward to obtain indicator of LCPUFA 
status is the plasma FA composition. Leaf and colleagues have measured the FA 
composition of plasma phosphatidylcholine, the most abundant phospholipid in plasma 
accounting for around 70%, in preterm infants directly after birth (Leaf et al. 1992b). 
They reported significant correlations of ARA and DHA with birthweight (correlation 
coefficient 0.564, p < 0.01 and 0.496, p < 0.05, respectively), and of DHA with 
gestational age (correlation coefficient 0.638, p<0.01), indicating increasing plasma 
LCPUFA levels with increasing gestational age/birthweight. When feeding preterm 
infants, ideally similar plasma LCPUFA levels should be achieved, to allow for similar 
circulating levels of LCPUFAs as would occur in utero by placenta nutrition (Leaf et al. 
1992a). Nevertheless, feeding preterm infants with BM, with FM (without LCPUFAs), or 
with a combination of both, in conjunction with parenteral feeding for the first 2 weeks 
after birth, resulted in a rapid decline of ARA and DHA within the first 2-6 weeks after 
birth (Leaf et al. 1992a). The decrease was less, but not significantly less, in BM fed 
infants. At the same time, a rapid increase in plasma LA occurred. This is not 
representing physiological levels that would have occurred in utero, since LA levels do 
not increase with gestational age (correlation coefficient 0.200) (Leaf et al. 1992b). This 
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is a further indicator that preterm infants have high LCPUFA requirements after birth, 
which should imitate the in utero accretion. 
In the U.K., no specific for enteral nutrition recommendations for preterm infants are 
available. Therefore, clinicians follow European guidance. The ESPGHAN Committee 
on Nutrition issued the following recommendations for PUFA intake for infants weighing 
between 1000 and 1800 g (Table 1-4) (Agostoni et al. 2010). Extremely preterm 
infants, mostly weighing less than 1000 g, are excluded from the recommendations due 
to lack of evidence, although they are the most vulnerable group for LCPUFA deficits.  
Table 1-4: PUFA intake recommendations by ESPGHAN  
 mg per kg bodyweight per day1 
LA 385 - 1540 
ALA 55 
ARA 18 - 42 
DHA 12 - 30 
 1
(Agostoni et al. 2010) 
Basing the dietary recommendations on the nutrient levels received in utero seems like 
a logic approach. Furthermore, early LCPUFA deficits should be considered. However, 
although the guideline was developed to achieve a growth rate similar to foetal growth, 
and satisfactory functional development (Agostoni et al. 2010), it is in huge discrepancy 
with the calculated intrauterine accretion rates for ARA and DHA (Lapillonne and 
Jensen 2009). Recommendations are based on suggested safety evidence and 
concentrations provided by BM and FM due to insufficient evidence. However, the 
evidence suggests that BM supplemented to 47 mg ARA per kg bodyweight per day 
and 59 mg DHA per kg bodyweight per day is safe for preterm infants (Henriksen et al. 
2008). ESPGHAN also considers ALA as major source for the synthesis of DHA, 
despite the reported low conversion efficiency (Carnielli et al. 2007). Evidence from 
tracer studies suggests that preformed DHA is a 7-fold better source for brain DHA 
accretion than ALA-derived DHA (Su et al. 1999), and it is an overall consensus that 
preformed DHA can raise blood DHA status beyond what is achievable with ALA 
(Brenna et al. 2009). This is important since erythrocyte DHA status has been 
correlated to brain DHA status (Makrides et al. 1994).  
The latest enteral nutrient intake recommendations for preterm infants were published 
by Koletzko and colleagues (2014). They recommend 35 to 45 mg ARA and 55 to 
60 mg DHA per kg bodyweight per day. DHA intake in this range increases plasma 
concentrations by 12% over 9 weeks, whereas a concentration of 32 mg DHA per kg 
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bodyweight per day, which is greater than the ESPGHAN recommendations, was not 
sufficient to prevent a decline (Henriksen et al. 2008).  
The incorporation of ARA and DHA into cell membranes is not only dependent on the 
ARA and DHA concentration, or the levels of precursor FAs, the ratio of LA to ALA is 
also important. In a study by Clark and colleagues, term infants were either fed a 
control FM A with 14% LA and 0.7% ALA (ratio 19:1), or experimental FMs with either 
B: 13% LA and 3.3% ALA (ratio 4:1) or C: 3.5% LA and 1.1% ALA (ratio 3:1) (1992). It 
is to note that at the time of the study, FM did not contain LCPUFAs. Decreasing the 
LA to ALA ratio increased the n-3 C20 and C22 incorporation into erythrocytes (A: 5.97 
± 0.76%, B: 8.98 ± 0.65% and C: 9.30 ± 0.95%) and did not change ARA levels in B 
(14.56 ± 0.76% vs. A: 14.81 ± 0.9%), but slightly decreased ARA in C (13.37 ± 1.05%). 
It is noteworthy that FM C with lower LA levels than FM B resulted in the best tissue 
incorporation of LCPUFAs (Clark et al. 1992), confirming earlier animal studies 
(McMurchie et al. 1990). Although FM provided very different amounts of FAs, the n-3 
LCPUFA incorporation was similar, indicating the importance of the LA to ALA ratio 
(Clark et al. 1992). Nevertheless, the experimental FMs were not able to raise DHA 
levels to that found in BM fed infants, and ARA levels were also different compared to 
breast fed infants, stressing once again the need of preformed ARA and DHA for 
feeding preterm infants. The study further concluded that the LA to ALA ratio should 
not be lower than 4:1 due to potential undesirable physiological consequences, 
resulting from C20 and C22 PUFA levels distinctively different from that seen in BM fed 
infants. The recommended LA to ALA ratio described by ESPGHAN ranges from 7:1 
up to 28:1, considering the lower and upper recommended intake for LA, and the 
minimum recommended intake for ALA (Agostoni et al. 2010). U.K. BM has a LA to 
ALA ratio of 8.5:1 (Yuhas et al. 2006). Considering the above mentioned study and the 
U.K. BM data, it might be advisable to not feed infants with a very high LA to ALA ratio 
of 28:1, although it falls into the ESPGHAN recommendations. Furthermore, the ratio of 
LA to ARA and DHA is very high in the ESPGHAN recommendations, and does not 
represent physiological ratios found in preterm BM or delivered by the placenta 
(Crawford et al. 1998). For example, the mid-range LA to mid-range ARA ratio is 32 in 
the recommendation, whereas it is 15 in mature preterm BM and 0.4 in umbilical cord 
plasma, and the mid-range LA to mid-range DHA ration is 54, whereas it is 41 in 
mature preterm BM and 0.8 in umbilical cord plasma (Genzel-Boroviczeny et al. 1997; 
Agostoni et al. 2010). 
ESPGHAN recommendations were developed more than 10 years ago. Therefore, 
LCPUFA recommendations are due for an update based on latest evidence. However, 
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more research is needed to define adequate dietary LCPUFA requirements in the 
perinatal period of preterm infants. 
1.1.10 Current dietary intake of LCPUFAs  
Lapillonne and Jensen fed preterm infants (< 1500 g) with preterm BM containing 
0.41% DHA and compared their blood to that of breast-fed term infants (2009). The 
preterm infants had 31% lower DHA red blood cell phospholipid content, indicating that 
preterm BM feeding alone leads to DHA deficiency of 56% at expected term. This also 
shows that functional development similar to in utero is not provided by exclusive BM 
feeding. Nevertheless, ESPGHAN recommendations are based on BM LCPUFA 
concentrations. 
Lapillonne and colleagues have also conducted the first study to estimate the available 
DHA for accretion in the first month of life of extremely preterm infants receiving 
standard care in France (2010). They estimated that only 7, 21, 30 and 39% of the 
normally accreted DHA was available to these infants during the first, second, third, 
and fourth week of life, respectively, from their nutritional intake (parenteral and 
enteral). This related to a DHA deficit of 661 ± 100 mg per kg bodyweight four weeks 
after birth. The authors concluded that BM or FM DHA levels of 1.5%, similar to the 
recommendations by Koletzko et al., are needed to compensate for the DHA loss 
during the first four weeks of life. However, they assumed that BM contains 0.42% 
DHA, whereas on average French BM more likely contains half of that (Brenna et al. 
2007). 
Following on from this study, De Rooy and colleagues calculated the intake of DHA as 
well as ARA from all sources of extremely preterm infants in the U.K. (2017) . Six 
weeks after birth, only 36.6% and 13.5% of the normally in utero accreted DHA and 
ARA, respectively was provided and the authors calculated that 183.4 mg ARA and 
28.5 mg DHA per kg bodyweight per day would be needed to compensate for the 
deficits. The ARA levels were significantly below ESPGHAN recommendations in 
weeks one to five and DHA levels were below ESPGHAN recommendations in week 
one. Whether ESPGHAN recommended LCPUFA intake levels should be raised 
becomes a secondary question when the current recommendations cannot be reached 
with the presently available feeding methods. The question remains how to improve 
LCPUFA intake of preterm infants, to reduce the LCPUFA gap of prematurity.  
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1.2 Preterm infants and LPPs 
1.2.1 Lipid peroxidation 
N-3 and n-6 PUFAs are highly susceptible to autoxidation by oxygen radicals. There is 
a linear dependency between the number of double bonds and the peroxidisability of 
the PUFA, such that DHA has a five times greater peroxidisability than LA (Cosgrove et 
al. 1987). Relative rates of ARA, ALA, LA, and 18:1n-9 oxidation are 40:20:10:1 (Saxby 
1996). One additional double bond in the FA structure at least doubles the rate of 
autoxidation (Holman and Elmer 1947). 
Lipid peroxidation can be enzymatic or non-enzymatic. Enzymatic lipid peroxidation is 
part of normal metabolism (Benzie 1996), in which The cyclo-oxygenase and 
lipoxygenase metabolises PUFAs into eicosanoids and other lipid mediators. These are 
involved in inflammation and immunity (Massey and Nicolaou 2011). Non-enzymatic 
lipid peroxidation is an uncontrolled process that can have detrimental effects. It is a 
chain reaction process (Figure 1-3), initiated by a radical abstracting a hydrogen atom 
from a methylene group of an unsaturated lipid (Ayala et al. 2014), leading to the 
formation of a lipid radical. This is stabilised by double bond rearrangement to form a 
conjugated diene (Gutteridge 1995). During the propagation stage, the lipid radical 
rapidly reacts with molecular oxygen, producing a lipid peroxyl radical. In the next chain 
reaction stage, the lipid peroxyl radical reacts with another unsaturated lipid to form a 
lipid hydroperoxide and a new lipid radical, which starts the reaction again. The chain 
reaction process terminates when antioxidants, such as vitamin E, scavenge the lipid 
peroxyl radical, or when two radicals combine. 
 
Figure 1-3: Lipid peroxidation chain reaction 
Amended form (Ayala et al. 2014) 
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Lipid hydroperoxides are unstable primary LPPs, which rapidly decompose in the 
presence of transition metal ions, such as iron or copper (Esterbauer et al. 1990), to 
form secondary LPPs (Ayala et al. 2014). These include alkoxyl and alkyl radicals, 
aldehydes, ketones, and carboxyl compounds (Chávez-Servín et al. 2008). More 
specifically, these include the following aldehydes: malondialdehyde (MDA) which is an 
unspecific secondary LPP of PUFAs with more than two double bonds, as well as 4-
hydroxy-2-nonenal (HNE) and 4-hydroxy-2-hexenal (HHE), resulting from n-6 and n-3 
PUFA peroxidation, respectively (Figure 1-4) (Van Kuijk et al. 1990; Esterbauer et al. 
1991; Ayala et al. 2014). Hexanal is the volatile secondary LPP of n-6 PUFAs (Romeu-
Nadal et al. 2004). Further volatile secondary LPPs are propanal, pentanal, octanal and 
nonenal. 
 
Figure 1-4: Schematic structure of LPPs 
 
LPPs are highly lipophilic and therefore often accumulate in lipid bilayers such as in cell 
membranes. Effects of secondary LPPs are dose dependant (Riahi et al. 2010) and 
they have been described as second messengers of free radicals (Ayala et al. 2014). 
They can act as signalling molecules and at low physiological concentrations (around 
1 µM, in humans and in cell culture) promote cell survival, for example via the up-
regulation of stress response pathways (Niki 1987; Ayala et al. 2014). However, at 
higher concentrations HNE, HHE, and MDA can react with membrane phospholipids 
and proteins and alter the membrane structure, fluidity and membrane function (Riahi 
et al. 2010). They can also form adducts with proteins and DNA and influence the 
inflammatory signalling (Yadav and Ramana 2013). Therefore, high concentrations 
(above 10 µM) have been shown to be toxic in cell culture systems and lead to cell 
cycle arrest or cell death (apoptotic or necrotic), due to unrepairable cell damage 
(Esterbauer et al. 1991; Esterbauer 1993; Ayala et al. 2014). Secondary LPPs can be 
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measured in human plasma (Mori et al. 1999; Guichardant et al. 2006); however, they 
are metabolised in the liver as part of the xenobiotic metabolism and mainly excreted 
via urine (Alary et al. 1998; Guichardant et al. 2004; Yan et al. 2010). The major 
secondary PUFA LPPs are described in detail below.  
MDA 
MDA is a widely used and reliable marker of oxidative stress in clinical situations (Ayala 
et al. 2014). In healthy patients, the plasma concentrations range from 0.1 to 1 µM (Del 
Rio et al. 2005), with men having lower concentrations than women (Steghens et al. 
2001). Extremely preterm infants have been shown to have plasma concentrations of 
1-2 µM in the first week of life (Drury et al. 1997).  
At physiological pH, MDA has a low reactivity, however at a lower pH, MDA is more 
reactive and rapidly attacks nucleophiles such as basic amino acid residues (lysine, 
histidine, arginine) or proteins (Ayala et al. 2014). Over 30 proteins, including enzymes, 
carrier proteins, cytoskeletal, mitochondrial and antioxidant proteins have been 
reported to be modified by MDA (Zarkovic et al. 2013). DNA damage induced by MDA 
includes mutations and strand breaks, which can lead to cell cycle arrest and apoptosis 
(Niedernhofer et al. 2003; VanderVeen et al. 2003; Ayala et al. 2014). Furthermore, 
MDA adducts can form intra or inter molecule crosslinks between proteins and/or DNA, 
which can lead to detrimental alterations in biochemical properties (Voitkun and 
Zhitkovich 1999; Niedernhofer et al. 2003). 
HNE  
HNE plasma concentrations in healthy men and women was 678.5 ± 421.2 nM and 
increased with age (Selley et al. 1989), these results were confirmed in another study 
with adults (Selley 1997). In moderate to late preterm neonates umbilical cord plasma 
levels of 100 nM have been reported (Schmidt et al. 1996). In tissue, HNE levels range 
from 0.1-3 µM under physiological conditions and can reach up to 12 mM under 
oxidative stress (Benedetti et al. 1984; Esterbauer et al. 1990).  
HNE has physiological and protective functions at lower concentrations, but is cytotoxic 
at higher concentrations (Ayala et al. 2014). At physiological concentrations (below 
10 µM), HNE can regulate transcription factors sensible to stress, such as nuclear 
factor erythroid 2-related factor (antioxidants and cytoprotective genes), activating 
protein-1 (glutathione), nuclear factor- (NF-; inflammation, cell proliferation and 
apoptosis), and peroxisome proliferator activated receptors (lipid metabolism, 
mitochondrial biogenesis, antioxidant defence) (Ayala et al. 2014). However, HNE is 
more toxic than MDA (Michiels and Remacle 1991). At medium levels, HNE induces 
autophagy, senescence and cell cycle arrest, but at high levels induces apoptosis or 
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necrosis (Ayala et al. 2014). Concentrations above 10 µM are cytotoxic (Zarkovic et al. 
1993). The toxicity can be explained by the rapid reaction with DNA and proteins. 4-
Hydroxyalkenals can react with almost all amino acids (Esterbauer et al. 1991). These 
HNE adducts can modify enzymes, carrier proteins, membrane transporters, receptors, 
cytoskeletal proteins, transcription factors and antioxidants (glutathione) (Ayala et al. 
2014). Similar to MDA, HNE can react with DNA and form crosslinks or DNA-protein 
conjugates. Genotoxicity is time and dose dependent (Eckl et al. 1993; Yadav et al. 
2008) and can lead to apoptosis or necrosis (Ayala et al. 2014).  
HHE 
The plasma concentration of HHE is approximately twice the plasma concentration of 
HNE (Guichardant et al. 2006). However, the physiological reactivity is lower (Bacot et 
al. 2007) and therefore the higher concentrations are less damaging (Riahi et al. 2010). 
Of the two 4-hydroxyalkenals, HHE is much less studied than HNE. Nevertheless, HHE 
mediated activation of NF-, was reported to lead to cellular dysfunction as well as 
apoptosis (Riahi et al. 2010).  
Isoprostanoids 
Isoprostanoids are LPPs that are formed non-enzymatically by free radical-catalysed 
peroxidation (Morrow et al. 1996). They are prostaglandin-like compounds which are 
widely used as markers of oxidative stress in vivo. F2-Isoprostanes are derived from 
ARA, F3-Isoprostanes from EPA, and DHA-derived compounds are termed 
neuroprostanes (Roberts et al. 2005). In situations with increased oxygen tension, e.g. 
in preterm infants with oxygen supplementation, isofurans and neurofurans, which have 
a substituted tetrahydrofuran ring in their structure, are increasingly formed (Fessel et 
al. 2002). 15-F2t-Isoprostane is a well described biomarker for oxidative stress 
(Montuschi et al. 2004; Czerska et al. 2016). At birth, term infants have significantly 
higher 15-F2t-isoprostane levels than healthy adults (approximately 2.3 vs. 9.9 pM), 
while preterm infants experience even higher oxidative stress and have significantly 
higher 15-F2t-isoprostane levels than term infants (approximately 36.7 pM) (Comporti et 
al. 2004). Isoprostanoids are primarily produced from FAs esterified to phospholipids 
(Morrow et al. 1992). Since BM, DHM, and FM mainly contain triglycerides (around 
98%), this thesis will focus on the toxic secondary LPPs MDA, HNE and HHE. 
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Table 1-5: Plasma LPP levels 
 Plasma concentration  Population 
MDA 
0.1-1 µM; higher in women Healthy adults 
1-2 µM Extremely preterm infants 
HNE 
678.5 ± 421.2 nM; increase with age Healthy adults 
100 nM  Moderate to late preterm infants 
HHE 






2.3 pM Healthy adults 
36.7 pM Preterm infants 
 
1.2.2 LPPs and preterm infants’ health  
Oxidative stress is defined as an imbalance between oxygen radicals and antioxidants, 
which can lead to oxidative damage (Betteridge 2000). The most common 
comorbidities of prematurity, retinopathy of prematurity, white matter damage, 
bronchopulmonary dysplasia, patent ductus arteriosus, and NEC, are classified as 
oxygen radical associated diseases (Saugstad 1990; O'Donovan and Fernandes 2004; 
Ozsurekci and Aykac 2016). Oxygen radicals, the consequential oxidative stress, and 
cellular as well as tissue injury play an important role in the development of these 
diseases (Saugstad 1990; Kelly 1993; O'Donovan and Fernandes 2004). 
At birth, preterm infants have immature antioxidant systems, the enzymatic 
antioxidants are not fully matured yet and non-enzymatic antioxidant levels are low due 
to interruption of the maternal-foetal transfer (Qanungo and Mukherjea 2000; Robles et 
al. 2001; Georgeson et al. 2002; Lee and Chou 2005). At the same time, the transition 
of the preterm infant from the foetal relatively hypoxic environment to the neonatal 
environment outside the womb rapidly increases tissue oxygenation and increases 
reactive oxygen species levels (Kuligowski et al. 2014; Kuligowski et al. 2015). Due to 
under developed lungs, preterm infants often receive supplemental/high doses of 
oxygen, which can cause further oxidative stress (Tin and Gupta 2007; Ezaki et al. 
2009), as oxygen is the precursor for oxygen radicals, for example produced by the 
hypoxanthine-xanthine-oxidase system (Saugstad 1988). Blood transfusions, which are 
common in preterm infants, can also increase oxidative stress (Wardle et al. 2002). 
Additionally, transferrin levels are low in preterm infants (Scott et al. 1975), leading to 
higher levels of free iron, which in turn can increase levels of hydroxyl radicals via the 
Fenton reaction (Saugstad 2003). Parenteral nutrition often contains peroxides, 
especially when not shielded from light (Laborie et al. 2002; Miloudi et al. 2012), and 
studies reported higher levels of lipid peroxides in FM than in BM (Michalski et al. 
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2008) (discussed further in Chapter 1.2.3 and 2.1.3). This large oxidative stress burden 
of preterm infants greatly increases the risk of endogenous lipid peroxidation and 
consequently tissue damage.  
Indeed, significantly higher levels of MDA have been found in cord blood of preterm 
compared to term infants (e.g. 1.86 vs. 1.11 nmol/L) (Negi et al. 2012; Abdel Ghany et 
al. 2016). Furthermore, urinary MDA was twice as high in extremely low birthweight 
infants compared to low birthweight infants (Schlenzig et al. 1993). Urinary MDA levels 
in preterm infants were also significantly higher with the incidence of 
bronchopulmonary dysplasia (Schlenzig et al. 1993; Weinberger et al. 2004), patent 
ductus arteriosus (Schlenzig et al. 1993), retinopathy of prematurity, white matter 
damage, and NEC (Weinberger et al. 2004). Recently, a correlation of urinary isofurans 
in the first four days of life with the later incidence of bronchopulmonary dysplasia was 
reported (Kuligowski et al. 2015).  
Activation of inflammatory pathways plays a crucial role in the aetiology of these 
diseases (Fink et al. 2016), and infection and inflammatory conditions in general are a 
major source of morbidity and mortality in premature infants. The generated LPPs can 
indirectly increase inflammation by damaging cells and tissues, but also have direct 
effects by activating inflammatory pathways, such as Toll-like receptors and NF- 
(Lavoie et al. 2010). Toll-like receptor activation plays a critical role in the development 
of NEC (Hackam and Sodhi 2018).  
LPP induced inflammation might also lead to adverse cognitive development. The 
Extremely Low Gestational Age Newborns Study (ELGAN) explored the relationship 
between inflammation and risk of subsequent development of brain disorders in 
preterm infants born at less than 28 weeks gestation, (O'Shea et al. 2009). The time-
course of inflammation (blood levels of 25 inflammation related proteins) was 
measured over two weeks after birth and was associated with a range of adverse 
cognitive outcomes, including impaired mental and motor development at two years of 
age (Kuban et al. 2015; Dammann et al. 2016; Kuban et al. 2017), and importantly 
these effects were shown to persist at 10 years of age (Kuban et al. 2017).  
1.2.3 LPPs in dietary sources for preterm infants 
Peroxidative damage of PUFAs in dietary sources for preterm infants not only 
decreases the PUFA levels, but also increases the LPP levels, which are ingested by 
the infants. Lipid peroxidation in dietary sources for preterm infants has been shown. 
For example, in BM the primary LPPs, lipid hydroperoxides were detected (Van 
Zoeren-Grobben et al. 1993). The presence of secondary LPPs has also been 
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demonstrated in several studies. Turoli and colleagues found conjugated dienes (24.33 
µM), thiobarbituric acid reactive substances (TBARS; an indirect measurement of MDA, 
3.17 µM), and lipid peroxides (6.15 µM) in fresh BM (2004). Michalski and colleagues 
measured MDA and 4-hydroxyalkenals in fresh BM and found higher levels of HHE/n-3 
FA than HNE/n-6 FA (2008). Silvestre and colleagues found MDA concentrations of 
0.72 µM in fresh BM (2010). Volatile LPPs can also be formed in BM. Pentanal, 
hexanal, octanal, nonenal have all been detected (Elisia and Kitts 2011). Lipid 
peroxidation in BM is life-style dependent, for example, BM from non-smoking mothers 
had the lowest MDA concentration (7.07 ± 1.2 µM), higher levels were found in BM 
from passive-smoking mothers (8.83 ± 1.91 µM), and the highest levels in active-
smoking mothers (10.6 ± 2.02 µM), (Ermis et al. 2005).  
BM storage leads to a time and temperature dependent increase in LPPs (Miranda et 
al. 2004; Michalski et al. 2008; Silvestre et al. 2010). For example, refrigerated storage 
for 48 hours almost doubled MDA in BM, and this increase was significant (Miranda et 
al. 2004). Frozen storage of BM at -20°C also significantly increased MDA in BM 
(+0.36 µM after 60 days storage) (Silvestre et al. 2010). DHM contains therefore higher 
levels of LPPs than fresh BM (Turoli et al. 2004). The effect of storage as well as other 
human milk banking practices on lipid peroxidation in DHM is described in greater 
detail in Chapter 5.3.4. However, specific levels of LPPs in DHM that would be fed to 
an infant in the neonatal unit have not been determined yet. 
In (preterm) liquid and powder FM, lipid hydroperoxides, MDA, TBARS, and volatile 
peroxidation products were detected (Manglano et al. 2005; Michalski et al. 2008; 
Chávez-Servín 2009; Cesa et al. 2012). LPP content was higher in preterm FM than in 
fresh BM (Zoeren‐Grobben et al. 1993; Raghuveer et al. 2002; Martysiak-Zurowska 
and Stolyhwo 2006; Michalski et al. 2008; Almansa et al. 2013), indicating a higher 
intake of LPPs from this non-maternal source. A significant time and temperature 
dependent increase in LPP content was also demonstrated in FM powder after storage 
for 21 days (Almansa et al. 2013; Cesa et al. 2015). Refer to Chapter 2.1.3 for a 
detailed overview of lipid peroxidation in FM. However, no study could be identified that 
reported the LPP levels of U.K. preterm FM after storage under current hospital storage 
conditions.  
Although levels of LPPs in non-maternal sources for preterm infants in the U.K. are not 
know, evidence suggests that LPPs are present. LPP intake from parenteral nutrition 
was associated with a higher risk (+32%) for bronchopulmonary dysplasia in preterm 
infants (Chessex et al. 2007). Results from animal studies suggest that LPP ingestion 
can have adverse effects on the gut and also outside of the digestive system (Izaki et 
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al. 1984; Awada et al. 2012) (for a detailed review see Chapter 3.1.2). Therefore, it is 
important to understand the effects of LPP ingestion on the preterm gut, which is more 
prone to inflammation. 
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2 Influence of current storage practices on LCPUFA and 
LPP content of preterm FM in the U.K. 
2.1 Introduction 
Specialised FMs are available for the dietary management of preterm and low birth 
weight infants. Specialised FMs are foods for special medical purposes and must be 
prescribed and used under medical supervision (Crawley et al. 2019). In the U.K. these 
FMs are bovine milk based and have a higher energy density (ca 80 kcal/100 mL in 
first FM and ca 75 kcal/100/mL in post-discharge FM vs. 66 kcal/100 mL in term FM) 
and contain more macronutrients (carbohydrates and protein, but not fat), vitamins, and 
minerals than term FM (Crawley et al. 2019). Preterm infants, as well as low 
birthweight infants, and immunocompromised infants are at high risks for infections. 
Since powdered infant FM cannot be produced sterile, and might be contaminated with 
Enterobacter sakazakii and Salmonella, the WHO recommends using sterile liquid FM 
for the above mentioned infant groups (WHO and FAO 2007).  
In the U.K., FMs for preterm infants (Nutriprem and Gold Prem) are provided by Cow & 
Gate (Nutricia Ltd) and SMA (Nestlé UK Ltd), respectively (Crawley et al. 2019). Both 
manufacturers provide ready to feed liquid FM for preterm/low birthweight infants 
(< 1800 g; Nutriprem 1 and Pro Gold Prem 1) and ready to feed liquid FM as well as 
powdered FM (Nutriprem 2 and Pro Gold Prem 2) for preterm infants post discharge or 
from 1800 g bodyweight onwards, up to six months corrected gestational age (infants 
age minus the number of weeks it was born early) (Figure 2-1).  
 
Figure 2-1: U.K. preterm FM 
 
Pro Gold Prem 1, Pro Gold Prem 2, Nutriprem 1, and Nutriprem 2 contain, 4.0, 3.8, 3.9, 
and 4.0 g fat per 100 mL FM, respectively (Danone Nutricia Early Life Nutrition 2017a, 
2017b; SMA Nutrition 2017a, 2017b), more than preterm BM which contains around 
3.4 g fat per 100 mL (Léké et al. 2019). Nutriprem FMs contain mainly vegetable oils 
(sunflower, rapeseed, coconut, palm, evening primrose), but also single cell oil, egg 
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lipids, and fish oil. The Gold Prem range contains vegetable oils (sunflower, palm, 
rapeseed, coconut), as well as single cell oils. 
In the last decades, the fat composition of FM was greatly improved to more and more 
mimic the fat composition of human BM (Zou et al. 2016; Wei et al. 2019a). First, 
vegetable oils were added to the bovine milk based FM, to match the type and levels of 
FAs (Wei et al. 2019a). These include coconut, palm, high oleic safflower, sunflower, 
soy, and canola oil. BM contains around 43% saturated FA, mainly palmitic acid (20%); 
monounsaturated FA (38%), mainly oleic acid (30%); and PUFAs (16%), mainly LA 
(12%). Fish oil, single cell oil or egg phospholipids are added to provide LCPUFAs (Wei 
et al. 2019a). Addition of these is necessary since Cow’s milk, for example, has one 
fourth of DHA compared to BM (0.09-0.11 vs. 0.37 ± 0.11 %) (Tripathi 2014; Fu et al. 
2016). BM contains around 98% triacylglycerols, with a specific distribution of FAs. 
Saturated FAs including palmitic acid (16:0) are mainly attached in the sn-2 position 
(70%), and oleic acid (18:1n-9) and LA in the sn-1, 3 position (Qi et al. 2018). This FA 
distribution is beneficial for infants, it influences fat absorption and metabolism (Wei et 
al. 2019a). However, cow’s milk fat and vegetable oil have a different triacylglycerol 
structure. Cow’s milk contains a similar amount of palmitic acid, but only 40% is in the 
sn-2 position, and in vegetable oil palmitic acid is mainly attached in the sn-1,3 
position, whereas oleic acid and LA are in the sn-2 position. During digestion, non-
esterified saturated FAs can form insoluble soaps with minerals in the gut, which 
cannot be absorbed and result in hard faeces and loss of nutrients (Zou et al. 2016). 
Therefore, specific structured triacylglycerols which mimic the FA distribution of BM 
were developed. These resulted in reduced soap excretion and softer stools (Yao et al. 
2014), as well as higher bone mineralisation (Beghin et al. 2019), due to better calcium 
absorption, in clinical trials.  
Latest research is focusing on the milk fat globule membrane and its provision of 
phospholipids. The milk fat globule membrane is a trilayer membrane that surrounds 
the triacylglycerols of BM. Phosphatidylethanolamine (10-36%), phosphatidylcholine 
(19-38%), phosphatidylinositol (<10%), phosphatidylserine (<10%) and sphingomyelin 
(29-45%) can be found in BM fat, which contains around 1% phospholipids (Wei et al. 
2019a). Cow’s milk also contains a milk fat globule membrane, which however is 
damaged during dairy processing, and vegetable oil has no membrane. Generally, the 
amount of phosphatidylcholine is much higher and the amount of sphingomyelin lower 
in FM than in BM (Wei et al. 2019b). Researchers have added milk fat globule 
membranes extracted from bovine milk to FM in clinical trials and reported better 
performance in cognitive tests at 12 months of age in experimental FM fed infants than 
in standard FM fed infants (Timby et al. 2014). Performance of the experimental FM 
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group was not different from the breast fed infants. Better IQ scores for hand eye 
coordination, and performance, as well as general IQ in infants receiving the 
experimental FM compared to infants receiving the control FM were also reported 
(Gurnida et al. 2012).  
2.1.1 LCPUFAs in preterm FM 
Addition of LCPUFAs to FM started in 1994 in Europe (Hadley et al. 2016). The 
composition of infant FM is regulated by the Regulation (EU) No 609/2013, and 
Commission Delegated Regulation (EU) 2016/128 and 2016/127. In contrast to the 
former Commission Directive 2006/141/EC, which will only be repealed in February 
2020, the new Delegated Regulation 2016/127 requires the addition of DHA but not 
ARA to infant FM and follow-on FM, whereas before, addition of both LCPUFAs was 
optional (Table 2-1).  
Table 2-1: Comparison of legal LCPUFA requirements of (preterm) FM  
 Commission Directive 2006/141/EC 
Delegated Regulation 
2016/127 
LA 300 mg – 1200 mg / 100 kcal 500mg – 1200 mg / 100 kcal 
ALA not less than 50 mg / 100 kcal 50 mg – 100 mg / 100 kcal 
ARA may be added; max 1% of total fat content 
may be added; max 1% of 
total fat content 
DHA 
may be added; shall not exceed that of n-6 
LCPUFAs 
20 mg – 50 mg / 100 kcal 
 
The Commission Delegated Regulation (EU) 2016/127 is based on the latest “Scientific 
Opinion on the essential composition of infant and follow-on formulae”, published by 
the European Food Safety Authority (EFSA) (EFSA Panel on Dietetic Products and 
Allergies 2014). The panel concluded “that there is no necessity to add ARA to infant 
formula even in the presence of DHA”. Well-known researchers in the field of 
LCPUFAs and infant nutrition have criticised the EFSA statement and its translation 
into European law (Crawford et al. 2013, 2015; Koletzko et al. 2015; Brenna 2016). 
One major critique point was that the EFSA panel only reviewed publications from 2000 
onwards. Crawford and colleagues have pointed out that this ignores the discovery of 
prostaglandins and related biologically active substances (a discovery that led to the 
1982 Nobel Prize in Physiology and Medicine) (2015). These are ARA metabolites 
responsible for homeostatic functions, and mediation of pathogenic mechanisms like 
inflammation (Ricciotti and FitzGerald 2011). Additionally, the EFSA panel disregards 
human physiology, in which ARA levels in BM are very similar across the world, and 
normally occur in comparable or higher levels than DHA (Fu et al. 2016), and human 
BM should be regarded as best nutritional source for term infants. A systematic review 
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identified that ARA was either similar or higher than in term BM (Bokor et al. 2007). 
Furthermore, when DHA and DHA+ARA supplementation of FM was compared in 
clinical trials, none of the studies investigated ARA specific outcomes such as immune 
or vascular function (Brenna 2016). However, it has been shown that omitting ARA 
from FM will lead to decreased circulating ARA levels (Makrides et al. 1995b). 
Furthermore, the critiquing authors point towards the Retina Foundation Southwest 
study performed by Birch and colleagues, in which term infants were fed either 0.35% 
DHA, or 0.36% DHA in combination with 0.72% ARA (1998). Follow up at four years of 
age revealed significantly lower verbal IQ scores in the DHA only group compared to 
breast fed infants, whereas there was no difference to breast fed infants in the 
DHA+ARA group (Birch et al. 2007). Koletzko and colleagues also critique that there 
are no scientific studies using FM with 1% DHA and no ARA, and therefore there is 
lack of knowledge of the effects, suitability and safety of these FMs (2015). Regarding 
this, it was also pointed out that omitting ARA from FM might have a similar effect as 
COX-2 inhibitors (Crawford et al. 2015). COX-2 is the enzyme responsible for the 
conversion of ARA into prostaglandins, a precursor of prostacyclin. These inhibitors 
were developed to prevent inflammation and pain in rheumatoid arthritis, however, use 
resulted in more cardiovascular and stroke events, due to prothrombotic activity 
(Mukherjee et al. 2001). In the presence of reduced circulating ARA levels, DHA can 
act as COX-2 inhibitor, potentially leading to infant cardiovascular events, strokes or 
potentially deaths (Crawford et al. 2015). Overall, the effects might be even more 
dramatic in preterm infants, who haven’t had the chance to accumulate large amounts 
of ARA during the last trimester. 
After the Delegated Regulation 2016/2017 came into force in February 2020, SMA had 
to make changes to their preterm FM to be compliant. The DHA content of Pro Gold 
Prem 1 changed from 18 mg/100 kcal to 25 mg/100 kcal (SMA Nutrition 2020a). They 
have also increased DHA levels in Pro Gold Prem 2 to the same levels as Pro Gold 
Prem 1 (SMA Nutrition 2020b). Both manufacturers have not omitted ARA from their 
preterm FMs, and maintained ARA levels at the same amount per 100 kcal as DHA 
(Danone Nutricia Early Life Nutrition 2020b, 2020a; SMA Nutrition 2020b, 2020a).  
Experiments carried out in this chapter used FM from 2017, therefore the following 
section describes preterm FMs at that time. All preterm FMs available in the U.K. in 
2017 contain both ARA and DHA (Danone Nutricia Early Life Nutrition 2017a, 2017b; 
SMA Nutrition 2017b, 2017a). LCPUFA levels in preterm FMs from 2017 are presented 
in Table 2-2.  
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Table 2-2: Absolute LCPUFA content of preterm FM in the U.K. 
 Nutriprem 11 Nutriprem 22 Pro Gold Prem 13 Pro Gold Prem 24 












77 / 96 75 / 103 
ARA 20 / 20 20 / 20 15 / 18 14.4 / 20 
DHA 10 / 20 10 / 20 15 / 18 14.4 / 20 
Data from the U.K. as of March 2017 
Amended from 
1
(Danone Nutricia Early Life Nutrition 2017a); 
2
(Danone Nutricia Early Life Nutrition 
2017b); 
3
(SMA Nutrition 2017b); 
4
(SMA Nutrition 2017a)  
These translate into the weight percentages (of total FAs) described in Table 2-3. 
Although preterm FMs contain more LCPUFAs than BM from women in the U.K., ARA 
levels are still below the worldwide levels of term BM (Yuhas et al. 2006; Fu et al. 2016; 
Danone Nutricia Early Life Nutrition 2017a, 2017b; SMA Nutrition 2017b, 2017a). In 
comparison, in Nutriprem products, DHA is similar to worldwide DHA term BM levels, 
and Pro Gold Prem products provide higher DHA levels, potentially taking into account 
that preterm BM contains more DHA than term BM (Bokor et al. 2007; Fu et al. 2016).  























LA 10.45 ± 0.41 13.7 13.5 15.41 17.46 
ALA 1.22 ± 0.06 1.97 1.86 2.11 2.28 
ARA 0.36 ± 0.01 0.48 0.46 0.41 0.43 
DHA 0.24 ± 0.01 0.37 0.35 0.41 0.43 
Amended from 
1
(Yuhas et al. 2006); 
2
(Danone Nutricia Early Life Nutrition 2017a); 
3
(Danone Nutricia Early 
Life Nutrition 2017b); 
4
(SMA Nutrition 2017b); 
5
(SMA Nutrition 2017a)  
Data from the U.K. as of March 2017 
In term and preterm BM, phospholipids also contain ARA (2.0-3.1%) and DHA (0.5-
1.6%). Nutriprem FMs contain soy lecithin and egg lipids, providing phospholipids. 
Composition of these are not provided by the manufacturer in the data cards. However, 
analysis of eight FMs in China revealed that the phospholipid composition was 
significantly different than that of BM, even though some of the FMs were 
supplemented with milk fat globule membrane, phospholipids, or lecithin (Wei et al. 
2019b). FM phospholipids contained only 0.2-1.2% ARA and no DHA at all.  
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Besides all efforts, FM total LCPUFA composition is still very different from BM 
LCPUFA composition. Although ARA and DHA levels are similar to reported 
concentrations in human BM worldwide (Brenna et al. 2007), little attention is paid to 
other LCPUFAs, including dihomo-γ-linolenic acid, eicosapentaenoic acid, adrenic acid, 
and docosapentaenoic acid n-3 and n-6. For example, according to the datasheets, 
SMA’s preterm range does not contain any of these LCPUFAs (SMA Nutrition 2020a, 
2020b), whereas Cow and Gate’s preterm range contains some of these LCPUFAs, 
albeit in very different concentrations compared to U.K. BM (dihomo-γ-linolenic acid: 
0.04 vs. 0.33%; eicosapentaenoic acid: 0.08 vs. 0.11%; adrenic acid: 0 vs. 0.08%; 
docosapentanoic acid n-3: 0.02 vs. 0.18%; docosapentaenoic acid n-6: 0 vs. 0.03%) 
(Yuhas et al. 2006; Danone Nutricia Early Life Nutrition 2017a, 2017b). Normally, 
adrenic acid rapidly accumulates in the developing brain after birth (Martínez and 
Mougan 1998), therefore a lack of adrenic acid, together with low levels of its precursor 
ARA, are concerning. Low levels of these other LCPUFAs are not surprising, since they 
are not regulated in the current law. Concerning these LCPUFAs, the Commission 
Directive 2006/141/EC only states that C20 and C22 n-3 LCPUFAs shall not exceed 
1% of total fat content, while the eicosapentaenoic acid content shall not exceed the 
DHA content. Furthermore, C20 and C22 n-6 LCPUFAs shall not exceed 2% of total fat 
content. Similarly, the Delegated Regulation 2016/127 states that other C20 and C22 
LCPUFAs may be added, while the n-6 LCPUFAs shall not exceed 2% of the total fat 
content, and eicosapentaenoic acid content shall not exceed the DHA content.  
2.1.2 Influences and alterations to LCPUFA content of FM  
During shelf-life 
FMs contain PUFAs as well as minerals such as iron, which in combination can lead to 
lipid peroxidation (Marshall and Roberts 1990), and loss of LCPUFAs. Studies have 
determined that storage of FM containing LCPUFAs for three, 12, or 18 months from 
production, had no significant effect on LCPUFA levels (Chávez-Servín 2009; Carmen 
García‐Martínez et al. 2010), suggesting that LCPUFAs are stable in FM during the 
shelf-life. However, significant peroxidation can occur in FM without decreasing 
LCPUFA levels (Chávez-Servín 2009) (Chapter 2.1.3). 
In FM that has been opened 
The LCPUFA content of FM that has been opened for use was reported in one study, 
in which opening and subsequent storage for 30 days had no effect (Zunin et al. 2015). 
In another study, hospital/domestic use was mimicked, by opening the FM three times 
per day, stirring it each time in the original packet and removing two scoops (Chávez-
Servín et al. 2008). Doing so for 70 days had no effect on LCPUFA percentage 
composition. 
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2.1.3 Influences and alterations to LPP content of FM  
In general, FMs containing LPCUAs are more susceptible to peroxidation than FMs not 
containing LCPUFAs; LCPUFA containing FMs had higher MDA concentrations (e.g. 
135 nmol/g vs. 35 nmol/g (Burg et al. 2010); 8.2 ppm vs. 2.8 ppm (Michalski et al. 
2008); 1066 ppm vs. 590 ppm (Cesa 2004)) and peroxide values (0.98 vs. 0.52 mequiv 
O2/kg) (Romeu-Nadal et al. 2007) than FMs without LCPUFAs. Furthermore, the MDA 
concentration correlated positively with the ARA, as well as the DHA concentration in 
FMs (Almansa et al. 2013). 
During shelf-life 
No differences in peroxidation products were detected when Spanish bovine-milk 
based infant FM was analysed three months after production (stored at 25°C) (Carmen 
García‐Martínez et al. 2010). However, an increase of 40% in MDA has been recorded 
for FMs that were stored for 12 months after manufacturing (Cesa et al. 2015), and a 
significant time-dependent increase in peroxide value, hydroperoxide content, and 
TBARS was reported for FM stored for 17 months after manufacturing, although the 
shelf life of these products was three years (Manglano et al. 2005). Volatile aldehydes 
such as propanal, pentanal and hexanal, also increased during the shelf-life (18 
months) of FM (Chávez-Servín 2009). 
In FM that has been opened 
Once FMs are opened, they are highly susceptible to lipid peroxidation (Chávez-Servín 
et al. 2008) due to increased oxygen exposure. Indeed, lipid peroxidation occurred in 
FM, with a significant increase of MDA and peroxide value over 21 days after opening 
of the box and storage at room temperature (Almansa et al. 2013; Ghazal et al. 2016). 
Similarly, FM storage at room temperature for 21 days increased MDA when FM was 
analysed six months after production, but did not change when FM was used directly 
after production (Cesa et al. 2015). This increase was also temperature dependent with 
higher MDA concentrations in samples stored at 28°C than at 20°C (75 vs. 25% 
increase in MDA, respectively) (Cesa et al. 2015). Surh and colleagues analysed the 
HHE and HNE content of Korean FM after opening and at 10 days (2007). The FM was 
opened for 3 minutes every day and stirred. They reported significant increases in the 
hydroxyalkenal content after 10 days. The tested term FMs contained similar levels of 
DHA to preterm FM in the U.K., but five times less ARA. Researchers in Spain opened 
20 term FM three times per day and discarded two scoops (Chávez-Servín et al. 2008). 
Seven of the 20 FMs contained DHA and 12 of the 20 FMs contained ARA, all in 
varying levels which were lower than levels in preterm FM in the U.K. During the 
storage for up to 70 days, FM was kept at room temperature (25°C), and significant 
increases in propanal, pentanal and hexanal were detected over the storage time in all 
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LCPUFA containing FMs. Storage of liquid FM, containing LCPUFAs, for 1 and 
24 hours at 4°C almost doubled and tripled the MDA concentration, respectively 
(Michalski et al. 2008).  
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2.2 Aim and objectives 
As reviewed above, LCPUFA stability and lipid peroxidation have been studied over the 
shelf-life of FM. However, only one study has investigated the effect of clinical/domestic 
storage and use on LCPUFA content after opening of the FM (Chávez-Servín et al. 
2008). Furthermore, although there have been more (five) studies investigating lipid 
peroxidation after FM opening, the majority of these studies have only opened the FM 
once and then analysed LPPs at various time-points afterwards. Only one study tried to 
actually mimic hospital/domestic use, in which FM powder is opened several times per 
day and FM is discarded (Chávez-Servín et al. 2008). Furthermore, all studies were 
performed on term FMs, which at least in the U.K. contain only around half as much 
LCPUFAs as preterm FM (Danone Nutricia Early Life Nutrition 2017b; SMA Nutrition 
2017a; Danone Nutricia Early Life Nutrition 2018; SMA Nutrition 2018).  
Manufacturers recommend preparing individual FM feeds when required, and the WHO 
guidance also recommends preparing feeds fresh as best practice. However, the WHO 
acknowledges that feeds may need to be prepared in advance for practical reasons in 
care settings or at home (WHO and FAO 2007). Therefore, it is recommended to store 
prepared, cooled feeds in a refrigerator (≤ 5°C) for a maximum of 24 hours. To the best 
of the authors’ knowledge, there have been no studies looking at the effect of storing 
prepared FM powder and only one study has investigated the effect of storing opened 
liquid FM (Michalski et al. 2008). 
Therefore, it was the aim of this study to investigate the effect of different storage 
conditions, which actually mimic the clinical care settings, on the LCPUFA and LPP 
content of preterm FM in the U.K. 
 The first objective was to quantify the initial LCPUFA levels in liquid and 
prepared powder FM and to compare them to the levels stated on the FM labels  
 The second objective was to quantify the absolute LCPUFA content in liquid 
and prepared powder FM, and to assess whether there was any decrease 
during FM storage 
 The third objective was to calculate the daily LCPUFA intake from FMs for a 1 
and 2 kg infant, and to compare it to ESPGHAN recommendations 
 The fourth objective was to calculate the LCPUFAs available for accretion for a 
1 and 2 kg infant and to compare it to estimated in utero accretion levels 
 The fourth objective was to investigate lipid peroxidation in liquid and prepared 
powder FM during storage by measuring TBARS and HNE levels    
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2.3 Material and methods 
Ethical approval for this project (Reference ID 12492) was obtained from Bournemouth 
University’s Research Ethics (Appendix II.I). Two standard preterm FMs are available 
in the U.K., which were included in the analysis (Table 2-4). Data cards are provided in 
Appendix II.II. Since preterm FM is only available on prescription, samples were 
provided by the manufacturers (Nutricia Ltd, Nestlé UK Ltd). The manufacturers had no 
involvement in the experimental design, data analysis, and dissemination of the results. 
Table 2-4: Preterm FMs included in the analysis 
Category Name Company Samples 
Infant milk for 
preterm 
infants 
Nutriprem 1 (liquid) 
Cow & Gate, 
Nestlé UK Ltd 
5 
Pro Gold Prem 1 (liquid) SMA, Nutricia Ltd 3 
Post-
discharge 
infant milk for 
preterm 
infants 
Nutriprem 2 (liquid) 
Cow & Gate, 
Nestlé UK Ltd 
5 
Nutriprem 2 (powder) 
Cow & Gate, 
Nestlé UK Ltd 
6 
Pro Gold Prem 2 (liquid) SMA, Nutricia Ltd 3 
 
Consultation with a Children’s Dietitian at Poole Hospital NHS Foundation Trust 
identified that opened liquid FM and made-up powder FM might be stored for up to 
12 hours and 24 hours, respectively, at 4°C in some hospitals. This was taken into 
consideration in the experimental design.  
Liquid FMs were analysed for FA content at opening and after 4 hours storage at 4°C. 
Since only fresh FM samples were to be analysed, FA could not be analysed at 1 and 
10 hours (Figure 2-2 A). Powder FMs were tested on day 0, 7, 14, 21, and 28 at 0, 4 
and 24 hours storage at 4°C after preparation, respectively (Figure 2-2 B). These time-
points were chosen to test the FM weekly after opening, for the recommended time of 
use by the manufacturers (28 days). To simulate normal use, powder was removed 
three times per day as it would be for feed preparation. Three times per day were 
chosen as pragmatic approach to represent top-up FM feeding. A similar approach has 
been used in other studies (Chávez-Servín et al. 2008), although in some cases in real 
life it would be more frequent. 
  
 




Figure 2-2: Time-line for preterm FM sampling 
A: Liquid FMs were opened at 0 hours and afterwards stored at 4°C. FA content was analysed at 0 hours 
and 4 hours. Samples for LPP analysis were taken at 0, 1, 4, 10 hours and stored at -80°C until analysis 
B: FM powder was prepared fresh at 0, 7, 14, 21, and 28 days and was then stored at 4°C. FA content 
was analysed at 0, 4 and 24 hours and samples for LPP analysis were taken at 0 ,4, 24 hours and stored 
at -80°C until analysis 
It is recommended that FM powder should be prepared using 1000 mL H2O, boiled and 
cooled for 30 min. It was determined that this temperature is 62°C. On the test day, FM 
powder (Nutriprem 2: 5.1 g/30 mL) was prepared using distilled H2O (dH2O) (62°C) and 
liquid FM was opened. Samples for FA analysis were processed directly, whereas 
samples for LPP analysis were stored under N2 and frozen at -70°C until analysis.  
2.3.1 FA quantification 
FA extraction and transesterification  
Lipids were extracted according to the Bligh and Dyer method (1959), which has been 
used previously in our laboratory to analyse FAs in BM (De Rooy et al. 2017), together 
with the transesterification according to Morrison and Smith (1964). 
Extractions were carried out in a room without artificial light and solvents were kept on 
ice prior to the start. 2,[6]-Di-tert-Butyl-p-cresol (butylated hydroxytoluene, Sigma, U.K.) 
was added to the solvents (0.05%, w/v) as an antioxidant (Wren and Szczepanowska 












1964), and tubes were flushed with N2 (grade N4.8, BOC, U.K.) whenever caps were 
opened, to further protect FAs. Sample preparation was practiced until a coefficient of 
variation (CV%) of ≤ 15% was consistently achieved (ARA: 11.7%, DHA 11.4%). 
Thereafter, only single samples were analysed. 
To 500 µL FM (liquid or powder prepared according to manufacturer’s instructions), 
700 µL dichloromethane/methanol/butylated hydroxytoluene (1:2, v/v, 0.05%, w/v) 
(Sigma Aldrich, U.K.), 400 µL C23:0 (25 mg/100 mL dichloromethane) as internal 
standard, and 800 µL methanol/butylated hydroxytoluene (0.05% w/v) were added and 
samples homogenised for 3 min. Next 625 µL dichloromethane/butylated 
hydroxytoluene (0.05% w/v) was added and samples homogenised for a further 3 min. 
In the next step, 625 µL dH2O was added and the samples homogenised for a further 
3 min, followed by a centrifugation step (2500 x g, 5 min, 10°C). The upper aqueous 
phase was discarded, and the organic phase filtered through Whatman phase 
separator filter paper (1PS, GE Healthcare Life Sciences, U.K.).  
The organic phase was collected in 5 mL Reacti-Vials (Thermofisher, U.K.) and directly 
transesterified (Morrison and Smith 1964). Therefore, 1 mL BF3-methanol solution 
(14%, Aldrich Chemistry, U.K.) was added and samples were placed in a Pierce 
Reacti-Therm Heating Module (Thermofisher, U.K.) for 20 min at 100°C. After 10 min 
cooling, 2 mL pentane (Sigma Aldrich, U.K.) and 1 mL dH2O were added and the 
samples homogenised for 3 min, followed by a centrifugation step (2500 x g, 5 min, 
10°C). The organic phase containing the FA methyl esters (FAMEs) was transferred to 
an amber gas chromatography (GC) vial (Agilent Technologies, U.K.), evaporated to 
dryness under a gentle stream of N2 (SC-3 Sample Concentrator, Techne, U.K.), and 
re-suspended in 100 µL hexane/butylated hydroxytoluene (0.05% w/v) (Sigma Aldrich, 
U.K.). Samples were analysed within 3 weeks and stored until then at -20°C under N2 
(grade N4.8, BOC, U.K.).  
FAME Quantification by GC 
Quantification of FAMEs was performed by GC coupled with flame ionisation detector 
(FID). The GC-FID consists of an Agilent Technologies 7820A gas chromatograph, 
fitted with an Omegawax 100 fused silica capillary column (15 m x 0.1 mm x 0.1 µm 
film thickness, Supelco, Sigma Aldrich, U.K.; constant N2 (grade N5.5, BOC, U.K.) flow 
at 0.2 mL/min, 39.5 psi pressure, average velocity 22.7cm/s). The temperature 
programme is described in Table 2-5.  
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Temperature (°C) Hold (min) 
Initial  140 0 
Ramp 1 60 200 0 
Ramp 2 20 250 11.5 
Total   15 
 
Usually, 1 µL sample was injected in the split inlet (50:1 split, 250°C, 39.5 psi pressure, 
10.7 mL/min). Detection was carried out with an FID (260°C, H2 (grade N5.5, BOC, 
U.K.) flow 40 mL/min; air flow 450 mL/min (HT15-00137, Bambi Air Compressors Ltd, 
U.K.); constant makeup (N2, grade N5.5) flow 30 mL/min). Identification of individual 
FAMEs was carried out in comparison to a range of analytical standards (Supelco 
PUFA No. 1 marine source; Supelco PUFA No. 2 animal source; Supelco 37 
Component FAME Mix; all Sigma-Aldrich, U.K.; Figure 2-3), run on each analysis day 
under the same conditions as FAME quantification. Different retention times occurred 
due to column changes between experiments. The column has to be shortened before 
re-instalment, leading to a shorter run through the column and therefore, different 
retention times.  
Analysis was performed using the ChemStation Software (Rev. C.01.04(35), Agilent 
Technologies, U.K.). Absolute values for FAs were calculated using the following 
formula (Benedetto 1987):  
𝐹𝐴 (𝑚𝑔/100 𝑚𝑙 𝐹𝑀) = 𝑎𝐹𝐴/𝑎𝑆𝑡𝑑 × 𝑤𝑆𝑡𝑑 × 𝑅𝐹 × 200 
aFA = peak area of FA; aStd = peak area of internal standard; wStd = weight of internal 
standard per 0.5 mL sample; RF = detector response factor 





 Figure 2-3: Representative chromatograms of analytical standards detected by GC-FID 
A: PUFA No. 1 from marine source; B: PUFA No. 2 from animal source. The chromatograms have stable 
baselines and well resolved, sharp peaks, as well as a low signal to noise ratio. FAs of interest are labelled 
below the chromatogram.   
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2.3.2 TBARS quantification 
MDA is one of the first stable molecules formed during lipid peroxidation and can be 
used as index for the beginning of the process (Cesa et al. 2012). MDA can form a 
coloured end-product with thiobarbituric acid under high temperature and acidic 
conditions. This product can be analysed photometrically to quantify MDA and other 
TBARS. This means that the TBARS assay is non-specific for MDA and might 
overestimate the MDA content. Other aldehydes, as well as amino acids, sialic acid, 
sugars and bilirubin can also react in this assay, even though MDA has the highest 
reactivity (Benzie 1996). Nevertheless, this assay is often used to measure lipid 
peroxidation in research. Analysis of this coloured end-product in FMs by third 
derivative spectrophotometry (Cesa et al. 2015), high-performance liquid 
chromatography (Almansa et al. 2013), or measuring fluorescent absorbance 
(Manglano et al. 2005) has been performed before. 
First, analysis of TBARS was conducted using a Parameter TBARS Assay from R&D 
Systems Inc. according to the manufacturer’s instructions. This assay was chosen as it 
requires a lower temperature than most other assays (45°C vs. 95°C), reducing the 
possibility of MDA production during the assay. However, due to technical issues 
encountered with this assay, the following assay was used for the final analysis.  
TBARS were quantified using a TBARS (Trichloroacetic Acid Method) Assay (700870, 
Cayman Chemical) following manufacturer’s instructions. Samples and standards 
(100 µL) were incubated with 100 µL TCA Assay Reagent (10%) and 800 µL Colour 
Reagent for 1 hour in a boiling water-bath (JB Nova, Grant). Next, samples and 
standards were placed in an ice bath for 10 min to cool. After centrifugation (1600 x g, 
10 min, 4°C), supernatants were transferred to a 96-well plate in duplicates and 
absorbance was measured at 540 nm using an absorbance microplate reader (ELx800, 
BioTek). Results were analysed using the Gen5 software (Version 2.09.2 for Windows, 
BioTek). A standard curve was included to quantify TBARS concentration in µM 
(Figure 2-4).  
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Figure 2-4: Standard curve for the determination of TBARS concentration in FM samples 
The graph shows a representative MDA standard curve (R
2
 = 0.9998; y = 0.0083x + 0.0024) determined 
by TBARS assay. Standards were analysed in duplicates. 
 
Since the assay was not validated for the use with FM, intra- and inter-assay CV% 
were determined (Salimetrics Inc 2017). Inter-assay CV% of less than 15 and intra-
assay CV% of less than 10 are generally defined as acceptable. The general formula 




 × 100 
The intra-assay CV% was calculated for 48 samples Nutriprem 2 (duplicates) analysed 
on one plate. The intra-assay CV% was 7.8%. The inter-assay CV% was determined 
on four plates, using quadruplicates of Nutriprem 2. The inter-assay CV% was 6.1%. 
Both these values are considered acceptable (Salimetrics Inc 2017), and therefore 
demonstrate that this assay can be used to analyse TBARs in FM.  
The FM matrix can have a significant effect on the recovery of MDA/TBARS (Cesa 
2004). Therefore, the recovery rate was determined by spiking FM (5 samples in 
duplicates) with 12.5 µM MDA (Fenaille et al. 2001). Recovery was calculated using the 
following formula:  
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 (%) =
(𝐶 𝑠𝑝𝑖𝑘𝑒𝑑 − 𝐶 𝑖𝑛𝑖𝑡𝑖𝑎𝑙)
𝐶 𝑎𝑑𝑑𝑒𝑑
× 100 
C spiked: TBARS concentration in spiked sample (µM); C initial: TBARS concentration in 
unspiked sample (µM), C added: MDA concentration added (µM) 
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Recovery was 39.0% for Nutriprem 1 (liquid), 61.0% for Nutriprem 2 (liquid), 49.11% for 
Nutriprem 2 (powder). Other researchers reported a recovery of 57 - 63% or 40 – 80% 
for MDA in different Italian FMs, respectively (Cesa 2004; Cesa et al. 2012). TBARS 
concentrations were adjusted accordingly and corrected for published fat content. 
2.3.3 HNE quantification  
HNE can form a stable adduct with proteins, called advanced lipid peroxidation end 
products. They can be quantified by comparison to an HNE-BSA standard curve using 
a competitive enzyme-linked immunosorbent assay (ELISA). 
HNE adducts were quantified using the OxiSelect HNE Adduct competitive ELISA Kit 
(STA-838, Cell Biolabs, Inc.), according to the manufacturer’s instructions. The 96-well 
plate was coated with 5 µg/mL HNE conjugate over night at 4°C. After washing with 
PBS, 200 µL Assay Diluent were added for 1 hour at room temperature. After removal, 
50 µL standard or sample were added in duplicates and the plate was incubated 
(10 min, room temperature, orbital shaker), followed by an incubation with 50 µL anti-
HNE antibody (1 hour, room temperature, orbital shaker). Next, plates were washed 
three times and incubated with 100 µL secondary Antibody-HRP Conjugate (1 hour, 
room temperature, orbital shaker). After three times washing, 100 µL Substrate 
Solution were added, and the plate was incubated for 10 min. The Stop Solution was 
added, and the absorbance was read at 450 nm, using an absorbance microplate 
reader (ELx800, BioTek). Results were analysed using the Gen5 software (Version 
2.09.2 for Windows, BioTek). An HNE-bovine serum albumin (BSA) standard curve 
was included to quantify HNE adducts in µg/mL (Figure 2-5). Values were corrected for 
published fat content of FMs. 























Figure 2-5: Standard curve for the determination of HNE-BSA in liquid FM samples 
The graph shows a representative HNE-BSA four parameter logistics standard curve (R
2
 = 0.9881) 
determined by ELISA. Standards were analysed in duplicates. 
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2.3.4 Statistics 
It would be best practice to anonymise FMs in the results section. However, LCPUFA 
levels were compared to the levels provided by the manufacturers, and the antioxidant 
composition was also discussed. Since these differ between the different brands of FM, 
and since there are only two preterm FMs available in the U.K., FMs could be easily 
identified and it was decided not to anonymise the results.  
Statistical analysis was performed using GraphPad Prism (Version 5.0). Due to small 
sample numbers, non-parametric tests were used. For comparisons between FMs, 
Mann Whitney test or Kruskal-Wallis test with Dunn’s multiple comparisons test 
comparing all columns were used. For comparison over storage time, Wilcoxon 
matched pairs test or Friedman test with Dunn’s multiple comparisons test comparing 
all columns was used. A one sample t-test was used to compare FA content to 
manufacturer’s values. Enteral LCPUFA supply, based on the analysed FA content, 
was calculated for hypothetical 28 weeks gestational age infant, weighing 1000 g at 
birth and receiving full enteral feeding (150 mL/kg/day) with infant FM, and later on 
(2000 g) with post-discharge FM. Values were compared to ESPGHAN recommended 
intake levels (Agostoni et al. 2010) using a one sample t-test and compared between 
the FMs using Mann Whitney or Kruskal-Wallis test. LCPUFAs available for accretion 
were also calculated for this hypothetical infant as described previously (De Rooy et al. 
2017), considering an absorption of 81.1% for ARA, and 78.4% for DHA (Carnielli et al. 
1998), as well as an endogenous synthesis of 26.7 mg/kg/day ARA and 12.6 
mg/kg/day DHA per day (Carnielli et al. 2007). Values were compared to estimated in 
utero accretion rates (Lapillonne and Jensen 2009) by one sample t-test. For 
comparisons between FMs, Mann Whitney  or Kruskal-Wallis test was used. Data 
presented as mean ± SD, and considered statistically significant at p < 0.05. * indicates 
p < 0.05, ** and *** p-values < 0.01 and < 0.001, respectively.  
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2.4 Results 
2.4.1 LCPUFAs 
LCPUFAs were analysed by GC-FID. Figure 2-6 shows a representative chromatogram 
of FAs detected in preterm FM.  
 
Figure 2-6: Representative chromatogram of preterm FM FAMEs detected by GC-FID 
Nutriprem 2 day 0, 0 hours. The chromatogram has a stable baseline and well resolved, sharp peaks, as 
well as a low signal to noise ratio. LCPUFAs and the internal standard are labelled below the 
chromatogram. Peak identification was carried out in comparison to analytical standards. 
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LCPUFA levels compared to manufacturers’ information 
Measured LCPUFA levels at opening were compared to the information provided on 
the labels by the manufacturers. Liquid Nutriprem 1 had ARA (15.49 ± 5.52 vs. 
20 mg/100 mL, p = 0.2004) and DHA (12.03 ± 4.45 vs. 10 mg/100 mL, p = 0.4280) 
levels comparable to the label. Liquid Nutriprem 2 had significantly higher ARA (23.77 
± 2.24 vs. 20 mg/100 mL, p = 0.0197) and DHA (13.44 ± 2.43 vs. 10 mg/100 mL, 
p = 0.0338) levels, than declared by the manufacturer. Nutriprem 2 powder had 
significant lower ARA levels (11.47 ± 2.10 vs. 20 mg/100 mL, p = 0.0002), but 
comparable DHA levels (8.24 ± 1.87 vs. 10 mg/100 mL, p = 0.0692). Liquid Pro Gold 
Prem 1 had significant lower levels of ARA (11.53 ± 0.79 vs. 15 mg/100 mL, 
p = 0.0169) and DHA (10.50 ± 0.95 vs. 15 mg/100 mL, p = 0.00146) at opening. Liquid 
Pro Gold Prem 2 levels were comparable to the label (ARA: 10.44 ± 2.06 vs. 
14.4 mg/100 mL, p = 0.0797; DHA: 10.36 ± 1.86 vs. 14.4 mg/100 mL p = 0.0639). 
There was no significant difference in the ARA (p = 0.4000) and DHA (p = 0.8571) 
concentration between the liquid preterm first FMs. Liquid Nutriprem 2 provided 
significantly more ARA than liquid Pro Gold Prem 2 and Nutriprem 2 powder (both 
p < 0.05). The DHA concentration was also significantly higher in liquid Nutriprem 2 
than in Nutriprem 2 powder (p < 0.01). There was no significant difference in the DHA 
concentration between liquid Pro Gold Prem 2 and liquid Nutriprem 2.  
LCPUFA levels during preterm FM storage 
There was no effect of 4 hours refrigeration on the ARA and DHA concentration in 
liquid preterm first FMs (Nutriprem 1: p = 0.8750 and p = 0.8750, respectively; Pro Gold 
Prem 1: p = 0.2500 and p = 0.2500, respectively) (Figurer 2-7 A, B, E, F). There was 
no effect of refrigerated storage (4 hours) on the ARA and DHA concentration in liquid 
post-discharge FMs (Nutriprem 2: p = 0.4375 and p = 0.8125, respectively; Pro Gold 
Prem 2: p = 0.5000 and p = 0.5000, respectively) (Figure 2-7 C, D, G, H). 
The ARA concentration in prepared Nutriprem 2 powder was 11.47 ± 2.10 mg/mL at 
opening (day 0, 0 hours) (Figure 2-8 A). Opened storage for 28 days did not result in a 
change in ARA concentration at 0 hours (directly after preparation; p = 0.0700). 
Refrigerated storage for up to 24 hours did not decrease ARA levels (Table 2-6). 
The DHA concentration in prepared Nutriprem 2 powder was 8.24 ± 1.87 mg/mL at 
opening (day 0, 0 hours) (Figure 2-8 B). Opened storage for 28 days did not change 
the DHA concentration in prepared preterm FM at 0 hours (directly after preparation; 
p = 0.0663). Storing prepared preterm FM at 4°C did not decrease DHA levels at any 
time-point (Table 2-7). 
 
























































































































































Figure 2-7: LCPUFA concentration in liquid preterm FM samples 
ARA (left panel) and DHA (right panel) concentration in (A and B) Nutriprem 1 (n=4), (C and D) 
Nutriprem 2 (n=5), (E and F) Pro Gold Prem 1 (n=3), and (G and H) Pro Gold Prem 2 (n=3). Refrigerated 
storage for 4 hours had no influence on LCPUFA concentrations (p > 0.05, respectively). Dashed lines 
indicate ARA and DHA levels provided on the label.   
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Figure 2-8: LCPUFA concentrations in Nutriprem 2 powder after preparation 
(A) ARA (p = 0.0700) and (B) DHA (p = 0.0663) concentration in Nutriprem 2 samples (n=6) directly after 
preparation (0 hours) over the course of the experiment (28 days). 
Table 2-6: ARA (mg/100 mL) in Nutriprem 2 
 0 hours 4 hours 24 hours 
Day 0 11.47 ± 2.10 11.75 ± 0.93 10.38 ± 2.46 
Day 7 9.96 ± 0.63 11.63 ± 1.71 10.90 ± 2.53 
Day 14 10.61 ± 2.34 13.58 ± 0.82 14.57 ± 1.60 
Day 21 13.36 ± 2.04 13.43 ± 1.46 15.42 ± 2.13 
Day 28 13.17 ± 2.92 13.54 ± 2.96 13.81 ± 1.66 
ARA concentration (± SD) in Nutriprem 2 samples (n=6) 
Day 0: p = 0.9563; day 7: p = 0.1416; day 14: p = 0.0055, significant differences in Dunn’s multiple 
comparison test (0 vs. 24 hours, p < 0.05); day 21: p = 0.0289, significant differences in Dunn’s multiple 
comparison test (0 vs. 24 hours, p < 0.05); day 28: p = 0.9563 
0 hours: p = 0.0700; 4 hours: p = 0.1468; 24 hours: p = 0.0155, significant differences in Dunn’s multiple 
comparison test (day 0 vs. 21, p < 0.05)  
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Table 2-7: DHA (mg/100 mL) in Nutriprem 2 
 0 hours 4 hours 24 hours 
Day 0  8.24 ± 1.87 7.91 ± 0.83 7.45 ± 1.34 
Day 7 7.61 ± 1.20 7.84 ± 1.22 7.07 ± 1.36 
Day 14 7.72 ± 2.05 8.81 ± 1.52 10.09 ± 1.46 
Day 21 9.85 ± 1.48 10.24 ± 1.93 11.72 ± 2.28 
Day 28 8.60 ± 1.96 8.17 ± 0.99 8.91 ± 1.13 
DHA concentration (± SD) in Nutriprem 2 samples (n=6) 
Day 0: p = 0.9563; day 7: p = 0.5705; day 14: p = 0.0289, significant differences in Dunn’s multiple 
comparison test (0 vs. 24 hours, p < 0.05); day 21: p = 0.0289, significant differences in Dunn’s multiple 
comparison test (0 vs. 24 hours, p < 0.05); day 28: p = 0.2522 
0 hours: p = 0.0663; 4 hours: p = 0.0289, no significant differences in Dunn’s multiple comparison test; 
24 hours: p = 0.0049, significant differences in Dunn’s multiple comparison test (day 0 vs. day 21, p < 
0.05; day 7 vs. day 21, p < 0.05) 
Estimated LCPUFA intake from preterm FM  
Based on the analysed FA content at day 0, 0 hours, estimated daily LCPUFA intake 
from liquid Nutriprem 1 and Pro Gold Prem 1 was calculated for a hypothetical preterm 
infant of 1000 g bodyweight assuming full enteral feeding (150 mL), and values were 
compared to ESPGHAN recommendations. Nutriprem 1 and Pro Gold Prem 1 provided 
23.23 ± 7.16 and 17.30 ± 0.97 mg/d ARA. These were not significantly different from 
the ESPGHAN minimum recommendation of 18 mg/d (ESPGHAN recommended range 
18-42 mg/d) (p = 0.2950 and p = 0.4146). DHA also reached the ESPGHAN minimum 
levels (18.05 ± 5.78 and 15.75 ± 1.17 vs. 12 mg/d, p = 0.1673 and p = 0.1123, 
respectively) (ESPGHAN recommended range 12-30 mg/d). LCPUFA intake was not 
significantly different from Nutriprem 1 and Pro Gold Prem 1 (ARA: p = 0.4000; DHA: 
p = 0.6286) 
Estimated LCPUFA intake from liquid Nutriprem 2, Pro Gold Prem 2, and Nutriprem 2 
powder was calculated for a hypothetical preterm infant of 2000 g bodyweight, 
assuming full enteral feeding (300 mL), and values were compared to ESPGHAN 
recommendations. Liquid Nutriprem 2 provided ARA levels significantly above the 
ESPGHAN minimum intake level (71.32 ± 6.02 vs. 36 mg/d, p = 0.0003), however, the 
levels were still below the maximum of 84 mg/d. ARA levels in liquid Pro Gold Prem 2 
and Nutriprem 2 powder were not significantly different from ESPGHAN 
recommendations (31.32 ± 5.05 and 34.41 ± 5.74 mg/d, p = 0.3204 and p = 0.563, 
respectively). ARA levels differed significantly between the post-discharge FMs 
(p = 0.0105). Liquid Nutriprem 2 provided significantly more ARA than liquid Pro Gold 
Prem 2 and Nutriprem 2 powder (p < 0.5) (Figure 2-9 A). 
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Daily DHA intake was significantly above the minimum ESPGHAN recommendation in 
liquid Nutriprem 2 (40.33 ± 6.51 vs. 24 mg/d, p = 0.0074), but below the maximum of 
60 mg/d. DHA levels in liquid Pro Gold Prem 2 and Nutriprem 2 powder were above the 
minimum ESPGHAN recommendation (31.08 ± 4.56 and 24.73 ± 5.11 mg/d, p = 0.159 
and p = 0.764, respectively). The post-discharge FMs provided significantly different 
levels of DHA (p = 0.0088). Liquid Nutriprem 2 provided significantly more DHA than 


































Figure 2-9: Daily enteral LCPUFA intake from post-discharge FMs 
Daily enteral (A) ARA and (B) DHA intake from liquid Nutriprem 2 (white, n=5), liquid Pro Gold Prem 2 
(grey, n=3), and Nutriprem 2 powder (black, n=6), for a 2000 g infant receiving full enteral feeding (300 
mL). Dashed lines indicate minimum ESPGHAN intake recommendations. 
Estimated LCPUFAs available for accretion 
ARA and DHA available for accretion from the different preterm FMs were calculated 
for the hypothetical infants. Full enteral feeding with liquid Nutriprem 1 and Pro Gold 
Prem 1 provided 45.54 ± 5.81 and 40.73 ± 0.79 mg/d of ARA, respectively. These 
values represent accretion of only 21.48 and 19.21% of the in utero ARA accretion, 
respectively. Both provide ARA significantly below in utero accretion rates of 212 mg/d 
(p < 0.0001, and p < 0.0001, respectively). DHA from Nutriprem 1 and Pro Gold Prem 1 
provided only 62.21 and 58.02% of the in utero DHA accretion. Therefore, DHA was 
also significantly below estimated in utero accretion rates (26.75 ± 4.53 and 24.95 ± 
0.92 vs. 43 mg/d, respectively; p = 0.0084, and p = 0.0013, respectively). There was no 
significant difference in the ARA and DHA availability for accretion from the two 
preterm first FMs. 
Liquid Nutriprem 2, Pro Gold Prem 2, and Nutriprem 2 powder provided 26.24, 18.59, 
and 19.18% of the in utero accreted ARA. These levels were all significantly below the 
estimated accretion rates (111.24 ± 4.88, 78.80 ± 4.10, and 81.31 ± 4.66 vs. 424 mg/d, 
respectively; p < 0.0001, p < 0.0001, and p < 0.0001, respectively). ARA available for 
accretion was significantly different between the post-discharge FMs (p = 0.0105). It 
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was higher in liquid Nutriprem 2 than in liquid Pro Gold Prem 2 and Nutriprem 2 powder 
(both p < 0.05). The post-discharge FMs provided 56.82 ± 5.11, 49.57 ± 3.57, and 
44.58 ± 4.01 mg/d DHA for accretion. These levels were significantly below estimated 
in utero accretion rates (86 mg/d; p = 0.0003, p = 0.0048, and p = 0.0001, respectively) 
and represent 66.07, 57.64, and 51.84% of the in utero accretion. DHA availability was 
significantly different between the post-discharge FMs (p = 0.0088) and was 
significantly higher from liquid Nutriprem 2 than from Nutriprem 2 powder (p < 0.01). 
2.4.2 TBARS 
In the TBARS assay, samples are centrifuged to precipitate proteins. Pro Gold Prem 
products contain partially hydrolysed whey protein. This formulation affected the 
samples’ ability to form precipitates, and therefore, the samples could not be 
transferred to the analysis plate without protein residue, interfering with the subsequent 
analysis. Therefore, the TBARS concentration for Pro Gold Prem products is not 
reported here.  
There was no significant difference between the Nutriprem FMs at opening 





















Figure 2-10: TBARS concentration in different Nutriprem FMs at opening 
TBARS concentration in Nutriprem 1 (white, n=5) and 2 (liquid, grey, n=5; powder, black, n=6) samples 
directly after opening were not significantly different (p = 0.0905).
 
TBARS concentration was 4.77 ± 0.44 μM in freshly opened liquid Nutriprem 1, and did 
not change significantly when the FM was stored in the fridge for 1, 4 or 10 hours 
(p = 0.5206, Figure 2-11 A). The liquid Nutriprem 2 TBARS concentration at opening 
was 4.03 ± 0.36 μM (Figure 2-11 B). No significant changes occurred when the FM was 
stored in the fridge for 1, 4, or 10 hours (p = 0.7709). 
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Figure 2-11: TBARS concentration in liquid Nutriprem FMs 
TBARS concentration in (A) liquid Nutriprem 1 (n=5; p = 0.5206) and (B) liquid Nutriprem 2 (n=5, 
p = 0.7709) samples directly after opening.  
 
The TBARS concentration in prepared Nutriprem 2 powder was 4.48 ± 0.53 μM at 
opening (day 0, 0 hours) (Figure 2-12). Opened storage for 28 days did not result in an 
increase of TBARS in the FM at 0 hours (p = 0.6798). Although there was a general 
increase in TBARS when prepared FM was stored in the fridge for 4 and 24 hours, the 
increase was only significant (p = 0.0289) between 4 and 24 hours at day 21 (p < 0.05) 
(Table 2-8). 
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Figure 2-12: TBARS concentration in Nutriprem 2 powder after preparation 
TBARS concentration in Nutriprem 2 samples (n=6) directly after preparing fresh FM (0 hours), over the 
course of the experiment (28 days). Friedman test p = 0.6798.  
 
 
Table 2-8: TBARS (µM / mg fat) in Nutriprem 2 
 0 hours 4 hours 24 hours 
Day 0 4.48 ± 0.53 4.25 ± 0.33 4.64 ± 0.67 
Day 7 3.93 ± 0.62 4.54 ± 0.77 4.63 ± 0.65 
Day 14 4.04 ± 0.65 4.36 ± 0.47 4.69 ± 0.65 
Day 21 4.12 ± 0.74 4.09 ± 0.58 4.85 ± 0.80 
Day 28 4.36 ± 0.64 4.55 ± 0.63 4.77 ± 0.53 
TBARS concentration (± SD) in Nutriprem 2 samples (n=6), determined by TBARS assay.  
Day 0: p = 0.5705; day 7: p = 0.4297; day 14: p = 0.7402; day 21: p = 0.0289, significant differences in 
Dunn’s multiple comparison test (4 vs. 24 hours, p < 0.05); day 28: p = 0.2522 
0 hours: p = 0.6798; 4 hours: p = 0.4245; 24 hours: p = 0.7603  
 
2.4.3 HNE 
There was a significant difference between the Nutriprem FMs at opening (p = 0.0094, 
Figure 2-13). Liquid Nutriprem 2 had a significantly lower HNE concentration at 
opening than Nutriprem 2 powder (p < 0.01). There was no significant difference 


























Figure 2-13: HNE concentration in different Nutriprem FMs at opening 
HNE concentration in Nutriprem 1 (white, n=5) and 2 (liquid, grey, n=5; powder, black, n=3) samples 
directly after opening were significantly different (p = 0.0094). 
HNE concentration was 1.61 ± 0.13 μg/mL in freshly opened liquid Nutriprem 1, and did 
not change significantly when the FM was stored in the fridge for 1, 4, or 10 hours 
(p = 0.0755, Figure 2-14 A). The concentration of HNE in Nutriprem 1 at opening was 
significantly higher than in Pro Gold Prem 1 (0.82 ± 0.11 μg/mL; p = 0.0357). Similar to 
Nutriprem 1, the concentration of HNE in Pro Gold Prem 1 did not change significantly 
when the FM was stored in the fridge for 1, 4, or 10 hours (p = 0.9583, Figure 2-14 B). 
The liquid Nutriprem 2 HNE concentration at opening was 1.27 ± 0.19 μM (Figure 
2-14 C). No significant changes occurred when the FM was stored in the fridge for 1, 4, 
or 10 hours (p = 0.0548). The HNE concentration was significantly higher in Nutriprem 
2 than in Pro Gold Prem 2 (0.72 ± 0.06 μg/mL) at opening (p = 0.0357). As in the other 
FMs, cold storage (4°C) did not affect the HNE concentration in Pro Gold Prem 2 
(p = 0.1476) (Figure 2-14 D).  
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Figure 2-14: HNE concentration in different liquid preterm FMs 
HNE-BSA concentration in (A) Nutriprem 1 (n=5, p = 0.0755), (B) Pro Gold Prem 1 (n=3, p = 0.9583), (C) 
Nutriprem 2 (n=5, 0.0548), (D) Pro Gold Prem 2 (n=3, p = 0.1476). 
The HNE concentration in prepared Nutriprem 2 powder was 8.10 ± 0.64 μg/mL at 
opening (day 0, 0 hours) (Figure 2-15). Opened storage for 28 days did not result in an 
increase of HNE in the FM at 0 hours (p = 0.1626) (Table 2-9). There was an effect of 
storage days on HNE concentration at 4 hours (p = 0.0172), and at 24 hours 
(p = 0.0009), with significant differences between HNE concentration at day 14 and 21 
(p < 0.05) (Table 2-9). The effect of storing FM in the fridge at opening (day 0) and at 
the end of the recommended opening time (day 28) is displayed in Figure 2-16. At day 
0 a slight but not significant increase in HNE concentration was seen (Figure 2-16 A). 
This increase became significant at 28 days (9.47 ± 0.16 vs. 26.56 ± 4.01 μg/mL; 
p < 0.5) (Figure 2-16 B). 
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Figure 2-15: HNE concentration in Nutriprem 2 powder after preparation 
HNE concentration in Nutriprem 2 samples (n=3) directly after preparing fresh FM (0 hours), over the 
course of the experiment (28 days). Friedman test p = 0.6798.  
 
Table 2-9: HNE-BSA (µg/mL / mg fat) in Nutriprem 2 
 0 hours 4 hours 24 hours 
Day 0 8.10 ± 0.64 13.72 ± 1.36 18.20 ± 4.70 
Day 7 7.66 ± 1.07 15.18 ± 0.34 15.33 ± 2.23 
Day 14 7.88 ± 0.60 12.69 ± 0.42 11.23 ± 2.04 
Day 21 7.72 ± 0.39 11.60 ± 0.34 30.0 ± 6.71 
Day 28 9.47 ± 0.16 16.17 ± 2.02 26.56 ± 4.01 
HNE concentration (± SD) in Nutriprem 2 samples (n=3), determined by ELISA.  
Day 0: p = 0.1944; day 7: p = 0.1944; day 14: p = 0.0278, no difference in Dunn’s multiple comparison test; 
day 21: p = 0.0278, no difference in Dunn’s multiple comparison test; day 28: p = 0.0278, significant 
differences in Dunn’s multiple comparison test (0 vs. 24 hours, p < 0.05) 
0 hours: p = 0.1626; 4 hours: p = 0.0172, no difference in Dunn’s multiple comparison test; 24 hours: 






















































Figure 2-16: HNE concentration in Nutriprem 2 after refrigeration 
HNE-BSA concentration in Nutriprem 2 samples (n=3) at (A) day 0 and (B) day 28 directly after preparing 
fresh FM (0 hours), and after storage for 4 or 24 hours at 4°C.  
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2.5 Discussion and conclusion 
Although maternal BM is the first choice for feeding (preterm) neonates (ESPGHAN 
Committee on Nutrition et al. 2009), breast feeding rates in the U.K. are low, with 19% 
of all mothers not even initiating breast feeding (McAndrew et al. 2012). The initiation 
rate is higher in mothers of extremely preterm infants (92%). However, some mothers 
cannot breast feed at all, and DHM is not available in all hospitals and will mostly be 
used only for extremely preterm infants. Furthermore, at discharge, only 29% of 
mothers exclusively breast feed their preterm infant, and 6% of mothers combine 
breast feeding with FM feeding (Bonet et al. 2011). Hence, hospitals and parents rely 
on preterm FM for feeding preterm infants. This study has, for the first time, 
investigated the effects of current hospital storage methods on the LCPUFA and LPP 
levels of different preterm FMs available in the U.K. 
No effect of refrigerated storage for 4 hours on the LCPUFA concentrations in liquid 
infant and post-discharge FMs from two different manufacturers was detected. 
Similarly, no differences in ARA and DHA concentrations were found when preterm 
powder FM was stored for 28 days after opening. There was also no difference in 
LCPUFA concentration when prepared powder FM was stored at 4°C for up to 24 
hours at day 0 and day 28. These results are in line with findings of other researchers. 
Zunin and colleagues found no effect of storage for 30 days after opening on LCPUFA 
content (2015). Another study which also mimicked use of FM, by opening and stirring 
the FM three times per day, also found no differences in ARA, EPA, and DHA levels 
when FM was stored for up to 70 days (Chávez-Servín et al. 2008). However, a 
significant decrease in LA at the end of the study was reported. We could not detect a 
significant difference in LA between day 0, 0 hours and day 28, 0 hours (data not 
shown).  
The preterm FMs used in this study were compliant with the Commission Directive 
2006/141/EC, which states that the ARA concentration should maximum be 1% of total 
FA content, and that the DHA content shall not exceed the ARA content. Kus-
Yamashita and colleagues found that some preterm and follow-on FM in Brazil 
contained more DHA than ARA, whereas the majority of FMs were compliant with the 
Codex Alimentarius (2016).  
All infant and post-discharge preterm FMs tested also provided ARA and DHA daily 
enteral intake levels compliant with ESPGHAN recommendations. Nevertheless, the 
LCPUFA concentrations were different between the preterm FM, with liquid Nutriprem 
2 providing more ARA than liquid Pro Gold Prem 2 and different concentrations 
between the preterm FM preparations, with liquid Nutriprem 2 providing more ARA and 
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more DHA than Nutriprem 2 powder. Likewise, another study found higher DHA levels 
in liquid ready to feed FM than in FM powder from the same brand (Loughrill and Zand 
2016). Differences between the FMs can be explained by variations in raw ingredients, 
due to differences in soil, climate, or agricultural practices (Loughrill and Zand 2016). In 
algae, the lipid levels and composition can be altered by the season, the location and 
the growth conditions (Stengel et al. 2011). The nutrient information on the label is 
usually calculated from databases, which do not consider differences in raw 
ingredients. This might also be the reason for the differences between the measured 
LCPUFA levels and the concentrations provided on the label, found in this study. Both 
brands use single cell oil as LCPUFA source. Liquid Nutriprem 2 had higher ARA and 
DHA levels than provided by the manufacturer, whereas Nutriprem 2 powder and liquid 
Pro Gold Prem 1 had significantly lower ARA, and ARA and DHA, respectively, than on 
the label. Significantly lower levels of LA, ALA, and DHA than on the label have 
previously been reported for powder FM in the U.K. (Loughrill and Zand 2016). The 
researchers hypothesized that this could be an effect of preparing the powder with hot 
water. FM cannot be prepared with cold water, and for safety reasons, it should be 
prepared with water > 70°C to destroy harmful bacteria (WHO and FAO 2007), which is 
especially important for preterm infants with an underdeveloped immune system (Davis 
and Auten 2010). It is more likely that the used database overestimated the PUFA 
content, as suggested by other researchers (Fernandez et al. 2002). They found a 50, 
60, 95, and 75% discrepancy between the actual and the calculated LA, ALA, ARA, 
and DHA levels in weaning foods. The authors also indicated that losses might occur 
due to processing of the raw ingredients.  
All preterm FMs provided ARA and DHA levels significantly below the estimated in 
utero accretion rates (Lapillonne and Jensen 2009). Therefore, they contribute to the 
LCPUFA gap of prematurity. These low levels are of concern when feeding preterm 
infants, in which neurological development is ongoing (Harris and Baack 2015). 
Furthermore, low ARA and DHA intake is associated with several comorbidities of 
prematurity such as respiratory distress syndrome, sepsis, and intraventricular 
haemorrhage (Fares et al. 2017). ARA and DHA levels might be further decreased by 
tube feeding, which can result in a triacylglycerol loss of up to 33% in BM, although it 
did not decrease triacylglycerols in FM in the same study (Tacken et al. 2009). 
Nevertheless, enteral feeding via nasogastric tube is often necessary in preterm 
infants, since their ability to suck, swallow and breathe is not developed until 32 weeks 
gestation (Lau et al. 2003), and not fully matured until 35 weeks gestation (Gibson et 
al. 2006). This indicates that LCPUFA levels in preterm FM should be higher than they 
were in 2017. However, the new Delegated Regulation 2016/127 has not taken this into 
consideration. To be compliant with the new Regulation, only the amount of DHA in 
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liquid Pro Gold Prem 1 needs to be increased from 18 to 20 mg/100 kcal, whereas the 
DHA concentration in the other preterm FMs does not need to be altered and 
manufacturers could omit ARA from their FMs. 
Analysis of the liquid and powder preterm FMs revealed LPPs directly after opening of 
the FMs. These initial levels of TBARS and HNE indicate that lipid peroxidation 
occurred before opening of the FMs. Additionally, differences between the two preterm 
FM brands in initial levels were detected and significantly higher HNE concentrations 
were identified in Nutriprem 2 powder, compared to liquid Nutriprem 2. These results 
were surprising; however, all FM HNE concentrations were within the assay’s range of 
detection, and can therefore be considered as true representation of the HNE 
concentration in FM. Liquid and powder FM HNE concentrations were analysed with 
the same assay, with the same LOT number, within 5 days from each other. 
Nevertheless, these results should be confirmed in further studies, and more sensitive 
methods like high-performance liquid chromatography (Goldring et al. 1993) should be 
used. Similarly to our results, Fenaille and colleagues identified much higher hexanal 
content in powder FM than in liquid FM (2006). One reason for the initial LPPs and the 
differences might be FM processing. Spray drying of FM powder uses high 
temperatures (180 – 220°C), which may catalyse lipid peroxidation (Cesa et al. 2015). 
Liquid FM is sterilised in the bottle (120°C, 15 minutes). Although this treatment did not 
change the peroxide value of experimental FMs, secondary LPPs were not analysed in 
this study and the levels of tocopherols decreased significantly (García‐Martínez et al. 
2012). Another explanation is an increase of LPPs over the shelf life up to the point of 
opening. Several studies reported an increase of LPPs during closed storage, including 
MDA (Cesa et al. 2015), peroxide value, and TBARS (Manglano et al. 2005), and 
propanal, pentanal and hexanal (Chávez-Servín 2009). Long-term storage of liquid 
enteral formulas for adults also increased lipid oxidation significantly (Rufian-Henares 
et al. 2005).  
FM is packed under a protective atmosphere. However, once FM powder is opened, it 
is exposed to oxygen and light, which renders the FM highly susceptible to lipid 
peroxidation (Chávez-Servín et al. 2008). Hence protective antioxidants are added. 
Preterm FM powder investigated in this study demonstrated no increase in TBARS or 
HNE over 28 days. Refrigerated storage of prepared powder FM for 4 and 24 hours 
increased TBARS concentration, however the increase was only statistically significant 
at 21 days from 4 to 24 hours. Similarly, refrigeration increased HNE concentrations, 
but the increase was only significant at 28 days. Refrigerated storage for up to 10 
hours had no effect on the TBARS or the HNE content of liquid infant and post-
discharge preterm FM. This indicates that the WHO recommendations as well as 
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clinical practice are acceptable and preterm infants can be fed with FM that has been 
opened or prepared and stored at 4°C. 
All identified studies found significant increases in MDA (Almansa et al. 2013), TBARS 
(Cesa et al. 2015), and peroxide value (Ghazal et al. 2016) after opening and 
subsequent storage of FM. Similarly, studies mimicking normal use also found 
significant increases in hydroxyalkenal and volatile (propanal, pentanal, hexanal) 
content (Surh et al. 2007; Chávez-Servín et al. 2008). These differences might be due 
to different antioxidant composition of the preterm FMs investigated. The Codex 
Alimentarius permits addition of tocopherols, β-carotene, ascorbic acid, ascorbyl 
palmitate, and citric acid as antioxidants in milk based FM (FAO/WHO 2016). The 
amount and composition of antioxidants is important for the antioxidative and radical 
scavenging properties of FM. Ascorbyl palmitate and ascorbic acid had higher 
antioxidant effects than α-tocopherols, β-carotene, and citric acid in experimental liquid 
FM (Zou and Akoh 2015). An ascorbyl palmitate concentration of 0.005% also had a 
better protective effect than a higher concentration (0.02%) Additionally, synergistic 
effects might occur, e.g. the antioxidant capacity of α-tocopherol and β-carotene 
individually was lower in FM than when a combination was used. A mix of α-, γ-, and δ-
tocopherols is also more effective as antioxidants than α-tocopherol alone (Liu et al. 
2002). Turoli et al. also found lower TBARS and conjugated dienes in FMs with higher 
vitamin A and E content (Turoli et al. 2004). A negative correlation of the MDA content 
and the vitamin E content in FM was also noted (Burg et al. 2010). Differences in 
antioxidants might also explain the differences found between the preterm FM brands. 
Pro Gold Prem products list ascorbyl palmitate as ingredients, whereas Nutriprem 
products do not contain ascorbyl palmitate (Danone Nutricia Early Life Nutrition 2017a; 
SMA Nutrition 2017b, 2017a)(see also Appendix II.II). Furthermore, Pro Gold Prem 
products contain tocopherol rich extracts, whereas Nutriprem products only list vitamin 
E in their ingredients. Furthermore, citric acid was only added to all liquid preterm FMs 
but not to Nutriprem 2 powder, which might further explain the higher HNE 
concentration in FM powder.  
Other researchers have also measured MDA levels in FM and compared them to levels 
in BM. Almansa and colleagues measured MDA using high performance liquid 
chromatography (2013). They detected initial MDA concentrations of 2.64 µM in FM, 
and significantly lower levels in BM (0.86 µM). The here reported TBARS 
concentrations where higher, however, this is not surprising as not only MDA but also 
other TBARS react in the assay. In the only study performed on preterm FM, 
significantly higher levels of TBARS and MDA were found in the FM compared to BM 
(Raghuveer et al. 2002). Levels of TBARS were similar to ours, however, data in this 
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study was corrected for fat content. Turoli and colleagues have measured TBARS in 
BM (3.17 µM) and FM (1.93 µM), and found significantly higher levels in the former 
(2004). Colostrum was used in this study, and the samples were standing at room 
temperature for three hours before analysis, which might have increased the 
concentrations. It remains to be tested whether preterm FM in the U.K. or preterm BM 
has higher LPP levels, as ideally it would be compared using the same assay.  
As mentioned before, preterm infants often receive FM via a nasogastric tube. This can 
further increase LPPs. Significantly higher ratios of LA hydroperoxide/LA were found 
after tube feeding in FM (Van Zoeren-Grobben et al. 1993). Additionally, the FM is 
exposed to light during tube feeding. When commercial fluid (bovine) milk is stored 
under light exposure, hexanal increased significantly (Kim and Morr 1996). Peroxide 
value also increased in intravenous lipid emulsions, when exposed to ambient light and 
levels were further increased when phototherapy was used (Silvers et al. 2001). Similar 
results were obtained when triacylglycerol hydroperoxides were measured in parenteral 
lipid emulsion when administered at ambient light or with phototherapy light (Neuzil et 
al. 1995). Therefore, it has been recently recommended by the European Medicines 
Agency to protect parenteral lipid solutions from light to inhibit the formation of toxic 
lipid degradation products (EMA/PRAC/347675/2019). Similar precautions should be 
used when feeding FM to vulnerable preterm infants using a tube. Furthermore, 
preterm infants often receive supplemental iron, added to FM. This can further increase 
LPPs (Raghuveer et al. 2002). 
LPPs in FM can be problematic, as they can increase the oxidative load of preterm 
infants. Preterm FM can be the only nutritional source for some of the infants for a 
prolonged period of time (up to six months), which can lead to chronic exposure to 
LPPs. Intake of LPPs has been associated with inflammation (Awada et al. 2012) and 
circulating MDA levels were correlated with development of retinopathy of prematurity, 
bronchopulmonary dysplasia, intraventricular haemorrhage, NEC and sepsis (Inder et 
al. 1996; Garg et al. 2012; Namdev et al. 2014; Abdel Ghany et al. 2016). Urinary MDA 
levels were also correlated to these common comorbidities of prematurity (Schlenzig et 
al. 1993; Weinberger et al. 2004). Protecting parenteral lipid emulsions from light, and 
thereby reducing the formation of LPPs, was associated with a 30% reduction in 
bronchopulmonary dysplasia in a clinical trial with preterm infants (Chessex et al. 
2007). It also prevents hypertriglyceridemia in preterm infants (Khashu et al. 2009). 
Nevertheless, currently in the EU, there are no upper tolerable levels for LPPs defined 
in the Commission Directive 2006/141/EC, which has led to criticism from researchers 
in the field (Martysiak-Zurowska and Stolyhwo 2006; Cesa et al. 2012). No studies 
have tested the effect of feeding oxidised FM to preterm infants/a model animal for 
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preterm infants. Animal models testing the effect of oxidised parenteral nutrition 
showed detrimental effects, with lower glutathione levels (Elremaly et al. 2012), and 
disturbed lipid metabolism (Maghdessian et al. 2010). The effect of feeding oxidised 
FM should therefore be tested, since the antioxidant systems is still not fully developed 
in preterm infants (Davis and Auten 2010) and lipids are needed for brain development 
(Clandinin et al. 1980). Due to a lack of safety data, manufacturers should aim to a 
produce FM with LPP levels below the ones found in BM. Future studies should aim to 
determine upper tolerable levels of LPPs for FM.  
Volatile compounds were not measured in this study. Yet, volatiles, including propanal, 
pentanal, and hexanal, were identified in FM, when it was stored during the shelf life 
(Romeu-Nadal et al. 2007; Chávez-Servín 2009), as well as when FM was stored open 
(Chávez-Servín et al. 2008). Therefore, it could be assumed that volatiles are also 
produced in the tested preterm FMs. Pentanal was described to have a woody, 
pungent, fruity flavour, and hexanal was described as green, grassy and fatty (Zou and 
Akoh 2015). A trained sensory panel described FMs directly after opening as 
significantly better smelling than FM that was stored and had increased volatile 
products (Chávez-Servín 2009). The latter was also described to have significantly 
more rancid flavour. These flavours might affect infants’ acceptance of the FM, and 
could result in a shorter feeding time and lower intake (Mennella et al. 2004), as well as 
in oral aversion, which can be detrimental in preterm infants.  
This is the first study investigating the effects of the real life storage conditions of 
preterm FM on the LCPUFA and LPP content. However, not all available preterm FMs 
could be tested, and sample numbers are relatively small, although they are 
comparable or higher than in other studies in this field of research (Michalski et al. 
2008; Carmen García‐Martínez et al. 2010; Almansa et al. 2013). Preterm FM is only 
available on prescription in the U.K. therefore, analysis was limited to samples provided 
by the manufacturers. Unfortunately, the TBARS concentration could not be analysed 
in Pro Gold Prem samples. TBARS development as well as LPP development in Pro 
Gold Prem 2 powder should be measured in the future, especially considering the 
differences between the brands in HNE content. Furthermore, during method 
development, an increase in TBARS over the storage times was identified in one box 
Gold Prem 2 powder, before the change in protein formulation. However, these are 
preliminary results that need to be confirmed in repeated testing. High performance 
liquid chromatography can be used as an alternative to specifically measure the MDA-
TBA product in samples, which has been separated from other TBARS. This method 
has been used to analyse FM samples with partially hydrolysed protein before (Cesa 
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2004). Furthermore, antioxidant levels should be measured simultaneously in future 
studies. 
In conclusion, the current FM storage conditions did not significantly affect LCPUFA 
and LPP content of liquid and powder infant and post-discharge preterm FM. 
Therefore, based on these results, the current FM storage conditions do not appear 
detrimental to preterm FM LCPUFAs. Although variations in LCPUFA levels were 
identified, it is possible to achieve ESPGHAN recommended levels with both brands. 
Nevertheless, LPPs have been detected in different levels in the analysed preterm 
FMs, and preterm FM contributes to the oxidative load of preterm infants. The effect of 
these levels on preterm infants, and especially their gut, should be investigated and 
upper tolerable levels of LPPs in FM should be defined, legislated and governed. 
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3 In vitro analysis of the effects of 4-hydroxyalkenals on a 
neonatal porcine intestinal cell line 
3.1 Introduction 
FMs containing LCPUFAs are also a source of LPPs. In Chapter 2, we reported 
TBARS and HNE-adducts in preterm FM in the U.K. Others have found further 
secondary LPPs in FM, including MDA (Cesa et al. 2015), HHE (Michalski et al. 2008), 
as well as the volatile secondary LPPs propanal, pentanal, and hexanal (Chávez-
Servín 2009) (for a detailed overview see Chapter 2.1.3). Lipid peroxidation of 
commercially available freshly prepared FM in France has been shown to result in the 
daily ingestion of 1.36 ± 1.17 µg 4-hydroxyalkenals per kg bodyweight (Michalski et al. 
2008). Research from Korea reports higher intakes of 4.2 µg per kg bodyweight per 
day (1.55 µg HHE and 2.66 µg HNE) (Surh et al. 2007). This is more than ten times 
higher than the average dietary 4-hydroxyalkenal intake of Korean adults (Surh and 
Kwon 2005). Upper tolerable levels for 4-hydroxyalkenals and other LPPs have not 
been defined for FM in the European Union. However, recently, the European 
Medicines Agency has acknowledged the risk of LPPs in parenteral lipid emulsions, 
and now recommends protecting parenteral nutrition from light, to avoid LPP mediated 
adverse outcomes for neonates (EMA/PRAC/347675/2019). 
3.1.1 Effects of LPP ingestion 
Metabolism 
After ingestion, 4-hydroxyalkenals pass the mouth, stomach, and duodenum and reach 
the jejunum unaltered, as indicated by an in vitro digestion model, which uses a three 
step digestion, adding heated digestive juices and adjusting pH levels at each step, 
before incubation (Goicoechea et al. 2011). In the jejunum of rats, the mucus-
associated glutathione-S-transferase has been shown to metabolise 4-hydroxyalkenals 
to less reactive products and minimise direct contact of the toxic compounds with the 
enterocytes (Samiec et al. 2000). 4-Hydroxyalkenals reaching the enterocyte are 
rapidly conjugated with glutathione (Grune et al. 1991), for excretion via the kidney and 
urine (Guichardant et al. 2004). Nevertheless, ingested 4-hydroxyalkenals can also be 
absorbed unaltered and have been observed in plasma of mice in a dose-dependent 
manner, with HHE plasma concentrations peaking (0.1% of fed dose) 2 hours post-
feeding (Awada et al. 2012). Providing humans with highly oxidised oil also results in 
significantly higher conjugated dienes (4.7-fold increase) and TBARS content (not 
detectable vs. 0.14 ± 0.03 nmol/µmol triglycerides) in postprandial chylomicrons 
(Staprans et al. 1994). In the circulation, postprandial increased oxidised lipids were 
detected for seven hours.  
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General effects on the body 
Adult mice received 500 µg MDA per g bodyweight per day in their drinking water for 
90 days and weight loss was observed after 50 days. By 90 days, irregularities in 
hepatic nuclei, as well as pancreatic lesions were found (Siu et al. 1983). Five week old 
rats fed with oxidised rapeseed oil for 13 weeks had higher relative liver and kidney 
weights, higher TBARS levels and lower hepatic glutathione and tocopherol levels, and 
lower tocopherol content in the serum (Izaki et al. 1984). In mice fed for 8 weeks with 
an oxidised diet, proinflammatory markers (IL-6 and MCP-1) increased significantly in 
plasma (Awada et al. 2012). Overall this demonstrates that ingestion of LPPs over a 
long period can have detrimental effects outside of the digestive system. 
Specific gastrointestinal effects 
Studies specifically reporting effect of diets with oxidised lipids on the intestine are rare. 
In vitro incubation of Caco-2 cells with oxidised mackerel oil (100 µg/mL, 24 hours) 
resulted in significantly lower cell viability and induction of apoptosis (Alghazeer et al. 
2008). Similarly, 50 µM MDA as well as 50 µM HNE reduced cell viability significantly. 
Furthermore, TBARS were significantly increased when cells were incubated with 
oxidised mackerel oil. In contrast, incubation of Caco-2/TC7 cells with 4-hydroxyalkenal 
concentrations up to 100 µM for 24 hours had no effect on cell integrity (Awada et al. 
2012). 
No human studies and only one animal study were identified by the author. Feeding 
mice with an oxidised high-fat diet (lipid blends in water (30% w/w) were kept at 50°C 
with continuous shaking until the α-tocopherol levels decreased by 50%, before 
incorporating into diet), for 8 weeks induced expression of glutathione peroxidase, as 
well as C/EBP homologous protein, a proapoptotic protein, in the intestine (Awada et 
al. 2012). Furthermore, a significant increase in phosphorylated NF-, a transcription 
factor involved in the regulation of inflammation, together with a significant increase in 
phosphorylation of Iα, its inhibitor, was seen in the jejunum. An increase in 
4-hydroxyalkenal protein adducts was also seen in the duodenum and jejunum. 
Although not provided orally, intraperitoneal injection of HNE (5 mg per kg daily for 7 
days) decreased tight junction proteins in the colon of mice, impairing the intestinal 
barrier, followed by toll-like receptor 4 activation and aggravated inflammatory bowel 
disease (Wang et al. 2019). 
3.1.2 Higher intestinal susceptibility of preterm infants 
Currently, the effects of 4-hydroxyalkenal ingestion on preterm infants are not known. It 
is particularly concerning that 4-hydroxyalkenal levels in FM are ten times higher than 
in an adult diet (Surh and Kwon 2005), since previously, LPP exposure form parenteral 
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lipid emulsion has been associated with bronchopulmonary dysplasia (Chessex et al. 
2007). In general, infants up to approximately six months after birth, have a reduced 
metabolic activity, leading to higher and prolonged blood levels of toxins (Scheuplein et 
al. 2002). Indeed, preterm infants have significantly lower plasma glutathione levels 
than term infants (Jain et al. 1995). Glutathione plasma levels are gestational age 
dependent, with extremely preterm infants having three times lower plasma levels than 
term infants. This can potentially impair their ability to metabolise 4-hydroxyalkenals 
into less toxic compounds. Additionally, preterm infants are more vulnerable to 
oxidative stress and LPPs in general since their antioxidant defence systems are 
immature (Qanungo and Mukherjea 2000).  
The immature gut of preterm infants is especially vulnerable to inflammation and is 
characterised by increased intestinal permeability and an immature mucosa barrier 
(Claud 2009). Nevertheless, the gut of viable preterm infants already consists of an 
intestinal epithelial monolayer that has formed in the first trimester, crypts and villi, 
which formed from 12 weeks gestation age onwards, which express microvilli on the 
apical surface, and are connected by tight junctions, formed from 10 weeks gestational 
age (Neu 2007; Halpern and Denning 2015). After the formation of tight junctions, 
chemical barriers are also expressed, like defensins, lysozyme and the mucus layer, 
although these mature with gestational age and are therefore immature at birth in 
preterm infants (Buisine et al. 1998; Halpern and Denning 2015). Additionally, 
decreased gut motility might result in longer exposure to 4-hydroxyalkenals from the 
diet. Induction of NF- and inflammatory cytokine production by 4-hydroxyalkenals 
(Yadav and Ramana 2013) might contribute to the development of NEC in these 
infants. Furthermore, the preterm gut also has higher toll-like receptor 4 expression, 
rendering it more prone to inflammation and NEC (Hackam and Sodhi 2018). HNE-
induced activation of toll-like receptor 4 was reported in inflammatory bowel disease 
(Wang et al. 2019). Similarly, HNE-induced activation of toll-like receptor 4 might 
contribute to the development of NEC in preterm infants.  
Inflammatory response in the intestine 
It is not entirely clear yet, how 4-hydroxyalkenals stimulate an inflammatory response in 
the intestine, or elsewhere in the body (Yadav and Ramana 2013). It is known that 
4-hydroxyalkenals activate the NF- pathway (Awada et al. 2012; Ayala et al. 2014), 
resulting in the release of inflammatory cytokines and inflammation. However, the 
upstream mechanisms are not clarified yet. It has also been shown that at least HNE 
can regulate many of the protein kinase C isozymes, which are upstream of NF- 
(Yadav and Ramana 2013). For example, PKK can phosphorylate IKKα and IKKβ, 
which are needed for NF- activation (Kim et al. 2014). However, the mechanisms 
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how HNE regulates protein kinase C have also not been identified yet (Yadav and 
Ramana 2013). It has been proposed that HNE could target upstream signals of 
protein kinase C, such as phospholipase C and diacylglycerol. Furthermore, it has also 
been shown that glutathione conjugated 4-hydroxyalkenals (part of the detoxification of 
4-hydroxyalkenals (Samiec et al. 2000)), after being reduced by aldose reductase, can 
also activate signalling molecules, via not yet identified pathways, that will activate the 
NF- pathway (Ramana et al. 2006; Yadav and Ramana 2013). A second mechanism 
by which 4-hydroxyalkenals might mediate an inflammatory response in the intestine is 
by increasing the permeability of the gut epithelium. Previously, it has been shown that 
HNE can increase epithelial permeability in Caco-2 cells (Cindric et al. 2013). Similarly, 
increased apoptosis of enterocytes, induced by high concentrations of 
4-hydroxyalkenals (Ayala et al. 2014), might also lead to a disruption of the intestinal 
epithelium (Claud 2009). Both can lead to bacterial translocation from the lumen to the 
lamina propria, initiating an immune response.  
In the gut, a number of cells play a role in the regulation of the immune response. The 
intestinal epithelium forms the first line of defence against pathogens (Santaolalla et al. 
2011). It consists of Paneth cells, enteroendocrine cells, absorptive enterocytes, goblet 
cells, and microfold cells. Chemokines and cytokines secreted by these cells will recruit 
and/or activate neutrophils, macrophages, dendritic cells, and T cells (Allaire et al. 
2018). Paneth cells are located in the base of the crypts and can modulate the 
microbiome and mediate the inflammatory response (Lueschow and McElroy 2020). 
They secrete antimicrobial molecules, including α-defensins, lysozyme, TNFα, and 
phospholipase A2. The main function of enteroendocrine cells is the production of 
hormones to mediate digestion, however, they can also sense microbial metabolites 
and, in response, release cytokines (Worthington et al. 2018). Goblet cells are 
distributed throughout the villi, between the enterocytes. They produce the mucus layer 
that covers the epithelium as a physical barrier against pathogens (Knoop and 
Newberry 2018). Furthermore, goblet cells secrete anti-microbial proteins, chemokines 
and cytokines. Recently, it has also been shown that goblet cells can form goblet cell-
associated antigen passages to present luminal content to the antigen-presenting cells 
in the lamina propria. Enterocytes mainly facilitate nutrient absorption, however, they 
also play a role in inflammation. They express toll-like receptors, which, once activated 
by e.g. pathogens, can lead to the release of β-defensins and initiate a signalling 
cascade resulting in the activation of NF-, and the release of cytokines and 
chemokines including TNF-α, IL-6, IL-8, IL-18, and CCL20 (Allaire et al. 2018). These 
can prime, and activate the underlying immune cells, and recruit further immune cells.  
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Macrophages and dendritic cells are located in the lamina propria underneath the 
epithelium (Santaolalla et al. 2011). Both macrophages and dendritic cells are largely 
responsible for the innate immune response in the intestine. The macrophages in the 
lamina propria can recognise bacteria or bacterial products that cross the epithelium or 
can take up dying epithelial cells that have previously acquired antigens (MacDonald et 
al. 2011). Activation of macrophages by phagocytosis, lipopolysaccharides, or 
cytokines, will lead to the release of proteases, collagenases, and other lysosomal 
enzymes (Pathmakanthan and Hawkey 2000). In response, they also produce 
proinflammatory cytokines, including IL-1, IL-6, IL-8 and TNF-α (MacDonald et al. 
2011). These cytokines can also recruit activated T and B cells to the site of 
infection/lamina propria (Pathmakanthan and Hawkey 2000). 
As mentioned above, cytokine and chemokine expression can recruit further immune 
cells. For example, IL-8 expressed by epithelial cells or macrophages can recruit 
neutrophils from the blood stream and also activate them (Claud 2009). Neutrophils are 
part of the innate immune system and can phagocytose pathogens and secrete anti-
microbial factors (e.g. defensins). A novel function of neutrophils identified in 2004, is 
the formation of neutrophil extracellular traps, by the release chromatin fibres and 
granule derived antimicrobial peptides and enzymes, which help binding and killing 
pathogens (Kaplan and Radic 2012; Li et al. 2020). They can also release cytokines to 
amplify the inflammation. Neutrophils will be cleared by macrophages (Bratton and 
Henson 2011).  
Microfold cells are located above Peyer’s Patches. They can sample luminal contents 
and can present antigens via transcytosis, phagocytosis or microvesicle shedding to 
the underlying dendritic cells for antigen processing and presentation (Allaire et al. 
2018). Dendritic cells are the link between the innate and adaptive immune response 
(Pathmakanthan and Hawkey 2000). Immature dendritic cells can then process the 
antigen and differentiate into mature dendritic cells, which in turn activate naïve T cells, 
either in the Peyer’s patch or the mesenteric lymph nodes (MacDonald et al. 2011). 
Similarly, dendritic cells in the lamina propria can have cytoplasmic extensions that 
extend through the epithelial layer into the lumen to sample antigens (Santaolalla et al. 
2011), or they can take up antigens from infected apoptotic epithelial cells. These 
dendritic cells can then migrate to the mesenteric lymph nodes and there, present 
antigens to naïve T cells to activate them. Depending on the major histocompatibility 
complex used to present the antigen, either CD8+ (T killer and T memory cells) or 
CD4+ (T helper) cells will be induced (Pathmakanthan and Hawkey 2000). Activated T 
helper cells can activate naïve B cells in the Payer’s Patch or in the mesenteric lymph 
nodes. This will lead to a class switch and induce the expression of IgA antibodies after 
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homing to the side of inflammation (lamina propria), mediated by cytokines from 
activated T helper cells. The activated CD8+ and CD4+ T cells travel to the lamina 
propria as well, partially controlled by the epithelial derived chemokines. CD8+ T killer 
cells help for example in killing infected epithelial cells. Under normal conditions without 
antigens/pathogens, dendritic cells produce IL-10, to supress the action of T killer cells.  
3.1.3 In vitro models of the intestine  
The intestinal epithelium has a dual function: it acts as a barrier for pathogens and 
toxins and at the same time needs to allow for the absorption of nutrients (Cencic and 
Langerholc 2010). Therefore, in vitro models should ideally display both these 
functions. Primary intestinal epithelial cells isolated from human tissue mimic the in vivo 
situation closely (Cencic and Langerholc 2010). However, these are difficult to obtain 
and to culture in vitro, and usually divide only for a limited number of times before they 
die, making it difficult to use them for long-term experiments (Lea 2015b). Additionally, 
inter-individual differences between the human donors exist, leading to low 
reproducibility (Cencic and Langerholc 2010). Therefore, continuously growing cell 
lines are preferred in vitro models of the intestinal epithelium. The most common 
models include human Caco-2, HT-29, and T84 cells (Cencic and Langerholc 2010). 
All three of these cell lines are derived from the colon but are morphologically and 
functionally similar to enterocytes of the small intestine.  
Caco-2 cells have many properties of small intestine enterocytes. They differentiate 
into polarized cells with microvilli expression on the apical site (Lea 2015b). Expression 
of tight junction proteins was reported as well as cytokine and digestive enzyme 
production (Lea 2015a). However, they do not produce mucin (Lea 2015b). Mucin 
production, however, is a property of HT-29 cells (Lea 2015b), which need to be 
differentiated by galactose in the culture medium (Martinez-Maqueda et al. 2015). This 
induces a polarised phenotype with tight junctions and hydrolases; however, their 
activity was reported to be lower than that in vivo. HT-29 cells are frequently used to 
study the intestinal immune response and can secrete a number of cytokines and 
growth factors. T84 cells are also frequently used as model for the epithelial barrier, 
albeit being less well characterised (Devriese et al. 2017). They form a polarised 
monolayer in culture, with tight junction expression and small microvilli at the apical 
site, resembling colonocytes more closely. Indeed, they also express more colonocyte-
specific genes, and fewer brush border hydrolases than Caco-2 cells. HUTU-80 cells 
are the only human small intestinal cell line. However, similarly to T84, HT-29, and 
Caco-2 cells, they are established from a carcinoma and are therefore a tumorigenic 
cell line. This might affect their proliferation and behaviour in response to 
environmental stimuli (Cencic and Langerholc 2010). 
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Therefore, non-tumorigenic animal cell lines are often used. Among these, the rodent 
cell lines IEC-6 and IEC-18, derived from the small intestine of rats, are favoured. 
However, the intestine of pigs, amongst all non-primates, best resembles the human 
gut (Vergauwen 2015). Therefore, the intestinal porcine enterocyte cell line (IPEC-J2) 
was established to study transepithelial ion transport and enterocyte differentiation. 
The IPEC-J2 cell line 
The IPEC-J2 cell line was originally isolated from the jejunum of a neonatal unsuckled 
piglet by Helen Berschneider in 1989 (Berschneider 1989). It is a non-tumorigenic, non-
transformed, permanent cell line that has been cultured continuously for up to 98 
passages (Vergauwen 2015), indicating that the cells can divide up to 98 times under 
optimal culture conditions. The cell line was first characterized by Schierack and 
colleagues for its suitability as an in vitro intestinal model (2006). In culture, IPEC-J2 
cells form a single cell monolayer. Cells rapidly differentiate (within 14 days), are 
polarised, and express microvilli of differing lengths and widths on the apical side. The 
tight junction proteins Claudin-3 and 4 as well as occludin were detected, whereas 
Claudin-14 and 16 could not be detected. Nevertheless, high transepithelial electrical 
resistance has been reported in these cells after 14 days of culture, indicating integrity 
of the cell monolayer. A thin, superimposed mucus layer on the IPEC-J2 cells has also 
been reported (Vergauwen 2015). IPEC-J2 cells also express and produce cytokines, 
defensins, and toll-like receptors. Expression of mRNA for Interleukin (IL)-1α, IL-6, IL-8, 
IL-12β, IL-18, transforming growth factor-β3, and tumour necrosis factor-α was 
reported (Brosnahan and Brown 2012). This resembles cytokine expression of human 
intestinal cells (Schierack et al. 2006). Of these cytokines however, only IL-6 and IL-8 
have been confirmed at protein level (Brosnahan and Brown 2012).  
IPEC-J2 cells mimic physiology and epithelial functionality of human enterocytes. 
Therefore, they have been used to study epithelial transport, interaction with enteric 
bacteria, as well as effects of probiotics and nutrients in the past (Vergauwen 2015). 
Furthermore, this cell line was characterized as a simple model for the inflammation-
sensitive preterm intestine (Stoy et al. 2013). Since then, the cell line has been used to 
analyse the effects of amniotic fluid as well as human milk oligosaccharides on the 
inflammatory response of preterm intestinal tissue. (Siggers et al. 2013; Rasmussen et 
al. 2017). Additionally, the cell line has been used to investigate the effects of 
antioxidants on oxidative stress in the intestine (Vergauwen et al. 2015). Overall, this 
makes the IPEC-J2 cell line the preferred in vitro model to investigate the effects of 
LPP ingestion from preterm FM.  
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3.2 Aim and objectives 
FM feeding will not only provide nutrients but also potentially harmful LPPs (Surh et al. 
2007; Michalski et al. 2008). 4-Hydroxyalkenals in FM might increase HNE and HHE 
adducts, as well as inflammation in the intestine (Awada et al. 2012), and have the 
potential to induce apoptosis in enterocytes (Alghazeer et al. 2008). However, there is 
a paucity of research investigating the effects of LPP ingestion in infants, and 
particularly in preterm infants, who have a more immature gut (Claud 2009), and may 
subsequently be more sensitive to their toxic effects (Scheuplein et al. 2002). IPEC-J2 
cells have previously been used as an in vitro model for the inflammation-sensitive 
preterm gut (Stoy et al. 2013), and have therefore been chosen as a model for this 
research.  
Therefore, the aim of this project was to investigate the effects of the 4-hydroxyalkenals 
HNE and HHE on the integrity and metabolism of enterocytes, using IPEC-J2 cells as 
in vitro model of the preterm gut.  
 The first objective was to identify the optimal treatment time-point for 
4-hydroxyalkenal incubations  
 The second objective was to characterize the effects of a single 
4-hydroxyalkenal treatment, measuring cell viability, metabolic activity, cell 
cycle, cell migration, and inflammatory markers 
 The third objective was to characterize the effects of repeated 4-hydroxyalkenal 
incubations, measuring cell viability, metabolic activity, cell cycle, cell migration, 
and inflammatory markers 
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3.3 Material and methods 
Ethical approval for this research project was granted by Bournemouth University’s 
Research Ethics Panel (ID 16130) (Appendix III.I). This project was carried out at the 
Human Nutrition and Metabolism Group, Department of Human Development and 
Health, Faculty of Medicine, University of Southampton, under the supervision of 
Dr Caroline E. Childs. A visitor’s contract was obtained for the University of 
Southampton and local rules and regulations were followed. 
3.3.1 Cell culture 
The IPEC-J2 cell line was obtained from DSMZ (ACC 701, DSMZ, Germany) and 
cultured following the supplier’s recommendations (Drexler et al. 2017). After thawing, 
IPEC-J2 cells were cultured in Dulbecco’s Modified Eagle Medium (containing 4.5 g/L 
glucose, and 4 mM L-Glutamine, Gibco, U.K.), supplemented with 20% heat 
inactivated, sterile filtrated (0.2 µm Minisart Plus, Supelco, U.K.) foetal bovine serum 
(Gibco, U.K.) for 4 days, before changing to standard medium containing only 10% 
foetal bovine serum. Penicillin and streptomycin were not added to the culture medium, 
as they can significantly reduce proliferation (Schierack et al. 2006). Medium was 
changed every other day and IPEC-J2 cells were maintained in a humidified 
atmosphere of 5% CO2 at 37°C (Drexler et al. 2017). Experiments were normally 
carried out seeding 2x104 cells/cm2 on 12-well plates (Corning, Fisher Scientific, U.K.), 
unless otherwise stated. Cells were used between passage 12 and 22.  
Sub-culturing 
Cells were sub-cultured at a density of approximately 70%, using trypsin/EDTA 
(0.25 mg/mL; 0.5 mL/10 cm2, 15 min, 37°C, Lonza, Belgium) after washing the cells 
with Dulbecco A Phosphate Buffered Saline (PBS, 2 mL/10 cm2, Oxoid Limited, U.K.) 
(Thermo Fisher Scientific Inc. 2016). Trypsin was inactivated using double the amount 
of standard medium, before seeding 2x104 cells/cm2 in a new tissue culture flask to 
maintain cells.  
Cell number determination 
To determine the cell number, 20 µL of cell suspension were added to a cell counter 
cuvette and diluted with 10 mL Coulter Isoton II Diluent (Beckman Coulter, U.K.), 
before analysing 500 µL with a Coulter Counter Z1 (Beckman Coulter, U.K.). The cell 
number/mL was calculated as follows:  
𝐶𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑚𝐿 =  
(𝐴 + 𝐵)
2
 ×  500 ×  2 
A: number of cells in first count; B: number of cells in second count 
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Trypan blue exclusion test 
Before freezing, cell viability was assessed using the trypan blue exclusion test. In this 
test, non-viable cells are distinct from viable cells by their blue stained cytoplasm 
visible using a light microscope (Strober 2015). Therefore, cells in suspension were 
diluted 1:2 with trypan blue solution (0.4%, Sigma-Aldrich, U.K.) and counted twice in 
four corner squares of a Haemocytometer (Neubauer improved counting chamber, 
Marienfeld, VWR, U.K.), using a light microscope (10x magnification, SM LUX, Leitz, 
Germany). Percentage viability was calculated as follows:  
𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠 
× 100 
Cryopreservation 
A stock of cryopreserved IPEC-J2 cells was collected after obtaining the cells 
(Yokoyama et al. 2012; Thermo Fisher Scientific Inc. 2016). Cells were cultured and 
detached as described above. Only cells with a viability greater than 70% were frozen. 
After centrifugation of the cell suspension (200 x g, 5 min, 4°C, 5810R centrifuge, 
Eppendorf, U.K.), the supernatant was discarded and the cells were dropwise re-
suspended in Cell Culture Freezing Media (Merck, U.K.) to freeze 2x106 cells/mL. The 
Cryo.S vials containing the cells (Greiner Bio-One, U.K.) were placed in a pre-cooled 
(4°C) CoolCell LX (biocision, U.K.) in the refrigerator for 30 min, before freezing at -
80°C for at least 12 h. For long-term storage, vials were transferred to a liquid nitrogen 
storage tank. 
3.3.2 Light microscopy 
IPEC-J2 cells were seeded in different densities (0.9, 1.3, 1.6, and 2.1x105 cells/well, 
respectively) on a 6-well plate for 5 days. Representative pictures of IPEC-J2 cells 
were obtained using an Axiovert 200 inverted light microscope (Carl Zeiss, Germany) 
with an AxioCam Mrm camera, using the Axio Vision software (version 4.7.2.0 for 
Windows, Carl Zeiss, Germany). Pictures were taken at 5x, 10x, 20x, and 40x 
magnification. 
3.3.3 Treatment time-point determination 
First, the optimal time-point for cell treatment needed to be specified. It was reported 
that IPEC-J2 cells show spontaneous differentiation within two weeks, with microvilli 
expression on the apical site, when grown on Trans-well collagen-coated PTFE filters 
(Schierack et al. 2006). To determine whether spontaneous differentiation also occurs 
on normal 12-well plates and how long IPEC-J2 cells can be cultured on these, 
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1x105 cells/well were seeded in triplicates on a 12-well plate and incubated for 14 days, 
with medium changed every other day. Cell number and cell viability were assessed at 
day 3, 5, 7, 10, 12, and 14 (n=3, respectively). Microvilli expression was quantified at 
day 2, 10, and 14 (n=1).  
Cell viability 
Cell viability was quantified by propidium iodide staining, using flow cytometry. 
Propidium iodide is a fluorescence dye, which is excited at 488 nm (R&D Systems 
2018). It binds to double stranded DNA by intercalating between the bases. It cannot 
cross the cell membrane and therefore, only DNA of non-viable cells with damaged 
and/or permeable cell membranes will be stained.  
After the incubation, cells were trypsinised and approximately 1x106 cells in suspension 
were centrifuged (200 x g, 5 min, room temperature), re-suspended in 200 µL PBS and 
incubated with 5 µL propidium iodine solution (1 mg/mL sterile filtrated H2O, Sigma-
Aldrich, U.K.) for 1 min in the dark. Negative controls did not contain propidium iodide. 
Cells were analysed on a FACSCalibur flow cytometer (BD Biosciences, U.K.). Data 
acquisition was performed using the CellQuest Pro software (Version 5.2.1 for Mac, BD 
Biosciences, U.K.) and 10000 events were collected per sample. Forward scatter and 
side scatter were adjusted to display the population of interest. Data was analysed 
using the FlowJo software (Version 10 for Windows, FlowJo, LLC, U.S.A.). Gating was 
performed relatively to the negative control (Figure 3-1).  
Scanning electron microscopy 
IPEC-J2 cells (1x105 cells/well) were seeded on sterile 16 mm circular glass coverslips 
(Agar Scientific, U.K.) in a 12-well plate. Specimen preparation was carried out 
according to a protocol provided by the Biomedical Imaging Unit of the University of 
Southampton. Cells were grown for 2, 10 or 14 days before fixation (3% glutaraldehyde 
(Agar Scientific, U.K.), 4% formaldehyde (Fisher Scientific, U.K.) in 0.1 M 1,4-
piperazinediethanesulforic acid buffer (Sigma-Aldrich, U.K.), pH 7.2, 20 min, room 
temperature). After rinsing the specimen twice for 10 min with 1,4-
piperazinediethanesulforic acid buffer (0.1 M, pH 7.2), specimens were post-fixed with 
osmium tetroxide (1% in 0.1 M 1,4-Piperazinediethanesulforic acid buffer, pH 7.2 
(Sigma-Aldrich, U.K.)) for 1 hour, followed by two more buffer washes. Specimens 
were gradually dehydrated using 30%, 50%, 70% and 95% ethanol (all Fisher 
Scientific, U.K.) for 10 min each, followed by two 20 min dehydration steps with 
absolute (100%) ethanol (Fisher Scientific, U.K.). Next, specimens were subjected to 
critical point CO2 drying (31.1°C, 1072 P.S.I, 1 hour, Blazers CPD 030, Bal-Tec, 
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Liechtenstein) and mounted on 12.5 mm aluminium pin stubs (EM Resolutions, UK), 
and sputter coated with 5 nm platinum (Q150R ES, Quorum, U.K.). 
 
          
Figure 3-1: Analysis of flow cytometry data for propidium iodide staining 
A: Gaiting for alive cells in the forward scatter (FWS) – side scatter (SSC) plot within the 10000 events 
collected. 
B: Histogram of fluorescence signal (FL2 channel) of unstained cells (negative control) in the alive cell 
sub-population. This was used to set the gate for propidium iodide (PI) positive cells. 
C: Histogram of fluorescence signal (FL2 channel) of stained cells in the alive cell sub-population with 
7.31% of cells being PI positive. 
Pictures were acquired at 1500x, 10000x and 25000x magnification using a FEI 
Quanta 250 FEG scanning electron microscope (High vacuum, Beam spot 2.5, high 
voltage 10.00 kV, 1.11 e-4 PA chamber pressure, 9.86e-8 Pa gun pressure, 254 µA 
emission current, Thermo Fisher, U.K.) and the xT microscope control software 
(Version 6.2.6 for Windows). Scanning electron microscope pictures were analysed 
using ImageJ (Version 1.51r for Windows, NIH, U.S.A.). Three pictures of day 2, 10 
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and 14 at 10000x magnification were analysed and in each, microvilli in six 10 µm2 
sized squares were quantified. 
3.3.4 Hydrogen peroxide as positive control 
H2O2 is a toxic reactive oxygen species that is produced physiologically during 
oxidative phosphorylation at the electron transport chain in mitochondria, or during 
oxidative stress, similar to lipid hydroperoxides (Sies 2017). Therefore, H2O2 was 
chosen as a positive control for the following experiments. In a first step, the optimal 
concentration had to be established. Extracellular H2O2 concentrations of >0.01 mM 
induce an oxidative stress response (Sies 2017).  
IPEC-J2 cells were grown for 10 days, before incubation with H2O2 (0, 0.1, 0.2, 0.5, 
0.75, 1, 1.5, 2, 2.5, 5, 10 mM, respectively, Sigma-Aldrich, U.K.) for 2 hours (n=3) to 
induce oxidative stress. H2O2 was diluted in sterile dH2O and the final medium 
contained maximum 0.5% dH2O2. Control cells were incubated with medium only. 
Outcome measurements included cell number, and cell viability (as described in 
section 4.3.3.1).  
3.3.5 Single exposure experiments 
The 4-hydroxyalkenals HHE and HNE have been found in FM (Surh et al. 2007). 
Based on these reported concentrations, it was calculated that preterm FM in the U.K. 
could contain approximately 0.11 µM HHE and 0.14 µM HNE directly after opening, 
and approximately 0.48 µM HHE and 0.76 µM HNE after 10 days storage. The mean 
gastric half-emptying time in FM fed preterm infants was previously determined to be 
65 min (Van Den Driessche et al. 1999). 
To mimic the effects of a single feed, 10 days differentiated IPEC-J2 cells were 
incubated with 0.01, 0.1, 0.25, 0.5, 5, 50 µM HHE or 0.005, 0.05, 0.5, 1, 10, 100 µM 
HNE, respectively, or in combination 0.25 µM HHE + 0.5 µM HNE, 0.5 µM HHE + 1 µM 
HNE, 5 µM HHE + 10 µM HNE, 50 µM HHE + 100 µM HNE, for 2 hours. 
4-Hydroxyalkenals were diluted in ethanol. Final ethanol concentration in the medium 
was 0.5%. Ethanol can have an influence on cell viability, however ethanol 
concentrations up to 1% for up to 18 hours have been shown not to affect IPEC-J2 cell 
viability (Vergauwen 2015). A solvent-carrier control consisting of 0.5% ethanol was 
included in all experiments. Outcome measurements included: cell viability (as 
described in 4.3.3.1, n=3), metabolic activity (n=3), cell cycle analysis (n=3), cell 
migration (n=1), IL-6 (n=1) and intracellular IL-8 (n=3) expression. Three hours after 
the 4-hydroxyalkenal incubations, cell supernatant was collected, centrifuged (200 x g, 
5 min, room temperature), and stored at -80°C until analysis. 
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MTT assay 
Cellular metabolic activity was measured using an MTT assay, in which the yellow 
tetrazolium salt (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, or MTT) 
is reduced by NAD(P)H-dependent oxidoreductases to purple, insoluble formazan 
(Sigma-Aldrich Co 2017). Absorbance of this product can be measured photometrically 
after dissolving in dimethyl sulfoxide. Darker colour indicates higher metabolic activity. 
For this assay, IPEC-J2 cells were seeded on 96 well plates (5 x 103 cells/well). After 
the 4-hydroxyalkenal incubation, cells were washed with PBS, and medium containing 
0.5 mg/mL MTT (Sigma-Aldrich, U.K.) was added, and cells were incubated for 4 h. 
Next, 75 µL medium were removed and replaced with dimethyl sulfoxide, plates were 
shaken and incubated for 30 min in the incubator, before measuring the absorbance at 
540 nm using a MultiskanEx (Thermo Labsystems, U.K.) plate reader with the Ascent 
Software (Version 2.6 for Windows, 2002). Metabolic activity was expressed relatively 
to metabolic activity of control cells.  
Cell cycle analysis  
Cells in different stages of the cell cycle (G1, S, G2 phase) were quantified by DNA 
quantitation using propidium iodide staining and flow cytometry (Abcam 2018). For the 
dye to bind to the DNA of all cells, cells need to be permeabilised. Alcohol is a 
dehydrating fixative that also permeabilises cells. The DNA amount in cells doubles 
during the S phase of the cell cycle and propidium iodide binds stoichiometric to the 
DNA. Therefore, quantitation can be performed based on the fluorescent signal. 
Directly after the 4-hydroxyalkenal incubation, cells were trypsinised and approximately 
1x106 cells in suspension were centrifuged (200 x g, 5 min, room temperature), washed 
with 500 µL PBS and again centrifuged (200 x g, 5 min, room temperature). The 
supernatant was decanted and 500 µL ice-cold 70% ethanol were added drop-wise 
while vortexing. Cells were incubated for 30 min on ice and centrifuged (850 x g, 5 min, 
room temperature), washed with 500 µL PBS, centrifuged (850 x g, 5 min, room 
temperature) and re-suspended in 150 µL PBS/RNAse A (200 µg/ml, Sigma, U.K.) for 
10 min at room temperature, before adding propidium iodide (25 µg/mL). Cells were 
analysed on a FACSCalibur flow cytometer (BD Biosciences, U.K.). Data acquisition 
was performed using the CellQuest Pro software (Version 5.2.1 for Mac, BD 
Biosciences, U.K.) and 10000 events were collected per sample. Forward scatter and 
side scatter were adjusted to display the population of interest. Data was analysed 
using the FlowJo software (Version 10 for Windows, FlowJo, LLC, USA). First, cell 
doublets were excluded, and single cells were identified using pulse processing (Figure 
3-2 A), then obvious debris was excluded in the forward scatter - side scatter plot 
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(Figure 3-2 B). Cells in G1, S and G2 phase were identified using the Watson 
Pragmatic model in FlowJo, with the constraint ‘Peak 2 = G1 x n’, with n being adjusted 
to provide the best fit of the model (smaller Root Mean Square value).  
            
 
Figure 3-2: Analysis of flow cytometry data for cell cycle determination 
A: Gaiting for single cells in the FL2-Width – FL2-Area plot within the 10000 events collected 
B: Gaiting for alive cells in the forward scatter (FWS) – side scatter (SSC) plot in the single cell sub-
population  
C: Histogram of the Watson Pragmatic model of cell distribution in the G1 (blue), S (brown), and G2 phase 
(green) based on propidium iodide staining (FL2-Area). 
Wound healing assay 
A wound healing or scratch assay assesses cell migration in vitro after creating an 
artificial gap (scratch) in a cell monolayer and visualising its closing (Liang et al. 2007). 
After the 4-hydroxyalkenal incubation, media was removed, and cells were washed 
with PBS. PBS was mostly removed, and the cell monolayer was scratched from top to 
bottom of the 12-well, using a sterile 200 µL pipette tip, applying uniform pressure. To 
remove the scratched cells, the monolayer was washed twice with PBS and the 
medium was replaced. Wound closing was assessed using a Nikon Eclipse Ti inverted 
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microscope (Nikon U.K. Limited, U.K.), fitted with a Nikon Digital sight D2.U3 Camera, 
a heated stage (37°C), and 5% CO2/ Air (BOC, U.K.) flow. Pictures were acquired 
using the NIS Elements (V 4.30.02, Nikon, Nikon U.K. Limited, U.K.) software. For 67 
hours, three pictures per well were taken every 30.1 min (brightfield, 4x magnification). 
Pictures were analysed using the MRI wound healing tool in ImageJ (Version 1.51r for 
Windows, NIH, U.S.A.). The variance option was used, with the filter radius set to 5, 
threshold 100, radius open 7 and min size of 10000. Manual adjustments were made if 
necessary. Wound closure (%) at 5 hours was calculated using the following formula:  
𝑊𝑜𝑢𝑛𝑑 𝑐𝑙𝑜𝑠𝑢𝑟𝑒 (%) = 100 − (
100
𝑠𝑐𝑟𝑎𝑡𝑐ℎ 𝑎𝑟𝑒𝑎 (0 ℎ) 
× 𝑠𝑐𝑟𝑎𝑡𝑐ℎ 𝑎𝑟𝑒𝑎 (5 ℎ)) 
 
IL-6 ELISA 
Porcine IL-6 expression was determined using the Quantikine sandwich ELISA (R&D 
systems, U.K.) following the manufacturer’s instructions. Briefly, standards and 
samples (50 µL, in duplicates) were added to the IL-6 polyclonal antibody pre-coated 
plate containing 50 µL of Assay Diluent RD1-63. After incubation (2 hours, 500 rpm on 
a horizontal orbital shaker, room temperature), the plate was washed 5-times. Next, 
100 µL of conjugated IL-6 antibody were added and the plate was incubated (2 hours, 
500 rpm on a horizontal orbital shaker, room temperature), followed by 5 washes. 
Afterwards, 100 µL of Substrate Solution were added and the plate was incubated 
(30 min, room temperature, light protected). The Stop Solution (100 µL) was added and 
the absorbance was measured at 450 nm, using an absorbance plate reader 
(Multiskan Ex, Thermo Labsystems, U.K.). Absorbance was also measured at 550 nm 
for correction. Results were acquired using the Ascent software (Version 2.6 for 
Windows, Thermo Scientific, U.K.). A four-parameter logistic standard curve was 
calculated to quantify the IL-6 concentration in pg/mL (Figure 3-3). The sensitivity of the 
assay was 4.3 pg/mL. IL-6 concentration was only measured after incubation with 0.01, 
0.1, 0.25, 0.5 µM HHE and 0.005, 0.05, 0.5, 1 µM HNE, respectively. 
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Figure 3-3: Standard curve for the determination of IL-6 in cell culture supernatant 
The graph shows a porcine IL-6 four parameter logistics standard curve (R
2
 = 0.9999) determined by 
ELISA. Standards were analysed in duplicates. 
Intracellular IL-8 staining 
IL-8 expression was analysed using intracellular cytokine staining and flow cytometry. 
To block cytokine release from IPEC-J2 cells, cells were incubated in media containing 
monensin. Monensin is a protein transport inhibitor, which interacts with the golgi 
transmembrane Na2+/H+ transport to prevent cytokine secretion into the medium, 
trapping them inside the cells (BD Biosciences 2018). For human IL-8, monensin is 
recommended over brefeldin A. Furthermore, cells treated with brefeldin A died within 
12 hours. The BioLegend Intracellular Cytokine Staining Protocol was followed 
(BioLegend 2007). 
Ten days differentiated IPEC-J2 cells were pre-incubated with monensin (final 
concentration 2 µM, BioLegend, U.K.) for 2 hours before the 4-hydroxyalkenal 
incubation. Cells were incubated with 4-hydroxyalkenals as described above, but the 
medium contained monensin all the time. After the 2 hour 4-hydroxyalkenal incubation, 
cells were washed with PBS and incubated for further 12 hours. Next, cells were 
trypsinised and centrifuged (350 x g, 5 min, room temperature) and the cell pellet was 
fixed (20 min, room temperature, in the dark) in 500 µL fixation buffer (BioLegend, 
U.K.), followed by a centrifugation (350 x g, 5 min, room temperature). Fixed cells were 
twice re-suspended in 500 µL 1x permeabilization wash buffer (BioLegend, U.K.), 
centrifuged (350 x g, 5 min, room temperature) and the supernatant was discarded. 
Cells were re-suspended in residual permeabilization wash buffer and incubated with 
primary antibody (mouse anti IL-8 IgG2a, ab34100, abcam, U.K. 1:10 in cell staining 
buffer, BioLegend, U.K.; 30 min, room temperature, in the dark). Cells were washed 
twice with permeabilization buffer, centrifuged (350 x g, 5 min, room temperature), and 
the supernatant was discarded, followed by secondary antibody incubation (goat anti 
mouse IgG H&L (Alexa Fluor 488), ab150113, abcam, U.K.; 1:2000 in cell staining 
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buffer, BioLegend, U.K.; 30 min, room temperature, in the dark). Next, cells were 
washed twice as above, and the pellet was re-suspended in 500 µL cell staining buffer, 
followed by immediate analysis. Cells were analysed on a FACSCalibur flow cytometer 
(BD Biosciences, U.K.). Data acquisition was performed using the CellQuest Pro 
software (Version 5.2.1 for Mac, BD Biosciences, U.K.) and 10000 events were 
collected per sample. Forward scatter and side scatter were adjusted to display the 
population of interest. No clear shift in the fluorescent signal between unstained and 
stained cells was detected. Therefore, data was analysed using a population 
comparison (SE Dymax %Positive cells) of the live cells in the FlowJo software 
(Version 10 for Windows, FlowJo, LLC, USA) (Figure 3-4). 
 
Figure 3-4: Population comparison for intracellular IL-8 staining 
The graph shows the FL-2 Height signal for unstained, control (black), and stained, H2O2 incubated IPEC-
J2 cells (blue). The signals were compared using the population comparison tool in FlowJo.  
3.3.6 Repeated exposure experiments 
Since infants receive FM several times per day (up to eight times for a 2000 g preterm 
infant), the effect of repeated 4-hydroxyalkenal exposure was investigated. Therefore, 
cells were incubated for 2 hours as described above. Next cells were washed with PBS 
and incubated for 1 hour with normal media. Incubation with 4-hydroxyalkenals was 
repeated two more times, intermitted by 1 hour normal media incubation (Figure 3-5). 
The same outcome measurements as described for single exposure experiments were 
used (Chapter 3.3.5).  
 
Figure 3-5: Time-line for repeated exposure experiments 
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3.3.7 Statistics 
Sample size for most experiments was relatively low (n=3). Therefore, data was not 
tested for outliers and normality, and non-parametric tests were used throughout. To 
compare cell numbers for the growth curve, Friedman test with Dunn’s multiple 
comparisons test comparing all columns to day 3 was used. For all 4-hydroxyalkenal 
treatment effects, Kruskal-Wallis test with Dunn’s multiple comparisons test, comparing 
all columns to control was used. For comparison of control cells to solvent control and 
H2O2, respectively, Mann Whitney test was used. Data presented as mean ± SD, and 
considered statistically significant at p < 0.05. * indicates p < 0.05, ** and *** p-values 
< 0.01 and < 0.001, respectively.  
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3.4 Results 
To investigate the effects of 4-hydroxyalkenals on preterm intestinal tissue in vitro, 





Figure 3-6: IPEC-J2 cells 
A: Representative pictures of IPEC-J2 cells (passage 20) at different confluences. Cells were grown on 
cell culture plates and detected by light microscopy (5x magnification).  
B: Representative pictures of IPEC-J2 cells (passage 20) at different magnifications. Cells were grown on 
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3.4.1 Time-point determination 
To define the experimental conditions and to investigate whether IPEC-J2 cell could be 
cultured long-term on normal 12-well cell culture plates, cell growth was monitored over 
a period of 14 days (Figure 3-7 A). As described for this cell line, cell number almost 
doubled twice from seeding to day 3 (80000 cells vs. 316000 ± 34779 cells). Following 
this pattern, there was an increase in cell number over time until day 10 on which it 
reached significance (740333 ± 50897 cells, p = 0.0003, Dunn’s multiple comparison 
test p < 0.01). Thereafter, cell number decreased. Viability of the cells, assessed by 
flow cytometry, was greater than 85% on all days (Figure 3-7 B). Splitting the total cell 
number into viable and non-viable cells, it was shown that on day 12, the number of 
non-viable cells from day 10 disintegrated, and that cell division decreased (Figure 3-7 
C). Since these disintegrated cells are lost from the cell culture system, it could be 
misleading to only consider viability without looking at cell numbers. Furthermore, these 
disintegrated cells could not be considered in any subsequent analysis, indicating a 
limitation, and therefore, only cells until day 10 should be used.  






















































Figure 3-7: Cell growth and viability of IPEC-J2 cells over 14 days 
A: Growth curve of IPEC-J2 cells cultured for 14 days on normal 12-well plates (p = 0.009) 
B: Relative viability of IPEC-J2 cells cultured for 14 days on normal 12-well plates (p = 0.0073) 
C: Absolute viability of IPEC-J2 cells cultured for 14 days on normal 12-well plates 
n=3 respectively, Dunn’s multiple comparisons test compared to day 3 
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IPEC-J2 cells have been reported to show spontaneous signs of differentiation, with 
microvilli expression on the apical site, within 2 weeks (Schierack et al. 2006). To 
investigate whether IPEC-J2 cells also show spontaneous differentiation with increased 
microvilli density when cultured on normal cell culture plates as opposed to trans-well 
plates, scan electron microscopy pictures were acquired on day 2, 10 and 14. Microvilli 
density increased significantly from day 2 to day 10 (Kruskal Wallis test p = 0.0509, 
Dunn’s multiple comparison test p < 0.05) (Figure 3-8). 
In summary, cell division slowed down after 10 days, cell viability was still greater 85% 
on day 10, and microvilli expression was significantly increased at day 10, indicating 























Figure 3-8: Microvilli expression of IPEC-J2 cells 
A: Quantification of microvilli per 10 µm
2
, n=3 pictures 
B: Representative scanning electron microscopy pictures of microvilli on IPEC-J2 cells cultured on glass 
coverslips for 2 and 10 days, 10000x magnification 
3.4.2 Hydrogen peroxide as positive control 
H2O2 is a reactive oxygen species that can be produced under oxidative stress 
conditions. Therefore, H2O2 was determined as positive control for the experiments. In 















outcome. A concentration dependent decline in cell viability was found for H2O2 (Figure 
3-9). Incubation with 1.5 mM H2O2 lead to a significant decrease in cell viability (-17.4% 
compared to control, p < 0.05). This concentration was chosen as positive control for 
the following experiments.  



















Figure 3-9: IPEC-J2 cell viability after H2O2 incubation 
Relative viability of IPEC-J2 cells incubated with various concentrations of H2O2 for 2 hours after 10 days 
differentiation. n=3 respectively 
3.4.3 Single exposure experiments 
In the first series of experiments, the effects of a single 2 hour exposure of IPEC-J2 
cells to various concentrations of 4-hydroxyalkenals, alone and in combination, were 
analysed, to mimic a single feed. All experiments were performed after 10 days of 
differentiation.  
Cell viability 
Cell viability was assessed by flow cytometry. Neither HHE (0.01, 0.1, 0.25, 0.5, 5, 
50 µM) nor HNE (0.005, 0.05, 0.5, 1, 10, 100 µM) exposure for 2 hour reduced cell 
viability significantly (p = 0.2119, and p = 0.0648, respectively). However, Dunn’s 
multiple comparison revealed a significant effect of 100 µM HNE (p < 0.05). 
Combination of HNE + HHE (0.5 + 0.25, 1 + 0.5, 10 + 5, 100 + 50 µM) also had no 
effect on cell viability (p = 0.2042) (Figure 3-10). The solvent had no effect 
(p = 0.7483), whereas H2O2 significantly decreased cell viability (-4%; p = 0.0022).  
Cell viability was 98.31 ± 0.40% for the control cells and ranged from 98.08 ± 0.24% 
(0.01 µM) to 98.45 ± 0.16% (50 µM) for cells incubated with HHE, and 98.23 ± 0.73% 
(0.005 µM) to 97.16 ± 0.12% (100 µM) for cells incubated with HNE. The combination 
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of HNE + HHE resulted in cell viabilities of 97.42 ± 0.77% (0.5 + 0.25µM) and 96.50 ± 
0.79% (100 + 50 µM).  







                                                           











Figure 3-10: IPEC-J2 cell viability after single 4-hydroxyalkenal incubation  
Relative viability of IPEC-J2 cells incubated with various concentrations of 4-hydroxyalkenals for 2 hours 
after 10 days differentiation. n=3 
Metabolic activity 
The metabolic activity was assessed using an MTT assay. Results are expressed in 
relation to control cells. There was no effect of HHE treatment (p = 0.3644) at any 
concentration tested (Table 3-1). The lowest metabolic activity was at 0.01 µM (87.3 ± 
4.29%), and the highest at 50 µM (107.8 ± 28.02%). HNE had a general treatment 
effect (p = 0.0070), however, no statistical difference for any concentration was 
detected with Dunn’s multiple comparison test (Table 3-1). A general effect of 
combined 4-hydroxyalkenals was seen (p = 0.0212); however, no statistical difference 
at any tested concentrations was detected (Figure 3-11). In general, lower 
concentrations decreased metabolic activity, whereas the highest concentration 
increased it, compared to control cells. No effect was identified for the solvent control 
(p = 1.0000) and H2O2 (p = 0.5368). 
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Table 3-1: Metabolic activity of IPEC-J2 cells after single 4-hydroxyalkenal incubation 
 
Metabolic activity in IPEC-J2 cells relative to control cells (100%). n=3 
 






                                                            
















Figure 3-11: Metabolic activity of IPEC-J2 cells after single 4-hydroxyalkenal incubation  
Relative metabolic activity of IPEC-J2 cells incubated with various concentrations of 4-hydroxyalkenals for 
2 hours after 10 days differentiation. n=3 
  
 Concentration (µM) Metabolic activity (%) P-value 
HHE  
0.01 87.3 ± 4.29 
0.3644 
0.1 89.54 ± 11.17 
0.25 107.0 ± 2.69 
0.5 90.69 ± 16.81 
5 89.69 ± 14.97 
50 107.8 ± 28.02 
HNE 
0.005 71.78 ± 6.96 
0.0070 
0.05 69.93 ± 15.27 
0.5 82.29 ± 5.57 
1 71.08 ± 3.04 
10 88.85 ± 15.76 
100 152.0 ± 31.73 
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Cell cycle 
Distribution of IPEC-J2 cells in the different phases of the cell cycle was analysed using 
flow cytometry. HHE incubation had an overall effect on cells in G1 phase (p =0.0284), 
but no effect on S or G2 phase (p = 0.0253 and p = 0.0635, respectively) (Figure 3-12 
A-C). Visually, an increase in cells in G1, together with a decrease in cells in S and G2 
phase can be noted at a concentration of 5 and 50 µM, however this was not 
statistically different. A similar trend can be seen for HNE at 10 and 100 µM (Figure 3-
12 D-E), although no statistical difference was seen (G1: p = 0.1250; S: p = 0.0811; 
G2: p = 0.2098).  





































































































































Figure 3-12: IPEC-J2 cells in different cell cycle phases after single 4-hydroxyalkenal incubation  
IPEC-J2 cells in G1, S, and G2 phase after 2 hours HHE (A-C) and HNE (D-F) incubation, after 10 days 
differentiation. n=3 
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This effect was not seen when HNE and HHE were combined. No statistical difference 
was detected (G1: p = 0.1396; S: p = 0.0631; G2: p = 0.2376; Table 3-2). Neither 
solvent control, nor H2O2 had an influence on the cell cycle of IPEC-J2 cells (p > 0.05 
for all). 











2 hours incubation after 10 days differentiation, n=3 
Cell migration 
Cell migration was assessed using a wound healing assay. There was no significant 
difference in cell migration after HHE and HNE exposure (p = 0.1772 and p = 0.2775, 
respectively). Combined HNE and HHE incubation showed no significant overall effect 
(p = 0.0902), however, significant lower cell migration was seen for 100 + 50 µM (100% 
vs. 16.92 ± 0.36% wound closure; p < 0.05) (Figure 3-13). Cell migration was not 
affected by the solvent (p = 0.1000). Although only one tenth of the wound closure was 
detected for H2O2, this decrease was not significant (57.4 ± 10.26% vs. 6.87 ±1.60%; 




G1 S G2 
Control - 89.5 ± 0.2 4.19 ± 0.24 5.97 ± 0.68 
HNE + 
HHE 
0.5 + 0.25 94.6 ± 1.51 2.83 ± 1.03 2.23 ± 2.22 
1 + 0.5 89.87 ± 0.76 5.01 ± 0.28 4.09 ± 1.01 
10 + 5 89.33 ± 4.13 4.47 ± 0.36 4.76 ± 2.02 
100 + 50 93.77 ± 0.65 3.85 ± 0.72 2.77 ± 1.07 
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Figure 3-13: Cell migration of IPEC-J2 cells after 4-hydroxyalkenal incubation  
The pictures display the scratch at (A) 0 hours and (B) 5 hours of control IPEC-J2 cells and cells incubated 
with 4-hydroxyalkenals for 2 hours after 10 days differentiation.  
Inflammatory markers 
IL-6 was measured using an ELISA. The IL-6 concentration in cell supernatant was 
below the limit of detection (4.3 pg/mL) under all conditions. IL-8 expression was not 
altered significantly when cells were incubated with HHE or HNE alone (p = 0.0889 and 
p = 0.3058, respectively). In combination, also no overall effect was seen (p = 0.0874), 
and no significant difference between the treatments was detected (Figure 3-14). In the 
HNE + HHE (100 + 50 µM) group, cells died and could therefore not be analysed. The 
solvent (p = 0.4848) and H2O2 (p = 0.6623) had no influence on intracellular IL-8 
expression.  
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Figure 3-14: IL-8 expression in IPEC-J2 cells after 4-hydroxyalkenal incubation  
Intracellular IL-8 expression in IPEC-J2 cells incubated with various concentrations of 4-hydroxyalkenals 
for 2 hours after 10 days differentiation. n=3 
3.4.4 Repeated exposure experiments 
In the clinical setting, or at home, preterm infants are fed several times per day. 
Therefore, the effects of repeated 4-hydroxyalkenal exposure on IPEC-J2 cells were 
investigated. In all experiments, cells were incubated three times for 2 hours with 
4-hydroxyalkenals, with a 1 hour wash off in between incubations. All experiments were 
performed after 10 days of differentiation. 
Cell viability 
Repeated HHE (0.01, 0.1, 0.25, 0.5, 5, 50 µM) exposure had no significant effect on 
cell viability (p = 0.0761). Cell viability was ≥ 97% in all treatment groups. Repeated 
HNE incubation had a significant effect on cell viability (p = 0.00362). However, no 
significant difference between the groups was detected, although cell viability was only 
43.97 ± 3.58% after incubation with 100 µM HNE. Cell viability in all other groups was 
≥ 98%. Combined 4-hydroxyalkenal exposure also affected cell viability (p = 0.0433). A 
significant reduction in viability at the highest concentration (100 µM HNE + 50 µM 
HHE) was identified (98.74 ± 0.19% vs. 25.53 ± 19.52; p < 0.05) (Figure 3-15). Viability 
in all other treatment groups was ≥ 98%. Repeated solvent-carrier exposure had no 
effect (p = 0.7922), whereas H2O2 significantly decreased cell viability (-38%; 
p = 0.0022).  
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Figure 3-15: IPEC-J2 cell viability after repeated 4-hydroxyalkenal incubation  
Relative viability of IPEC-J2 cells incubated with various concentrations of 4-hydroxyalkenals for three 
times 2 hours after 10 days differentiation. n=3 
Metabolic activity 
Repeated HHE exposure had an effect on the metabolic activity of IPEC-J2 cells 
(p = 0.0174). There was a significant increase in metabolic activity in the 50 µM treated 
cells (100% vs. 163.7 ± 14.65%; p < 0.05). Similarly, although repeated HNE exposure 
changed the metabolic activity (p = 0.0131), no significant differences between the 
treatment groups were detected. Slightly higher metabolic activity was seen for all 
concentrations but 10 µM, which showed a decreased metabolic activity. When cells 
were repeatedly incubated with HNE + HHE, no effect was seen (Figure 3-16). 
However, a similar dose-dependent increase as in the single exposure experiment was 
detected. Repeated solvent-carrier exposure had no detectable influence on the 
metabolic activity (p = 0.3429). No significant difference was seen when cells were 
incubated with H2O2 (p
 = 0.3429). 




















Figure 3-16: Metabolic activity of IPEC-J2 cells after repeated 4-hydroxyalkenal incubation  
Relative metabolic activity of IPEC-J2 cells incubated with various concentrations of 4-hydroxyalkenals for 




Repeated HHE incubation had a general effect of altering cell cycle phase distribution 
of the IPEC-J2 cells (G1: p = 0.0076; S: p = 0.0452; G2: p = 0.1582). Although post-
hoc tests revealed no significant differences between the concentrations, an increase 
in cells in G1 phase alongside a decrease of cells in the S phase was noted at 5 µM 
and 50 µM (Table 3-3). Repeated HNE incubation had a similar effect as HHE 
incubations (G1: p = 0.0173; S: p = 0.0281; G2: p = 0.1114). Cells in G1 phase 
increased and cells in S phase decreased when incubated with 10 or 100 µM HNE, 
although this was not significant (Table 3-3). Repeated solvent exposure did not 
influence the cell cycle (p = 1.0000). Also, H2O2 exposure had no effect on the cell 
cycle of IPEC-J2 cells. 
Table 3-3: IPEC-J2 cells in different cell cycle phases after repeated 4-hydroxyalkenal incubation 
 
Repeated 2 hours incubation after 10 days differentiation, n=3 
When cells where repeatedly incubated with HNE + HHE, an effect on cell cycle could 
be seen, with significant differences in S phase (p = 0.0337; G1: p = 0.1005; G2: 




G1 S G2 
Control - 67.55 ± 7.14 15.70 ± 8.42 14.13 ± 1.65 
HHE 
0.01 62.90 ± 1.56 21.33 ± 1.95 13.97 ± 0.32 
0.1 62.07 ± 1.03 22.17 ± 1.82 12.60 ± 2.0 
0.25 61.73 ± 1.86 22.23 ± 0.64 13.17 ± 0.55 
0.5 59.17 ± 1.24 22.97 ± 3.37 13.87 ± 1.79 
5 80.40 ± 2.21 6.62 ± 1.84 11.44 ± 3.58 
50 92.73 ± 0.40 4.02 ± 1.29 5.91 ± 2.70 
HNE 
0.005 62.20 ± 1.78 22.30 ± 2.60 13.0 ± 1.57 
0.05 61.17 ± 3.0 19.93 ± 2.14 15.73 ± 1.15 
0.5 61.0 ± 0.79 21.27 ± 3.0 14.73 ± 2.15 
1 60.43 ± 1.10 21.50 ± 1.45 14.63 ± 0.64 
10 79.87 ± 1.60 4.85 ± 0.5 12.37 ± 1.84 
100 80.23 ± 2.23 4.61 ± 0.69 10.52 ± 3.05 
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cells in G1 and significantly less cells in S phase after incubation with HNE (100 µM) + 
HHE (50 µM). 

































































Figure 3-17: IPEC-J2 cells in different cell cycle phases after repeated 4-hydroxyalkenal incubation  
IPEC-J2 cells in G1, S, and G2 phase after three times 2 hours HNE + HHE incubation, after 10 days 
differentiation. n=3 
Cell migration 
Repeated HHE exposure influenced cell migration (p = 0.0425), with a significant 
increase in cell migration detected at 5 µM HHE (Table 3-4). There was also an 
influence of repeated HNE exposure on cell migration (p = 0.0125), although no 
significant differences between the concentrations were detected (Table 3-4). The 
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lowest (0.005 µM) and highest (100 µM) concentration decreased cell migration, 
whereas 0.05, 0.5, 1, and 10 µM increased it. Repeated exposure of IPEC-J2 cells to 
HNE + HHE had no effect on cell migration (p = 0.0984) (Table 3-4). 
Table 3-4: Cell migration of IPEC-J2 cells after repeated 4-hydroxyalkenal incubation 
 
* Significant different to control 
n=3, three times 2 hours repeated incubations after 10 days of differentiation 
 
Inflammatory markers 
The IL-6 concentration in cell supernatants was below the limit of detection (4.3 pg/mL) 
under all conditions. Intracellular IL-8 expression in IPEC-J2 cells was not significantly 
different after repeated HHE (p = 0.0609), HNE (p = 0.2942), and combined HNE + 
HHE (p = 0.0609) exposures (Figure 3-18). At 100 µM HNE and at 100 µM HNE + 
50 µM HHE cells died, and therefore, no intracellular IL-8 concentration can be 
reported. Similarly, H2O2 induced cell death in IPEC-J2 cells under these conditions. 
Repeated exposure to solvent did not change the intracellular IL-8 expression 
(p = 0.8182). 
 Concentration (µM) Wound closure (%) P-value 
Control - 53.96 ± 10.58 - 
HHE 
0.01 52.01 ± 3.74 
0.0425 
0.1 75.4 ± 1.72 
0.25 53.0 ± 12.7 
0.5 49.05 ± 9.75 
5 99.02 ± 1.7 * 
50 51.67 ± 11.65 
HNE 
0.005 37.63 ± 4.67 
0.0125 
0.05 80.85 ± 14.26 
0.5 61.42 ± 27.59 
1 53.34 ± 21.08 
10 81.36 ± 22.35 
100 36.35 ± 3.96 
HNE + 
HHE 
0.5 + 0.25 54.44 ± 19.27 
0.0984 
1 + 0.5 90.62 ± 11.26 
10 + 5 65.13 ± 26.78 
100 + 50 - 
 
  115 
































Figure 3-18: IL-8 expression in IPEC-J2 cells after repeated 4-hydroxyalkenal incubation  
Intracellular IL-8 expression in IPEC-J2 cells incubated with various concentrations of 4-hydroxyalkenals 




3.5 Discussion and conclusion 
FM contains 4-hydroxyalkenals (Surh et al. 2007; Michalski et al. 2008). However, the 
effect of these on the integrity and metabolism of the gut, and particularly the immature 
preterm intestine, is not known. Therefore, this study investigated the effects of several 
4-hydroxyalkenal concentrations, alone and in combination, on the immature intestinal 
epithelium, using the IPEC-J2 cell line as an experimental model.  
The IPEC-J2 cell line was successfully established in the laboratory. Proliferation and 
differentiation of the cells was in line with previously reported data (Schierack et al. 
2006), indicating that IPECJ-2 cells could be used as a model to analyse the effects of 
4-hydroxyalkenal exposure on the preterm intestine.  
Single and repeated exposure with 100 µM HNE, as well as repeated exposure with 
100 µM HNE + 50 µM HHE decreased cell viability. Similarly, cell viability of Caco-2 
cells was also significantly decreased after 50 µM HNE incubation for 24 hours 
(Alghazeer et al. 2008). Lower concentrations, similar to those in FM, had no effect on 
cell viability. Metabolic activity of IPEC-J2 cells was reduced at lower concentrations 
but increased at higher 4-hydroxyalkenal concentrations, although cells showed 
reduced viability. MTT reduction in the assay is associated with mitochondrial enzymes 
(Jo et al. 2015). However, intracellular reductases can also perform the MTT reduction 
to formazan. Dehydrogenases are partly responsible for HNE degradation (Hartley et 
al. 1995), and might be upregulated in response to high HNE concentrations. This, 
together with membrane damage caused by HNE (Bacot et al. 2007), could have led to 
false positive MTT results in non-viable cells. Similar effects have been reported for 
glioblastoma cells after ethanol incubation (Jo et al. 2015).  
Surprisingly, neither the single, nor the repeated exposure experiments resulted in an 
increase of inflammatory cytokines, although 4-hydroxyalkenals have been shown to 
activate the NF- pathway (Yadav and Ramana 2013). However, NF- induction by 
HNE is cell specific. For example, in hepatocytes, cortical neurons, and colorectal 
carcinoma cells, HNE inhibited the activity whereas in vascular smooth muscle cells, 
fibroblasts, and macrophages HNE induced the activity of the transcription factor 
(Ayala et al. 2014). HNE-mediated activation of NF- in IPEC-J2 cells has not been 
tested yet, and should therefore be clarified in the future, e.g. on mRNA level by 
quantitative polymerase chain reaction, and more importantly, on protein level e.g. by 
assessing nuclear translocation by western blotting, immunocytochemistry, or imaging 
flow cytometry. 
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Nevertheless, IL-6 and IL-8 expression was shown for this cell line after stimulation 
with lipopolysaccharides (E. coli O26:B6, 1µg/mL) for 24 hours in serum-free medium 
(Rasmussen et al. 2017) .Lipopolysaccharides can bind to toll-like receptor 4 and 
activate the NF- pathway. Similarly, differentiated IPEC-J2 cells, cultured in trans-
well plates, incubated for 2 hours with bacteria, showed increased IL-6 and IL-8 levels 
in the apical medium after 24 hours (Devriendt et al. 2010). In the future, it should be 
confirmed whether IPEC-J2 cells can, under the same culture conditions as used here, 
express IL-6 and IL-8, e.g. by treating them with lipopolysaccharide, as positive control. 
Since no shift in the fluorescent signal was detected and considering that golgi blocker 
can induce cell death (Hicks and Machamer 2005), ELISAs should be preferred over 
intracellular cytokine staining. Not knowing whether IPEC-J2 cells cultured under the 
here described conditions can produce cytokines in response to a pro-inflammatory 
stimulus is a limitation of this study. 
Oxidative stress, induced by H2O2 did not change the relative gene expression of IL-6 
in IPEC-J2 cells before, and relative gene expression of IL-8 was increased at 1 mM 
H2O2, but not at 2 mM H2O2 (Paszti-Gere et al. 2012). It may be that the incubation time 
was insufficient for protein transcription and translation. However, for IL-6 
measurements, supernatant was collected three hours post-incubation and intracellular 
IL-8 was measured 12 hours post-incubation. The increased gene expression levels 
after 1 mM H2O2 incubation in the previous study translated into increased IL-8 levels in 
supernatant after 4 hours (Paszti-Gere et al. 2012), indicating that the sampling time 
was sufficient. The authors also speculated that higher levels of H2O2 might not lead to 
an increase in IL-8 due to the induced oxidative damage. Insignificant increases of 
intracellular IL-8 expression were noted in our experiments at the lower concentrations, 
whereas 10 and 5 µM HNE + HHE reduced the expression, and cells died when 
incubated with 100 µM HNE + 50 µM HHE after a single exposure, although other 
assays indicated cells were fine at this concentration. To stain for intracellular 
cytokines, their release from the cell needs to be blocked. Therefore, monensin, a 
protein transport inhibitor, which interacts with the golgi transmembrane Na2+/H+ 
transporter, was added to the medium (BD Biosciences 2018). Monensin was chosen 
over brefeldin A, another golgi blocker, since in contrast to the latter, it did not induce 
cell death in control cells in a pre-test. Nevertheless, monensin has been shown before 
to induce cell death (Verma and Das 2018), and it is known that block of the golgi 
complex can initiate cell signalling pathways to trigger apoptosis (Hicks and Machamer 
2005). Therefore, there might have been synergistic effects of monensins and high 
doses of 4-hydroxyalkenals, which on their own have been shown to reduce cell 
viability before (Alghazeer et al. 2008), leading to the observed cell death.  
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Overall, these preliminary results suggest no detrimental effects of 4-hydroxyalkenals 
in concentrations found in FM on the gut. However, it is postulated that the 
experimental set up may have affected the results. Especially considering that 
repeated exposure to 4-hydroxyalkenals was expected to have an effect on IPEC-J2 
cells. However, in these experiments, new media containing foetal bovine serum was 
provided to the cells after each incubation period. Cell culture medium, including 
Dulbecco’s Modified Eagle Medium, provides a number of components, including 
cysteine, tyrosine, tryptophan and phenol red, that can contribute to the total 
antioxidant capacity (TAC) of media (Lewinska et al. 2007). Although TAC of media is 
lower than TAC of blood plasma, it needs to be considered that preterm infants in 
general have much lower antioxidative capacity than adults (Davis and Auten 2010). 
Addition of foetal bovine serum can further increase TAC of media (Lewinska et al. 
2007), and has also been shown to decrease reactive oxygen species and to increase 
transcription of antioxidants in cell cultures of in vitro-produced porcine embryos (Mun 
et al. 2017). Therefore, TAC of our cell culture model could have been much higher 
than expected in vivo in preterm infants, and might have contributed to the results of 
this study.  
Although 4-hydroxyalkenals were not detrimental in these in vitro experiments, this can 
only be used as a first indication. Stoy and colleagues have demonstrated major 
differences between gene expression, including immune response related genes, of 
IPEC-J2 cells and intestinal tissue of piglets after incubation / feeding with FM and 
colostrum, with two distinct groups separating the cell line and the tissue in a principal 
component analysis (2013). This demonstrates the limitations of extrapolation of results 
from the cell line to the in vivo situation. Differences might be due to the heterogeneity 
of cells in the intestine (enterocytes, goblet cells, enteroendocrine cells, and Paneth 
cells) (Lea 2015b), compared to the homogenous cell line, which does not represent 
the physiological conditions (Stoy et al. 2013). Furthermore, the here described 
repeated exposure experiments consisted of three times two hour exposure during one 
day, whereas preterm infants receive FM up to eight times per day for up to six months. 
HNE alters proteasomal activity, which in turn leads to a decrease in protein turnover 
and an accumulation of HNE crosslinked proteins, resulting in cellular dysfunction 
(Riahi et al. 2010). This process happens over time, and it might be that repeated 
exposures over a longer time period are needed, to be able to quantify effects. 
Similarly, accumulation of HNE DNA adducts or HNE phospholipid adducts, influencing 
the cell membranes (Bacot et al. 2007), might need more time before detrimental 
effects are observed. It might also be that the 4-hydroxyalkenal levels in FM have no 
effect on IPEC-J2 cells, and on the intestine of preterm infants, although further 
research is needed to explore this. Even if 4-hydroxyalkenals would have no 
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detrimental effects on the intestine, they may still increase inflammatory cytokines in 
plasma (Awada et al. 2012), or affect the body elsewhere, as previously reported. Oral 
ingestion of LPPs over weeks affected the liver, pancreas, overall weight gain, and 
antioxidant levels in animal experiments (Siu et al. 1983; Izaki et al. 1984). 
In general, the question remains whether IPEC-J2 cells are the ideal model for the 
immature intestine of preterm infants and for these experiments. Certainly, for non-
primary cells and a non-primate cell line, IPEC-J2 cells resemble the human physiology 
closely (Vergauwen 2015). However, cells were differentiated for 10 days, whereas the 
preterm enterocytes are immature and resemble the foetal intestine. Also, the 
premature gut is characterised by increased intestinal permeability (Claud 2009). 
Addition of foetal bovine serum to the culture medium in our experiment, as 
recommended (Drexler et al. 2017), results in very high transepithelial electrical 
resistance values, as tested by others, indicating a high integrity of the cell monolayer 
(Zakrzewski et al. 2013). Using porcine serum, which is more physiologic for a porcine 
cell line, results in lower transepithelial electrical resistance values, closer to what is 
reported for human cell lines, and potentially resembling the in vivo situation better. 
Therefore, the choice of serum might have also affected the results.  
The use of normal cell culture plates in contrast to transwell plates could be seen as 
limitation of this study, and might have influenced the results. Usually, IPEC-J2 cells 
are cultured on transwell collagen coated PTFE filters (Schierack et al. 2006; 
Vergauwen 2015) to mimic the intestine, and especially when studying nutrient 
absorption. This cell culture system mimics the intestinal situation more closely with an 
apical (luminal) and a basal (lamina propria) side, although our IPEC-J2 cells, cultured 
on normal cell culture plates, also differentiated into cells with microvilli expression on 
the apical side. However, amongst others, this transwell cell culture model could give 
an indication about 4-hydroxyalkenal absorption through the enterocyte. Furthermore, 
using this culture model, transepithelial electrical resistance can be analysed. It is a 
quantitative measurement of the integrity of a cell monolayer, provided by tight 
junctions (Srinivasan et al. 2015). Transepithelial electrical resistance can be measured 
in real time, without damaging cells. Therefore, using a transwell cell culture system, 
the effect of 4-hydroxyalkenals on epithelial integrity could be investigated. This could 
provide some further information about the effects of 4-hydroxyalkenals on the preterm 
gut, beyond inflammatory markers. Caco-2 cells treated with HNE (160 µM) showed 
significantly increased permeability, when cultured on transwell plates (Cindric et al. 
2013), and similarly, HNE increased endothelial cell permeability in lung endothelial 
cells (Usatyuk and Natarajan 2004) and in a model of the blood brain barrier (Mertsch 
et al. 2001) in vitro. Increased intestinal permeability has also been shown in human 
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infants with NEC (Moore et al. 2016). 2Additionally, expression of tight junction proteins 
should be investigated after 4-hydorxyalkenal incubation. This could provide a second 
measure of the intestinal integrity. Previously, occluding as well as Claudin-3 and 4 
have been detected in IPEC-J2 cells (Schierack et al. 2006). Incubating bovine lung 
microvascular endothelial cells with 25 µM HNE for 30 min resulted in redistribution of 
zonula occludens-1, a tight junction protein, and caused intercellular gap formation, 
visualised by immunostaining (Usatyuk et al. 2006). Further research is needed to 
understand the effects of 4-hydroxyalkenals on tight junctions in the intestine and 
especially in the preterm intestine.  
Another limitation of this work was the use of only one cell type in our model system, 
which does not mimic the composition of the normal gut epithelial layer (Hidalgo 1996). 
The human intestinal epithelium is made up of several cell types, including enterocytes, 
goblet cells, Paneth cells, enteroendocrine cells and stem cells (Kleiveland 2015). The 
absorptive enterocytes and goblet cells make up the majority of the cells. Goblet cells 
are mucus producing cells, responsible for the mucus layer on the epithelial surface, 
which is part of the barrier function. Therefore, co-cultivation systems of enterocytes 
and goblet cells have been implemented (Kleiveland 2015). For example, Caco-2 cells 
can be cultured together with HT-29MTX cells (derived from intestinal goblet cells), in 
physiological relevant ratios between 90:10 and 75:25. This co-cultivation system and 
the resulting mucus layer should be considered when studying the effect of 
4-hydroxyalkenals on the intestine in the future, since the mucus layer acts as barrier 
and has been shown to affect the absorption of lipophilic compounds (Behrens et al. 
2001). However, the introduction of goblet cells, which do not form tight junctions, will 
increase the epithelial layer permeability. This will also mimic the physiological situation 
in the intestine more closely (Srinivasan et al. 2015). Especially when studying the 
inflammatory response and cytokine release, macrophages should be considered as 
well, since they produce the majority of cytokines in the gut (Pathmakanthan and 
Hawkey 2000). Therefore, Trapecar and colleagues have proposed an alternative co-
culture model for studying immunomodulation in the developing small intestine (2014). 
This model consists of non-transformed polarised human neonatal small intestinal 
epithelial cells (H4-1) cultured on the apical side of a transwell, and non-transformed 
human macrophages (TLT) on the basal side, resulting in a reductionist 3D model of 
the human immature intestine. The model clearly indicated differences in the immune 
response (NF- p65 and STAT1 translocation) when cells were cultured alone or in 
combination, and the authors speculate that epithelial cells need soluble, macrophage-
derived factors as feedback regulator for an appropriate, more physiological immune 
response, indicating the importance of co-culture models. Considering the above 
mentioned role of the mucus as well, it is proposed to establish a human three cell co-
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culture model, consisting of absorptive enterocytes, cultured together with goblet cells 
on the apical side, and macrophages on the basal side of a transwell to investigate the 
effect of 4-hydroxyalkenals on the preterm gut in the future. Overall, an animal study 
might be more conclusive. As described above, 4-hydroxyalkenals might be influencing 
the intestinal integrity by influencing tight junctions (Usatyuk et al. 2006). It might be 
possible that the above described inflammatory changes in the jejunum and in plasma 
of mice seen by Awada and colleagues (Awada et al. 2012) have been mediated more 
indirectly, by decreasing tight junctions and increasing intestinal permeability, resulting 
in translocation of gut bacteria or bacterial products into the lamina propria and the 
systemic circulation. This can trigger the immune system and lead to an inflammatory 
response. Similarly, intraperitoneal injection of HNE in mice has been shown to 
decrease expression of the tight junction protein occludin in the colon, and therefore, to 
increase permeability, resulting in higher concentrations of toll-like receptor 4 ligands 
(lipopolysaccharides and bacterial products) in plasma, which in turn increased toll-like 
receptor 4 activation in the systemic circulation (Wang et al. 2019). In this model, 
increased expression of the IL-6 gene was also seen in the colon. The possibility of this 
mechanistic pathway should be explored in further animal studies. Both of the above 
mentioned studies have used mice as animal model. For investigating the effect of 4-
hydroxyalkenals on the preterm intestine, it is suggested to use a preterm pig animal 
model.  
The gut of pigs has high similarity with the gut of humans; therefore, preterm piglets 
should be used as appropriate animal model (Geens and Niewold 2011) in future 
studies. Preterm piglets have been used previously to study NEC (Stoy et al. 2015; 
Rasmussen et al. 2017). In a second step, oxidised FM should be provided to the 
preterm pigs, instead of 4-hydroxyalkenals alone, to truly investigate the effects of 
oxidised diets. 4-Hydroxyalkenals are most likely not the only LPPs in FM and there 
might be synergistic detrimental effects of LPPs. Furthermore, the antioxidant content 
of the FM should also be considered. Outcome measurements should cover the gut 
(inflammatory status, tight junction expression, LPP adducts), but also plasma levels of 
LPPs, ligands for toll-like receptor 4 (e.g. lipopolysaccharides) and inflammatory 
cytokines, as well as investigation of other tissues, including lung, eye and brain, since 
LPPs have been linked to the most common co-morbidities of preterm infants, which 
affect these tissues (Inder et al. 1996).  
In conclusion, preliminary results from this experiment revealed no detrimental effects 
of HHE and HNE on intestinal cells at concentrations found in FM. The highest 
concentrations induced some negative effects, however, FM HHE and HNE 
concentrations would need to increase by 100 times to reach these concentrations. 
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Nevertheless, the in vitro model has several constraints and it needs to be considered 
that preterm infants are exposed several times per day to LPPs in FM, for an extended 
period of time. Further research, potentially in an animal model, is needed to fully 
understand the effects of 4-hydroxyalekenals and other LPPs in FM on not only the 
preterm intestine but the whole body. 
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4 Human milk banking practices in the U.K. – Potential 
influences on LCPUFA and LPP content of DHM 
4.1 Introduction 
4.1.1 DHM 
DHM is defined as BM expressed by a mother and processed by a HMB for the use by 
a recipient that is not the mother’s own baby (National Institute for Health and Clinical 
Excellence 2010). The World Health Organisation, as well as the ESPGHAN 
Committee on Nutrition and the American Academy of Pediatrics recommend DHM 
from a HMB as the preferred choice if mothers are unable to provide sufficient or 
appropriate BM for their preterm baby (WHO 2003; American Academy of Pediatrics 
2012; Arslanoglu et al. 2013a; AAP Committee on Nutrition et al. 2017). 
The idea of using BM from women other than the baby’s own mother is not new. Before 
the introduction of FM, wet nurses were common when mother’s own BM was not 
available (Stevens et al. 2009). Nowadays, DHM is provided by HMBs, and the first 
HMB was opened in Vienna in 1909. There are 15 NHS based HMBs and one non-
NHS based HMB in the U.K. (Figure 4-1), which are in the United Kingdom Association 
for Milk Banking (UKAMB) (UKAMB 2017). In 2014, 7000 litres of DHM were 
distributed to 183 neonatal units in the U.K. and Ireland, whereas one neonatal unit 
may obtain DHM from more than one HMB (British Association of Perinatal Medicine 
2016b). In 2013, 60.7% of neonatal units in the U.K reported the use of DHM, with a 
mean length of use of three weeks, and the main recipients being preterm infants 
(Zipitis et al. 2015). No national guideline is available to regulate the use of DHM, 
however most neonatal units agree that extremely preterm infants should receive it 
(British Association of Perinatal Medicine 2016b). 
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Figure 4-1: HMB locations in the UK 
Adapted from (UKAMB 2017) 
1: One Milk Bank for Scotland, Glasgow; 2: The Human Milk Bank, Irvinestown; 3: Calderdale and 
Huddersfield Donor Breast Milk Bank, Salterhebble; 4: Northwest Human Milk Bank, Chester; 5: The 
Birmingham Women’s and Children’s Hospital Milk Bank, Birmingham; 6: Neonatal Unit, Addenbrooke’s 
NHS Trust, Cambridge; 7: Hearts Human Milk Bank, Hertfordshire; 8: Oxford Human Milk Bank, Oxford; 9: 
The Southwest Neonatal Network Donor Milk Bank, Bristol; 10: St Peter’s Hospital Milk Bank, Chertsey; 
11: Queen Charlotte’s and Chelsea Hospital, London; 12: Guy’s and St Thomas’ NHS Foundation Trust, 
London; 13: St George’s Hospital Milk Bank, London; 14: King’s College Hospital Milk Bank, London; 15: 
Medway Maritime Hospital Milk Bank, Chatham; 16: Southampton Human Milk Bank, Southampton  
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DHM is preferred over FM due to its attributed benefits. A Cochrane review compared 
the effect of feeding preterm or low birth weight infants with FM compared to DHM 
(Quigley and McGuire 2014). Only nine trials were identified to be included in the 
analysis, and of these, only two trials were conducted after 2000, clearly demonstrating 
a recent lack of high quality studies in this field. Nevertheless, the systematic review 
demonstrated that DHM feeding of preterm infants significantly decreases the risk of 
feeding intolerance and developing NEC (Quigley and McGuire 2014), a severe 
gastrointestinal disease with a mortality rate of 30% in ELBW infants (Fitzgibbons et al. 
2009).  
The Cochrane review also assessed the effects of DHM feeding on 
neurodevelopmental outcomes (Quigley and McGuire 2014). Although no significant 
differences in neurodevelopment were found between the two groups, this conclusion 
is only based on two trials. Following from this, the DoMINO trial (Unger et al. 2014) 
was started in 2010. In this trial again no statistical differences in neurodevelopment at 
18 months of age in very low birth weight infants was noticed when supplemental DHM 
was compared to supplemental preterm FM (O'Connor et al. 2016). However, the 
authors themselves noted that the Bayley Scales of Infant and Toddler Development III 
is a tool to assess early developmental delays, and not improvements in function. 
Therefore, it should probably not be used to test for improvements in function and 
these results should be viewed critically. Better outcome measurements, e.g. 
electrophysiological assessments instead of psychophysiological assessments 
(Cheatham et al. 2006), are needed to assess the effects of DHM feeding on 
neurodevelopment.  
Bronchopulmonary dysplasia is one of the most common co-morbidities of preterm 
birth (Glass et al. 2015). A meta-analysis found a significant reduction in mean days on 
mechanical ventilation in randomised controlled trials and observational studies, as well 
as a significant reduction of bronchopulmonary dysplasia (oxygen dependency at 36 
weeks post-menstrual age) in observational studies, when using DHM supplementation 
compared to preterm FM supplementation (Villamor-Martinez et al. 2018). 
Bronchopulmonary dysplasia however was not a primary outcome in any of the 
included trials. Based on these findings, there is a need for an adequately powered, 
randomised controlled trial to investigate the effect of DHM feeding on rates of 
bronchopulmonary dysplasia. 
One recent study by Corpeleijn and colleagues found no benefit of supplementing 
mother’s own milk with DHM compared to supplementation with FM on severe 
infections, NEC, or morality (2016). However, the supplementation period was only ten 
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days, with an intake of mother’s own milk of > 89% in the DHM group and > 84% in the 
FM group, which might have masked the effect of DHM. 
DHM feeding also resulted in a gut microbiota closer in composition as well as 
metabolic profile to the microbiota of a maternal BM fed preterm infant, when compared 
to a FM fed preterm infant (Parra-Llorca et al. 2018). This could lead to beneficial long-
term health effects on for example intestinal functionality, immune system and 
metabolism. Follow-up of a study feeding preterm infants DHM vs. preterm FM 
revealed a significant, clinically relevant lower low-density lipoprotein cholesterol to 
high-density lipoprotein cholesterol ratio in adolescents (13-16 years) assigned to the 
DHM group. C-reactive protein was also significant lower in the same group and both 
outcomes remained significant after adjusting for confounding factors (Singhal et al. 
2004). After adjusting, the apolipoprotein B concentration was also noted to be 
significantly lower in the DHM group. In general, these markers are associated with the 
development and severity of atherosclerosis. Follow-up of the same group of preterm 
infants at 13-16 years also revealed clinical relevant significant lower mean arterial 
blood pressure and diastolic blood pressure in the DHM group, indicating the potential 
benefit in terms of prevention of hypertension (Singhal et al. 2001). These studies 
demonstrate a long-term (more than 13 years) effect of early life DHM feeding (until 
2000 g or discharge) on cardiovascular health, which is persisting into adolescence (13 
to 16 years).  
Use of DHM in neonatal units has also been associated with earlier initiation of enteral 
feeding and time to full enteral feeding, decreased use of FM, and increased breast 
feeding rates at discharge (Simmer and Hartmann 2009; Utrera Torres et al. 2010; 
Arslanoglu et al. 2013b). The absolute costs for DHM are higher than the cost of FM 
(£10-20 vs. £0.53 per 100 ml) (British Association of Perinatal Medicine 2016b; 
Crawley et al. 2019). Nevertheless, the use of DHM in neonatal intensive care units 
can lead to relative savings of $11 for every $1 spend on DHM due to a reduction in 
length of hospital stay, NEC cases and late-onset sepsis (Wight 2001). A recent 
economic model calculated that increasing the use of human milk, including DHM, from 
currently 35% to 100% in neonatal units could save the NHS £30.1 million during the 
first year of life of preterm infants, due to fewer episodes of NEC and sepsis, and the 
prevention of 190 deaths (Mahon et al. 2016). It is relevant to mention that this model 
did not include the cost of using DHM. The use of DHM can also have a positive impact 
on the environment. FM has excessive water, methane and carbon footprint, needs 
transportation at several stages during production and sales, and produces great 
amounts of waste (Joffe et al. 2019). Breast feeding for six months can save 
approximately 95-153 kg CO2 per baby compared to FM use.  
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4.1.2 Human milk banking practices in the U.K. 
Human milk banking practices in the U.K. are guided by the NICE Clinical Guideline 93 
“Donor breast milk banks: the operation of donor milk bank services” (National Institute 
for Health and Clinical Excellence 2010), which provides best practice advice on the 




Figure 4-2: Human milk banking process in the U.K. 
Adapted from (National Institute for Health and Clinical Excellence 2010) 
Donors are recruited for example through leaflets, general practitioners, or staff at the 
antenatal and postnatal wards, (National Institute for Health and Clinical Excellence 
2010). They are screened for eligibility and will have an informal interview with 
questions related to their health and life styles, and concerning the well-being of their 
babies. Serological testing is performed to avoid transmission of the human 
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immunodeficiency virus, hepatitis B and C, syphilis and the human t-lymphotropic virus. 
Afterwards, donors start expressing BM at home and store it for maximal 24 hours at 
4°C, if needed, before transfer to the freezer (-18°C or below) for up to 3 months 
(Figure 4-3). The frozen BM is then transported to the HMB either by the donor or her 
family, milk banking staff (National Institute for Health and Clinical Excellence 2010), or 
by a volunteer courier service e.g. Service by Emergency Rider Volunteers (SERV) or 
Blood Bikes (personal communication, Gillian Weaver, International Milk Banking 
Consultant, 23 April 2016). At the HMB, DHM is stored frozen (-20°C) until pooling, 
microbiological testing and Holder pasteurisation (62.5 °C, 30 min, latest 3 months after 
expression) (National Institute for Health and Clinical Excellence 2010). Afterwards 
DHM is refrozen (-20°C) until it is cleared to be release to hospital neonatal units. DHM 
has an expiry date of six months, counted from the date of expression. At the neonatal 
unit, DHM needs to be used within 24 hours of defrosting. 
Pre-collected BM can also be accepted from a mother whose baby has died, or who 
had collected expressed BM while her baby was on the neonatal unit (National Institute 
for Health and Clinical Excellence 2010). However, these donors must undergo the 
serological testing and answer the screening questions retrospectively. 
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Figure 4-3: DHM storage and processing conditions  
Donor human milk (DHM) is exposed to various storage conditions at donors’ homes, the HMB, and the 
neonatal unit. This figure displays the recommended conditions for storage and use as per guidance of the 
National Institute of Health and Clinical Excellence Guideline 93 (National Institute for Health and Clinical 
Excellence 2010). Amended from (Nessel et al. 2019) 
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4.1.3 LCPUFA content of DHM  
LCPUFA levels have not been reported for DHM in the U.K. One European study 
conducted in Sweden reported 0.30% ARA and 0.19% DHA in DHM, these levels were 
significantly lower than the levels in preterm BM (Ntoumani et al. 2013). Valentine et al. 
reported DHA levels of 0.1 molecular weight % of total FAs for DHM from the Mother’s 
Milk Bank of Ohio, U.S.A (Valentine et al. 2010) and suggested that these levels are 
too low for preterm infants, considering the in utero accretion rates. Two years later, 
Baack et al. reported levels of ARA and DHA to be 0.40% and 0.14% respectively in 
DHM, with significant differences in DHA levels between the four studied American 
HMBs (Baack et al. 2012). ARA levels were relatively stable among the HMBs. These 
levels are noticeably below the reported worldwide ARA and DHA levels in BM (Fu et 
al. 2016), but only slightly below levels reported for the U.S.A. (0.45 ± 0.02% ARA; 0.17 
± 0.02% DHA) (Yuhas et al. 2006). Although it is good that levels were not far below 
average BM levels in the respective country, this does not mean that these LCPUFA 
levels are ideal for preterm infants. Furthermore, it is to consider that LCPUFA levels in 
BM have changed in the last decades due to a change in diet, with an increased intake 
of LA (Sanders 2000). Ways to increase the LCPUFA levels in DHM need to be 
explored, especially considering the LCPUFA gap of prematurity in the majority of the 
recipients, and the health benefits of LCPUFAs for preterm infants. 
DHM in the U.S.A. is always pooled from several donors (O'Hare et al. 2013), whereas 
in the U.K., DHM is not pooled (National Institute for Health and Clinical Excellence 
2010). Hence, LCPUFA levels might be more variable in U.K. DHM. 
4.1.4 Influences and alterations to LCPUFA content of DHM 
Several factors can influence the LCPUFA content of DHM, including diet, storage, and 
processing. The human BM LCPUFA composition is dependent on maternal adipose 
tissue composition, the LCPUFA synthesis from precursor FA, and the dietary intake of 
PUFAs (Demmelmair et al. 1998). Adipose tissue composition is reflective of the long-
term (approximately 2 years) dietary fat intake (van Staveren et al. 1986; Hodson et al. 
2008), which highlights the need of sufficient LCPUFA intake not only during pregnancy 
and lactation, but also preconception. The major dietary source of DHA is (oily) fish 
whereas ARA can be found solely in animal products such as meat and eggs (Meyer et 
al. 2003), which has implications for donors with a restricted diet, e.g. vegetarians or 
vegans. 
BM DHA content is highly responsive to dietary intake and approximately 20% of 
dietary DHA is secreted into BM (Fidler et al. 2000). This leads to a high variability in 
BM DHA levels (Yuhas et al. 2006). For example, adding two n-3 PUFA enriched eggs 
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daily to the usual maternal diet significantly increases DHA, but not ARA levels, in BM 
(Cherian and Sim 1996). In contrast, 89% of BM ARA is derived from maternal adipose 
tissue, which reflects the dietary fat intake of the last 2 years (Del Prado et al. 2001; 
Hodson et al. 2008).  
Furthermore, the human milk banking practices can have an influence on the LCPUFA 
levels of DHM. The effect of freezing on total fat content is inconclusive. Some 
researchers report freezing at -20°C does not affect the total fat content or 
triacylglycerol content, whereas others show a significant decrease after storage 
(Berkow et al. 1984; Romeu-Nadal et al. 2008b; Thatrimontrichai et al. 2012). A time 
and temperature dependent increase in free FAs has been reported (Dill et al. 1984; 
Lavine and Clark 1987). Repeated freezing and thawing can also decrease 
triacylglycerols, decrease the relative amount of LA, and further increase free FAs 
(Wardell et al. 1981; Berkow et al. 1984; Morera Pons et al. 1998). Pasteurisation does 
not affect the relative LCPUFA content, but might affect the total fat content and 
decreases total fat, and therefore LCPUFAs, absorption (Andersson et al. 2007; 
Garcia-Lara et al. 2013; Delgado et al. 2014).  
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4.2 Aim and objectives 
Extremely preterm infants often receive DHM as supplementation to their mother’s own 
BM, and they have higher LCPUFA requirements than term babies. Therefore, 
attention should be paid to provide DHM with the highest possible LCPUFA content. 
Several studies have demonstrated effects of storage time and temperature on the 
LCPUFA quantity and quality.  
The NICE Clinical Guideline 93 focuses mainly on the safe and effective operation of 
HMBs, but not on the nutritional quality of DHM. Indeed, the research 
recommendations stated within the guideline, recommend assessing the effect of 
human milk banking practices on the nutritional and immunological components of 
DHM (National Institute for Health and Clinical Excellence 2010). However, before 
these effects can be assessed, the current human milk banking practices need to be 
ascertained. 
The main aim of this study was to ascertain human milk banking practices in the U.K., 
with respect to international guidance and best practice recommendations, with special 
focus on LCPUFA content.  
 The first objective was to ascertain the human milk banking practices in the 
U.K. with respect to LCPUFAs, using a questionnaire based survey. 
Additionally, the types of nutritional information or advice donors receive from 
HMBs with particular focus on LCPUFAs were investigated 
 The second objective was to assess HMBs’ adherence to the NICE Clinical 
Guideline 93  
 The third objective was to compare practices between HMBs in the U.K. and to 
compare U.K. practices to international published guidance  
 The comparison led to the development of recommendations that should be 
considered for inclusion in the NICE Clinical Guideline 93 and similar 
international guidance, to protect and preserve LCPUFAs in DHM   
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4.3 Material and methods 
Ethical approval for this project (IRAS ID 205068) was obtained from the Health 
Research Authority for England (REC reference 16/HRA/5005), NHS Research 
Scotland for Scotland (R&D reference GN16HS659), and Research Gateway for 
Northern Ireland (HSC Trust ref: WT16/54). Hospital Research and Development 
Offices provided local approvals. Additionally, approval was obtained from 
Bournemouth University’s Research Ethics Committee - Science, Technology and 
Health Panel. Confirmation letters are listed in Appendix IV.I-IV. This study was carried 
out in accordance with the Declaration of Helsinki (1964) and the Data Protection Act 
(1998). 
To include all HMBs in the U.K., and considering the busy nature of Milk Bank 
Managers, an electronic questionnaire was chosen to collect data, to facilitate the most 
efficient form of response. Appendix IV.V provides an overview of all HMBs in the U.K., 
which were identified through the UKAMB website (http://www.ukamb.org/milk-banks/, 
accessed on 17/10/2017). 
The questionnaire was designed to cover all aspects of human milk banking. Sections 
on donor selection, nutrition, DHM storage, transportation and handling by mothers and 
HMBs, as well as general questions about human milk banking were included. The 
questionnaire was specifically developed for this study, using relevant literature and 
knowledge about milk banking practices from a visit to the HMB in Southampton.  
Face and content validity were established within the research team and through 
questionnaire testing (Bourke et al. 2016, pp.33-37). Questionnaire testing included 
pre-testing through expert review (Gillian Weaver, International Human Milk Banking 
Consultant), and field testing, including a pilot test with the Support Manager of the 
Northwest HMB. Feedback obtained through these measures further informed the 
questionnaire design. The final questionnaire can be found in Appendix IV.VI. The 
research proposal was also discussed at the UKAMB annual meeting (08/06/2016, 
London) and the obtained feedback further informed the study design.  
All HMBs in the U.K. received an invitation e-mail, including the survey information 
sheet, the questionnaire and the optional spreadsheet. HMBs were asked to complete 
the questionnaire within three weeks, if no response was obtained in this time frame, 
reminders were sent. Returning the questionnaire was considered as “implicit” consent 
(as described in IRAS Question-specific guidance_Part A Version 2.3, June 2009).  
Descriptive statistics were used to analyse the quantitative parts of the mixed-methods 
questionnaire. Analysis was performed using GraphPad Prism (version 5.0 for 
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Windows). Thematic analysis was used for the qualitative parts of the questionnaire 
(Guest et al. 2012) using and inductive semantic approach as described by Braun and 
Clarke (2006). Coding and themes can be found in Appendix IV.VII. Practices were 
compared to the NICE Clinical Guideline 93 (National Institute for Health and Clinical 
Excellence 2010) and other international human milk banking guidelines.   
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4.4 Results 
The aim was to ascertain human milk banking practices of all HMBs in the U.K. The 
King’s College Hospital Milk Bank was closed for refurbishment during the recruitment 
period (November 2016 to February 2018). Therefore, there were only 15 HMBs 
eligible to take part in the study. A response rate of 93% was achieved, one HMB 
declined participation due to staff shortage (Figure 4-4). No HMB completed the 
optional prospective spreadsheet detailing DHM storage at the HMB.  
 
Figure 4-4: Consort flow chart of HMB recruitment and data analysis 
One HMB was excluded from the study as it was closed for refurbishment. One HMB declined participation 
due to staff shortage. Response rate 93% (14 of 15 HMBs). 
4.4.1 Donor selection 
The majority of HMBs (12/14, 85.7%) allowed mothers to start donating up to six 
months after birth. 1/14 (7.1%) HMBs had no cut-off limit and another one (1/14, 7.1%) 
had three months as latest start point. Overall, reasons included a change in BM 
quality (6/14, 42.8%), including concerns about micronutrients such as iron and 
magnesium (1/6, 16.6%), trace elements (1/6, 16.6%), and energy content (1/6, 16.6%, 
HMB with three months cut-off). Further reasons included, BM contamination (1/14, 
7.1%), cost efficiency (1/14, 7.1%), and that babies are usually weaned around this 
time (2/14, 14.3%). 
Varying time-limits were in place for the last accepted donation (Table 4-1). HMBs with 
later time-limits noted that most mothers would have stopped donating before that time-
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point, however, a cut off at twelve months may help to increase the amount of available 
DHM in times of low supply. Again, change in BM quality was the time determining 
factor, stated by 5/14 (35.7%) HMBs. 1/14 (7.1%) HMBs reported that an internal audit 
revealed that donations are often wasted due to declining donor hygiene when the 
baby gets older. 








Varying time-limits for last DHM donations. Responses to question1.6. Response rate 14 of 14. 
All HMBs (14/14, 100%) accepted donations from women who had multiple 
pregnancies. Tandem feeding (simultaneously feeding a new-born and an older child) 
was allowed in 12/14 (85.7%) HMBs. 2/14 (14.3%) HMBs did not accept DHM from 
tandem feeding due to potential unsuitable BM composition for preterm neonates. 
4.4.2 Nutrition and nutritional information 
12/14 (85.7%) HMBs did not exclude mothers from donating if they follow a restricted 
diet, such as being vegan. 1/14 (7.1%) HMBs would potentially exclude donors after 
careful assessment of implications. 1/14 (7.1%) HMBs excluded vegans without vitamin 
B12 supplementation. Only 9/14 (64.3%) HMBs assessed donors’ dietary habits. Of 
these nine HMBs, 4/9 (44.4%) assessed dietary habits before, and 5/9 (55.5%) before 
and during the period of donation. Dietary aspects of interest included following a 
vegetarian or vegan diet (5/9, 55.5%), an extreme exclusion diet (2/9, 22.2%), a dairy 
free diet (1/9, 11.1%), a nut free diet (1/9, 11.1%), a cow’s milk protein free diet (1/9, 
11.1%), a varied diet (1/9, 11.1%), caffeine intake (1/9, 11.1%) and oily fish intake (1/9, 
11.1%).   
Time after childbirth HMBs (%) 
6 months 2 (14.3) 
7 months 2 (14.3) 
6 to 8 months 1 (7.1) 
9 months 2 (14.3) 
9 to 10 months 1 (7.1) 
12 months 4 (28.6) 
No limit 2 (14.3) 
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Only 4/14 (28.6%) HMBs offered information about a healthy diet for breast feeding 
mothers to donors, 10/14 (71.4%) HMBs reported not to have any information available 
(Figure 4-5 A). It is important to note that in only 2/14 (14.3%) HMBs a registered 
dietitian was part of the team. In 8/14 (57.1%) HMBs, registered dietitians could be 
consulted at the hospital and 4/14 (28.6%) HMBs had no access to a registered 

























Figure 4-5: Provision of nutritional information and availability of registered dietitians 
A: Nutritional information provided to donors. Responses to question 2.1. Response rate 14 of 14.  
B: Availability of a registered dietitian for consultation. Responses to question 2.2. Response rate 14 of 14. 
4.4.3 Handling of DHM at donor’s home 
DHM was collected in clear bottles in the majority of HMBs (13/14, 92.9%). 1/14 (7.1%) 
HMBs used clouded bottles. The bottles were provided by the HMBs (14/14, 100%), or 
by the hospitals which provided either HMB approved bottles (8/14, 57.1%) or own 
bottles (2/14, 14.3%). In 1/14 (7.1%) HMBs, mothers could donate BM providing their 
own containers.  
Immediate freezing of expressed BM was requested by 4/14 (28.6%) HMBs, whereas 
pooling over 24 hours in the refrigerator was allowed by 10/14 (71.4%) HMBs. 8/10 
(80%) HMBs further specified that BM should be stored on a shelf in the refrigerator. 
Table 4-2 displays the maximum storage time of DHM in donors’ freezers. Based on 
estimations from two HMBs, the majority of DHM was stored for two to eight weeks 
before transportation to the HMB.  






























Maximum storage time of DHM in donors’ freezers. Responses to question 3.2. Response rate 14 of 14. 
No minimum amount of DHM needed to be collected for donation in 5/14 (35.7%) 
HMBs. 1/14 (7.1%) HMB has no set minimum but expects 1000 mL. This was also the 
minimum in one other HMB (1/14, 7.1%). 4/14 HMBs (28.6%) expect at least 2000 mL, 
whereas one of them (1/4, 25%) would accept less from a bereaved mother. 2/14 
(14.3%) HMBs specified a minimum of 3000 mL and one (7.1%) HMB specified that 
3000 mL need to be collected over the whole time of donations. 6/9 (66.7%) HMBs 
indicated their limits were set to be cost effective (3x 3000 mL, 2x 2000 mL, 1x 1000 
mL). 
4/14 (28.6%) HMBs informed that DHM should be specifically labelled if the donor had 
delivered preterm (< 37 weeks gestational age). In 1/14 (7.1%) HMBs, DHM was 
labelled as cow’s milk free and in another one (1/14, 7.1%) as dairy free. Other dietary 
habits were not specified. Colostrum was specifically labelled in two (14.3%) HMBs, 
one of those also specifically labelled transitional DHM (not further specified). 
4.4.4 Transportation of DHM 
The majority of HMBs (12/14, 85.7%) reported that they liaised with volunteer courier 
services for DHM collection. Five of them (35.7%) were exclusively using volunteer 
courier services. Staff collections were used in 7/14 (50%) HMBs, commercial couriers 
in 3/14 (21.4%) HMBs, and in 8/14 (57.1%) HMBs the donor or her family were 
transporting the DHM. Only 1/14 (7.1%) HMBs used dry-ice for transportation. 1/14 
(7.1%) HMBs reported to sometimes use dry-ice. The general transportation time-limit 
policy varied greatly (Table 4-3).  
Duration of storage HMBs (%) 
2 to < 4 weeks 1 (7.1) 
1 to < 2 months 3 (21.4) 
2 to < 3 months 10 (71.4) 
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Time-limit for frozen DHM transportation to the HMB. Responses to question 5.9. Response rate 14 of 14. 
1/14 (7.1%) HMBs responded that a freezer vehicle will be used for any transportation 
over four hours. DHM was only accepted if it remained frozen during transportation by 
one of the HMBs without time-limit (1/5, 20%). 6/14 (42.9%) HMBs stated that DHM is 
examined for signs of defrosting on arrival and 3/14 (21.4%) HMBs reported that 
immediate pasteurisation is considered if there are concerns about DHM integrity.  
4.4.5 Handling of DHM at the HMB 
Unpasteurised DHM was stored at -20°C in 11/14 (78.6%) HMBs. 3/14 (21.4%) HMBs 
reported lower storage temperatures (one at -21°C; one at -20°C to -40°C; one 
at -20°C to -26°C). An estimation of DHM storage time until pasteurisation was 
provided by 3/14 (21.4%) HMBs. Accordingly, the majority of DHM was pasteurised 
between one and four weeks of arrival at the HMB. 1/14 (7.1%) HMBs prioritised DHM 
from bereaved mothers, to award the thank you card and donor badge faster to those 
mothers after distributing their DHM. Additionally, colostrum was pasteurised 
immediately upon arrival and preterm BM was prioritised for processing over term BM. 
11/14 (78.6%) HMBs stated to pool unpasteurised DHM from one donor. 2/14 (14.3%) 
HMBs would only sometimes pool DHM from the same donor if they receive very small 
volumes, and 1/14 (7.1%) HMBs does not pool DHM. It was documented that DHM is 
thawed, pooled if applicable, and directly pasteurised after taking a sample for 
microbiological testing (12/14, 85.7%). The other 2/14 (14.3%) HMBs reported to 
refreeze the bottles for 48 hours or to store the bottles in the refrigerator for 24 hours, 
respectively, before pasteurisation (Figure 4-6). Pasteurisation frequency can be found 
in Table 4-4. 
Duration of transportation HMBs (%) 
30 minutes 2 (14.3) 
1 hour 3 (21.4) 
2 hours 1 (7.1) 
4 hours 2 (14.3) 
5 hours 1 (7.1) 




























Figure 4-6: DHM processing after thawing and pooling 
DHM is thawed, pooled (from one donor), and then either directly pasteurised, stored at 4°C for 24 hours, 
or stored at -20°C for 48 hours before pasteurisation. One HMB does not pool DHM from the same donor 
but would directly pasteurise. Responses to question 5.7. Response rate 14 of 14. 
 









Pasteurisation frequency of DHM in HMBs. Responses to question 4.3. Response rate 14 of 14. 
All HMBs (14/14, 100%) reported freezing DHM after pasteurisation. The freezing 
temperatures were -20°C in 10/14 (71.4%) HMBs and varied in the other 4/14 (28.6%) 
HMBs (one at -20 °C to -40°C, one at -21°C; one at -40°C, one at -20°C to -26°C). 
Distribution followed the “first in, first out” principle in 11/14 (78.6%) HMBs. 4/14 
(28.6%) HMBs reported that preterm BM is distributed to preterm babies as preference, 
when available. Similar, 2/14 (14.3%) HMBs would provide preterm babies with DHM 
from a mother of a younger baby, if available. 3/14 (21.4%) HMBs try to provide DHM 
Pasteurisation (per week) HMBs (%) 
Daily 1 (7.1) 
3 times 4 (28.6) 
2 to 3 times 1 (7.1) 
2 times 3 (21.4) 
1 to 2 times 1 (7.1) 
1 time 1 (7.1) 
Depending on staffing and 
amount of DHM 
3 (21.4) 
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from one donor for one recipient. 1/14 (7.1%) HMBs estimated the DHM storage time 
at the HMB to be one to two weeks for the majority of DHM.  
Nutritional assessment of DHM for energy and macronutrient content was performed 
by HMB staff in 5/14 (35.7%) HMBs, of which 3/5 (60%) performed the analysis post-
pasteurisation. Fortification of DHM with Cow and Gate BM fortifier was performed very 
rarely in 1/14 (7.1%) HMBs.  
4.4.6 General questions and further comments 
Five respondents described their HMB as working well. The incoming milk supply was 
also described as good in three HMBs. This is reflected by an increase of 51.5% of 
DHM provided by nine HMBs from 2014 to 2015 (4575.0 L vs. 6928.9 L), whereas the 
number of donors only increased by 6.6% (1135 vs. 1210) in the same period. 10/14 
(71.4%) HMBs have never had to refuse the request for DHM from hospitals. One HMB 
reported that they are revising the criteria for DHM use, to make DHM available to a 
larger number of babies. DHM is for example used on the postnatal ward to support 
breastfeeding for small babies. One HMB placed emphasis on the donors’ role: 
“We look after our donors and really appreciate their time and effort to help 
these babies and try to make it as easy as possible to donate to us” (HMB #14). 
11/14 (78.6%) HMBs reported that they were never asked to provide DHM from donors 
with specific dietary habits. 1/14 (7.1%) HMBs provided cow’s milk free diet DHM on 
request once in the last year. Another HMB was asked to provide high caloric DHM for 
infants with poor growth. Colostrum was provided regularly on request from the 
neonatal unit for extremely preterm infants in 1/14 (7.1%) HMBs. DHM for Muslim 
babies was provided by 1/14 (7.1%) HMBs. 1/14 (7.1%) HMBs was asked twice to 
provide low fat DHM. 2/14 (14.3%) HMBs regularly provided DHM from mothers of 
preterm babies.  
Regular donations, where mothers start collecting BM for donation after their initial 
screening and training, accounted for the majority of BM donations (7/14 HMBs, 50%, 
ranging from 70 to 95% of donations). However, two HMBs described processing 



























Figure 4-7: Predominantly processed DHM at HMBs 
DHM can either be donated regularly after screening and training, or pre-collected milk can be donated. 
Donations were considered regular if more than 70% of the DHM came from regular donations. 
Responses to question 6.5. Response rate 9 of 14.  
4.4.7 Areas for improvement 
9/14 (64.3%) respondents suggested areas for improvement. The overall emergent 
theme was lack of resources. Indicative of this, three corresponding sub themes were 
identified: (1) lack of time, (2) staff training, (3) work environment. Lack of time was the 
most mentioned theme in the analysis, stated by four representatives. Staffs were 
working overtime in one HMB, and there was not enough time to pasteurise on more 
days in another HMB. In three HMBs, the milk bank managers had not enough time for 
the operation of the HMB due to too many additional responsibilities. This is 
underpinned by the following quote:  
“I have to see breast feeders in difficulty, do breast feeding support groups and 
provide the training for both our staff and peer support mothers for UNICEF 
baby friendly. At present I am auditing this too. I really feel that a milk bank 
manager should have one sole role.” (HMB #2). 
Time was also lacking to further staff knowledge in one HMB, leading to the second 
sub theme staff training. This was brought up by a second HMB which stated that more 
experienced staff would be needed to expand the HMB. Work environment was 
brought up by four representatives. One HMB needed more physical space, another 
one would like a dedicated space away from the neonatal unit. Furthermore, HMBs 
needed a new, more efficient pasteuriser, a bar coding system to save time and avoid 
human error, more computers and a dedicated HMB phone line and answer machine. 
Beyond that, one respondent stated that they were looking to streamline donor 
recruitment. One HMB struggled with organising phlebotomy for distant donors. One 
very important point for improvement was raised by an HMB manager: 
“It would be ideal if every milk bank operated in the same way” (HMB #5).  
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4.5 Discussion 
This study aimed to provide a representative summary of the human milk banking 
practices in the U.K., specifically focusing on factors that may affect LCPUFA content 
of DHM. An overall response rate of 93% was achieved (14/15 HMBs), hence the 
collected data is a highly representative summary of the human milk banking practices 
in the U.K. at the time of data collection. The results show great variation in practices 
amongst the different HMBs in the U.K., which can have a significant impact on the 
nutritional quality of DHM. 
DHM might be the only enteral nutrition preterm babies receive for a prolonged period 
of time and it needs to provide all nutrients needed for infants’ development. Therefore, 
it is imperative to provide preterm babies with the best possible quality of DHM. One 
key priority for the implementation of the NICE Clinical Guideline 93 was quality 
assurance. Part of the quality assurance is that DHM that will be administered in the 
NHS should be from HMBs that can demonstrate adherence to the Clinical Guideline 
93 (National Institute for Health and Clinical Excellence 2010). Considerable variations 
were identified across all areas of human milk banking practices in this study. 
Therefore, it was analysed whether the variations are within the scope of the NICE 
Clinical Guideline 93. Furthermore, the different practices used across the U.K. were 
compared amongst each other and with practices used in other countries. Considering 
the available evidence, best practice recommendations for the handling of DHM with 
the aim to protect LCPUFAs were produced. 
4.5.1 Donor inclusion and exclusion criteria  
The NICE guideline does not regulate the latest starting point for donation, or the time-
point for the last donation (National Institute for Health and Clinical Excellence 2010). 
Section 1.35 only states consideration of the number of babies receiving DHM, the 
DHM stocks, and donor’s preferences when deciding how long women can donate BM 
(National Institute for Health and Clinical Excellence 2010). Therefore, it is not 
surprising that the HMBs had varying cut-off levels. Similarly, tandem feeding and 
accepting donations from donors with multiple pregnancies is not considered in NICE 
Clinical Guideline 93. Two HMBs did not accept tandem feeding, due to potential 
unsuitable BM composition. In relation to the latest starting point or the last time-point 
for donating, HMBs were mostly concerned about the nutritional quality of DHM, 
including micronutrient content.  
Indeed, zinc and copper concentrations significantly decline during the first four months 
of lactation (Yalcin et al. 2015). A significant decline in copper and zinc during the first 
twelve months of lactation was also demonstrated, with significant lower concentrations 
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during months seven to twelve compared to months four to six (Rajalakshmi and 
Srikantia 1980). One more study showed significant reduced copper and zinc levels at 
one year postpartum (Vaughan et al. 1979). All HMBs accepted donations until at least 
six months after childbirth. Considering this evidence, cut off limits after six months 
should not be based on concerns for zinc and copper concentrations. 
HMBs specifically mentioned concerns about the iron content of BM. Iron content was 
20% greater at the beginning of lactation compared to one year postpartum (Vaughan 
et al. 1979). Another study found that BM iron levels decline by 47% during the first five 
months of lactation (Siimes et al. 1979). Iron concentrations are especially of concern 
when feeding preterm infants. They often have iron deficiencies due to prematurely 
interrupted placental iron transfer (Scott et al. 1975). Iron status in preterm infants is 
linked to their neuro-behavioural status, with lower levels correlating with poorer neuro-
behavioural development (Armony-Sivan et al. 2004). Iron plays a role in 
neurodevelopment, more specifically in myelination, monoamine metabolism, energy 
metabolism, and dendritic growth in the hippocampus (Georgieff and Innis 2005; 
Georgieff 2008). Indeed, iron-deficiency at birth results in a poorer mental and 
psychomotor development of school aged children (Tamura et al. 2002). Iron also has 
a link to the LCPUFA metabolism, the FA desaturases have an active diiron centre 
(Shanklin et al. 2009).  
HMBs were also especially concerned about the magnesium content of BM. 
Magnesium levels showed no consistent pattern of change during time of lactation in 
one study (Vaughan et al. 1979), whereas Rajalakshmi and Srikantia demonstrated a 
significant decrease in magnesium levels from colostrum to mature milk at one month 
of lactation, although no further decreases were recorded up to one year postpartum 
(Rajalakshmi and Srikantia 1980). Therefore, concerns about magnesium levels should 
not influence the cut off levels for donation.  
HMBs did not raise concerns about LCPUFAs, however they should be considered 
when the DHM is intended for preterm infants, since they are prone to have a LCPUFA 
gap after birth. The LCPUFA composition of BM changes with the duration of lactation. 
DHM is mostly donated by mothers of term babies, who have established a sufficient 
and stable BM supply (Valentine et al. 2010; Valentine et al. 2013). Relative DHA and 
ARA concentrations have been shown to decline over the first 20 days (Genzel-
Boroviczeny et al. 1997), and were significantly lower at three months (Nilsson et al. 
2018), four months (Makrides et al. 1995c), and twelve months (Mitoulas et al. 2003) in 
studies. The absolute DHA and ARA levels also decline significantly within the first six 
weeks of lactation (De Rooy et al. 2017). However, during the first year of lactation, the 
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total fat content of BM increases (Bitman et al. 1983b; Mitoulas et al. 2003). The 
absolute amount of DHA and ARA in 150 mL BM at months 1, 2, 4, 6, 9, 12 of lactation 
were calculated, using the relative FA composition and absolute fat concentration at 
these times reported by Mitoulas et al. (2003). This shows that a preterm infant 
(28 weeks gestational age, 1000 g, assuming 150 mL per kg bodyweight per day as full 
enteral feeding) would receive similar amounts of DHA and ARA from DHM expressed 
during the first or the twelfth month of lactation (Appendix IV.VIII). However, this 
calculation is based on the values of five BM samples only. Larger studies are needed 
to confirm the results. Analysis of BM FA composition and fat content in the second 
year postpartum should also be performed. Perrin and colleagues have found no 
changes in fat content in BM samples from eleven to 17 months postpartum and based 
on this and their other results, they are recommending HMBs accept donations beyond 
one year postpartum to increase the DHM supply (2016).  
The available evidence does not support the need to provide recommendations for the 
latest starting point or the time-point for the last donation with regards to LCPUFA 
levels. Other micronutrients need to be considered when informing guidelines, and as 
mentioned by Perrin et al. mineral fortification of DHM may be required (Perrin et al. 
2016).  
4.5.2 Nutritional status, dietary habits, and LCPUFAs 
The NICE Clinical Guideline 93 recommends assuring that potential donors are in good 
general health (section 1.13) (National Institute for Health and Clinical Excellence 
2010), which is not further defined. One HMB reported that dietary habits are discussed 
as part of the general health questions. Since maternal nutrition during lactation is not 
included within the remit of the NICE Clinical Guideline 93, there was wide variability in 
HMBs consideration of donors’ diet. Five HMBs did not assess donor’s dietary habits, 
whereas two HMBs excluded donors if they follow a restricted diet, although this is not 
specified in the exclusion criteria in the NICE Clinical Guideline 93 section 1.12 
(National Institute for Health and Clinical Excellence 2010). 
It is established that nutrition has an impact on LCPUFA levels and especially DHA 
levels of BM (Cherian and Sim 1996; Yuhas et al. 2006). Hence, it seems obvious that 
dietary habits of donors should be assessed. Swedish HMBs asses dietary habits and 
do not accept BM from donors who eliminate important staple foods (Polberger et al. 
2016), although these are not further specified. The Swedish guideline also 
recommends that vegetarians should take food supplements to ensure a balanced diet. 
In the U.K., only one HMB excluded vegans who do not take vitamin B12 supplements. 
Vegan diets do not contain any natural vitamin B12, hence, their BM vitamin B12 levels 
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are lower (Specker et al. 1990), leading to vitamin B12 deficiency in infants. This can 
lead amongst others to irritability, failure to thrive, and developmental regression (Dror 
and Allen 2008). Therefore, the European Milk Bank Association recommends 
exclusion of donors that follow a vegan diet without supplementing vitamin B12 
(Weaver et al. 2019). 
Similarly, vegans and vegetarians also have significantly lower DHA levels in BM than 
omnivores (Sanders and Reddy 1992), whereas ARA BM levels are comparable to 
omnivores, although vegetarian and vegan diets provide little or no ARA (Sanders and 
Reddy 1992; Sanders 2009). This should especially be considered when DHM is 
intended for feeding preterm infants, due to the LCPUFA gap of prematurity.  
BM LCPUFA levels are not only influenced by their respective dietary intake, but also 
by the levels of precursor fatty acids in the diet, which can influence the precursor 
conversion to LCPUFAs (Nakamura and Nara 2004), and therefore, the LCPUFA BM 
levels. High PUFA and especially LA intake can reduce DHA levels (Gibson et al. 
2013). Hence, it is also important to consider C18 PUFA intake in donors. LA intake 
has significantly increased over the last decades. For example, in 1980, LA intake 
accounted for about 3% of the total energy intake, while this increased to 5% by 1992 
(Sanders 2000). The increased LA intake has also been reflected in increased LA and 
decreased DHA levels in BM in the last decades (Crawford et al. 1976a; Yuhas et al. 
2006). Increased use of vegetable fats with high LA content, e.g. sunflower and corn 
oils, and a decrease of animal fats are a main reason for this increase (Sanders 2000). 
The International Society for the Study of Fatty Acids and Lipids considers an LA intake 
of 2% of total energy intake as adequate (ISSFAL 2004). The high intake of LA is also 
reflected in the currently high n-6 to n-3 ration in Western diets (16:1) (Simopoulos 
2002). In contrast to this, the hunter-gatherer diet in the Paleolithic period had a ratio of 
about 1:1 (Kuipers et al. 2010), while nowadays, a ratio of 5:1 is often recommended. 
Recommendation 1: Assess dietary habits of donors to ensure high nutritional quality 
of DHM.  
The use of fish oil or DHA supplements can be useful to increase BM DHA levels in 
donors that eliminate fish from their diet, as well as in vegetarian and vegan donors. 
Although vegetarian diets can be high in ALA, preformed DHA is a better source for 
brain accretion (Su et al. 1999) and should therefore be provided to preterm infants. 
DHA supplementation of lactating mothers has been shown to dose-dependently 
increase BM DHA levels (Makrides et al. 1996), whereas flaxseed oil (high in ALA) 
supplementation does not increase DHA BM levels (Francois et al. 2003). Smithers 
and colleagues conclude from the DINO trial that BM exceeding 1% DHA may be 
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needed to increase the DHA status of preterm infants to levels of term infants (2008). 
Colostrum DHA levels of 1.15% were achieved after supplementing mothers with 2.2 g 
DHA from 20 weeks gestation until delivery (Dunstan et al. 2007). No adverse 
outcomes were reported using this dose. 
Recommendation 2: Inform donors with restricted diets and/or no or low fish intake 
about the potential of DHA supplements to increase their BM DHA status and the likely 
benefits of this. 
Changing donor’s dietary habits could not only benefit the nutritional quality of the DHM 
but could also benefit the donor’s own baby. Although ten HMBs reported having 
registered dietitians available for consultation, uptake of this service was not assessed 
by this survey. General nutritional advice for lactating women is not available to most 
HMBs. However, regarding fish and therefore DHA intake, the Scientific Advisory 
Committee on Nutrition’s “Advice on fish consumption” is accessible, which states that 
lactating women should consume at least two portions of fish per week including one 
portion of oily fish, with restrictions on high methylmercury containing fish (marlin, 
swordfish, shark, and tuna) (Scientific Advisory Committee on Nutrition 2004). 
Methylmercury is a neurotoxin that can lead to neurological and developmental deficits 
(Farina et al. 2011). Nevertheless, several studies, summarised in a systematic review, 
show that there are no net adverse effects of seafood consumption on neurocognitive 
development, even in the highest intake group, consuming more than three portions of 
seafood (>340 g) per week (Hibbeln et al. 2019). Overall, the nutrients in seafood, 
including DHA, lead to a beneficial effect of seafood consumption on neurocognitive 
development, besides the presence of methylmercury (Spiller et al. 2019). 
Furthermore, results from the ALSPAC (Avon Longitudinal Study of Parents and 
Children) study indicate that children of women who consumed less than 340 g of 
seafood per week during pregnancy had an increased risk of being in the lowest 
quartile for verbal intelligence quotient (OR 1.09, 1-340 g vs. >340 g) (Hibbeln et al. 
2007). This indicates that the current recommendations to limit seafood intake could 
even be detrimental (Hibbeln et al. 2007), and women should be encouraged to eat 
seafood/fish. Despite this, in the U.K., fish consumption recommendations are not met. 
The National Diet and Nutrition Survey defined a portion as 140 g of fish, however, the 
average intake of oily fish of women (19-64 years) was only 8 g per day or 56 g per 
week in 2012-2014 (Public Health England 2016). Furthermore, data from BM donors 
in the U.S.A. suggest that their dietary DHA intake is significantly less than 
recommended (Valentine et al. 2013). Therefore, fish intake could be improved in the 
U.K. to increase BM DHA, potentially by providing donors with this nutritional advice. 
Gibson and colleagues also recommend a blend of sunola oil with small amounts of 
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linseed and canola oil for cooking, resulting in a FA composition of 5% PUFAs with an 
LA to ALA ratio of around 2:1, which would be ideal to improve the n-3 status (Gibson 
et al. 2011), and therefore, most likely also the DHA content in BM. 
Providing donors specifically with intake recommendations for lactating mothers might 
increase their BM DHA levels as demonstrated in a study by Juber et al. In this study, 
lactating mothers in the U.S.A. were informed about their BM DHA levels and provided 
with information on the recommended DHA intake for them (Juber et al. 2016). Within 
one month, the DHA BM levels increased significantly from 0.19% to 0.22% of total FA. 
Obviously, providing nutritional advice can only have an impact prospectively. Results 
from this questionnaire indicate that the majority of DHM in the U.K. is donated 
prospectively and not from pre-collected BM. Therefore, providing nutritional 
information to donors could be successful in the U.K.  
Recommendation 3: Provide nutritional information to donors, especially the SACN 
recommendation of one portion (140 g) of oily fish per week and improve access to 
nutritional advice for lactating mothers. 
4.5.3 Storage of DHM 
Storage containers 
Section 1.41 recommends that only BM collected in HMB provided or approved bottles 
can be accepted for donation (National Institute for Health and Clinical Excellence 
2010). In two HMBs, mothers were able to donate BM, providing their own containers; 
however, this does not violate the guideline if the HMBs approve of the bottles. In all 
but one HMB, the bottles used for BM collection were clear. Chang and colleagues 
found that BM storage in light brown coloured polyether sulfone bottles led to the least 
fat loss compared to storage in other plastic or glass containers (1.2% less fat loss than 
in polyethylene bags) (2012). Similarly, BM storage in amber glass bottles for 4 months 
at -18 °C inhibits hexanal formation, and therefore lipid peroxidation, significantly 
(Vangnai et al. 2017). Protecting bottles from light exposure during collection, for 
example by wrapping collection bottles in foil, resulted in a 13% greater riboflavin 
(vitamin B2) content of BM (Bates et al. 1985). Since most HMBs provide the collection 
bottles, it would be a simple process to implement the use of different bottles.  
Recommendation 4: Use light protective, e.g. amber coloured, bottles, or wrap bottles 
in aluminium foil, when collecting and storing DHM, to improve the nutritional quality.  
Storage in the refrigerator 
Section 1.38 recommends freezing expressed BM as soon as possible and allows 
pooling of BM from one donor over a 24 hour period in the refrigerator (National 
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Institute for Health and Clinical Excellence 2010). All HMBs complied with the guideline 
in this point.  
Storage of BM at 4C for up to 96 hours has been shown not to change the total lipid 
content (Slutzah et al. 2010). Similarly, LCPUFA content is not significantly altered 
when BM is stored for up to 96 hours at 4C (Romeu-Nadal et al. 2008b). However, 
refrigerated storage for up to 24 hours increases free FAs significantly (Dill et al. 1983; 
Lavine and Clark 1987; Bertino et al. 2013). The highest increase was noted for n-3 
PUFAs (Bertino et al. 2013). Free FA can bind to other components of BM, e.g. 
proteins or calcium, thereby decreasing the LCPUFA absorption (Dill et al. 1984; 
Lavine and Clark 1987). Free FAs in BM show cytotoxic activity, and high 
concentrations can lead to cytolysis of erythrocytes (Ogundele 1999), and leukocytes 
(Sakaguchi et al. 1995). Free FAs, and especially LCPUFAs, are prone to lipid 
peroxidation (Cosgrove et al. 1987; Silvestre et al. 2010). Indeed, storage at 4C for 
48 hours significantly increased MDA levels in mainly term BM (Miranda et al. 2004). 
However, similar storage did not increase MDA in preterm BM (Bertino et al. 2013), 
potentially due to higher antioxidant capacity (Turhan et al. 2011). LPPs can bind to 
DNA and proteins, potentially leading to cell and tissue damage and thereby increase 
inflammation (Yadav and Ramana 2013).There is vast evidence that refrigeration also 
decreases vitamin C levels (Buss et al. 2001; Rechtman et al. 2006; Romeu-Nadal et 
al. 2008b), whereas it does not have an effect on α- and γ-tocopherol levels (Moffatt et 
al. 1987; Romeu-Nadal et al. 2008b).  
A recent publication from the United States recommended best practice for handling 
and storing DHM (Steele 2018). However, this review only summarised some current 
published guidelines, and recommended that fresh BM can be stored for 48 hours in 
the refrigerator. In Italy, BM for donation can be stored in the refrigerator at 4°C for up 
to 24 hours (Arslanoglu et al. 2010). If the donor’s refrigerator has no temperature 
monitoring system, the BM needs to be transferred to the freezer within 12 hours. The 
Australian milk banking guideline recommends storing expressed BM immediately in 
the coldest part of the freezer, which is specified as in the lower part towards the rear 
of the freezer (Hartmann et al. 2007). The NICE guideline does not specify where BM 
should be stored in the refrigerator (National Institute for Health and Clinical Excellence 
2010), and of the ten HMBs which allow pooling of BM in the refrigerator, only eight 
instruct their donors to store BM on a shelf in the refrigerator. 
Recommendation 5: Freeze DHM immediately in a domestic freezer (≤ -18°C) after 
expression and do not allow pooling in the refrigerator over a 24 hour period.  
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One main reason for pooling DHM is to minimise the space used in the freezer. 
Providing donors with different sized containers could help to reduce the space used 
for DHM storage. The Italian milk banking guideline also specifies that the container 
should be stored in the coldest area of the refrigerator, distant from the door 
(Arslanoglu et al. 2010).  
Recommendation 6: If pooling in the refrigerator for up to 24 hours is allowed, instruct 
donors to store BM in the coldest part of the refrigerator and not in the door. 
Frozen storage 
The majority of HMBs allowed frozen (< -18°C) storage of DHM at donors’ homes for 
up to three months, which is compliant with section 1.40 (National Institute for Health 
and Clinical Excellence 2010). However, the same section also states that frozen BM 
should be transported to the HMB as soon as possible. Therefore, having wide 
variations regarding the minimum amount of DHM that needs to be collected before the 
first donation in nine HMBs disagrees with the guideline.  
Data on the effects of frozen storage on the fat content and LCPUFA levels in DHM are 
inconclusive. Several researchers found that storage at -20°C for nine months does not 
affect total fat content (Ahrabi et al. 2016), and the absolute FA and relative FA content 
was not significantly altered in studies from 30 days storage (Lacomba et al. 2012) up 
to twelve months (Romeu-Nadal et al. 2008b). Storage at -18°C for 28 days does not 
change total triacylglycerols (Tacken et al. 2009). However, storage at -20°C leads to a 
significant loss of total fat after 48 hours (Chang et al. 2012), a significant decrease in 
total lipid concentrations after eight days (Pardou et al. 1994), a significant loss of total 
fat after 30 days storage (Thatrimontrichai et al. 2012) and resulted in a 10% decrease 
in triacylglycerols after five months (Berkow et al. 1984). Garcia-Lara and colleagues 
also found a significant reduction in fat content after seven days and up to 90 days 
after BM storage at -20°C, whereas the biggest decrease occurred during the first week 
(-0.027 g/dL/day) (2012). The variation in findings might be explained by the different 
analytical methods used (Silvestre et al. 2014). Additionally, BM might have not been 
homogenised sufficiently before analysis, BM storage in the fridge or on the bench for 
thawing after being frozen results in a rise of milk fat globules to the top, where they 
form a cream layer (Jensen and Jensen 1992). Other reasons might include 
differences in fat adherence to container walls (Chang et al. 2012; Lev et al. 2014), or 
differences in thawing methods which can influence fat content (Thatrimontrichai et al. 
2012).  
BM contains the bile salt-dependent lipase, which aids in the digestion of milk fat and 
compensates for the immature digestive system in new-borns (Hernell 1975; Watkins 
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1985). However, the bile salt-dependent lipase loses its bile salt-dependency during 
two weeks frozen storage at -10°C (Mehta et al. 1982), which can lead to lipolysis of 
triacylglycerols and increase in free FA levels. Longer-chain PUFAs seem to be more 
susceptible to hydrolysis than shorter-chain FAs and the degree of hydrolysis is 
temperature and time dependent (Lavine and Clark 1987). Indeed, free FAs in BM 
increase significantly after eight weeks storage at -11°C (Lavine and Clark 1987). An 
accumulation of free FAs was also already observed after 24 hours frozen storage 
(-20°C), further increasing after 180 days (Dill et al. 1983). Other studies also show 
significant increases in free FA after BM storage at -20°C for two to five months 
(Bitman et al. 1983a), four months (Morera Pons et al. 1998), or nine months (Ahrabi et 
al. 2016). Elevated levels of free FAs have the potential to increase lipid peroxidation, 
(Turoli et al. 2004; Martysiak-Zurowska and Stolyhwo 2006). Indeed, significant 
increases in MDA levels are seen after 60 days storage at -20°C, but not after 15 or 30 
days (Silvestre et al. 2010). Storage at -18°C also increases hexanal significantly in 
pooled BM after three months storage, with a further significant increase after five and 
six months (Vangnai et al. 2017). Furthermore, the protective vitamin C content is 
significantly reduced after storage at -20°C (Bank et al. 1985; Marinkovic et al. 2016). 
However, storage at -18°C is the only option at donors’ homes. This might be the 
reason why in Brazil, DHM storage in a freezer is allowed for no more than five days 
prior to processing (Gutierrez and de Almeida 1998). In Italy, the maximum total 
storage time for DHM that is intended to feed preterm babies is three months 
(Arslanoglu et al. 2010). To reduce pre-pasteurisation time, DHM should be transported 
to the HMB as soon as possible after expression. To facilitate this, ideally HMBs should 
not restrict the minimum amount of DHM that needs to be collected before the first 
donation. However, HMBs highlighted setting limits to be cost effective. One HMB 
mentioned that they are expecting the collection of 3000 mL over the course of 
donation. 
Recommendation 7: Reduce DHM pre-pasteurisation storage time at -20°C to a 
minimum. Issues regarding cost effectiveness can be addressed by setting a minimum 
volume of DHM for the course of donation instead of a minimum for the first donation. 
Storing DHM awaiting pasteurisation at -20 °C for a maximum of three months after the 
date of expression is recommended in section 1.53 (National Institute for Health and 
Clinical Excellence 2010). Based on the answers from three HMBs, DHM is normally 
stored for up to one month at the HMB. As described previously, the pre-pasteurisation 
storage time should be minimised. BM storage at -80°C for five or 12 months 
respectively, does not affect saturated or monounsaturated FAs, or PUFAs (Romeu-
Nadal et al. 2008b) or triacylglycerols (Berkow et al. 1984). Another study found a 
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significant fat decrease after 44 days of storage at -80°C (Lev et al. 2014), although no 
comparison was made to storage at -20°C, so it is not known which storage condition 
would be better. BM storage at -80°C also prevented the formation of free FAs in 
several studies storing BM for up to five months (Bitman et al. 1983a; Lavine and Clark 
1987; Morera Pons et al. 1998). Although it is not achievable to store unpasteurised 
DHM at -80°C at donors’ homes, this would be feasible at HMBs.  
Section 1.62 specifies storing frozen (-20°C) DHM for a maximum of six months after 
the date of expression (National Institute for Health and Clinical Excellence 2010). 
Frozen storage for three months at -20°C post-pasteurisation has no effect on total fat 
content (Lepri et al. 1997). Storage of pasteurised BM for one month at -25°C (Friend 
et al. 1983b), or for three months at -20°C (Lepri et al. 1997) resulted in no significant 
change in free FA content. One explanation for this is the inactivation of the bile salt-
dependent lipase and lipoprotein lipase during Holder pasteurisation (Henderson et al. 
1998). Therefore, post-pasteurisation storage at -20°C seems to have no negative 
effect on DHM lipid quantity and quality.  
Recommendation 8: Store DHM at -80°C at HMBs, especially pre-pasteurisation. 
Light protection 
HMBs also prefer to have glass door freezers, which limit the opening time of the 
freezer (personal communication, Dr Natalie Shenker, Co-Founder Hearts Milk Bank, 
31 January 2018). However, these freezers increase the exposure of DHM to room 
light and potentially sunlight. Similarly, DHM awaiting pooling or other handling at the 
HMB, is exposed to room light or potentially sunlight. Some components of DHM are 
light sensitive. Light exposure (five hours) results in a significant decrease of vitamins 
B6 and C in BM (Van Zoeren-Grobben et al. 1987). Bates and colleagues also found 
an approximately 40% decrease in riboflavin (vitamin B2) and an approximately 50% 
decrease in vitamin A content in BM after three hours of daylight exposure (1985). 
Phototherapy light decreases total antioxidant capacity (TAC) in BM (Unal et al. 2019). 
The effect of light exposure on LCPUFA levels in BM has not been described yet. 
Tacken et al. found no difference in triacylglycerol levels when BM was protected from 
light versus unprotected during tube feeding for six hours (Tacken et al. 2009). Another 
study also found no difference in LA hydroperoxides after six hours of light exposure 
(Van Zoeren-Grobben et al. 1993). Since LCPUFAs are more prone to lipid 
peroxidation than shorter chain PUFAs (Cosgrove et al. 1987), it would have been 
interesting to see the effects on other and longer-chain PUFAs. The effect of light 
exposure has been investigated on parenteral lipid emulsions. Total peroxides 
increased by approximately 500 µM after six hours exposure of Intralipid, an 
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intravenous fat emulsion, to ambient light (Silvers et al. 2001). Light protective tubing 
helped to reduce total peroxides, although it was not as effective as wrapping the 
tubing in foil. The Swedish human milk banking guideline explicitly recommends 
avoiding light exposure of BM outside of fridges and freezers, since light can impact on 
the nutritional quality of DHM (Polberger et al. 2016). The guideline recommends 
covering DHM with a towel. Similarly, the new European Milk Bank Association 
consensus statement recommends that HMBs should minimize the exposure of DHM 
to sunlight, as well as phototherapy lights, at all times (Weaver et al. 2019).  
Recommendation 9: Protect DHM from light exposure in the freezers, on the bench, 
and during feeding.  
4.5.4 Transportation of DHM 
Five HMBs had no time-limit for DHM transportation, although section 1.44 of the NICE 
guideline states that critical transport conditions, including temperature- and time-limits, 
need to be defined by the individual HMBs (National Institute for Health and Clinical 
Excellence 2010). Varying transportation equipment, as well as different transportation 
modes might have resulted in the different time-limits applied by the different HMBs. 
The Human Milk Banking Association of North America further recommends 
transporting DHM on dry ice when mothers live out of town (Jones 2011; O'Hare et al. 
2013). More research is needed to explore appropriate time-limits, based on 
transportation time, temperature and equipment. 
Recommendation 10: There should be clear evidence based time-limits for 
transportation of DHM, considering outside temperature, mode of transportation, and 
transportation equipment, such as cool boxes.  
4.5.5 Processing of DHM 
Section 1.58 of the NICE guideline describes that a sample of each batch of pooled 
DHM should be tested for microbial contamination before pasteurisation (National 
Institute for Health and Clinical Excellence 2010). It is also recommended that DHM 
should be thoroughly thawed before testing and that it can be kept in the refrigerator for 
maximum 24 hours (section 1.55). Twelve HMBs followed the normal protocol of 
thawing the DHM, taking a sample for microbiological assessment and then 
pasteurising. One HMB however, described storing the bottle in the refrigerator for 
24 hours after taking the sample and before pasteurisation and another described 
refreezing the DHM for 48 hours before pasteurisation, after taking a sample for 
microbiological assessment, which is a deviation of the NCIE Clinical Guideline 93. No 
reason was provided for these practices. Probably, HMBs are waiting for 
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microbiological clearance before pasteurisation to avoid unnecessary pasteurisation 
and to save costs and time. As described above, BM storage at 4°C does not seem to 
affect the total fat content or LCPUFA content, but it increases free FAs and LPPs 
(Miranda et al. 2004; Bertino et al. 2013). Therefore, storage time at 4°C should be 
kept to a minimum. Furthermore, freezing-and thawing can disrupt the milk fat globule 
membrane and further increase free FA concentrations (Morera Pons et al. 1998). 
Repeated freezing and thawing has also been shown to increase triacylglycerol losses 
(Berkow et al. 1984). In Sweden, the sample for microbiological testing is obtained by 
using a sterile device to scrape a sample from frozen DHM (Polberger et al. 2016).  
Recommendation 11: Directly pasteurise DHM after taking a sample for 
microbiological testing to avoid repeated freeze-thaw cycles or prolonged storage at 
4°C. If direct pasteurisation after sampling is not possible or not cost effective, a frozen 
DHM sample can be tested.  
Pasteurisation 
BM is a biological specimen also containing bacteria and viruses. Therefore, it is 
necessary to heat treat DHM to make it safe for the use in preterm or ill infants. Most, if 
not all, international milk banking guidelines recommend Holder pasteurisation (62.5°C, 
30 minutes) (Hartmann et al. 2007; Arslanoglu et al. 2010; National Institute for Health 
and Clinical Excellence 2010; Jones 2011; Polberger et al. 2016). All HMBs in the U.K. 
pasteurise DHM. Holder pasteurisation is effective in destroying human 
immunodeficiency virus and cytomegalovirus (Orloff et al. 1993; Hamprecht et al. 
2004). It can also destroy bacteria such as Staphylococcus, Enterococci, and 
Streptococcus (Landers and Updegrove 2010). However, pasteurisation also affects 
the anti-microbial properties of BM (Van Gysel et al. 2012). Furthermore, it reduces 
amongst others, vitamins (vitamin C and B6), immunoglobulin G4, cytokines 
(interleukin-7, macrophage inflammatory protein-1β, monocyte chemoattractant 
protein-1), and hormones (insulin and adiponectin) significantly (Peila et al. 2016). The 
effect of Holder pasteurisation on total fat content of BM is inconclusive, with studies 
reporting a significant decrease (Ley et al. 2011; Vieira et al. 2011; Garcia-Lara et al. 
2013), or no change in fat content (Lepri et al. 1997; Fidler et al. 2001; Goes et al. 
2002). Again, insufficient homogenisation or differences in adherence to container 
walls might be the reason for varying results (Jensen and Jensen 1992; Chang et al. 
2012; Lev et al. 2014). Holder pasteurisation also affects the free FA concentration, 
which doubled after pasteurisation (Lepri et al. 1997). Nevertheless, Holder 
pasteurisation does not affect LCPUFA content (%weight) of BM (Henderson et al. 
1998; Fidler et al. 2001; Romeu-Nadal et al. 2008a; Valentine et al. 2010; Moltó-
Puigmartí et al. 2011; Baack et al. 2012; Delgado et al. 2014). Yet, Holder 
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pasteurisation decreases total fat absorption in infants by 17% (Andersson et al. 2007), 
most likely due to inactivation of the bile salt-dependent lipase and lipoprotein lipase 
(Henderson et al. 1998), which further limits the LCPUFA intake of preterm infants. 
Holder pasteurisation has no effect on MDA concentration of mature BM (Silvestre et 
al. 2008). However, the samples were immediately pasteurised after sampling, which is 
different from the milk banking setting, and no storage that could have increased the 
more susceptible free FAs had occurred. Similar, no increase in TBARS was found 
after pasteurisation of BM stored for 3 weeks at -80°C (Martysiak-Żurowska et al. 
2017). Therefore, more research is needed to investigate the effects of Holder 
pasteurisation in a milk banking setting. 
Currently research is focusing on processing techniques other than Holder 
pasteurisation to ensure not only safety of DHM, but also better preservation of 
nutritional, immunological and functional components (Peila et al. 2017). These 
techniques include high-temperature-short-time pasteurisation as well as the non-
thermal methods of high pressure processing, ultraviolet irradiation, and ultrasonic 
processing. High pressure processing for example has shown to be superior to Holder 
pasteurisation in terms of Immunoglobulin G, adiponectin, growth factor and lactoferrin 
preservation (Wesolowska et al. 2018), however, Delgardo and colleagues found a 
significant decrease in DHA and ARA weight% after high pressure processing at 400 or 
600 MPa for three or six minutes (2014). On the other hand, Moltó-Puigmartí and 
colleagues found no differences in LCPUFA weight% after high pressure processing at 
400, 500 or 600 MPa for five minutes (2011). Results from cow’s milk processing show 
no difference in ARA weight% after high-temperature-short-time (85°C 30 s) 
processing, whereas DHA levels were not measured (Rodriguez-Alcala et al. 2014). 
The effects on LCPUFA content of DHM following such methods should be assessed in 
future studies. 
4.5.6 Areas for improvement 
Nine HMBs suggested barriers to optimal practice and improvements among HMB 
practice. The predominant theme was lack of resources. In general, resources in the 
NHS are scarce (Howard 2010). Similarly to the HMBs, the Toolkit for High Quality 
Neonatal Services defines staffing, as well as professional competence, education, and 
training as key elements to deliver high quality neonatal services (Howard 2010). 
Understaffing is an overall problem in neonatal units in the NHS (Cole 2009; Pillay et 
al. 2012).  
The international non-profit global health organisation PATH has defined four key 
principles for the establishment of effective HMBs. The first principle is a strong base or 
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foundation, which includes staff, appropriate space and facilities, equipment, as well as 
staff training (DeMarchis et al. 2017). Without these, HMBs cannot function to a high 
quality, safety, and ethical standard, and reach their full potential, as the base will link 
to the other three key principles of awareness and advocacy for breast feeding, 
networking, and developing key protocols. The potential for HMBs to have an impact is 
demonstrated by Brazil, which has the largest human milk banking system in the world. 
It is estimated that the provision of DHM to preterm and low birth weight babies saved 
the Brazilian Ministry of Health approximately $540 million in one year (Arnold 2006). 
This highlights the potential for benefit if the NHS invests more in HMBs. Some 
investments are relatively low cost and easy to implement e.g. a dedicated phone line 
or more computers as requested by HMBs in the U.K.  
Improvements in care lead to increased survival of extremely preterm infants (Glass et 
al. 2015), and this will continue in the future. The need for DHM will therefore increase 
as mothers are less likely to be able to express BM for their extremely preterm infants 
(Jones and Spencer 2005). For vulnerable preterm infants Arnold declares DHM as 
human right (2006).  
4.5.7 Data collection 
This survey provided a first step to ascertain human milk banking practices in the U.K. 
and provides a highly representative summary of the current practices. The survey was 
sent out to all 15 HMBs in the U.K. Although this is in general a small number of 
questionnaires, data collection for this study took 15 months. A vast portion of the time 
was attributed to the ethical approval process and the Research and Development 
Office approval in the hospitals. Obtaining ethical approval for low-risk health service 
research in the U.K. can be bureaucratic and lengthy, as also noted by other 
researchers (van Teijlingen et al. 2008). Despite the fact that the Health Research 
Authority determined that participating NHS organisations in England are not expected 
to formally confirm capacity and capability, almost all Research and Development 
Offices wanted to assess the study and confirm capacity and capability. This took up to 
six months in several NHS Trusts. Delays in study set up at NHS Trusts are not 
unusual (Al-Shahi Salman et al. 2007).  
However, waiting for participant responses also took more time than expected. Only 
three HMBs responded within the set three weeks’ timeframe, and two HMBs 
answered within a week after the deadline. The average response time was 70 days. 
One HMB took nine months to respond. Lack of time with not enough dedicated time 
for the HMB operation was one of the identified sub-themes in the qualitative analysis. 
Therefore, the delayed responses are not surprising. Even though the period of data 
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collection was protracted, no major changes in practices are anticipated as the NICE 
Clinical Guideline 93 was not due to be updated before 2019 (National Institute for 
Health and Clinical Excellence 2010).  
An overall response rate of 93% was obtained (14/15 HMBs). Several studies report 
that response rates for surveys completed by healthcare professionals are 
considerably lower (38% for online questionnaires (Cho et al. 2013), 60% for electronic 
surveys (Cook et al. 2009)). Having sent regular reminders might have helped to 
facilitate responses (Cook et al. 2009). Furthermore, using a personalised invitation 
letter and the statement that UKAMB was supporting the research might have further 
increased the response rate (VanGeest et al. 2007). Hence the collected data is overall 
a highly representative summary of the human milk banking practices in the U.K. at the 




The current human milk banking practices in the U.K. were ascertained using an 
electronic questionnaire. A very high response rate (93%, 14/15 HMBs) was achieved, 
and great variations in all aspects of human milk banking, including donor selection and 
nutrition, as well as DHM storage, transportation, and processing were detected 
amongst the HMBs. Predominantly, the practices are within the scope of the NICE 
Clinical Guideline 93. The only deviation was extended cold storage of DHM after 
thawing before pasteurisation. Several practices that might influence DHM quality, such 
as inquiring about nutritional habits of donors, or time-limits for transportation, are not 
included in the Clinical Guideline 93. Additionally, the guideline is not specific enough, 
e.g. it advices immediate freezing of expressed BM, but also allows pooling BM from 
one donor over 24 hours in the refrigerator. This may contribute to the variations in 
practices found with this study. These results clearly indicate that the guidance needs 
to be more specific, to ensure that HMBs within the U.K. work towards the same 
standards and implement them effectively. This will ensure that future research can 
effectively address remaining questions such as clarifying the effects of human milk 
banking practices on the nutritional components of DHM, which is one of the aspects 
raised by the authors of the NICE Clinical Guideline 93.  
Some of the identified practices, such as BM refrigeration, prolonged storage at -20°C, 
or light exposure, have the potential to decrease LCPUFA quantity and quality in DHM. 
This is especially of concern for preterm infants, who present with a LCPUFA gap of 
prematurity. The first 1000 days of life, from conception up to two years, are crucial for 
infants’ development and health (Agosti et al. 2017) and environmental factors, such as 
nutrition can have life-long consequences on infants’ morbidity and mortality. For 
example, good nutrition can reduce the risk for later malnutrition, and for chronic and 
non-communicable diseases such as heart diseases, cancer, and type 2 diabetes. 
Therefore, as a result of this study, recommendations for best human milk banking 
practice with focus on LCPUFAs were developed, based on available evidence, and 
under consideration of international human milk banking guidelines. The 
recommendations are summarised in Table 4-5. Some of these recommendations only 
require small changes in practice to potentially make a big difference in maintaining or 
protecting the LCPUFA content, as well as other nutritional components (e.g. 
vitamin C) of DHM, which will ultimately benefit the mostly preterm recipients and might 
help to reduce the potentially negative effects of the LCPUFA gap of prematurity. 
Most studies investigating the effect of storage and processing conditions on the quality 
of DHM have only mimicked the HMB setting and investigated an isolated process. 
However, it might be the interplay of the various milk banking practices, e.g. the rise of 
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free FA concentrations after storage at 4°C in combination with the heat of Holder 
pasteurisation, that leads to a decreased nutritional quality of DHM. It is therefore 
extremely important that future research is conducted using actual DHM samples to 
ascertain the nutritional quality and the LCPUFA and LPP levels at bedside in a 
hospital setting. This will provide a realistic insight into the impact of current human 
milk banking practices. Overall, as also mentioned in the NICE Clinical Guideline 93, 
more research is needed to understand the effects of human milk banking practices on 




Table 4-5: Best practice recommendations to provide DHM with high LCPUFA levels 
 
Recommendations 
 Assess dietary habits of donors to ensure high nutritional quality of DHM 
 Inform donors with restricted diets and/or no or low fish intake about the 
potential of DHA supplements to increase their BM DHA status and the 
likely benefits of this 
 Provide nutritional information to donors, especially the SACN 
recommendation of one portion (140 g) of oily fish per week and improve 
access to nutritional advice for lactating mothers 
 Use light protective, e.g. amber coloured, bottles, or wrap bottles in 
aluminium foil, when collecting and storing DHM 
 Freeze DHM immediately in a domestic freezer (≤ -18°C) after expression 
and do not allow pooling in the refrigerator over a 24 hour period 
 If pooling in the refrigerator for up to 24 hours is allowed, instruct donors to 
store BM in the coldest part of the refrigerator and not in the door 
 Reduce DHM pre-pasteurisation storage time at -20°C to a minimum. 
Issues regarding cost effectiveness can be addressed by setting a 
minimum volume of DHM for the course of donation instead of a minimum 
for the first donation 
 Store DHM at -80°C at HMBs, especially pre-pasteurisation 
 Protect DHM from light exposure in the freezers, on the bench, and during 
feeding 
 There should be clear evidence based time-limits for transportation of 
DHM, considering outside temperature, mode of transportation, and 
transportation equipment, such as cool boxes 
 Directly pasteurise DHM after taking a sample for microbiological testing to 
avoid repeated freeze-thaw cycles or prolonged storage at 4°C. If direct 
pasteurisation after sampling is not possible or not cost effective, a frozen 




5 The effects of storage conditions on LCPUFAs, lipid 
mediators, and antioxidants in DHM – A review 
Many of the processes involved in human milk banking can influence the nutritional 
quality and quantity of DHM. However, although this area has been widely investigated, 
studies have yielded conflicting results. Moreover, at the time of writing, no review had 
been published summarising the effects of human milk banking practices, including 
storage and processing, on the nutritional quality and quantity of DHM. Therefore, a 
narrative review was undertaken, investigating the effects of storage conditions on the 
fat and LCPUFA content of DHM. Human milk banking practices can also lead to 
lipolysis; therefore, the effect on free FAs was also reviewed. Since the lipid fraction of 
DHM comprises not only of triacylglycerols, but also lipid mediators such as 
eicosanoids, SPMs, and endocannabinoids, these were also included in the review. 
Antioxidants play a role in the protection of LCPUFAs from lipid peroxidation, and 
preterm infants also need enteral antioxidants since they have inadequate antioxidant 
capacity (Choe and Min 2009; Davis and Auten 2010). Whilst this manuscript was 
under review, Gao and colleagues published a systematic review on a similar topic 
(2019), highlighting some key issues in this area of study. Our review differs from the 
one by Gao and colleagues as it not only considers the fat content, but also lipid 
peroxidation, bioactive lipid mediators, and antioxidants. Thus, it provides for the first 
time an overall perspective of factors that affect DHM lipid quality. 
Gao and colleague’s review concluded that the fat content of expressed BM is not 
influenced by storage conditions and that the variations found are due to insufficient 
homogenisation or methodological variation, since most changes were less than 10%, 
or not significant (Gao et al. 2019). Indeed, our review also found discordant 
information on the effect of frozen storage on fat content (Nessel et al. 2019). As 
further detailed in the review, insufficient homogenisation and fat adherence to 
container walls could influence the results. However, seven studies were identified 
(three more than by Gao and colleagues) with three studies reporting effects ≥ 10%, 
which indicates an effect of storage at -20°C on fat content of DHM. Furthermore, Gao 
and colleagues themselves described in their review that a 20% fat loss results in a 
10% energy loss for a 2 kg preterm infant receiving full enteral feeding (150 mL/kg/day) 
(2019), which may have significant deleterious effects on the infant, and should be 
considered.  
The following section is the narrative review, published in the peer-reviewed journal 
Prostaglandins, Leukotrienes and Essential Fatty Acids (doi: 10.1016/j.plefa.2019.07. 
162 
009) (Nessel et al. 2019). An author contribution statement can be found in Appendix 





Mother’s own BM is the accepted best practice for feeding neonates (ESPGHAN 
Committee on Nutrition et al. 2009) and exclusive breast feeding for the first six months 
of life is recommended (WHO 2003) for term infants. For preterm infants as well, 
mother’s own BM is the favoured feeding choice. However, it may need to be fortified 
to accommodate the preterm infant’s requirements (Agostoni et al. 2010). Producing an 
inadequate milk supply is nearly three times more likely in preterm mothers than in 
term mothers (Hill et al. 2005). Underlying reasons can be physiological, such as 
incomplete development of the mammary glands, or poor hormonal response, as well 
as psychological (Jones and Spencer 2005). In some cases, maternal BM might not be 
appropriate, due to illness or medication. In these instances, donor human milk (DHM) 
from a human milk bank is the best alternative (WHO 2003; American Academy of 
Pediatrics 2012; Arslanoglu et al. 2013a). Although, at least in the U.K., there are no 
clear guidelines regulating the use of DHM to a specific preterm gestation, most 
clinicians agree that extremely preterm infants (born at less than 28 weeks gestational 
age) should receive DHM (British Association of Perinatal Medicine 2016b). Similarly 
the Human Milk Banking Association of North America recommends the use of DHM 
for preterm infants or infants with a birth weight of less than 1750 g (Jones 2011). The 
American Academy of Pediatrics recommends use of DHM for all preterm infants, 
especially those weighing <1500 g, when mother’s own milk is not available or 
sufficient (AAP Committee on Nutrition et al. 2017). 
BM is generally the only food infants receive for the first few months of life. It provides 
macro- and micronutrients, immunological factors, hormones, enzymes, growths 
factors, essential fatty acids and other biologically active compounds, essential for the 
infant’s development (Picciano 2001). Adequate dietary nutrient supply is especially 
important for preterm infants since their maternal nutrient supply has been interrupted 
prematurely. For example, during the last trimester, the brain weight increases 
approximately five-times and at the same time around 80% of the brain 
docosahexaenoic acid (DHA, 22:6n-3) and arachidonic acid (ARA, 20:4n-6) are 
accumulated (Clandinin et al. 1980). Preterm birth also deprives the infant of enzymatic 
and non-enzymatic antioxidants that would have been matured or gained through 
maternal transfer in the third trimester, respectively (Qanungo and Mukherjea 2000; 
Georgeson et al. 2002). 
DHM undergoes prolonged cold storage, freeze-thaw cycles, and processing, before it 
is fed to infants, which may negatively affect the BM composition. For example, in the 
U.K., expressed BM for donation can be stored for up to 24 h at 4°C, before 
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transferring to a -18°C (or below) freezer for up to three months (National Institute for 
Health and Clinical Excellence 2010). BM is then thawed, Holder pasteurised (62.5°C, 
30 minutes) and refrozen for up to three months. Before feeding, thawed pasteurised 
DHM can be stored at 4°C for up to 24 h. These conditions have been summarised in 
Figure 5-1. Similar guidelines are followed widely, including in Australia, North America, 
Sweden, Italy, Spain, and India (Hartmann et al. 2007; Arslanoglu et al. 2010; Infant 
and Young Child Feeding Subspecialty Chapter 2013; O'Hare et al. 2013; Polberger et 
al. 2016; Calvo et al. 2018). Additionally, in Italy, BM undergoing direct pasteurisation 
after expression, can be stored for up to 72 h at 4°C (Arslanoglu et al. 2010). In 
Sweden, fresh and pasteurised DHM can be stored for 48 h at 4°C and can be kept for 
a maximum of two h at room temperature (Polberger et al. 2016). Lack of evidence is 
one reason for the different practices used for some aspects of human milk banking 
(Weaver et al. 2019).  
 
Figure 5-1: Donor human milk storage and processing conditions 
Donor human milk (DHM) is exposed to various storage conditions at donors’ homes, the human milk 




Institute of Health and Care Excellence (NICE) guidelines (National Institute for Health and Clinical 
Excellence 2010). Similar processes are used worldwide. 
Recommendations for human BM storage conditions were predominantly developed to 
minimise bacterial growth, rather than to preserve nutritional components (Buss et al. 
2001; Romeu-Nadal et al. 2008b). However, with the increasing demand for DHM, and 
improvements in neonatal care leading to even younger infants surviving, it is now 
imperative that the nutritional quality of DHM is prioritised. Therefore, this article 
reviews the effects of current storage and processing conditions on long-chain 
polyunsaturated fatty acid (LCPUFA) content, bioactive lipid mediators, and 
antioxidants in human BM. Gao and colleagues recently published a systematic review 
on the effects of storage, handling and processing on BM fatty acid composition (Gao 
et al. 2019). This present article compliments and extends these observations by also 
reviewing lipid peroxidation, bioactive lipid mediators and endogenous antioxidants. 
The effects of Holder pasteurisation on nutrients have been described elsewhere (Peila 
et al. 2016), and are not part of this review.  
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5.2 Search methodology 
A search and discovery tool was used to search 80 databases, including Scopus, Web 
of Science, Medline, and Cinahl, using the following search terms: ((human milk) OR 
(donor milk) OR (donor human milk) OR (breast milk)) AND ((thaw* OR freeze* OR 
storage OR processing OR (cold storage) OR (-20°C) OR (-80°C) OR refrigeration) OR 
stability) AND ((fat OR lipid* OR triacylglycerol* OR triglyceride* OR (fatty acid) OR 
(long chain polyunsaturated fatty acid*) OR (polyunsaturated fatty acid*) OR 
(docosahexaenoic acid) OR (arachidonic acid) OR (free fatty acid*) OR lipolysis OR 
macronutrient* OR eicosanoid* OR leukotriene OR prostaglandin OR thromboxane OR 
(specialized pro resolving mediator*) OR (specialized pro-resolving mediator*) OR 
lipoxin* OR resolvin* OR protectin* OR maresin* OR endocannabinoid* OR 
(arachidonoyl ethanolamide) OR (docosahexaenoyl ethanolamide) OR 
arachidonylglycerol OR (lipid peroxidation) OR hexanal OR alkenal OR (lipid 
hydroperoxide*) OR malonyldialdehyde OR TBARS OR MDA OR hydroxynonenal OR 
hydroxyhexenal OR antioxidant* OR (vitamin C OR ascorbic acid) OR (vitamin E) OR 
tocopherol* OR (superoxide dismutase) OR catalase OR glutathione OR (glutathione 
peroxidase) OR (total antioxidant capacity)) OR (antioxidant capacity) OR (antioxidant 
status)). Furthermore, ‘snowballing’, searching the reference lists of the identified 
literature, was used (Greenhalgh and Peacock 2005), as well as searching google 
scholar. Studies were included when full text was available, the language of the 
publication was English and the publication date was before April 2019. Studies 





5.3 Results  
5.3.1 Total fat content and LCPUFAs 
BM contains DHA and ARA, LCPUFAs of the omega-3 and omega-6 series, 
respectively (Brenna et al. 2007). DHA levels in BM are highly variable, ranging from 
0.17% to 0.99% of total fatty acids, whereas ARA levels are more constant (0.36% to 
0.49% of total fatty acids) (Yuhas et al. 2006). Intrauterine accretion rates for DHA and 
ARA peak in the last trimester (Lapillonne and Jensen 2009), a time when DHA is also 
selectively favoured for placental transport to the foetal circulation (Haggarty et al. 
1999). This leads to a bio-magnification of LCPUFAs in the foetus, providing it with 
substrates for the developing brain (Crawford et al. 1976b). In preterm infants, maternal 
supply has been interrupted prematurely, and they therefore have an elevated 
requirement for enteral LCPUFA intake. Indeed, preterm infants have significantly 
lower DHA and ARA blood levels than term infants (Baack et al. 2015). Term infants 
fed with formula milk devoid of DHA will rapidly exhaust their adipose tissue DHA 
stores (Farquharson et al. 1993). This is also reflected by significant decreased 
erythrocyte DHA levels at day five of feeding formula milk devoid of DHA to term 
infants (Makrides et al. 1995b). Importantly, erythrocyte DHA status has been 
correlated with brain DHA status (Makrides et al. 1994). Preterm infants have in 
contrast to term infants very low adipose tissue stores (Clandinin et al. 1981; Lapillonne 
and Jensen 2009), which makes them even more dependent on adequate enteral 
LCPUFA intake. Inefficient conversion rates from precursor fatty acids (Uauy et al. 
2000; Carnielli et al. 2007), as well as an enteral LCPUFA absorption rate of only 80% 
(Carnielli et al. 1998), and the prolonged period it may take until full enteral feeding is 
achieved, further limit the LCPUFA availability for preterm infants. However, it is critical 
to provide preterm babies with sufficient amounts of LCPUFAs optimal for brain and 
visual development, as well as cell and immune system function (Lapillonne et al. 
2013; Smith and Rouse 2017). Although preterm BM may contain higher DHA levels 
than term BM, (Bokor et al. 2007), we have previously shown that extremely preterm 
infants under standard care receive very low levels of DHA and ARA, which are 
reflected in low blood fatty acid levels (De Rooy et al. 2017). Importantly, DHM is 
provided generally by mothers of term infants and consequently lower in LCPUFA 
levels (Valentine et al. 2013). It is therefore imperative that all appropriate steps are 
taken to maintain LCPUFA levels on the journey from donor to recipient. Since the total 
fat and LCPUFA content of DHM may be sensitive to human milk banking practices, 
the following section provides an overview of the literature investigating the effects of 
different storage conditions on human BM lipids, and is summarised in Table 5.1.  
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Storing BM at 4C for 48 h has been shown to not significantly change the absolute or 
relative fatty acid content (Lacomba et al. 2012), or triacylglycerol content (Tacken et 
al. 2009). The latter was also not affected by refrigeration at 4C for up to three days 
(Yuen et al. 2012). Total lipid content was also unchanged by refrigeration at 4C for 
24 h (Ezz El Din et al. 2004), or up to 96 h (Slutzah et al. 2010). Similarly, 
polyunsaturated fatty acid (PUFA) content (including linoleic acid (LA, 18:2n-6), α-
linolenic acid (ALA, 18:3n-3), ARA and DHA), as well as saturated and 
monounsaturated fatty acid content was not significantly altered when stored for 96 h at 
4°C (Romeu-Nadal et al. 2008b) or 6.8°C (Bertino et al. 2013).  
Several studies show that total fat content is not significantly altered following storage 
at -20°C for nine months (Ahrabi et al. 2016), nor does absolute fatty acid and relative 
fatty acid content change significantly in studies ranging from storage for 30 days 
(Lacomba et al. 2012) to 12 months (Romeu-Nadal et al. 2008b). Furthermore, storage 
at -20°C for 3 days, or -18°C for 28 days does not change total triacylglycerols levels 
(Tacken et al. 2009; Yuen et al. 2012). Total fat and relative fatty acid levels were 
unaffected by storage at -25°C for three months, although these samples were 
refrigerated for up to 48 h before baseline analysis (Friend et al. 1983b). Consistent 
with these observations, storing BM for one week at -4 to -8°C did not change the fat 
content (Ezz El Din et al. 2004). However, others have found that storage at -20°C 
significantly decreases total fat after 48 h (Chang et al. 2012), 30 days 
(Thatrimontrichai et al. 2012; Janjindamai et al. 2013), and up to 24 weeks (Orbach et 
al. 2019). Similarly, total lipid concentrations (Pardou et al. 1994), and triacylglycerols 
(Berkow et al. 1984), significant decrease after eight days, and five months, at -20°C 
respectively. Significant reductions in fat content after storage at -20°C were also seen 
after seven days and up to 90 days, with the biggest decreases in the first week 
(-0.027 g/dL/day) (Garcia-Lara et al. 2012). Freezing at -80°C for five months did not 
affect saturated or monounsaturated fatty acids, or PUFAs (Romeu-Nadal et al. 
2008b), or triacylglycerols for 12 months (Berkow et al. 1984). Although -80°C storage 
was shown to result in a significant decrease of fat, this was lower than the decreases 
seen at -20°C (Orbach et al. 2019). In contrast, significant decreases in fat content of 
91% were seen after 44 days of BM storage at -80°C, which led to the conclusion of 
the authors that storage at -80°C should not be the gold standard as recommended by 
other researchers (Lev et al. 2014). This result is unexpected and since no comparison 
was undertaken with storage at -20°C, the results should be considered within the 
context of the wider literature. Discordant observations have also been seen post-
pasteurisation, with storage at -20°C for 90 and 180 days resulting in 5.7% and 2.9% 




whereas, no differences in total fat content (Friend et al. 1983a; de Waard et al. 2018), 
or relative fatty acid concentrations (Friend et al. 1983a) of pasteurised BM stored for 
1 month at -25°C or up to 12 months at -20°C, respectively were seen.  
During human milk banking BM is thawed and then refrozen, which has the potential to 
affect the milk fat quality. Three-times freezing and thawing has been shown to lead to 
reductions in fresh BM triacylglycerols of up to 5% (Berkow et al. 1984). Freezing and 
thawing BM for three-cycles before storing it at -20 °C for five months resulted in an 
additional 3% triacylglycerol loss (13% in total, compared to 10% after freezing only). 
Relative amounts of saturated, and monounsaturated fatty acids of BM triacylglycerols 
did not change significantly after two freeze thaw cycles, whereas the relative LA 
content decreased by -65% (Wardell et al. 1981). It is noteworthy that thawing in the 
fridge (4°C) for 24 h, as recommended in the U.K. (National Institute for Health and 
Clinical Excellence 2010), significantly reduced total fat loss compared to thawing in a 
water-bath (37°C, 30 minutes) (Thatrimontrichai et al. 2012). Vieira and colleagues 
found no significant difference in total fat content when pasteurised BM was thawed in 
a water-bath (40°C, 10 minutes) or thawed in a microwave (45 s) (Vieira et al. 2011). 
No difference in fat content was found when thawing under tepid water and thawing by 
a waterless dry heat warmer were compared (Handa et al. 2014). Chang and 
colleagues also found that storage (-20°C, 48 h) in light brown coloured 
polyethersulfone bottles resulted in the least fat decreases (Chang et al. 2012).  
In conclusion, the available evidence suggests that storage at 4°C is sufficient to 
minimise decreases in total fat and LCPUFAs in BM for up to 96 h. However, for 
longer-term storage the data for storage at -20°C is highly discordant, especially pre-
pasteurisation. These differences may be related to variations in analytical methods 
used (Silvestre et al. 2014; Zhu et al. 2017), or methodological variations, such as not 
sufficiently homogenising the BM after storage (Jensen and Jensen 1992), differences 
in fat adherences to the container walls (Chang et al. 2012; Lev et al. 2014), 
particularly to polyethylene (Arnold 1995), and variations in fat loss due to different 
thawing methods (Thatrimontrichai et al. 2012), which are not specifically defined in the 
literature. Furthermore, BM is a complex biological matrix, and variations in 
unmeasured endogenous antioxidant levels or other components, may influence fat 
content stability during storage, discussed further in Section 5.3.5 below. However, 
overall the evidence suggests storage at -80°C is the best option for longer-term 
storage to maintain total fat and LCPUFA levels.  
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Table 5-1: Summary of studies investigating the effects of storage conditions on total fat and LCPUFA content 




4°C for 48 h, or -20°C for 30 days 
No significant differences in absolute or relative fatty acid content between fresh, 
refrigerated, or frozen BM 
(Tacken et al. 
2009) 
Fresh 
4°C for 48 h, or -18°C for 28 days 
No significant differences in triacylglycerol content between fresh, refrigerated, or 
frozen BM 
(Yuen et al. 
2012) 
Fresh 
4°C for 72 h, or -20°C for 72 h 
No significant differences in triacylglycerol content between fresh, refrigerated or 
frozen BM 
(Ezz El Din et 
al. 2004) 
Fresh 
4-6°C for 24 h, or -4 to -8°C for 1 week 
No significant differences in fat content between fresh, refrigerated or frozen BM 
(Slutzah et al. 
2010) 
Fresh 
4°C for 24, 48, 96 h 
All samples were stored at -80°C until analysis 
No significant differences in total lipid content between fresh, or refrigerated BM  
(Romeu-Nadal 
et al. 2008b) 
Fresh 
4°C for 3, 6, 9, 12, 24, 48, 72, 96 h 
-20°C or -80°C for 3, 5, 8, 12 months 
No significant differences in relative LA, ALA, ARA, DHA, saturated, 
monounsaturated, or polyunsaturated fatty acid content between the different 
storage times and temperatures 
(Bertino et al. 
2013) 
Fresh (within 3 h of collection) 
6.8°C for 24, 48, 72, 96 h 
No significant differences in absolute saturated or monounsaturated fatty acids, 
PUFAs, LCPUFAs, or the saturated to unsaturated fatty acid ratio between fresh 
and refrigerated BM at any storage time 
(Ahrabi et al. 
2016) 
Fresh 
4°C for 72 h and then stored at -20°C for 1, 3, 6, 9 months 
All samples stored at -80°C after the initial storage time until 
analysis 
No significant differences in total fat content between fresh, refrigerated and 




(Friend et al. 
1983b) 
Fresh (up to 48 h at 4°C )  
-25°C for 1 week, 1, or 3 months  
No significant differences in total lipid or relative fatty acid concentration between 
fresh or frozen BM  
(Chang et al. 
2012) 
Samples stored in 9 different commercial milk containers for 
maximum 3 days at 4°C, before transfer to -20°C for 2 days 
No significant differences in total fat content of BM stored in different containers 
Least fat loss in light brown coloured polyethersulfone bottles 
Significant total fat decrease in BM after freezing, storing and thawing (-0.27 to -
0.30 g/dL, p = 0.02) 
(Thatrimontric
hai et al. 2012) 
Fresh 
-20°C for 30 days, then thawed at 4°C for 24 h, or at 37°C for 
30 minutes 
Total lipids (g/100 mL): Fresh: 2.98 vs thawing at 4°C: 2.76 vs thawing at 37°C: 
2.66  
Significant less mean fat loss in frozen BM thawed at 4°C compared to thawing at 
37°C (p = 0.02) 
(Janjindamai 
et al. 2013) 
Fresh  
-20°C for 30 days 
Significant fat decrease after frozen storage  
Fat (g/100 mL): Fresh: 2.98 vs 30 days frozen: 2.66 (p < 0.001) 
(Orbach et al. 
2019) 
Fresh (up to 24 h at 4°C) 
-20°C or -80°C for 4, 12, 24 weeks 
Fat content was consistently higher in BM stored at -80°C than at -20°C 
(p < 0.0005) 
Difference in fat content between 4 and 24 weeks was 0.3 g/100 mL at -20°C 
(p = 0.001) and 0.14 g/100 mL at -80°C (p = 0.009) 
(Pardou et al. 
1994) 
Fresh 
-20°C for 4, 8 days  
Significant total lipid decrease in BM stored at -20°C 
Lipids (g/100 mL): Group 1 (no bacterial growth): fresh: 3.92 vs frozen for 4 days: 
3.61 vs frozen for 8 days: 3.54, no significant differences 
Group 2 (containing saprophytes): fresh: 3.84 vs frozen for 4 days: 3.8 vs frozen 
for 8 days: 3.61 (p = 0.003) 
Group 3 (containing potential pathogens): fresh: 4.75 vs frozen for 4 days: 4.76 vs 
frozen for 8 days: 4.65, (p = 0.002) 
(Berkow et al. 
1984) 
Fresh (up to 3 h before analysis) 
Analysed directly after 1, 2, or 3 freeze-thaw cycles (dry ice 
and acetone-cold water for thawing)  
Maximum 5% decrease in triacylglycerols after freeze-thawing of fresh BM 
BM storage at -20 °C resulted in a 10% decrease of triacylglycerols, or a 13% 
decrease after 3 freeze-thaw cycles 
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Storage at -20°C or -70°C for 5 months after 0, 1, 2, or 3 
freeze-thaw cycles 
Storage at -70°C resulted in no significant changes 
(Garcia-Lara 
et al. 2012) 
Fresh 
-20°C for 7, 15, 30, 60, 90 days 
Significant total fat reduction in BM at each day after storage 
Fat (g/dL): Fresh: 4.88 vs 7 days frozen: 4.69 (p = 0.002) vs 15 days frozen: 4.54 
(p = 0.001) vs 30 days frozen: 4.54 (p < 0.001) vs 60 days frozen: 4.37 (p < 0.001) 
vs 90 days frozen: 4.19 (p < 0.001) 
 
(Lepri et al. 
1997) 
Fresh (4°C during same day transport to the laboratory) 
Pasteurised, then stored at -20°C for 35, 70, 90 days 
Post-pasteurisation frozen storage for 90 days decreased total fat concentration by 
5.7%, which was above the relative standard deviation of fresh BM 
 
(Garcia-Lara 
et al. 2013) 
Storage in donors’ freezers until transfer to the hospital 
Storage at -20°C at the hospital 
Thawing, heating to 40°C and homogenisation, Holder 
pasteurisation, heating to 40°C and homogenisation 
Analysis day 0 (post-pasteurisation) 
Storage at -20°C for 30, 60, 90, 120, 150, 180 days 
Significant total fat decrease over time (p = 0.001) in frozen BM  
Mean difference between 0 and 180 days was -0.13 g/dL  
(Friend et al. 
1983a) 
Fresh (up to 48 h at 4°C )  
Holder pasteurised, then stored at -25°C for 1 month 
No significant differences in total lipid or relative fatty acid concentration between 
fresh or pasteurised and frozen BM 
(de Waard et 
al. 2018) 
Pasteurised, then stored at -20°C for 1, 2, 3, 4, 5, 6, 8, 10, 12 
months 
No significant differences in total fat between any of the storage times 
(Lev et al. 
2014) 
Fresh (up to 24 h at 4°C) 
-80°C for mean of 43.8 days (range 8-83 days) 
Significant decrease of total fat concentration after frozen storage 
Total fat (g/100 mL): Fresh: 37.2 vs frozen: 3.36 (p < 0.001) 
(Wardell et al. 
1981) 
Fresh (up to 3 h at 18-20°C)  
Frozen at -20°C, thawed at room temperature once, twice or 
three times  
Freezing and thawing resulted in a loss of absolute milk triacylglycerols 
Relative amounts of saturated and monounsaturated fatty acids of BM 




Relative LA concentration (%) changed significantly: Control: 6.64 vs freeze 
thaw 1: 4.71 vs freeze thaw 2: 2.35 (p < 0.01) vs freeze thaw 3: 2.60 (p < 0.002)  
ALA could not be measured accurately 
(Vieira et al. 
2011) 
Frozen at -20°C, thawed in a water-bath (40°C, 10 minutes) 
or in a microwave (45 seconds) 
No significant difference in fat content between the two thawing methods 
(Handa et al. 
2014) 
Frozen at -20°C, thawed under tepid water or by waterless 
dry heat warmer 
No significant differences in fat content between the two thawing methods 
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5.3.2 Free FA levels 
The lipid portion of BM consists of approximately 98% triacylglycerols, 1% 
phospholipids, and 0.4% cholesterol and cholesterol esters (Lammi-Keefe and Jensen 
1984). BM also contains the bile salt-dependent lipase, which aids in the digestion of 
milk fat and compensates for the immature digestive system in new-borns (Hernell 
1975; Watkins 1985). However, the bile salt-dependent lipase loses its bile salt 
specificity during two weeks frozen storage at -10°C (Mehta et al. 1982), potentially 
resulting in lipolysis of triacylglycerols and an increase in free fatty acid levels. Freezing 
and thawing also damages the fat globule membrane, allowing the lipases greater 
access to triacylglycerols, thereby increasing free fatty acid levels (Berkow et al. 1984; 
Morera Pons et al. 1998). LCPUFAs appear more susceptible to hydrolysis than 
shorter-chain fatty acids and the degree of hydrolysis is temperature and time 
dependent (Lavine and Clark 1987). Additionally, elevated levels of free fatty acids 
have the potential to increase lipid peroxidation (Turoli et al. 2004; Martysiak-Zurowska 
and Stolyhwo 2006), discussed in Section 5.3.4.  
Storing BM at 4°C increases the free fatty acid content significantly from 51% to 454% 
after 24 h (Dill et al. 1984; Lavine and Clark 1987; Bertino et al. 2013), from 76% to 
502% after 48 h (Lavine and Clark 1987; Bertino et al. 2013), from 85% to 101% after 
72 h (Lavine and Clark 1989) and by 265% after 96 h (Slutzah et al. 2010), although 
BM samples in the latter study were stored at -80°C after refrigeration, until subsequent 
free fatty acid analysis (Slutzah et al. 2010). In a time course experiment, higher free 
fatty acid levels were seen at 48 h compared to 24 h, although not statistically 
significant, whereas levels were significantly higher at 72 h, with the greatest increases 
seen with omega-3 PUFAs (Bertino et al. 2013). However, pasteurised, frozen, and 
thawed DHM samples stored at 4°C for up to 96 h show no change in free fatty acid 
levels following thawing (Slutzah et al. 2010). 
Free fatty acids in BM increased significantly (+589% vs baseline) after eight weeks 
storage at -11°C (Lavine and Clark 1987), also, an accumulation of free fatty acids has 
been seen after 24 h at -20°C, increasing by 167% after 30 days, and 833% after 180 
days (Dill et al. 1983). This is supported by other studies showing significant increases 
in free fatty acids after storage at -20°C for two to five months (Bitman et al. 1983a), 
four months (Morera Pons et al. 1998), five months (Berkow et al. 1984), and nine 
months (Ahrabi et al. 2016). No free fatty acids were detected after BM storage 
at -80°C for four months (Morera Pons et al. 1998). Storage for two months (Lavine 
and Clark 1987), two to five months (Bitman et al. 1983a), or five months (Berkow et al. 




of Holder pasteurised BM for one month at -25°C (Friend et al. 1983a), or for three 
months at -20°C (Lepri et al. 1997) did not significantly alter the free fatty acid content, 
and heating for 1.5 minutes at 80°C prevented the formation of free fatty acids in BM 
samples stored for four months at -20°C (Morera Pons et al. 1998).  
Thoroughly thawing DHM and keeping it in the fridge for a maximum of 24 h is 
recommended by the U.K. guidelines (National Institute for Health and Clinical 
Excellence 2010); however, thawing BM at 4°C for 24 h resulted in 10% and 29% 
higher free fatty acid concentrations than thawing at room temperature for 2.5 to 
4.25 h, or thawing in a water-bath (50°C, 12 to 30 minutes), respectively (Chan et al. 
2011). A significant increase in free fatty acids was found after thawing (tepid water or 
waterless dry heater) BM (Handa et al. 2014). Furthermore, refrigeration of thawed BM 
for up to 24 h before warming and feeding further increased free fatty acids compared 
to only warming. Thawing and storing BM for 24 h at 4°C, after 30 days storage 
at -20°C, further increased the free fatty acid concentration by approximately 288%, 
compared to storage at -20°C for 30 days alone (Dill et al. 1983).  
Overall, the evidence strongly suggests that storing BM at 4°C prior to pasteurisation 
significantly increases the free fatty acid levels, although these changes are not 
observed post-pasteurisation. These differences are potentially due to inactivation of 
the BM lipases (Henderson et al. 1998). Similarly, pre-pasteurisation storage at -20°C 
has been shown to increases free fatty acid levels, which are also not seen in post-
pasteurisation BM. Therefore, in order to minimise increases in free fatty acids levels, it 
is recommended expressed BM should be frozen immediately and stored at the lowest 
possible temperature (ideally -70°C or below) prior to pasteurisation.  
5.3.3 Lipid Mediators 
Eicosanoids 
Eicosanoids include the eicosapentaenoic acid (EPA, 20:5n-3) and ARA-derived 
thromboxanes, prostaglandins and leukotrienes, which are important mediators of the 
inflammatory response (Dyall 2017). Prostaglandins also modulate gastrointestinal 
function and may protect against gastrointestinal injuries (Ianiro et al. 2014). 
Eicosanoids (leukotriene E4, prostaglandin E2, cysteinyl leukotrienes, prostaglandins E 
and F, as well as the inactive thromboxane A2, prostacyclin, and prostaglandin F 
metabolites thromboxane B2, 6-keto-prostaglandin F1α, and 13,14-dihydro-15-
ketoprostaglandin) are secreted into BM (Lucas and Mitchell 1980; Laiho et al. 2003; 
Garcia-Ravelo et al. 2018). To the authors’ knowledge, there have to date been no 
published studies looking at the effects of storage conditions or DHM processing on 
eicosanoid levels in BM. However, Lucas and Mitchel hypothesize that a low 13,14-
176 
dihydro-15-ketoprostaglandin F:prostaglandin F ratio in BM suggests that 
prostaglandins are not rapidly metabolised in BM and may persist long enough to have 
an effect in the infant (Lucas and Mitchell 1980), and tritiated prostaglandins show 
minimal degradation after incubation in BM for 30 minutes at 37°C (Bedrick et al. 
1989), suggesting that further work should seek to explore this area. 
Specialised pro-resolving mediators 
Specialised pro-resolving mediators (SPMs) facilitate the resolution of inflammation, 
are anti-inflammatory, reduce pain, and facilitate wound healing (Serhan et al. 2008; 
Serhan and Levy 2018). They include the ARA-derived lipoxins, EPA-derived resolvins, 
and docosapentaenoic acid (22:5n-3) and DHA-derived resolvins, (neuro)protectins 
and maresins (Dyall 2015). BM contains the SPMs resolvin D1, resolvin D2, resolvin 
D3, resolving D4, resolvin D5, resolvin D6, protectin 1, maresin 1, resolvin E2, 
resolvion E3, lipoxin A4 and lipoxin B4 in biologically relevant concentrations, which 
have shown to reduce the maximum neutrophil number and to shorten the resolution 
interval in vivo and to stimulate efferocytosis in vitro (Arnardottir et al. 2016). Resolution 
of inflammation is especially important for extremely preterm infants, in which sustained 
elevated inflammation in the first month of life is associated with cognitive impairment 
at ten years of age (Kuban et al. 2017). To the authors’ knowledge, there are currently 
no studies that have investigated the effects of storage conditions on specialised pro-
resolving mediator levels in BM. Interestingly, the BM samples in the above study 
(Arnardottir et al. 2016) were obtained from a commercial supplier, who stores BM 
at -20°C, and therefore, it is likely that specialised pro-resolving mediators tolerate 
some frozen storage; however further work should seek to extend these observations 
and investigate the effects of different storage and processing conditions on SPM 
levels. 
Endocannabinoids 
Endocannabinoids include the ARA derived compounds arachidonoyl ethanolamide 
(anandamide, AEA), 2-arachidonoylglycerol (2-AG), and the DHA-derived 
docosahexaenoyl ethanolamide (DHEA) (Dyall 2017), which have been identified in BM 
(Fride et al. 2001; Wu et al. 2016). The endocannabinoid system plays an important 
role in neuronal development and neuroprotection early in life (Fride 2004; Dyall et al. 
2016). Animal studies showed that 2-AG and activation of the Cannabinoid Receptor 1 
plays a critical role in milk suckling, holding on to the nipple, and therefore, growth and 
survival in the first week of life (Fride et al. 2001; Fride 2004). An analysis of BM found 
a non-significant increase of 503% in 2-AG levels after storage at 4°C for 24 h and a 
significant increase (1166%) after storage at -20°C for three months (Wu et al. 2016). 




was no longer detectable after storage at 4°C for one day, or storage at -20°C or -80°C 
for three months. The authors suggested that the concentrations of 
12 endocannabinoid related compounds (2-AG, AEA, oleoylethanolamide, 
palmitoylethanolamide, N-arachidonoyl glycine, eicosapentaenoyl ethanoalmide, 
DHEA, N-palmitoleoyl-ethanolamine, dihomo-γ-linolenoylethanolamine, 
N-stearoylethanolamine, prostaglandin F2α ethanolamide, prostaglandin E2 
ethanolamide) in BM are stable for a maximum of 24 h at 4°C, maximum one week 
at -20°C and that longer term storage requires temperatures of -80°C. The same group 
also demonstrated that two freeze-thaw cycles, as used in human milk banking, 
resulted in losses of 37% AEA, 49% 2-AG, and 36% DHEA in bovine milk (Gouveia-
Figueira and Nording 2014). Additionally, it has been shown that 2-AG in culture 
medium and biological buffers adheres to glass and plastic surfaces (Rouzer et al. 
2002), which could impact on their availability for the infant.  
5.3.4 LPPs 
Omega-3 and omega-6 LCPUFAs are highly susceptible to peroxidation by oxygen 
radicals (Dyall 2011). There is a linear dependency between the number of double 
bonds and the oxidisability of PUFAs (Cosgrove et al. 1987). Lipid hydroperoxides are 
unstable primary lipid peroxidation products, which react further to form secondary lipid 
peroxidation products (Ayala et al. 2014). For example, malondialdehyde (MDA) is 
produced from the unspecific peroxidation of PUFAs with more than two double bonds. 
At high levels, lipid peroxidation products can bind to DNA and proteins, which can lead 
to cell and tissue damage, and may thereby increase inflammation (Yadav and 
Ramana 2013). Repeated intake of lipid peroxidation products has been shown to 
induce growth retardation, intestinal irritation, cardiovascular diseases, and to be 
carcinogenic in animal studies (Esterbauer 1993). Direct activation of inflammatory 
pathways such as nuclear factor β has also been shown after feeding lipid 
peroxidation products to mice (Awada et al. 2012). More importantly, lipid peroxidation 
products do not only act locally in the intestine, but can also be absorbed and act 
elsewhere in the body (Awada et al. 2012). 
Various lipid peroxidation products have been detected in BM, including MDA (Miranda 
et al. 2004; Martysiak-Zurowska and Stolyhwo 2006), the omega-6 and omega-3 PUFA 
derived 4-hydroxy-2-hexanal (4-HNE) and 4-hydroxy-2-nonenal (4-HHE), respectively 
(Michalski et al. 2008), lipid hydroperoxides (Van Zoeren-Grobben et al. 1993; Turoli et 
al. 2004), isoprostanes (Szlagatys-Sidorkiewicz et al. 2012), alkanals including 
pentanal, hexanal, octanal, nonanal, and 2-octanal (Elisia and Kitts 2011), as well as 
conjugated dienes (Turoli et al. 2004). Storage of fresh BM for 24 h at room 
temperature significantly increases the 4-HNE:omega-6 fatty acid ratio (Michalski et al. 
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2008). Storage at 4°C for 48 h was shown to significantly increase MDA content of BM 
(Miranda et al. 2004), whereas others found storage at 4C for 96 h has no effect on 
MDA content of preterm milk (Bertino et al. 2013) potentially due to higher antioxidant 
capacity in the latter (Turhan et al. 2011). Although thiobarbituric acid reactive 
substances increased by 66% and conjugated dienes by 31% in the same samples, 
this was not statistically significant (Bertino et al. 2013). Storage at 4°C for four days 
increases LA hydroperoxides significantly (Van Zoeren-Grobben et al. 1993).  
No significant increases in BM MDA levels were seen after storage at -20°C for ten 
days (Miranda et al. 2004), or 15 or 30 days, although increases were found after 60 
days (Silvestre et al. 2010). Similarly, no increases in thiobarbituric acid reactive 
substances or conjugated dienes were seen after storage at -20°C for two months, 
although significant increases in precursor lipid hydroperoxides were found (Turoli et al. 
2004). However, it should be noted that the fresh BM samples were from different 
donors than the frozen samples. MDA levels also significantly increased in term BM 
stored at -80°C for 60 days (Silvestre et al. 2010). Hexanal levels significantly 
increased after three months storage at -18°C, with further increases after five and six 
months (Vangnai et al. 2017). In this study, four months storage of BM in amber glass 
bottles also reduced the hexanal increase significantly compared clear glass bottles or 
low density polyethylene bags. Overall, the literature suggests an increase in lipid 
peroxidation when BM is stored at 4°C, with short-term storage at -20°C for maximal 
one month preferable, although there needs to be more research to clarify this, as well 
as whether storage at -80°C would be beneficial.  
5.3.5 Antioxidants 
Preterm infants have immature antioxidant systems and inadequate antioxidant 
capacity (Davis and Auten 2010) and there is a frequent requirement for blood 
transfusions, which increases oxidative stress (Wardle et al. 2002). Furthermore, the 
foetal to neonatal transition rapidly increases tissue oxygenation, thereby abruptly 
increasing the generation of reactive oxygen species (Kuligowski et al. 2015), and 
oxygen therapy as well as total parenteral nutrition expose the premature infant to 
further sources of oxidative stress (Lavoie et al. 2010). As a consequence, there is 
great potential for peroxidation of endogenous lipids and subsequent tissue damage. 
Bronchopulmonary dysplasia, retinopathy of prematurity, necrotising enterocolitis and 
peri-ventricular leukomalacia are common co-morbidities in preterm infants, which are 
classified as oxygen radical associated diseases (Saugstad 2005). Moreover, 
extremely and very preterm infants are not routinely supplemented with dietary 
antioxidants, as there has been limited research in this area and the outcomes of some 




(e.g. superoxide dismutase, glutathione peroxidase) and non-enzymatic (e.g. vitamin 
C, vitamin E, glutathione) antioxidants, is the only enteral source of antioxidants for 
preterm infants. However, DHM, compared to BM, has significantly lower 
concentrations of several antioxidants (Hanson et al. 2016).  
Antioxidants are not only beneficial to the infant directly, but they also serve to protect 
PUFAs in the BM from lipid peroxidation and may subsequently decrease the levels of 
potentially toxic compounds (Shahidi and Zhong 2010). For example, vitamin C can 
directly prevent lipid peroxidation by scavenging free radicals, and thereby preventing 
the initiation stage of lipid peroxidation (Choe and Min 2009), and vitamin E can 
scavenge lipid peroxyl radicals and is then regenerated by vitamin C (Kamal-Eldin and 
Appelqvist 1996), which in turn is regenerated by glutathione (Wells et al. 1995). 
Glutathione and the glutathione peroxidase can form more stable lipid alcohols from 
lipid hydroperoxides (Niki 1987), and glutathione is also involved in the detoxification of 
MDA (Ankrah et al. 2000). Although evidence for the prevention of lipid peroxidation in 
human milk by antioxidants is limited, evidence suggests that the vitamin E content of 
formula milk is inversely related to thiobarbituric acid reactive substances and 
conjugated dienes (Marshall and Roberts 1990; Turoli et al. 2004), and lower 
glutathione peroxidase activity is associated with higher MDA concentrations in BM 
following refrigeration (Miranda et al. 2004). Due to the interplay and synergistic effects 
between antioxidants, antioxidant capacity should also be considered an appropriate 
measure of the antioxidant status of BM.  
Vitamin C 
Term BM contains around 34.7 ± 1.33 mg/L vitamin C (ascorbic acid + dehydroascorbic 
acid) (Romeu-Nadal et al. 2008b). Significant reductions in the vitamin C content of 
term BM have been reported after storage at 4°C for six h, and 24 h (Garza et al. 1982; 
Bank et al. 1985; Buss et al. 2001; Ezz El Din et al. 2004; Rechtman et al. 2006), and 
after one week at -4 to -8°C (Ezz El Din et al. 2004), as well as after two months 
at -16°C (Buss et al. 2001). Interestingly, significant decreases in vitamin C were seen 
after three months storage at -20°C in term, but not preterm BM (Bank et al. 1985), 
although, in another study significant decreases were seen in preterm BM after seven 
and 30 day storage at the same temperature (Marinkovic et al. 2016). However, others 
have reported that vitamin C levels are stable at -20°C in pooled BM for four week 
(Goldsmith et al. 1983), and up to three months, but significantly decrease after eight 
months (Romeu-Nadal et al. 2008b). Vitamin C content appears stable with storage 
at -80°C for eight months, although a significant decrease of 12% was seen at 12 
months (Romeu-Nadal et al. 2008b). Overall, although the results are somewhat 
mixed, the evidence supports BM storage at lower temperatures to protect Vitamin C 
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content, with storage at both 4°C and -20°C leading to decreases, and storage at -80°C 
preferable, for the maximum recommended storage time of six months, although this is 
based on one publication. 
 
Vitamin E 
Vitamin E is a class of compounds including α-, β-, γ- and δ-tocopherol, with α-
tocopherol being the main isomer in term mature BM, and one of the main contributors 
to antioxidant capacity of BM, which is found at concentrations of 2.32 ± 0.11 mg/L 
(Tijerina-Saenz et al. 2009). Storage of BM at 4°C for 24 h did not affect α- and γ-
tocopherol levels in several studies (Moffatt et al. 1987; Ezz El Din et al. 2004; Romeu-
Nadal et al. 2008b), likewise, no significant changes were found after 48 h for α-, β-, γ-, 
and δ-tocopherol (Lacomba et al. 2012), although others have reported significant 
reductions in α- and γ-tocopherol levels after 48 h (Romeu-Nadal et al. 2008b). Storing 
BM at -4 to -8°C for one week resulted in a significant decrease in vitamin E (Ezz El 
Din et al. 2004). Storage at -20°C did not affect vitamin E levels of BM stored for 30 
days (Lacomba et al. 2012), 16 weeks (Moffatt et al. 1987), six months (Wei et al. 
2018), or 12 months (Romeu-Nadal et al. 2008b), and no changes in vitamin E levels 
were seen after storage for 16 weeks (Moffatt et al. 1987), or six months at -70°C (Wei 
et al. 2018), or 12 months at -80°C (Romeu-Nadal et al. 2008b). Overall, the evidence 
suggests that current human milk banking storage processes are safe to protect the 
vitamin E content in DHM. 
Superoxide dismutase, glutathione, and glutathione peroxidase 
Superoxide dismutase is an enzyme involved in the dismutation of the superoxide 
radical. Its activity has been reported to be 36 U/mL in term mature BM (L'Abbe and 
Friel 2000). Although there is a paucity of research in this area, superoxide dismutase 
activity was reported to be significantly reduced after preterm BM was stored at -20°C 
for seven and 30 days (Marinkovic et al. 2016). Glutathione content of mature BM is 
approximately 163.9 µmol/L (Ankrah et al. 2000). A significant 79% loss of glutathione 
was noted after two h storage at 4°C as well as at -20°C (-81% vs baseline) (Ankrah et 
al. 2000). Glutathione peroxidase activity in mature term BM was reported as 
38.8 U/mL (Hojo 1986). Significant reductions in activity were seen in term milk after 48 
h at 4°C (Miranda et al. 2004), although these were not reported following storage of 
preterm BM for 30 days at -20°C (Marinkovic et al. 2016). Activity decreases were 
reported with increased storage time at -20°C, with activity completely lost after one 
week (Hojo 1986), and significant reductions in activity after 15, 30 and 60 days in 
another study (Silvestre et al. 2010). However, significant reductions were only shown 
after 60 days at -80°C, where the activity was not significantly different between 






Total antioxidant capacity 
Total antioxidant capacity (TAC) measures the additive effects of antioxidants and may 
provide a more useful measure than the assessment of individual antioxidants (Ghiselli 
et al. 2000). However, the different analytical methods for TAC have a weak or no 
correlations (Cao and Prior 1998), making it difficult to compare results between 
studies. Significant reductions in the TAC of preterm and term BM have been reported 
after storage at 4°C for 48 (Xavier et al. 2011), and 72 h (Aksu et al. 2015), although, 
others have shown that storing pooled preterm BM at 6.8°C for up to 96 h not affect 
TAC (Bertino et al. 2013). Freezing BM at -20°C shows significantly reduced 
antioxidant capacity after 48 h, which further decreased after one week (Hanna et al. 
2004), and a significant decrease after one week with further decrease after one month 
(Paduraru et al. 2018), with similar effects seen at -8°C (Xavier et al. 2011). However, 
others report no changes in TAC after storing preterm milk for 30 days at -20°C 
(Marinkovic et al. 2016), or storing DHM at -20°C for two months (Turoli et al. 2004). 
Preterm colostrum stored for up to three months at -80°C did not show any change in 
TAC (Akdag et al. 2014), whereas term mature BM stored at -80°C showed 
significantly lower TAC after two months (Sari et al. 2012). Thawing BM at 4°C for 24 h 
(as recommended by the U.K. guideline (National Institute for Health and Clinical 
Excellence 2010)), as well as thawing at room temperature for 2.5 to 4.25 h did not 
change TAC (Chan et al. 2011), whereas using a water-bath for thawing (50°C, 12 to 
30 minutes) resulted in a significant decrease in TAC. Overall, the evidence of different 
storage conditions on TAC is equivocal, potentially due to differences in analytical 
techniques, or it may be an indicator of potential variations in the antioxidant 





5.4 Conclusion and recommendations 
Current human milk banking practices have been developed to provide microbiological 
safe DHM, with limited emphasis on the nutritional quality of DHM. There are currently 
no globally accepted guidelines for human milk banking practices, with wide variations 
in practices, regulations, and organization in each country, in part due to a lack of 
robust evidence (Weaver et al. 2019). However, more consideration must be given to 
the nutritional quality of DHM to ensure optimum nutritional intake for the infants. 
Specific focus should be given to components such as LCPUFAs, bioactive lipid 
mediators, and their supporting antioxidants, as their levels are essential for the health 
and development of preterm infants. The literature reviewed within this article clearly 
demonstrates that the quality of DHM can be influenced by the various storage and 
processing conditions used in human milk banking. The observations of minimal 
changes in fat composition are consistent with a recent systematic review (Gao et al. 
2019); however, levels of lipid peroxidation products, and endogenous antioxidants 
appear more sensitive to the storage conditions, and when considering the effects of 
human milking banking practices on overall DHM lipid nutritional quality these aspects 
should also be considered, although further research is needed to understand these 
effects. 
Due to the diversity of methodological approaches, and biological variability of the 
human BM samples, there remain many uncertainties and a general lack of 
consistency in the current literature around the optimal DHM storage conditions. 
Indeed, this is even more apparent when considering a range of different nutritional 
components, where there are different sensitivities to the storage conditions and 
processing. It is clear that further research is needed to improve the evidence base for 
human milk banking practices, particularly on the effects of storage conditions on 
bioactive compounds such as eicosanoids, SPMs and the TAC of DHM. However, in 
the interim, in order to maximise the LCPUFA content, and to ensure maintenance of 
supporting antioxidants we must accept a certain degree of uncertainty and adopt a 
precautionary approach. Therefore, we suggest considering the following 
recommendations where possible, to supplement current local and national guidelines: 
 BM containers should protect the milk from exposure to light, either through the 
use of amber containers, or if unavailable, other approaches should be put in 
place, such as wrapping containers in aluminium foil, and putting covers over 
fridges and freezers with glass doors. 
 DHM should be frozen at -20°C directly after expression, instead of pooling over 
24 h in the fridge. 
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 Storage at 4°C at the human milk bank should be minimized wherever possible, 
and every effort should be made to transport DHM to the human milk bank as 
soon as possible after expression. 
 At the human milk bank the DHM should ideally be frozen at -70°C or below, 
particularly prior to pasteurisation, although more research is needed to explore 
the effects of long-term storage of post-pasteurised DHM. 
 Using different thawing methods (at room temperature, in the fridge or using a 
water-bath), affects BM components differently, and currently, the evidence 





6 LCPUFAs and LPPs in DHM in the U.K.: Results from the 
LIMIT two-centre cross-sectional study 
The importance of LCPUFAs for preterm infant health and development has been long 
known (Crawford 1993) and led to the addition of LCPUFAs to FM in 1994 in Europe 
and in 2001 in the U.S.A. (Hadley et al. 2016). Regardless, DHM is preferred over FM 
for feeding preterm infants (WHO 2003) due to its multitude of benefits (Quigley and 
McGuire 2014). LCPUFA percentage composition of DHM in the U.S.A., Canada, and 
Sweden (Valentine et al. 2010; Baack et al. 2012; Pitino et al. 2019) are too low for 
preterm infants, who have higher LCPUFA requirements than term infants (as 
described in detail in Chapter 1.1.6). DHM LCPUFA levels might be even lower in the 
U.K., since U.K. BM LCPUFA levels are below the worldwide averages (Yuhas et al. 
2006; Fu et al. 2016). Furthermore, DHM in the U.K. is not pooled from several donors 
during processing (National Institute for Health and Clinical Excellence 2010), which 
could lead to greater variability, and in some cases extremely low LCPUFA levels. 
Additionally, the total fat concentration of DHM is less than in preterm BM (Ntoumani et 
al. 2013).  
Chapter 5 identified several human milk banking practices that might negatively affect 
the LCPUFA quality and quantity of DHM and might increase LPPs (Nessel et al. 
2019). Additionally, the HMB Survey (Chapter 4) identified that these practices are 
used in HMBs in the U.K. However, the actual effects of the complete (U.K.) milk 
banking process on absolute LCPUFA and LPP content had not been investigated. 
Researchers have measured FA percentage composition (Valentine et al. 2010), used 
unprocessed DHM (Ntoumani et al. 2013), or mimicked the milk banking process 
(Garcia-Lara et al. 2013) in their studies. The effects of specific aspects of human milk 
banking, e.g. pasteurisation, were also investigated individually. For example, Holder 
pasteurisation, after short time storage at -80°C, did not increase hexanal or MDA 
levels (Elisia and Kitts 2011). However, the combination of the different processes, e.g. 
pooling of BM in the fridge over 24 hours, followed by prolonged frozen storage (-20°C) 
combined with Holder pasteurisation, may have additive negative effects on the 
nutritional quality. Consequently, it is important to investigate nutrient levels in DHM 
that has undergone the whole milk banking process. It was, therefore, the aim of the 
LIMIT study (Investigating Lipid Peroxidation Products in Donor Human Milk – a Two-
Centre Study) to quantify for the first time the relative and absolute levels of LCPUFAs, 
and LPPs in DHM provided for administration two two neonatal units in the U.K., from 
two different HMBs. Comparison was undertaken with BM from mothers of term infants 
(since the majority of DHM is provided by term mothers) and also with BM from 
mothers of preterm infants, the primary milk provision for the preterm infant. Total 
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enteral LCPUFA intake, as well as LCPUFA levels available for accretion from DHM 
were also calculated and compared to levels provided by preterm BM. This along with 
comparison to enteral intake recommendations form ESPGHAN (Agostoni et al. 2010), 
and published in utero accretion rates (Lapillonne and Jensen 2009), were utilised to 
provide information about suitability of current DHM for preterm infants, focusing on 
LCPUFA provision.  
The following section is the original article, accepted for publication (10/12/2019) in the 
peer-reviewed Journal of Parenteral and Enteral Nutrition (Wiley, doi: 
10.1002/jpen.1773) (Nessel et al. 2020). An author contribution statement can be found 





Docosahexaenoic acid (22:6n-3, DHA) and arachidonic acid (20:4n-6, ARA) are 
omega-3 and omega-6 long-chain polyunsaturated fatty acids (LCPUFAs), 
respectively, essential for optimal visual and brain development, and immune system 
function (Dyall 2015). The last trimester is the period of maximal brain growth, and an 
interrupted maternal-foetal LCPUFA transfer, low adipose tissue reserves, limited 
conversion of LCPUFAs from precursor fatty acids, and low provisions of preformed 
LCPUFAs put preterm infants at an increased risk of ARA and DHA deficiencies (De 
Rooy et al. 2017). It is therefore essential to ensure adequate postnatal provision of 
LCPUFAs (Harris and Baack 2015). 
Breast milk (BM) provides ARA and DHA, and BM from mothers of preterm infants has 
higher DHA levels than that of term mothers (Bokor et al. 2007). However, producing 
an adequate BM supply is three times less likely in preterm mothers (Hill et al. 2005), 
and donor human milk (DHM) from a human milk bank is recommended (WHO 2003). 
The use of DHM is growing world-wide due to reported benefits, such as reduced 
necrotising enterocolitis (Quigley and McGuire 2014) and bronchopulmonary dysplasia 
(Villamor-Martinez et al. 2018). However, human milk banking practices, such as 
prolonged storage at -20°C, thawing in the refrigerator, and frequent container 
changes, may decrease total fat content and LCPUFAs (Nessel et al. 2019). The 
LCPUFA content of DHM is not well studied, and unknown in the U.K. Variations in 
LCPUFA content of DHM have been shown in the U.S.A. depending on the milk bank 
location, and levels may fall below preterm infant recommendations (Baack et al. 
2012). DHM in the U.S.A. is pooled from several donors (O'Hare et al. 2013), whereas 
in other countries, including the U.K., it is not pooled (National Institute for Health and 
Clinical Excellence 2010). Since LCPUFA levels are highly dependent on maternal 
nutrition, age, length of lactation, and genetic variation, non-pooled DHM potentially 
has greater variability in LCPUFA levels (Juber et al. 2016).  
LCPUFAs are susceptible to lipid peroxidation (Dyall 2011) by oxygen radicals. Lipid 
hydroperoxides are primary lipid peroxidation products, which react further to form 
secondary lipid peroxidation products. Malondialdehyde (MDA), the unspecific 
peroxidation product of PUFAs with more than two double bonds, as well as 4-hydroxy-
2-nonenal (HNE), the specific peroxidation product of omega-6 PUFAs, and hexanal, 
have been identified in BM (Michalski et al. 2008). Milk banking practices, such as 
storage and processing conditions, can increase lipid peroxidation (Nessel et al. 2019). 
Preterm infants are prone to oxygen radical associated diseases, such as necrotising 
enterocolitis (NEC), bronchopulmonary dysplasia and retinopathy of prematurity 
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(Saugstad 2005), which may be exacerbated by intake of lipid peroxidation products 
(Awada et al. 2012).  
The aims of this study are to quantify for the first time absolute and relative LCPUFA 
content of BM from milk banks provided to neonatal units in the U.K. and compare 
these values with BM from mothers of preterm and term infants. MDA, HNE and 
hexanal levels were also measured to explore whether DHM is a source of lipid 




6.2 Material and Methods 
6.2.1 Ethics, participants, and samples 
This cross sectional two-centre study was performed in the U.K. between December 
2018 and February 2019 (www.ClinicalTrials.gov: NCT03573531). The protocol was 
approved by London-South East Research Ethics Committee (reference 18/LO/1330). 
5 mL of unused, bedside DHM was collected in two neonatal units, served by two 
human milk banks, but as DHM is anonymised informed consent could not be obtained 
from donors. DHM in the U.K. is always from only one donor (non-pooled), Holder 
pasteurised, and frozen at -20°C for a maximum of six months from expression 
(National Institute for Health and Clinical Excellence 2010). Preterm BM (5 mL) was 
collected at a neonatal unit, and term BM (5 mL) from the community. Eligible 
participants were 18 years, healthy, and delivered either before or after 37 weeks 
gestation for preterm and term BM samples, respectively. Exclusion criteria were not 
understanding study information in English, clinical chorioamnionitis or sepsis, smoking 
(including e-cigarettes), mastitis, or receiving treatment for (chronic) infection or 
inflammatory disease. Participants gave informed consent and the study was 
conducted according to the Declaration of Helsinki. A sample size of 10/20 per group 
was chosen as pragmatic approach, considering outcome measurements. After 
collection, samples were frozen at -70°C until analysis, which was within three months. 
6.2.2 Quantification of fatty acids and total fat content 
Lipids were extracted and analysed as described previously (De Rooy et al. 2017). 
Briefly, tricosanoic acid was added as internal standard to homogenised BM and fatty 
acids analysed by gas chromatography with flame ionisation detector (Agilent 
Technologies, 7820A). Since BM contains 98% triacylglycerols (Koletzko 2016), the 
sum of the absolute fatty acid values was used to estimate total fat content.  
6.2.3 Quantification of MDA 
MDA was analysed using a thiobarbiturc acid reactive substances assay (Cayman 
Chemical) following manufacturer’s instructions. Samples were incubated with trichloric 
acid and colour reagent and absorbance measured in duplicates at 540 nm. All 
samples were analysed on the same plate. Absolute MDA levels were adjusted 
according to previously determined recovery rate of 36.44% (unpublished data), and 
corrected for estimated total fat content, as fat content differed significantly between 
samples and may influence MDA concentrations. 
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6.2.4 Quantification of HNE 
HNE adducts were quantified using OxiSelect HNE Adduct competitive ELISA Kit (Cell 
Biolabs, Inc.) following manufacturer’s instructions. After coating the plate overnight, 
samples were added and incubated, before adding anti-HNE antibody. After secondary 
antibody incubation absorbance was measured at 450 nm, and samples measured on 
the same plate. HNE adducts may depend on protein content; however, no significant 
differences were detected using Bradford Reagent, and no correction was performed. 
Values were corrected for estimated total fat content. Nine samples (six DHM, one 
preterm BM, two term BM) were above the limit of quantification (LoQ) (200 µg/mL); 
whereas 12 samples (six DHM, two preterm BM, four term BM) were below LoQ 
(1.56 µg/mL). To remove potential bias in the results, values above and below LoQ 
were set at the upper and lower LoQ, respectively, as recommended (Duval and 
Karlsson 2002).  
6.2.5 Quantification of Hexanal 
Hexanal was measured using solid phase micro-extraction (SPME) (Elisia and Kitts 
2011). BM was homogenised and 25% NaCl (w/v) added. After equilibration, 
headspace volatiles were sampled using a polydimethylsiloxane fiber (100 µm, 
Supelco) before injection into a gas chromatograph with flame ionisation detector 
(Agilent Technologies, 7820A) fitted with a merlin micro seal, SPME liner, and J&W 
HP-5 column. Hexanal peak area was corrected for percentage recovery based on fat 
content, as suggested (Elisia and Kitts 2011), and adjusted for estimated total fat 
content.  
6.2.6 Statistical analysis 
Data is reported according to STROBE guidelines (von Elm et al. 2014). There was 
one missing value for hexanal in the DHM group, due to limited sample volume. 
Grubbs’ test was used to detect significant outliers, which were excluded. Statistical 
analysis was performed using GraphPad Prism (Version 5.0). Data was tested for 
normality. Participant demographics where compared using a t-test. Pump expression 
was compared using Fisher’s exact test. All other values were compared by One-Way 
ANOVA with Tukey’s multiple comparisons test comparing all groups or Kruskal-Wallis 
test with Dunn’s multiple comparisons test comparing all columns. For correlations, 
Spearman correlation was used.  
Enteral fat, PUFA, and protein supply was calculated for hypothetical 30+6 week 
gestational age infant, weighing 1400 g and receiving full enteral feeding (150 




Hepatology and Nutrition (ESPGHAN) recommended intake levels (Agostoni et al. 
2010) using a one sample t-test and compared between the groups using t-test or 
Mann Whitney test. LCPUFAs available for accretion were also calculated for this 
hypothetical infant as described previously (De Rooy et al. 2017), and compared to 
estimated accretion rates (Lapillonne and Jensen 2009) by one sample t-test. For 
comparisons between groups, t-test or Mann Whitney test was used. Data presented 
as mean ± SD, and considered statistically significant at P<0.05. * indicates P<0.05, ** 
and *** P-values <0.01 and <0.001, respectively.  
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6.3 Results  
6.3.1 Participant and sample characteristics 
40 samples were collected: 19 DHM, 10 preterm and 11 term BM samples (Figure 6-1). 
Most DHM samples (n = 15; 79%) were collected at St. George’s University Hospitals 
NHS Foundation Trust, and the remaining at Poole Hospital NHS Foundation Trust, 
these hospitals are served by two different human milk banks. DHM was pasteurised 
within three months of expression (81 ± 18.8 days), and stored for an average of 177 ± 
5.6 days. 
 
Figure 6-1: Participant flow through the study  
Preterm BM samples were collected at the Neonatal Unit at St. George’s University Hospitals NHS 
Foundation Trust, and term BM samples from the community at Bournemouth University. 
 
Preterm and term BM donor characteristics are shown in Table 6-1; DHM donor 
characteristics cannot be reported, due to anonymization. There was no statistical 
difference between preterm and term BM donors’ age (33.1 ± 5.8 vs. 29.5 ± 5.6 years). 
Infants of preterm BM donors were significantly younger than infants of term BM 
donors (1.6 ± 1.4 vs. 5.6 ± 3.4 months; P=0.0026), and there was a significant 






Table 6-1: Preterm and term BM donor characteristics  
 
 
6.3.2 BM fat content and composition 
Estimated total fat content differed between the groups (P<0.0001). DHM had the 
lowest levels (1.74 ± 0.52 g/100 mL), followed by preterm BM (2.44 ± 0.65 g/100 mL), 
with both significantly lower than term BM (4.79 ± 1.60 g/100 mL; both P<0.001). 
Levels of fatty acids expressed as percentage of total fatty acids are shown in Table 
6-2. There were no significant differences in total saturated fatty acids (SFA) or 
monounsaturated fatty acids (MUFAs), or total omega-3 and omega-6 PUFAs. ARA 
was significantly higher in preterm than term BM (+0.11%; P<0.05), and preterm BM 
DHA was significant higher than both DHM and term BM (+0.24% P<0.01, and +0.22% 
P<0.05, respectively). 20:3n-6, 22:4n-6, and docosapentaenoic acid (22:5n-3, DPAn-3) 
were also significantly higher in preterm than term BM, and eicosapentaenoic acid 
(20:5n-3, EPA), and DPAn-3 were also significantly higher in preterm BM than DHM. 
In contrast to percentage composition, absolute total SFAs and MUFAs, and total 
omega-3 and omega-6 PUFAs were significantly lower in DHM than term BM (all 
P<0.001), Table 6-3. For individual fatty acids, all except 22:4n-6 were significantly 
lower in DHM than term BM. Total omega-3 PUFAs were significantly lower (P<0.05) in 
DHM than preterm BM. 18:3n-6, 20:3n-6, ARA, and 22:4n-6 were significantly lower in 
DHM than preterm BM, although total omega-6 PUFA content was not significantly 
different. Total SFAs and MUFAs, and total omega-6 PUFAs, but not total omega-3 
PUFAs, were significantly lower in preterm than term BM. DHM had the lowest ARA, 
which was significantly lower than preterm and term BM (-6.24 mg/100 mL 
and -11.16 mg/100 mL; P<0.01 and P<0.001, respectively). DHA was significantly 
lower in DHM than preterm and term BM (-9.95 mg/100 mL and -13.69 mg/100 mL; 
P<0.05 and P<0.001, respectively).  
Donor characteristics Preterm Term p-value 
Number (n) 10 11 N/A 
Maternal age (years) 33.1 ± 5.8 29.5 ± 5.6 0.1809 
Infant age (months) 1.6 ± 1.4 5.6 ± 3.4 0.0026 
Delivery at (weeks + days) 30+6 ± 3+3 40+4 ± 0+5 <0.0001 
Pump expression (n (%)) 10 (100%) 6 (55%) 0.0351 
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Table 6-2: Relative fatty acid composition of DHM, preterm and term BM  
* significant different to DHM, 
# 
significant different to term BM  
  
% of total fatty 
acids 
DHM Preterm BM Term BM P-value 
10:0 1.48 ± 0.24 1.62 ± 0.42 1.68 ± 0.42 0.2859 
12:0 6.50 ± 1.78 6.86 ± 1.30 7.05 ± 1.95 0.6889 
14:0 6.71 ± 1.51 7.68 ± 2.00 6.59 ± 1.46 0.4110 
16:0 21.58 ± 1.13 20.19 ± 2.68 20.70 ± 3.00 0.2474 
18:0 8.16 ± 3.24 9.88 ± 5.97 10.71 ± 6.29 0.6840 
20:0 0.11 ± 0.06 0.09 ± 0.05 0.12 ± 0.08 0.6903 
 SFA 44.77 ± 3.56  47.83 ± 7.45 46.85 ± 6.37 0.3466 
16:1n-7 2.45 ± 0.59 2.43 ± 0.71 2.30 ± 0.52 0.8043 
18:1n-7/n-9 36.28 ± 3.55 32.96 ± 4.88 34.21 ± 6.16 0.1927 
20:1n-9 0.53 ± 0.07 0.59 ± 0.12 0.58 ± 0.33 0.2005 
24:1n-9 0.07 ± 0.02 0.05 ± 0.03 0.06 ± 0.02 0.0672 
 MUFA 39.41 ± 3.83 36.02 ± 5.40 39.06 ± 4.27 0.1432 
18:2n-6 (LA) 12.93 ± 1.64 12.74 ± 3.05 11.90 ± 1.70 0.2868 
18:3n-6 0.13 ± 0.02 0.13 ± 0.04 0.14 ± 0.05 0.7162 
20:3n-6 0.40 ± 0.08
#
 0.42 ± 0.11
#
 0.31 ± 0.09* 0.0186 
20:4n-6 (ARA) 0.47 ± 0.09 0.53 ± 0.13
#
 0.42 ± 0.07 0.0520 
22:4n-6 0.11 ± 0.05 0.13 ± 0.07
#
 0.07 ± 0.02 0.0275 
 Omega-6 PUFAs 14.04 ± 1.80 13.94 ± 3.02 12.83 ± 1.73 0.2626 
18:3n-3 (ALA) 1.25 ± 0.25 1.21 ± 0.37 1.42 ± 0.24 0.1797 
20:5n-3 (EPA) 0.06 ± 0.02 0.11 ± 0.06* 0.09 ± 0.04 0.0311 
22:5n-3 (DPAn-3) 0.15 ± 0.03 0.22 ± 0.07** 
#
 0.17 ± 0.06 0.0031 
22:6n-3 (DHA) 0.29 ± 0.08 0.52 ± 0.70** 
#
 0.31 ± 0.15 0.0018 





Table 6-3: Absolute fatty acid composition of DHM, preterm and term BM 
 
* significant different to DHM, 
# 




DHM Preterm BM Term BM P-value 
10:0 26.53 ± 9.09
###
 38.19 ± 11.81
###
 78.05 ± 29.55*** <0.0001 
12:0 112.0 ± 41.09
###
 179.8 ± 65.90* 
###
 315.20 ± 96.89*** <0.0001 
14:0 115.1 ± 37.23
###
 239.1 ± 125.9** 310.3 ± 111.1*** <0.0001 
16:0 378.5 ± 119.2
###
 498.8 ± 152.2
###
 1154 ± 585.1*** <0.0001 
18:0 152.6 ± 103.3
###
 217.5 ± 130.6
#
 462.8 ± 296.1*** 0.0005 
20:0 2.03 ± 1.36
##
 3.07 ± 1.87 5.29 ± 3.50** 0.0024 
 SFAs 809.5 ± 293.2
###
 1145 ± 341.2
###
 2198 ± 822.7*** <0.0001 
16:1n-7 40.28 ± 13.49
###
 65.49 ± 26.86
##
 126.5 ± 64.87*** <0.0001 
18:1n-7/n-9 610.5 ± 173.7
###
 910.2 ± 367.0
###
 1831 ± 699.9*** <0.0001 
20:1n-9 9.47 ± 2.97
###
 14.41 ± 4.43
##
 34.15 ± 23.29*** <0.0001 
24:1n-9 1.32 ± 0.55
###
 1.25 ± 0.69
###
 2.97 ± 1.45*** <0.0001 
 MUFAs 664.2 ± 190.7
###
 993.8 ± 396.8
###
 2004 ± 756.5*** <0.0001 
18:2n-6 (LA) 223.6 ± 65.04
###
 308.6 ± 93.81
###
 587.1 ± 214.1*** <0.0001 
18:3n-6 2.26 ± 0.69
###
 3.36 ± 1.10* 
###
 6.80 ± 1.70*** <0.0001 
20:3n-6 6.95 ± 2.26
###
 11.45 ± 5.06* 14.20 ± 4.40*** <0.0001 
20:4n-6 (ARA) 8.26 ± 2.90
###
 14.86 ± 6.97** 19.78 ± 5.97*** <0.0001 





 340.9 ± 100.5
###
 631.0 ± 224.2*** <0.0001 
18:3n-3 (ALA) 22.28 ± 9.49
###
 39.66 ± 28.81 68.93 ± 24.21*** 0.0003 
20:5n-3 (EPA) 1.10 ± 0.48
###
 3.26 ± 2.76* 4.58 ± 2.80*** 0.0003 
22:5n-3 (DPAn-3) 2.85 ± 1.37
###
 6.49 ± 4.00* 9.38 ± 6.07*** 0.0001 
22:6n-3 (DHA) 4.70 ± 1.67
###





 64.07 ± 40.67* 97.21 ± 38.59*** 0.0001 
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6.3.3 Estimated PUFA and protein intake from DHM and preterm BM  
Preterm infants in this study were born at 30+6 weeks gestational age, and to provide 
an estimate of potential daily enteral fat, PUFA, and protein intake from DHM and 
preterm BM, values were calculated for a hypothetical preterm infant of 1400 g 
bodyweight assuming full enteral feeding (210 mL), and values were compared to 
ESPGHAN recommendations (Agostoni et al. 2010). DHM provided significantly lower 
fat than recommended by ESPGHAN (3.67 ± 1.06 g/d vs. 6.72 g/d; P<0.0001), 
whereas preterm BM achieved recommended levels (6.0 ± 2.92 g/d). Daily fat intake 
from preterm BM was significantly higher than from DHM (+2.33 g/d; P=0.0095). 
Similarly, DHM levels of LA, ALA, ARA, and DHA were all significantly below 
ESPGHAN recommendations (Table 6-4). Preterm BM levels were above the minimum 
recommendations, with DHA significantly above, although still below the upper daily 
limit (42 mg).  
Table 6-4: Daily enteral PUFA supply compared to ESPGHAN recommendations 
 
 
Enteral PUFA supply from DHM or preterm BM (210 mL) for a hypothetical 1400 g infant 
Feeding an infant exclusively DHM for seven days would result in ARA and DHA 
deficits of 55.05 and 43.29 mg/week, respectively, compared to ESPGHAN 
recommendations. Whereas feeding exclusively preterm BM would provide significantly 
more ARA (+97.1 mg/week; P=0.0012) and DHA (+141.07 mg/week; P=0.0048), and 
achieve recommendations (Agostoni et al. 2010). 
DHM and preterm BM provide protein levels significantly below the ESPGHAN 
recommendations (1.96 ± 0.41 g/d and 2.46 ± 0.71 g/d vs. 4.9 g/d; both P<0.0001). 
Exclusive DHM or preterm BM for seven days results in deficits of 20.58 and 
17.08 g/week protein, respectively. Protein intake from DHM is significantly below 








18:2n-6 (LA) 469.6 ± 132.94* 737.1 ± 319.76 539 
18:3n-3 (ALA) 46.79 ± 19.4*** 83.29 ± 57.4 77 
20:4n-6 (ARA) 17.36 ± 5.92*** 31.20 ± 13.88 25.2 




6.3.4 Estimated LCPUFAs available for accretion 
ARA and DHA available for accretion from DHM and preterm BM were calculated for 
the hypothetical infant. Full enteral feeding with DHM or preterm BM provides 51.44 ± 
4.80 and 62.68 ± 11.25 mg/d of ARA, respectively, significantly below estimated in 
utero accretion rates (Lapillonne and Jensen 2009) of 296.8 mg/d, by 82.7% and 
78.9%, respectively (both P<0.0001). After one week of exclusively DHM or preterm 
BM feeding deficits of 1717.53 mg and 1638.12 mg, respectively, occur, with ARA 
significantly higher in preterm BM than DHM (P=0.0012). DHA from DHM and preterm 
BM was also significantly below estimated in utero accretion rate (25.97 ± 3.62 and 
41.77 ± 13.28 mg/d, at 43.13% and 69.38% of in utero accretion of 60.2 mg/d; 
P<0.0001 and P=0.0024, respectively), producing deficits of 239.64 mg or 129.03 mg 
after seven days of full enteral feeding with DHM or preterm BM, respectively. DHA 
availability is significantly higher from preterm BM than DHM (P=0.0048).  
  
198 
6.3.5 Lipid peroxidation 
MDA 
Uncorrected MDA content was different between groups (Figure 6-2 A). DHM levels 
were significantly lower than preterm BM (38.83 ± 11.05 µM vs. 55.32 ± 16.54 µM; 
P<0.05), but not than term BM (51.27 ± 19.66 µM) MDA is derived from PUFAs, and 
MDA content was therefore corrected for estimated fat content (Figure 6-2 B). After 
correction for total fat, MDA concentration remained significantly different between 
groups (P<0.0248); with both DHM and preterm BM levels significantly higher than 
term (23.46 ± 6.28 µM vs. 9.12 ± 2.66 µM, and 21.53 ± 6.83 µM vs. 9.12 ± 2.66 µM, 
respectively, both P<0.001). 
 
 
Figure 6-2: Absolute MDA concentration of DHM, preterm and term BM (A) and corrected for fat  
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HNE 
HNE content did not differ significantly between groups (Figure 6-3 A). When HNE was 
corrected for fat content, a significant difference was seen (P=0.0482; Figure 6-3 B). 
DHM was significant higher than term BM (59.99 ± 75.13 µg/mL vs. 8.18 ± 13.14 
µg/mL; P<0.05). Preterm BM was not significantly different from the other groups. 
 



























































There was a significant difference in hexanal between groups (P=0.0091; Figure 6-4 
A). DHM was significantly higher than preterm BM (124.5 ± 90.86 mm2 vs. 34.43 ± 
32.85 mm2; P<0.05), but not term BM. Following correction for fat, there were 
significant difference between groups (P=0.0009; Figure 6-4 B). DHM levels were 
significantly higher than both preterm and term BM (67.68 ± 52.40 mm2 vs. 16.12 ± 
19.58 mm2 and 9.47 ± 6.41 mm2, respectively, both P<0.01). 
 
















































Figure 6-4: Absolute hexanal concentration of DHM, preterm and term BM (A) and corrected for fat  
content (B) 
 















Correlations of ARA and DHA with lipid peroxidation products 
Absolute ARA and DHA were correlated with uncorrected MDA and hexanal, and ARA 
with uncorrected HNE content. There were significant positive correlations between 
both ARA and DHA and MDA (r=0.4700; P=0.0025, and r=0.3587; P=0.0249, 
respectively). There was no significant correlation between DHA and hexanal or ARA 




6.4 Discussion and conclusion 
This study investigated the LCPUFA and lipid peroxidation product content of DHM 
provided to two neonatal units in the U.K, and compared these values to preterm and 
term BM. Significantly lower fat, absolute ARA and DHA and increased lipid 
peroxidation product levels were identified in DHM, which can have important clinical 
implications for preterm infant nutrition and health outcomes.  
The relative fatty acid percentage composition was consistent with reported values in 
the U.K. (Yuhas et al. 2006), and was not significantly different between DHM and term 
BM, suggesting milk banking practices do not affect levels. Similarly, a recent 
systematic review reported the fatty acid composition of DHM is not negatively 
influenced by milk banking processes (Gao et al. 2019). However, when expressing 
fatty acids in absolute levels, significantly lower SFAs and MUFAs, and omega-3 and 
omega-6 PUFAs were found in DHM compared to term BM. This dissonance supports 
the recommendation that both relative and absolute fatty acid composition data should 
be reported (Brenna et al. 2018).  
Preterm BM had higher DHA than term BM, consistent with previous observations 
(Bokor et al. 2007). If maternal BM is unavailable, DHM is the recommended 
alternative (WHO 2003). However, significantly lower relative DHA and absolute ARA 
and DHA were found in DHM compared to preterm BM. Based on the estimated intake 
of a 1400 g infant this would lead to intake significantly below ESPGHAN 
recommendations, consistent with analyses of DHM in the U.S.A. (Baack et al. 2012). 
ESPGHAN recommendations consider LA and ALA precursors of ARA and DHA, 
respectively; however, DHM levels of these were also below recommendations 
(Agostoni et al. 2010). 
DHM and preterm BM were also estimated to provide ARA and DHA significantly below 
in utero accretion rates (Lapillonne and Jensen 2009). These deficits are of particular 
concern for preterm infants, where neurological development and immune system 
function are underdeveloped (Harris and Baack 2015). Low ARA and DHA intake are 
also associated with morbidities of prematurity, such as NEC, bronchopulmonary 
dysplasia, retinopathy of prematurity, and white matter injury (Fares et al. 2017). DHM 
and maternal BM can be fortified with commercial fortifiers. However, in the U.K., 
currently only bovine BM fortifiers for preterm infants are available. Of these, one 
contains no source of fat and is therefore not a source of LCPUFAs, whereas the other 
one contains LA, ALA, and DHA, but not ARA. This study strongly supports the use of 
a commercial fortifier providing both DHA and ARA. However, fortified BM will still 
provide LCPUFA levels below calculated in utero accretion rates, as also described by 
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Harris and Baack (Harris and Baack 2015). When BM is expressed for donation, or 
expressed by mothers for their preterm infants, strategies to increase the overall fat 
content, such as hind milk expression, may also be helpful, since hind milk contains a 
higher fat content (Mizuno et al. 2009).  
When controlling for the overall fat content of the different milk, significantly higher 
levels of MDA, HNE and hexanal were identified in DHM compared to term BM. This 
study cannot identify if milk banking practices contributed to these higher levels, 
although these practices have the potential to increase lipid peroxidation. For example, 
storage at 4°C increases HNE and MDA, storage at -20°C for 60 days increases MDA, 
and storage at -18°C for three months increases hexanal (Nessel et al. 2019). Not 
protecting BM from light has also been demonstrated to increase hexanal levels 
(Vangnai et al. 2017).  
The highest proportion of lipid peroxidation products was identified in DHM. More 
research is needed to define safe upper intake levels for lipid peroxidation products. 
However, studies suggest ingesting lipid peroxidation products increases inflammation, 
potentially via activation of the nuclear factor β signalling pathway (Awada et al. 
2012). Repeated intake of lipid peroxidation products has been shown to be 
carcinogenic, and associated with growth retardation, intestinal and cardiovascular 
diseases. The latest European Medicines Agency recommendation 
(EMA/PRAC/347675/2019) is to protect parenteral lipid solutions from light to avoid 
adverse outcomes in neonates due to toxic lipid degradation products, and a similar 
strategy should be used for DHM. Endogenous antioxidants in BM may provide 
protective effects; however, milk banking processes may have detrimental effects on 
their levels (Nessel et al. 2019).  
This is the first study to quantify relative and absolute LCPUFAs and lipid peroxidation 
in DHM, preterm and term BM in the U.K. DHM levels were measured at one time-
point, and not over the journey from expression to administration, so the role of milk 
banking practices can only be inferred. It cannot be discounted that donor BM had low 
fat and LCPUFAs to begin with. Therefore, further research is needed to confirm our 
findings and clarify the relative contribution of milk banking to the observed differences 
between DHM and term BM. In the meantime, we have provided recommendations for 
human milk banking practices to maximise the LCPUFA levels and maintain nutritional 
quality of DHM (Nessel et al. 2019).  
A strength of the study is that DHM was measured from samples provided by two 
neonatal units, served by two different human milk banks, giving a clinically relevant 




samples of surplus rather than fresh DHM, as DHM is rare in the U.K. and provision to 
the infant has priority. The study also used a range of endpoints to measure lipid 
peroxidation, providing a more complete assessment. A limitation is that the effects of 
milk banking practices on LCPUFAs and lipid peroxidation products can only be 
inferred; however, the results provide novel information on the actual levels of 
LCPUFAs and lipid peroxidation products in DHM that would have been provided to 
preterm infants. 
In conclusion, the results suggest DHM has lower LCPUFA and higher lipid 
peroxidation than preterm or term milk. Estimated LCPUFA intake provided by DHM is 
significantly below ESPGHAN recommendations and far below foetal accretion rates. 
This implies that DHM is not suitable long-term as sole diet for preterm infants, and 
should be used in conjunction with preterm BM wherever possible. The lower LCPUFA 
and higher lipid peroxidation product levels may be due to milk banking practices. 
These results have important implications internationally, as milk banking guidelines 
and practices are often mirrored across countries. In addition, higher lipid peroxidation 
levels in DHM may leave preterm infants more vulnerable to common co-morbidities. 
These results highlight a need for further research to confirm our findings and explore 




The authors wish to thank the participants and anonymous milk donors, and Suzy 
Wignall, Clinical Governance Advisor, Bournemouth University.  
  
206 
6.5 Supplementary material 
The following supplementary information does not form part of the publication and is 
added only as part of this thesis to provide further information.  
6.5.1 Study design 
Ethical approval for this project (IRAS ID 221198) was obtained from the London-South 
East Research Ethics Committee (REC reference 18/LO/1330), the Health Research 
Authority, and Bournemouth University (ID 22015) (Appendix VI.II-VI.V). The study was 
sponsored by Bournemouth University and was performed in collaboration with Poole 
Hospital NHS Foundation Trust (local Principal Investigator: Prof Minesh Khashu) and 
St George’s University Hospitals NHS Foundation Trust (local Principal Investigator: Dr 
Laura De Rooy). An Honorary Contract was obtained for Poole Hospital NHS 
Foundation Trust. Capacity and Capability to perform this research was confirmed by 
the local Research and Development Offices. Confirmation letters are listed in 
Appendix VI.VI-VIII. This study was carried out in accordance with the Declaration of 
Helsinki (1964) and the Data Protection Act (2018).  
A sample size of twelve per group has been recommended for a pilot study (Julious 
2005). Considering the outcome measurements, 10/20 samples per group were 
chosen as a pragmatic approach.  
6.5.2 Recruitment 
Potential preterm BM donors at the neonatal unit were identified and approached by 
the local Principle Investigator. Additionally, recruitment posters (Appendix VI.IX) were 
displayed on the neonatal unit. To recruit term BM donors, recruitment posters 
(Appendix VI.IX) were displayed at Bournemouth University and posted on the 
Bournemouth University Research Blog 
(https://blogs.bournemouth.ac.uk/research/2019/02/06/bu-research-into-breast-milk-
quality-participants-needed-2/). Information was also spread by word of mouth.  
Preterm and term BM donors received an invitation letter (Appendix VI.X) and the 
participant information sheet (Appendix IV.XI), and had the opportunity to ask 
questions before signing the consent form (Appendix IV.XII). All participants were 
reminded about their right of non-participation. Preterm BM donors were reminded that 
non-participation would not compromise their or their infants’ clinical care. All 
participants were informed about their right to withdraw at any time, but were reminded 




6.5.3 Outcome measurements 
Quantification of FAs  
FAs were analysed using GC-FID, as described in Chapter 2.3.1. Additionally to the 
absolute concentration, the percentage composition of FAs was analysed, using the 
following formula:  
𝐹𝐴 % 𝑤𝑡 𝑤𝑡⁄ = 100 ∑ 𝑎𝐹𝐴
19
𝑖=1
⁄ × 𝑎𝐹𝐴 × 𝑅𝐹 
aFA = peak area of FA, RF = detector response factor 
 
The detector response factor was 1.1 for C22:5n-3, C24:1n-9, and DHA.  
FA data for this study was acquired and reported according to published best practice 
recommendations (Brenna et al. 2018). However, the proposed A list (21 FA in total, 
∑ ≥ 95% of total plasma FAs; individual FA >30% of total FAs, or FAs critical for 
interpreting metabolism,) for FAs to be reported in studies is based on abundance of 
plasma FAs and some of these FAs are found in relative low levels in BM (C22:0: 
0.08%; C24:0: 0.06%; C20:3n-9: not reported; C22:5n-6: 0.03% (Yuhas et al. 2006)), 
and were therefore not reported in our study. Furthermore, C20:2n-6, which has a 
relative abundance of 0.22% (Yuhas et al. 2006) could not be accurately identified 
using our available standards and is therefore also not reported. Figure 6-5 shows a 
representative chromatogram of DHM FAs.  
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Figure 6-5: Representative chromatogram of DHM FAMEs detected by GC-FID 
The chromatogram has a stable baseline and well resolved, sharp peaks, as well as a low signal to noise 
ratio. The 19 analysed FAs and the internal standard are labelled below the chromatogram. Peak 




Quantification of MDA 
MDA was analysed using a TBARS (Trichloroacetic Acid Method) Assay (700870, 
Cayman Chemical) as described in Chapter 2.3.2. The standard curve is displayed in 
Figure 6-6.  

























Figure 6-6: Standard curve for the determination of TBARS in BM samples 
The graph shows a MDA standard curve (R
2
 = 0.9999; y = 0.0079x – 0.0006) determined by TBARS 
assay. Standards were analysed in duplicates. 
Quantification of HNE 
HNE adducts were quantified using the OxiSelect HNE Adduct competitive ELISA Kit 
(STA-838, Cell Biolabs, Inc.), as described in Chapter 2.3.3. The HNE-BSA standard 
curve is displayed in Figure 6-7.  
 
Figure 6-7: Standard curve for the determination of HNE-BSA in BM samples 
The graph shows an HNE-BSA four parameter logistics standard curve (R
2
 = 0.9969) determined by 




Since the HNE protein adducts may depend on the protein concentration, BM protein 
content was estimated using Bradford Reagent (Sigma Aldrich, U.K.), according to the 
manufacturer’s protocol. During the assay, a complex forms between the Brillian Blue 
G dye and the proteins (Bradford 1976). Formation of the complex shifts the absorption 
maximum from 465 to 595 nm, and the absorption is proportional to the protein 
concentration.  
The linear concentration range of this test is 0.1-1.4 mg/mL, therefore, BM samples 
were diluted 1:15 with dH2O. Samples (5 µL) were transferred to a 96-well plate in 
duplicates, mixed with 250 µL Bradford Reagent, mixed for 30 s on a shaker, and 
incubated for 10 min, before the absorption was measured at 595 nm, using an 
absorbance microplate reader (ELx800, BioTek). Results were analysed using the 
Gen5 software (Version2.09.2 for Windows, BioTek). Protein content was determined 
using a bovine serum albumin standard curve (Figure 6-8) ranging from 0-1.2 mg/mL 
(Sigma Aldrich, U.K.). 
























Figure 6-8: Standard curve for the determination of protein concentration in BM samples 
The graph shows a BSA standard curve (R
2
 = 0.9958; y = 0.2903x – 0.0083) determined by Bradford 
assay. Standards were analysed in duplicates. 
Hexanal quantification 
Hexanal is the major volatile aldehyde that is generated during lipid peroxidation in BM 
(Elisia and Kitts 2011). SPME coupled with GC-FID is more sensitive, and 
demonstrates better precision and accuracy in detecting hexanal than dynamic 
headspace analysis by GC (Marsili 1999). 
Hexanal was measured using SPME, based on the method described by Elisia and 
Kitts (2011). BM (1.5 mL) was thawed, homogenised, and added to a vial containing 




min with continuous stirring (Elisia and Kitts 2011). Headspace volatiles were sampled 
for 20 min using a preconditioned (250°C, 30 min) polydimethylsiloxane fiber (100 µm, 
Supelco).  
Analysis was performed using an Agilent 7820A gas chromatograph (Agilent 
Technologies; constant N2 (grade N5.5) flow at 9.9 mL/min, 27.9 psi pressure, average 
velocity 102.8 cm/s, holdup 0.48623 min), fitted with a merlin micro seal, SPME liner, 
and J&W HP-5 column (30 m x 0.32 mm x 0.25 µm). Oven temperature started at 40°C 
for 2 min, increased by 15°C/min to 60°C, further increased by 40°C/min to 300°C, and 
was held for 6 min.  
The SPME fiber was immediately thermally desorbed in the gas chromatograph inlet 
(split-less mode, purge flow to split vent at 50 mL/min after 1 min, 250°C, 27.9 psi 
pressure). Detection was carried out with an FID (300°C, H2 (grade N5.5) flow 
40 mL/min, air flow 450 mL/min; constant makeup (N2, grade N5.5) flow 30 mL/min). 
Peak identification was carried out in comparison to a hexanal standard (Figure 6-9), 
an example chromatogram of DHM is shown in Figure 6-10. Hexanal peak area was 
corrected for percentage recovery based on fat content (Elisia and Kitts 2011), and was 
also adjusted for the estimated total fat content.  
 
Figure 6-9: Representative chromatogram of hexanal standard detected by SPME GC-FID 





Figure 6-10: Representative chromatogram of hexanal in DHM detected by SPME GC-FID 
The chromatogram has a stable baseline and well resolved, sharp peaks, as well as a low signal to noise 





6.6 Supplementary results and discussion 
The following supplementary results do not form part of the publication and are added 
only as part of this thesis to provide further information. Following the LIMIT study, 
LCPUFA and LPP levels in the enteral non-maternal nutritional sources for preterm 
infants were compared against each other and to preterm BM. 
LCPUFA levels of non-maternal sources for preterm infants 
In this thesis, absolute LCPUFA levels of the two enteral non-maternal nutritional 
sources for preterm infants, which are preterm FM (Nutriprem 1 and Pro Gold Prem 1) 
and DHM have been measured (Chapter 2 and 6). For comparison, BM from mothers 
who delivered preterm infants was also analysed. A summary of LCPUFA levels in 
enteral nutritional sources for preterm infants in the U.K. is provided in Table 6-5. In 
most neonatal units, DHM would be used in conjunction with a BM fortifier (Klingenberg 
et al. 2012). Therefore, LCPUFA levels of DHM supplemented with SMA BM fortifier 
were calculated based on manufacturer’s published LCPUFA values. 
Table 6-5: LCPUFAs in enteral nutritional sources for preterm infants in the U.K. 
 ARA (mg/100 mL) DHA (mg/100 mL) 
Nutriprem 1 15.49 ± 5.52 12.03 ± 4.45 
Pro Gold Prem 1 11.53 ± 0.79 10.50 ± 0.95 
DHM  8.26 ± 2.90 4.70 ± 1.67 
DHM + SMA BM fortifier 8.26 ± 2.90 11.46 ± 2.26 
Preterm BM 14.86 ± 6.97 14.65 ± 8.50 
 
There was no significant difference between the LCPUFA content of the liquid preterm 
FMs, as described in Chapter 2.4.1. Nutriprem 1 had significantly higher levels of ARA 
(p = 0.0316) than DHM, and both preterm FMs provided significantly more DHA than 
DHM (Nutriprem 1: p = 0.0134 and Pro Gold Prem 1: p = 0.0006). When SMA’s BM 
fortifier is added to DHM as recommended by the supplier, the DHA content of DHM 
increases to 11.46 ± 2.26 mg/100 mL. This is no longer significantly different from 
Nutriprem 1 and Pro Gold Prem 1 (p = 0.4410 and p = 0.5030). The BM fortifier does 
not contain ARA, so levels remain unchanged.  
When compared to preterm BM, ARA levels in both FMs were not significant different. 
ARA levels were significantly lower in fortified DHM than in preterm BM (p = 0.0031), 
since the fortifier does not contain ARA. Both preterm FMs and fortified DHM had DHA 
levels that were not significantly different from preterm BM.  
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LPPs in non-maternal sources for preterm infants 
LPP levels in non-maternal sources for preterm infants were also explored in this thesis 
(Chapter 2 and 6). For comparison, LPPs in preterm BM were also analysed. Table 6-6 
provides a summary of the fat corrected LPP levels in preterm FM, DHM, and preterm 
BM.  
Table 6-6: LPPs in nutritional sources for preterm infants 
 TBARS (µM) HNE (µg/mL) 
Nutriprem 1 4.77 ± 0.44 1.61 ± 0.13 
Pro Gold Prem 1 - 0.82 ± 0.11 
DHM  23.46 ± 6.28 59.99 ± 75.13 
Preterm BM 9.12 ± 2.66 24.77 ± 28.48 
Due to the partially hydrolysed whey protein formulation, TBARS could not be measured in Pro Gold 
Prem 1  
DHM had significantly higher TBARS content than Nutriprem 1 (p = 0.0008). The 
TBARS concentration of DHM and preterm BM was not significantly different, whereas 
Nutriprem 1 had significantly lower TBARS content (p = 0.0007) than preterm BM.  
The HNE content of Nutriprem 1 was significantly higher than of Pro Gold Prem 1 
(p = 0.0357). HNE in preterm FMs and DHM was not significantly different. When 
compared to preterm BM, preterm FMs had significantly lower HNE content 
(Nutriprem 1: p = 0.013 and Pro Gold Prem 1: p = 0.0070), whereas DHM was not 
significantly different (p = 0.8702).  
Other researchers have also compared LPP levels in BM and FM. Michalski and 
colleagues found significantly higher 4-hydroxyalkena/related PUFA levels in FM 
powder as well as in liquid FM, compared to fresh BM (2008). Similarly, MDA/PUFA 
was also significantly lower in fresh BM. Martysiak and Stolyhwo found 19.35 µg 
MDA/100 mL BM, compared to on average 55.33 µg MDA/100 mL FM (2006). These 
studies report the opposite of our results. However, it is to note that in these studies 
MDA was measured by high-performance liquid chromatography, whereas we used a 
TBARS assay. One study that also reports higher LPP levels in BM than in FM has 
also used a TBARS assay (Turoli et al. 2004). As mentioned already in Chapter 2.3.2., 
the TBARS test is not specific for MDA and thiobarbituric acid can react with other 
molecules in the assay (Benzie 1996). BM has a much more complex matrix than FM 





Recommendations and implications for clinical practice 
For feeding preterm infants, maternal BM is normally the best choice, and is 
recommended by several organisations (WHO 2003; Agostoni et al. 2010). When 
maternal BM is not available or suitable, DHM remains the second-best choice. 
Undeniably, DHM, had lower ARA levels than preterm FM and preterm BM. When 
DHM was supplemented with BM fortifier, DHA levels were no longer different from 
DHA levels in preterm FM or preterm BM. Furthermore, HNE content was not 
significantly higher in DHM than in preterm FMs. It is recommended that ideally a BM 
fortifier is used that contains ARA and DHA, although, currently, only Prolacta’s Human 
Milk Fortifier contains LCPUFAs, albeit in varying levels. When choosing a bovine BM 
fortifier, SMA should be preferred, since it can increase the DHA content of DHM. 
When neither maternal BM nor DHM is available, a preterm FM should be used. 
Preliminary results from this study indicate higher LCPUFA levels in the preterm FM 
that declared lower LCPUFA levels on the label. Further research is needed to confirm 
these results, to be able to make recommendations. Based on the here investigated 
parameters, the results indicate that current FM storage conditions are safe and do not 
need to be changed. However, care should be taken to not use powder FM longer than 





7 General discussion and conclusion 
The aim of this thesis was to investigate the quantity and quality of LCPUFAs provided 
to preterm infants in the U.K. from the non-maternal nutritional sources used in the 
perinatal period, and therefore also to investigate whether feeding DHM and preterm 
FM contributes to the LCPUFA gap of prematurity. The LCPUFA content, as well as a 
range of secondary LPPs, were measured in DHM, as well as in the available preterm 
FMs (April 2017), thereby covering the non-maternal enteral nutritional sources for 
preterm infants. The main findings from this PhD dissertation are discussed below.  
Previous research from our laboratory has demonstrated that preterm infants receiving 
standard care in the U.K. receive very low levels of LCPUFAs (De Rooy et al. 2017). A 
limitation of this study was that LCPUFA intake from FM was calculated based on the 
manufacturers’ published values. However, the present research found preliminary 
evidence that in two of the preterm FMs analysed ARA was significantly below the 
manufacturer’s published values, and in one of the preterm FMs DHA levels were 
significantly below those published. These discrepancies are likely to lead to an 
overestimation of LCPUFA intake, not only in the research setting but also clinically. 
Furthermore, we measured for the first time in the U.K. absolute LCPUFA levels in 
DHM, and demonstrated that it provides significantly less LCPUFAs than preterm BM. 
This has previously been indicated by lower DHA weight% in DHM in the U.S.A. 
(Valentine et al. 2010; Baack et al. 2012). Since DHM LCPUFA levels were also not 
measured in the previous work from our laboratory (De Rooy et al. 2017), the LCPUFA 
intake deficit of preterm infants may be greater than reported, contributing to the 
LCPUFA gap of prematurity.  
Although the low LCPUFA intake potentially contributes to the neurodevelopmental 
problems seen in preterm infants (Henriksen et al. 2008; Makrides et al. 2009; 
Westerberg et al. 2011), the optimal enteral level of LCPUFA intake is unknown 
(Lapillonne and Jensen 2009). LCPUFA levels from non-maternal sources were 
compared to ESPGHAN recommendations, which European paediatricians use as 
guidance for feeding preterm infants (Agostoni et al. 2010). Preterm FM in the U.K. 
contains LCPUFA levels that reach minimum ESPGHAN recommendations, whereas 
DHM provides LCPUFA levels significantly below ESPGHAN recommendations. When 
DHM is supplemented with a commercial bovine BM fortifier as suggested, it reaches 
ESPGHAN recommendations for DHA, but not ARA, since the fortifier contains only 
DHA, further contributing to the ARA/LCPUFA gap of prematurity. This clearly 
demonstrates the need for BM fortifiers containing not only DHA but also ARA. 




accretion in utero (Lapillonne and Jensen 2009). Results from this PhD indicate that 
both DHM and preterm FM provide LCPUFA levels significantly below the estimated in 
utero accretion rates.  
Reaching ESPGHAN recommendations does not necessarily equal adequate LCPUFA 
supply for the preterm infants. Currently, LCPUFA levels in both non-maternal 
nutritional sources, and preterm BM are likely to lead to a decline in plasma LCPUFA 
concentrations, as shown for even higher LCPUFA levels in BM (Henriksen et al. 
2008). This can predispose preterm infants to the development of multiple morbidities 
and perinatal death (Fares et al. 2017). This work provides, therefore, for the first time 
evidence that non-maternal nutritional sources for preterm infants in the U.K. provide 
insufficient LCPUFA levels. Additionally, it also confirms previous results from our 
laboratory (De Rooy et al. 2017), showing that maternal BM LCPUFA levels are also 
too low for preterm infants. FM manufacturers provide FM to several European 
countries, and human milk banking practices are similar worldwide (Hartmann et al. 
2007; Arslanoglu et al. 2010; National Institute for Health and Clinical Excellence 
2010). Therefore, our results are not only applicable to the U.K., but also to other 
countries. More research is needed to define the optimal LCPUFA levels for preterm 
infants, especially extremely preterm infants, who are currently not included in the 
ESPGHAN recommendations. Studies should test various dosages of DHA in 
combination with ARA, considering short and long-term health outcomes. In the 
meantime, the most recent LCPUFA intake recommendations from Koletzko and 
colleagues (35-45 mg ARA and 55-60 mg DHA per kg bodyweight per day) (2014) 
seem more suitable. These recommend DHA levels comparable to the in utero 
accretion rates. Similar concentrations (32 mg ARA and 59 mg DHA per kg bodyweight 
per day) have been shown to be safe in a clinical trial, and to increase plasma DHA 
and to decrease the decline in plasma ARA (Henriksen et al. 2008). Furthermore, these 
levels have been shown to significantly improve cognitive development at six months 
(higher score on the problem-solving subtest of the Ages and Stages Questionnaire).  
With the LIMIT study, we provided preliminary evidence that absolute LCPUFA levels 
are currently very low in DHM and that DHM, therefore, is unsuitable long-term as an 
exclusive nutritional source for preterm infants. Although further work is needed to 
support these observations, addition of a BM fortifier may be prudent. A Human Milk 
Fortifier has recently been introduced to the U.K. market and is likely to be introduced 
in neonatal units in the future, due to the previously reported benefits over bovine BM 
fortifiers, including earlier discharge, lower mortality and lower incidence of NEC, late-
onset sepsis, retinopathy of prematurity and bronchopulmonary dysplasia (Abrams et 
al. 2014; Hair et al. 2016a; Hair et al. 2016b). Based on the available evidence (Nessel 
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et al. 2019), and considering the low levels of LCPUFAs found in DHM in the U.K. 
(Nessel et al. 2020), it is likely that the current human milk banking practices influence 
LCPUFA levels. Since Prolacta’s Human Milk Fortifiers are subject to similar storage 
and processing conditions as DHM (frozen storage at donor’s home, pasteurisation, 
frozen storage and shipment) (Prolacta Bioscience Inc 2020), it could be speculated 
that they have low LCPUFA levels, and therefore, studies investigating the effects of 
these practices on their LCPUFA content are required. Practicality and safety of direct 
LCPUFA supplementation of DHM on the neonatal unit, for example by sonication of 
LCPUFA rich oil into DHM, as performed previously in clinical trials investigating the 
effects of LCPUFA supplementation (Henriksen et al. 2008), should be given 
consideration. 
In this thesis, it was suggested that the DHA gap of prematurity concept, proposed by 
Harris and Baack in 2015, should be broadened into the “LCPUFA gap of prematurity”, 
since several proposed mechanisms leading to the DHA gap also apply to ARA (see 
Chapter 1.1.6). There is now further evidence that current feeding practices in the U.K. 
might contribute to this LCPUFA gap, when feeding the non-maternal nutritional 
sources DHM and preterm FM. Besides not knowing optimal enteral LCPUFA intake 
levels, it is known that feeding maternal BM to preterm infants will result in a decline in 
ARA and DHA blood levels, while at the same time in utero, these levels would have 
increased until birth (Leaf et al. 1992a). This suggests that even preterm BM LCPUFA 
levels are not sufficient. Hence, although this PhD identified that ARA and DHA levels 
in preterm FM, and DHA levels in fortified DHM were not significantly lower than in 
preterm BM, both will still contribute to the LCPUFA gap. Furthermore, this research 
has demonstrated that ARA levels in DHM, fortified or not, are significantly below ARA 
levels in preterm BM, contributing even more to the LCPUFA gap, and potentially 
leaving preterm infants with a greater ARA than DHA gap of prematurity.  
When talking about the LCPUFA gap of prematurity, the influence of precursor C18 
PUFA levels, such as LA and ALA, should also be considered, since high levels of 
these can influence their conversion to LCPUFAs and inhibit the LCPUFA incorporation 
into tissue (McMurchie et al. 1990; Clark et al. 1992; Nakamura and Nara 2004; Gibson 
et al. 2013). Additionally, other LCPUFAs important for brain development and health, 
such as e.g. adrenic acid, should be considered as well in this concept, and further 
research is needed to ascertain the total LCPUFA needs of preterm infants.  
Using a rough estimation based on an adrenic acid accretion of about half the ARA 
accretion in the last trimester (Martinez 1992), this would result in a need for 




and Jensen (2009). Considering data from the LIMIT study, DHM and preterm BM 
provide much lower adrenic acid levels (2.8 ± 1.5 and 9.7 ± 5.7 mg/kg/d, respectively, 
considering 150 ml/kg/d) (Nessel et al. 2020), and according to the manufacturers’ data 
sheets, preterm FM does not contain any adrenic acid (Danone Nutricia Early Life 
Nutrition 2017b; SMA Nutrition 2017a, 2017b). It should be considered that in a study 
in baboons, 17% of enteral ARA contributed to postnatal brain adrenic acid accretion. 
Nevertheless, even adding 17% of the enteral ARA (data from the LIMIT study: 2.1 and 
3.8 mg/kg/d for DHM and preterm BM, respectively (Nessel et al. 2020)), this would 
only result in 4.9 and 13.5 mg/kg/d adrenic acid available for accretion, respectively. 
The endogenous synthesis of ARA form precursor FAs could also be considered. If 
17% of endogenous synthesised ARA (27 mg/kg/d, (Carnielli et al. 2007)) are added, 
this increases the adrenic acid levels for accretion by 4.6 mg/kg/d, to 9.5 and 18.1 
mg/kg/d in DHM and preterm BM fed infants, respectively. This accounts for only 8.9 
and 17.1% of the in utero accreted adrenic acid. Therefore, the LCPUFA gap of other 
LCPUFAs than ARA and DHA might also be significant and should be investigated and 
considered in the future.  
The LCPUFA gap of prematurity might also contribute to the common comorbidities of 
preterm infants. Not only are LCPUFA levels lower in red blood cells of infants with 
respiratory distress syndrome and intraventricular haemorrhage (Fares et al. 2017), 
Crawford and colleagues also provide a pathophysiological explanation, linking 
LCPUFA and antioxidant levels to these comorbidities of prematurity (Crawford et al. 
1997; Crawford et al. 1998). Preterm infants have low LCPUFA levels at birth, which 
further decrease with the current feeding conditions (Leaf et al. 1992b; Baack et al. 
2015), resulting in fragile cell membranes (Crawford et al. 1998). Furthermore, 
antioxidant levels are also low in preterm infants (Qanungo and Mukherjea 2000; 
Robles et al. 2001), while at the same time, tissue oxygenation increases rapidly after 
birth, although in utero, the environment would have been relatively hypoxic 
(Kuligowski et al. 2014). High oxygen levels combined with low antioxidant levels can 
lead to peroxidation of lipids/LCPUFAs in cell membranes. This damage can lead to 
leakage and rupture of the cell membrane, normally followed by vasoconstriction and 
cell adhesion for repair, mediated by the free ARA levels (Crawford et al. 1998). 
However, continuous damage, due to the fragile cell membranes, continuous 
peroxidation, and shortage of LCPUFAs for membrane repair, can lead to cell 
infiltration, oedema, haemorrhage, and ischaemia. These are common signs of the 
comorbidities of prematurity, e.g. intraventricular haemorrhage, or the ischaemic lesion 
of periventricular leukomalacia, retinopathy of prematurity and bronchopulmonary 
dysplasia (Crawford et al. 1997). Therefore, postnatal provision of LCPUFAs needs to 
be increased, to reduce the LCPUFA gap of prematurity and to improve preterm 
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infants’ health and development. Brain DHA and ARA accumulation continues 
throughout the first two years of life (Lauritzen et al. 2016). Therefore, complementary 
foods, introduced after six months of exclusive BM/FM feeding, could potentially help to 
increase brain LCPUFA levels, and to mitigate the consequences of the LCPUFA gap 
of prematurity. Indeed, trial complementary foods containing oily fish increased red 
blood cell DHA and plasma DHA (Libuda et al. 2016), and visual acuity was better in 
term infants receiving DHA enrich complementary food after exclusive breast feeding 
(Hoffman et al. 2004). However, in the U.K., even fish-based complementary foods 
provide significantly less LCPUFAs than recommended (Loughrill and Zand 2016). This 
further indicates the need to provide preterm infants with sufficient levels of LCPUFAs 
in the perinatal period before complementary feeding is introduced. 
For optimal brain development, further FAs besides the two LCPUFAs ARA and DHA 
are important. White matter, especially myelin, contains high levels of nervonic acid 
(24:1n-9) and a rapid increase in brain nervonic acid was reported after birth (Martínez 
and Mougan 1998). Recently, significantly lower levels of nervonic acid were reported 
for DHM in Sweden compared to preterm colostrum/transitional BM (Ntoumani et al. 
2013). Our results do not indicate differences between relative or absolute levels of 
nervonic acid in DHM and preterm mature BM. Levels were similar to the reported 
levels in Swedish DHM. Other researchers have also reported significantly higher 
levels of nervonic acid in colostrum than in mature preterm BM (Thakkar et al. 2019). 
More research is needed to understand the role and need of nervonic acid in nutritional 
sources for preterm infants, especially in the first weeks after birth.  
Since evidence suggests that LCPUFA intake levels are currently insufficient for 
preterm infants, this raises the question whether the LCPUFA levels can be optimised 
in non-maternal nutritional sources. We have investigated whether preterm FM storage 
conditions can lead to a decline in LCPUFA levels. Results indicate that the current 
clinical storage conditions of liquid and powdered preterm FM do not significantly 
decrease LCPUFA levels, and therefore, do not contribute to a further decrease to the 
LCPUFAs provided to preterm infants. Furthermore, the results also suggest that these 
clinical practices do not increase the secondary LPPs measured in this study (TBARS 
and HNE adducts). 
A number of benefits of DHM feeding for preterm infants have been reported, including 
a reduction in NEC and bronchopulmonary disease (Quigley and McGuire 2014; 
Villamor-Martinez et al. 2018). Additionally, using DHM is associated with higher breast 
feeding rates at discharge (Arslanoglu et al. 2013b), which can result in life-long health 




peroxidation (Nessel et al. 2020) need to be addressed in further studies. Based on the 
available evidence in the literature, we have provided a number of recommendations 
for human milk banking, focusing on optimisation of LCPUFA quality and quantity in 
DHM (Nessel et al. 2019). Due to the similarity of human milk banking practices 
worldwide, the recommendations are also applicable to HMBs outside the U.K. 
However, effectiveness of these recommendations has yet to be tested. The list of 
recommendations is by no means exhaustive. It would be useful to also understand the 
additive effects of human milk banking practices, as well as the most detrimental 
practices through rigorous testing of absolute LCPUFA levels at each step, to 
specifically focus on optimisation of these aspects. Furthermore, the effects of DHM 
storage at -80°C, especially pre-pasteurisation, on LCPUFAs, LPPs and antioxidants 
need to be better investigated.  
Several studies have reported that refrigerated or frozen storage has no effect on 
LCPUFA levels in DHM (Friend et al. 1983a; Friend et al. 1983b; Romeu-Nadal et al. 
2008b). All these studies based their observations on quantification of the LCPUFA 
levels by relative percentage FA composition. Results from our LIMIT study also 
showed that human milk banking does not affect the percentage composition of DHM 
(Nessel et al. 2020). However, we also reported the absolute levels of LCPUFAs, 
where significant differences in LCPUFA content were found between DHM and term 
BM. This shows the need to not only report FA percentage composition but to always 
include absolute amounts when reporting on the effect of human milk banking 
processes on LCPUFA levels in future trials. Reporting FAs in different units can lead 
to contradicting results (Brenna et al. 2018). Therefore, best practice recommendations 
for the reporting of FA data also stress the need to include sufficient data to convert 
relative to absolute FA concentrations. 
The first U.K. national HMB survey by our group revealed that the majority of HMBs 
have no nutritional information available for donors and that only two HMBs have 
registered dietitians. Optimising donors’ nutrition is an important way of increasing the 
LCPUFA levels of DHM. Indeed, providing donors with nutritional information was 
successful in increasing BM DHA levels in the U.S.A. (Juber et al. 2016). Unpublished 
data from our group also indicates that BM donors would appreciate nutritional 
information, preferably in form of a website (Casey 2018). Effectiveness of a website 
providing nutritional advice for BM donors in the U.K. should be investigated by 
measuring BM LCPUFA levels as well as other markers, for example antioxidants, 
before and after providing access to the website. The majority (89.5%) of donors would 
also consider taking supplements (Casey 2018). Providing donors with complementary 
supplements could be considered to increase LCPUFA levels. Acceptance, as well as 
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effectiveness of this should be tested in the U.K. Supplementation of mothers has been 
shown previously to dose-dependently increase BM DHA levels (Makrides et al. 1996). 
Supplementation of donors with 1 g DHA/day also increased their DHA levels 
significantly (Valentine et al. 2013). 
LCPUFAs are needed for preterm infants health and development (Koletzko et al. 
2001). However, LCPUFA administration is always coupled to the risk of lipid 
peroxidation (Dyall 2011). This PhD project has shown that the LCPUFA content of 
non-maternal nutritional sources is associated with lipid peroxidation. Several 
secondary LPPs in preterm FM as well as in DHM were identified.  
Taking this into account, we performed a preliminary analysis of the effects of 
4-hydroxyalkenal concentrations expected in preterm FM on neonatal porcine intestinal 
cells. Preliminary results of this study indicated no detrimental effect of these HHE and 
HNE concentrations in vitro. However, the study had several limitations, including no 
positive control that elicited a positive inflammatory response, no analysis of tight 
junctions or permeability of the monolayer, and the use of only one cell type. For future 
investigations into the effects of 4-hydroxyalkenals on the preterm gut, it is strongly 
suggested to use transwell plates and co-culture models in vitro (Trapecar et al. 2014; 
Kleiveland 2015), and to consider preterm piglets for in vivo studies (Geens and 
Niewold 2011). It is also suggested to not study HHE and HNE isolated, but to 
investigate the effects of feeding oxidised FM, which will provide not only further LPPs, 
but also antioxidants. Further investigations are required, considering that preterm 
infants receive preterm FM several times per day for an extended period of time, the 
increased susceptibility of FM fed preterm infants to NEC (Quigley and McGuire 2014), 
and the correlation of LPPs with the common comorbidities of preterm infants (Inder et 
al. 1996). Antioxidants can prevent lipid peroxidation and protect LCPUFAs. However, 
antioxidant levels in DHM are, similarly to LCPUFA levels, also low (Hanson et al. 
2016). As mentioned above, milk donors would consider taking supplements, and 
antioxidant supplementation has been shown to increase BM antioxidant levels 
(Zarban et al. 2015). Interestingly, supplementation with probiotics can also increase 
BM antioxidant capacity and decrease MDA levels (Mahdavi et al. 2017). An increase 
in antioxidants levels, especially in vitamin E, would not only be beneficial for LCPUFA 
protection in DHM, but also for the preterm infants, which have lower antioxidant 
capacity (Davis and Auten 2010). 
Existence of HNE and TBARS in preterm FM and DHM, as well as hexanal in DHM, 
can imply that further LPPs, such as lipid hydroperoxides, HHE, and pentanal are 




and Kitts 2011). Overall, this indicates that non-maternal nutritional sources have the 
potential to increase the oxidative load of preterm infants, which might contribute to the 
development of oxygen radical associated diseases (Saugstad 2001). These diseases 
have also all been associated with higher plasma and/or urinary LPPs (Schlenzig et al. 
1993; Weinberger et al. 2004). 
Deuterated PUFAs, in which hydrogen is replaced by deuterium at the bis-allylic sites, 
are less prone to lipid peroxidation and replacement of normal PUFAs in cell 
membranes with deuterated PUFAs can protect from oxidative stress (Hill et al. 2012). 
Currently, deuterated PUFAs are used in clinical trials of Friedreich’s ataxia and 
infantile neuroaxonal dystrophy, two diseases related to lipid peroxidation (Adams et al. 
2018; Zesiewicz et al. 2018). In the future, the possibility of including these deuterated 
lipids in preterm FM, or addition to DHM in the clinic, or direct supplementation of 
preterm infants should be explored, to reduce LCPUFA lipid peroxidation and to 
potentially provide protection from oxygen radical associated diseases in preterm 
infants.  
In summary, although the optimal dose of LCPUFAs for preterm infants is still not 
known, our results show that ARA and DHA levels in non-maternal nutritional sources 
for preterm infants in the U.K., i.e. DHM and preterm FM, are too low and can 
contribute to the LCPUFA gap of prematurity. DHM should not be used exclusively 
long-term and use of a BM fortifier is recommended. We have also demonstrated that 
both non-maternal nutritional sources for preterm infants are a source of LPPs and 
might increase the oxidative load of preterm infants. Further research is needed to 
understand whether current LPP levels in nutritional sources are detrimental for 
preterm infants. We have started to provide evidence-based recommendations how to 
increase LCPUFA levels and also to prevent lipid peroxidation especially in DHM. 
Clearly, more research is needed to study and evaluate these recommendations and to 
fully understand the most detrimental current practices in human milk banking and 
provision of non-maternal BM to infants. When evaluating our results, we have 
highlighted the need to report absolute LCPUFA levels to truly capture the effects. 
Overall, LCPUFA quality and quantity can still be improved in non-maternal sources for 
preterm infants, which should only be used if maternal BM is unavailable or 




AAP Committee on Nutrition, AAP Section on Breastfeeding and AAP Committee on 
Fetus and Newborn, 2017. Donor Human Milk for the High-Risk Infant: 
Preparation, Safety, and Usage Options in the United States. Pediatrics 
[online], 139 (1). 
Abcam, 2018. Flow cytometric analysis of cell cycle with propidium iodide DNA 
staining. Cambridge: Abcam.  
Abdel Ghany, E. A., Alsharany, W., Ali, A. A., Younass, E. R. and Hussein, J. S., 2016. 
Anti-oxidant profiles and markers of oxidative stress in preterm neonates. 
Paediatr Int Child Health [online], 36 (2), 134-140. 
Abrams, S. A., Schanler, R. J., Lee, M. L. and Rechtman, D. J., 2014. Greater mortality 
and morbidity in extremely preterm infants fed a diet containing cow milk protein 
products. Breastfeed Med [online], 9 (6), 281-285. 
Adams-Chapman, I., Heyne, R. J., DeMauro, S. B., Duncan, A. F., Hintz, S. R., 
Pappas, A., Vohr, B. R., McDonald, S. A., Das, A., Newman, J. E., Higgins, R. 
D., Follow-Up Study of the Eunice Kennedy Shriver National Institute of Child, 
H. and Human Development Neonatal Research, N., 2018. 
Neurodevelopmental Impairment Among Extremely Preterm Infants in the 
Neonatal Research Network. Pediatrics [online], 141 (5). 
Adams, D., Dastgir, J., Flora, C., Molinari, R., J, Heerinckx, F. and Milner, P., G, 2018. 
Treatment of infantile neuroaxonaldystrophy (INAD) with a stabilized 
polyunsaturated fatty acid drug: Report of 2 cases. Rare Diseases & Orphan 
Products Breacjthrough Summit, Washington 16/10/18.  
Agosti, M., Tandoi, F., Morlacchi, L. and Bossi, A., 2017. Nutritional and metabolic 
programming during the first thousand days of life. Pediatr Med Chir [online], 39 
(2), 157. 
Agostoni, C., Buonocore, G., Carnielli, V. P., De Curtis, M., Darmaun, D., Decsi, T., 
Domellof, M., Embleton, N. D., Fusch, C., Genzel-Boroviczeny, O., Goulet, O., 
Kalhan, S. C., Kolacek, S., Koletzko, B., Lapillonne, A., Mihatsch, W., Moreno, 
L., Neu, J., Poindexter, B., Puntis, J., Putet, G., Rigo, J., Riskin, A., Salle, B., 
Sauer, P., Shamir, R., Szajewska, H., Thureen, P., Turck, D., van Goudoever, 
J. B. and Ziegler, E. E., 2010. Enteral nutrient supply for preterm infants: 
commentary from the European Society of Paediatric Gastroenterology, 
Hepatology and Nutrition Committee on Nutrition. J Pediatr Gastroenterol Nutr 
[online], 50 (1), 85-91. 
Ahrabi, A. F., Handa, D., Codipilly, C. N., Shah, S., Williams, J. E., McGuire, M. A., 
Potak, D., Aharon, G. G. and Schanler, R. J., 2016. Effects of Extended Freezer 




Akdag, A., Sari, F. N., Dizdar, E. A., Uras, N., Isikoglu, S., Erel, O. and Dilmen, U., 
2014. Storage at -80 degrees C preserves the antioxidant capacity of preterm 
human milk. J Clin Lab Anal [online], 28 (5), 415-418. 
Aksu, T., Atalay, Y., Türkyılmaz, C., Gülbahar, Ö., Hirfanoğlu, I. M., Demirel, N., Önal, 
E., Ergenekon, E. and Koç, E., 2015. The effects of breast milk storage and 
freezing procedure on interleukine-10 levels and total antioxidant activity. The 
Journal of Maternal-Fetal & Neonatal Medicine [online], 28 (15), 1799-1802. 
Al-Shahi Salman, R., Brock, T. M., Dennis, M. S., Sandercock, P. A., White, P. M. and 
Warlow, C., 2007. Research governance impediments to clinical trials: a 
retrospective survey. J R Soc Med [online], 100 (2), 101-104. 
Alary, J., Debrauwer, L., Fernandez, Y., Cravedi, J. P., Rao, D. and Bories, G., 1998. 
1,4-Dihydroxynonene mercapturic acid, the major end metabolite of exogenous 
4-hydroxy-2-nonenal, is a physiological component of rat and human urine. 
Chem Res Toxicol [online], 11 (2), 130-135. 
Alghazeer, R., Gao, H. and Howell, N. K., 2008. Cytotoxicity of oxidised lipids in 
cultured colonal human intestinal cancer cells (caco-2 cells). Toxicol Lett 
[online], 180 (3), 202-211. 
Allaire, J. M., Crowley, S. M., Law, H. T., Chang, S.-Y., Ko, H.-J. and Vallance, B. A., 
2018. The Intestinal Epithelium: Central Coordinator of Mucosal Immunity. 
Trends in Immunology [online], 39 (9), 677-696. 
Almansa, I., Miranda, M., Jareño, E. and Silvestre, D., 2013. Lipid peroxidation in infant 
formulas: Longitudinal study at different storage temperatures. International 
Dairy Journal [online], 33 (1), 83-87. 
American Academy of Pediatrics, 2012. Breastfeeding and the use of human milk. 
Pediatrics [online], 129 (3), e827-841. 
Anderson, P., Doyle, L. W. and Victorian Infant Collaborative Study, G., 2003. 
Neurobehavioral outcomes of school-age children born extremely low birth 
weight or very preterm in the 1990s. JAMA [online], 289 (24), 3264-3272. 
Anderson, R. E., 1970. Lipids of ocular tissues: IV. A comparison of the phospholipids 
from the retina of six mammalian species. Experimental Eye Research, 10 (2), 
339-344. 
Andersson, Y., Savman, K., Blackberg, L. and Hernell, O., 2007. Pasteurization of 
mother's own milk reduces fat absorption and growth in preterm infants. Acta 
Paediatr [online], 96 (10), 1445-1449. 
Ankrah, N. A., Appiah-Opong, R. and Dzokoto, C., 2000. Human breastmilk storage 
and the glutathione content. J Trop Pediatr [online], 46 (2), 111-113. 
226 
Armony-Sivan, R., Eidelman, A. I., Lanir, A., Sredni, D. and Yehuda, S., 2004. Iron 
status and neurobehavioral development of premature infants. J Perinatol 
[online], 24 (12), 757-762. 
Arnardottir, H., Orr, S. K., Dalli, J. and Serhan, C. N., 2016. Human milk proresolving 
mediators stimulate resolution of acute inflammation. Mucosal Immunol [online], 
9 (3), 757-766. 
Arnold, L. D., 1995. Storage containers for human milk: an issue revisited. J Hum Lact 
[online], 11 (4), 325-328. 
Arnold, L. D., 2006. Global health policies that support the use of banked donor human 
milk: a human rights issue. Int Breastfeed J [online], 1, 26. 
Arslanoglu, S., Bertino, E., Tonetto, P., De Nisi, G., Ambruzzi, A. M., Biasini, A., Profeti, 
C., Spreghini, M. R. and Moro, G. E., 2010. Guidelines for the establishment 
and operation of a donor human milk bank. J Matern Fetal Neonatal Med 
[online], 23 Suppl 2, 1-20. 
Arslanoglu, S., Corpeleijn, W., Moro, G., Braegger, C., Campoy, C., Colomb, V., Decsi, 
T., Domellof, M., Fewtrell, M., Hojsak, I., Mihatsch, W., Molgaard, C., Shamir, 
R., Turck, D. and van Goudoever, J., 2013a. Donor human milk for preterm 
infants: current evidence and research directions. J Pediatr Gastroenterol Nutr 
[online], 57 (4), 535-542. 
Arslanoglu, S., Moro, G. E., Bellu, R., Turoli, D., De Nisi, G., Tonetto, P. and Bertino, 
E., 2013b. Presence of human milk bank is associated with elevated rate of 
exclusive breastfeeding in VLBW infants. J Perinat Med [online], 41 (2), 129-
131. 
Awada, M., Soulage, C. O., Meynier, A., Debard, C., Plaisancie, P., Benoit, B., Picard, 
G., Loizon, E., Chauvin, M. A., Estienne, M., Peretti, N., Guichardant, M., 
Lagarde, M., Genot, C. and Michalski, M. C., 2012. Dietary oxidized n-3 PUFA 
induce oxidative stress and inflammation: role of intestinal absorption of 4-HHE 
and reactivity in intestinal cells. J Lipid Res [online], 53 (10), 2069-2080. 
Ayala, A., Munoz, M. F. and Arguelles, S., 2014. Lipid peroxidation: production, 
metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-
nonenal. Oxid Med Cell Longev [online], 2014, 360438. 
Baack, M. L., Norris, A. W., Yao, J. and Colaizy, T., 2012. Long-chain polyunsaturated 
fatty acid levels in US donor human milk: meeting the needs of premature 
infants? J Perinatol [online], 32 (8), 598-603. 
Baack, M. L., Puumala, S. E., Messier, S. E., Pritchett, D. K. and Harris, W. S., 2015. 
What is the relationship between gestational age and docosahexaenoic acid 
(DHA) and arachidonic acid (ARA) levels? Prostaglandins Leukot Essent Fatty 




Bacot, S., Bernoud-Hubac, N., Chantegrel, B., Deshayes, C., Doutheau, A., Ponsin, G., 
Lagarde, M. and Guichardant, M., 2007. Evidence for in situ ethanolamine 
phospholipid adducts with hydroxy-alkenals. Journal of Lipid Research [online], 
48 (4), 816-825. 
Bank, M. R., Kirksey, A., West, K. and Giacoia, G., 1985. Effect of storage time and 
temperature on folacin and vitamin C levels in term and preterm human milk. 
Am J Clin Nutr [online], 41 (2), 235-242. 
Bates, C. J., Liu, D. S., Fuller, N. J. and Lucas, A., 1985. Susceptibility of riboflavin and 
vitamin A in breast milk to photodegradation and its implications for the use of 
banked breast milk in infant feeding. Acta Paediatr Scand [online], 74 (1), 40-
44. 
BD Biosciences, 2018. Intracellular Flow [online]. San Jose: Available from: 
http://www.bdbiosciences.com/us/applications/research/intracellular-
flow/m/745716/techniques/cytokinedetection [Accessed 15/10/2018]. 
Bedrick, A. D., Britton, J. R., Johnson, S. and Koldovsky, O., 1989. Prostaglandin 
stability in human milk and infant gastric fluid. Biol Neonate [online], 56 (4), 192-
197. 
Beghin, L., Marchandise, X., Lien, E., Bricout, M., Bernet, J. P., Lienhardt, J. F., 
Jeannerot, F., Menet, V., Requillart, J. C., Marx, J., De Groot, N., Jaeger, J., 
Steenhout, P. and Turck, D., 2019. Growth, stool consistency and bone mineral 
content in healthy term infants fed sn-2-palmitate-enriched starter infant 
formula: A randomized, double-blind, multicentre clinical trial. Clin Nutr [online], 
38 (3), 1023-1030. 
Behrens, I., Stenberg, P., Artursson, P. and Kissel, T., 2001. Transport of Lipophilic 
Drug Molecules in a New Mucus-Secreting Cell Culture Model Based on HT29-
MTX Cells. Pharmaceutical Research [online], 18 (8), 1138-1145. 
Benedetti, A., Comporti, M., Fulceri, R. and Esterbauer, H., 1984. Cytotoxic aldehydes 
originating from the peroxidation of liver microsomal lipids: Identification of 4,5-
dihydroxydecenal. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid 
Metabolism [online], 792 (2), 172-181. 
Benedetto, C. E., 1987. Prostaglandins and related substances : a practical approach. 
Bennett, M. and Gilroy, D. W., 2016. Lipid Mediators in Inflammation. Microbiol Spectr 
[online], 4 (6). 
Benzie, I. F., 1996. Lipid peroxidation: a review of causes, consequences, 
measurement and dietary influences. Int J Food Sci Nutr [online], 47 (3), 233-
261. 
228 
Berkow, S. E., Freed, L. M., Hamosh, M., Bitman, J., Wood, D. L., Happ, B. and 
Hamosh, P., 1984. Lipases and lipids in human milk: effect of freeze-thawing 
and storage. Pediatr Res [online], 18 (12), 1257-1262. 
Bernabe-Garcia, M., Villegas-Silva, R., Villavicencio-Torres, A., Calder, P. C., 
Rodriguez-Cruz, M., Maldonado-Hernandez, J., Macias-Loaiza, D., Lopez-
Alarcon, M., Inda-Icaza, P. and Cruz-Reynoso, L., 2019. Enteral 
Docosahexaenoic Acid and Retinopathy of Prematurity: A Randomized Clinical 
Trial. JPEN J Parenter Enteral Nutr [online], 43 (7), 874-882. 
Berschneider, H. M., 1989. Development of normal cultured small intestinal epithelial 
cell lines which transport Na and Cl. Gastroenterology [online], 96 (5, Part 2), 
A1-A568. 
Bertino, E., Giribaldi, M., Baro, C., Giancotti, V., Pazzi, M., Peila, C., Tonetto, P., 
Arslanoglu, S., Moro, G. E., Cavallarin, L. and Gastaldi, D., 2013. Effect of 
prolonged refrigeration on the lipid profile, lipase activity, and oxidative status of 
human milk. J Pediatr Gastroenterol Nutr [online], 56 (4), 390-396. 
Betteridge, D. J., 2000. What is oxidative stress? Metabolism [online], 49 (2 Suppl 1), 
3-8. 
Binns, C., Lee, M. and Low, W. Y., 2016. The Long-Term Public Health Benefits of 
Breastfeeding. Asia Pac J Public Health [online], 28 (1), 7-14. 
BioLegend, 2007. Intracellular Cytokine Staining Protocol. San Diego: BioLegend, Inc.  
Birch, E. E., Carlson, S. E., Hoffman, D. R., Fitzgerald-Gustafson, K. M., Fu, V. L., 
Drover, J. R., Castaneda, Y. S., Minns, L., Wheaton, D. K., Mundy, D., 
Marunycz, J. and Diersen-Schade, D. A., 2010. The DIAMOND (DHA Intake 
And Measurement Of Neural Development) Study: a double-masked, 
randomized controlled clinical trial of the maturation of infant visual acuity as a 
function of the dietary level of docosahexaenoic acid. Am J Clin Nutr [online], 91 
(4), 848-859. 
Birch, E. E., Garfield, S., Castaneda, Y., Hughbanks-Wheaton, D., Uauy, R. and 
Hoffman, D., 2007. Visual acuity and cognitive outcomes at 4 years of age in a 
double-blind, randomized trial of long-chain polyunsaturated fatty acid-
supplemented infant formula. Early Hum Dev [online], 83 (5), 279-284. 
Birch, E. E., Hoffman, D. R., Uauy, R., Birch, D. G. and Prestidge, C., 1998. Visual 
acuity and the essentiality of docosahexaenoic acid and arachidonic acid in the 
diet of term infants. Pediatr Res [online], 44 (2), 201-209. 
Bitman, J., Wood, D. L., Mehta, N. R., Hamosh, P. and Hamosh, M., 1983a. Lipolysis 
of triglycerides of human milk during storage at low temperatures: a note of 




Bitman, J., Wood, L., Hamosh, M., Hamosh, P. and Mehta, N. R., 1983b. Comparison 
of the lipid composition of breast milk from mothers of term and preterm infants. 
Am J Clin Nutr [online], 38 (2), 300-312. 
Black, L., Hulsey, T., Lee, K., Parks, D. C. and Ebeling, M. D., 2015. Incremental 
Hospital Costs Associated With Comorbidities of Prematurity. Manag Care 
[online], 24 (12), 54-60. 
Blencowe, H., Cousens, S., Chou, D., Oestergaard, M., Say, L., Moller, A. B., Kinney, 
M., Lawn, J. and Born Too Soon Preterm Birth Action Group, 2013. Born Too 
Soon: The global epidemiology of 15 million preterm births. Reproductive 
Health [online], 10. 
Blencowe, H., Cousens, S., Oestergaard, M. Z., Chou, D., Moller, A. B., Narwal, R., 
Adler, A., Vera Garcia, C., Rohde, S., Say, L. and Lawn, J. E., 2012. National, 
regional, and worldwide estimates of preterm birth rates in the year 2010 with 
time trends since 1990 for selected countries: a systematic analysis and 
implications. Lancet [online], 379 (9832), 2162-2172. 
Bligh, E. G. and Dyer, W. J., 1959. A rapid method of total lipid extraction and 
purification. Can J Biochem Physiol [online], 37 (8), 911-917. 
Bokor, S., Koletzko, B. and Decsi, T., 2007. Systematic review of fatty acid composition 
of human milk from mothers of preterm compared to full-term infants. Ann Nutr 
Metab [online], 51 (6), 550-556. 
Bonet, M., Blondel, B., Agostino, R., Combier, E., Maier, R. F., Cuttini, M., Khoshnood, 
B. and Zeitlin, J., 2011. Variations in breastfeeding rates for very preterm 
infants between regions and neonatal units in Europe: results from the MOSAIC 
cohort. Arch Dis Child Fetal Neonatal Ed [online], 96 (6), F450-452. 
Bourke, J., Kirby, A. and Doran, J., 2016. SURVEY & QUESTIONNAIRE DESIGN : 
Collecting Primary Data to Answer Research Questions [Book]. Ireland: 
NuBooks. 
Bradford, M. M., 1976. A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 
[online], 72 (1), 248-254. 
Bratton, D. L. and Henson, P. M., 2011. Neutrophil clearance: when the party is over, 
clean-up begins. Trends in immunology [online], 32 (8), 350-357. 
Braun, V. and Clarke, V., 2006. Using thematic analysis in psychology. Qualitative 
Research in Psychology [online], 3 (2), 77-101. 
Brenna, J. T., 2016. Arachidonic acid needed in infant formula when docosahexaenoic 
acid is present. Nutr Rev [online], 74 (5), 329-336. 
230 
Brenna, J. T., Plourde, M., Stark, K. D., Jones, P. J. and Lin, Y. H., 2018. Best 
practices for the design, laboratory analysis, and reporting of trials involving 
fatty acids. Am J Clin Nutr [online], 108 (2), 211-227. 
Brenna, J. T., Salem, N., Jr., Sinclair, A. J. and Cunnane, S. C., 2009. alpha-Linolenic 
acid supplementation and conversion to n-3 long-chain polyunsaturated fatty 
acids in humans. Prostaglandins Leukot Essent Fatty Acids, 80 (2-3), 85-91. 
Brenna, J. T., Varamini, B., Jensen, R. G., Diersen-Schade, D. A., Boettcher, J. A. and 
Arterburn, L. M., 2007. Docosahexaenoic and arachidonic acid concentrations 
in human breast milk worldwide. Am J Clin Nutr [online], 85 (6), 1457-1464. 
Brion, L. P., Bell, E. F. and Raghuveer, T. S., 2003. Vitamin E supplementation for 
prevention of morbidity and mortality in preterm infants. Cochrane Database 
Syst Rev [online], (4), CD003665. 
British Association of Perinatal Medicine, 2016a. The Provision of Parenteral Nutrition 
within Neonatal Services - A Framework for Practice [online]. London: BAPM.  
British Association of Perinatal Medicine, 2016b. The Use of Donor Human Expressed 
Breast Milk in Neborn Infants A Framework for Practice [online]. London: BAPM  
Brosnahan, A. J. and Brown, D. R., 2012. Porcine IPEC-J2 intestinal epithelial cells in 
microbiological investigations. Vet Microbiol [online], 156 (3-4), 229-237. 
Buisine, M. P., Devisme, L., Savidge, T. C., Gespach, C., Gosselin, B., Porchet, N. and 
Aubert, J. P., 1998. Mucin gene expression in human embryonic and fetal 
intestine. Gut [online], 43 (4), 519. 
Burg, A., Silberstein, T., Yardeni, G., Tavor, D., Blumenfeld, J., Zilbermann, I. and 
Saphier, O., 2010. Role of Radicals in the Lipid Peroxidation Products of 
Commercial Infant Milk Formula. Journal of Agricultural and Food Chemistry 
[online], 58 (4), 2347-2350. 
Bush, R. A., Malnoe, A., Reme, C. E. and Williams, T. P., 1994. Dietary deficiency of 
N-3 fatty acids alters rhodopsin content and function in the rat retina. Invest 
Ophthalmol Vis Sci [online], 35 (1), 91-100. 
Buss, I. H., McGill, F., Darlow, B. A. and Winterbourn, C. C., 2001. Vitamin C is 
reduced in human milk after storage. Acta Paediatr [online], 90 (7), 813-815. 
Calder, P. C., 2007. Dietary arachidonic acid: harmful, harmless or helpful? Br J Nutr 
[online], 98 (3), 451-453. 




Calvo, J., Garcia Lara, N. R., Gormaz, M., Pena, M., Martinez Lorenzo, M. J., Ortiz 
Murillo, P., Brull Sabate, J. M., Samaniego, C. M. and Gaya, A., 2018. 
Recommendations for the creation and operation of maternal milk banks in 
Spain. An Pediatr (Barc) [online], 89 (1), 65 e61-65 e66. 
Cao, D., Kevala, K., Kim, J., Moon, H. S., Jun, S. B., Lovinger, D. and Kim, H. Y., 2009. 
Docosahexaenoic acid promotes hippocampal neuronal development and 
synaptic function. J Neurochem [online], 111 (2), 510-521. 
Cao, G. and Prior, R. L., 1998. Comparison of different analytical methods for 
assessing total antioxidant capacity of human serum. Clin Chem [online], 44 (6), 
1309-1315. 
Carlson, S. E., Montalto, M. B., Ponder, D. L., Werkman, S. H. and Korones, S. B., 
1998. Lower incidence of necrotizing enterocolitis in infants fed a preterm 
formula with egg phospholipids. Pediatr Res [online], 44 (4), 491-498. 
Carmen García‐Martínez, M. d., Rodríguez‐Alcalá, L. M., Marmesat, S., Alonso, L., 
Fontecha, J. and Márquez‐Ruiz, G., 2010. Lipid stability in powdered infant 
formula stored at ambient temperatures. International journal of food science & 
technology [online], 45 (11), 2337-2344. 
Carnielli, V. P., Simonato, M., Verlato, G., Luijendijk, I., De Curtis, M., Sauer, P. J. and 
Cogo, P. E., 2007. Synthesis of long-chain polyunsaturated fatty acids in 
preterm newborns fed formula with long-chain polyunsaturated fatty acids. Am J 
Clin Nutr [online], 86 (5), 1323-1330. 
Carnielli, V. P., Verlato, G., Pederzini, F., Luijendijk, I., Boerlage, A., Pedrotti, D. and 
Sauer, P. J., 1998. Intestinal absorption of long-chain polyunsaturated fatty 
acids in preterm infants fed breast milk or formula. Am J Clin Nutr [online], 67 
(1), 97-103. 
Casey, C., 2018. An exploration of nutritional preferences in breast mil donors: A pilot 
study.  (MSc Nutrition and Behaviour). Bournemouth University. 
Cencic, A. and Langerholc, T., 2010. Functional cell models of the gut and their 
applications in food microbiology--a review. Int J Food Microbiol [online], 141 
Suppl 1, S4-14. 
Cesa, S., 2004. Malondialdehyde contents in infant milk formulas. J Agric Food Chem 
[online], 52 (7), 2119-2122. 
Cesa, S., Casadei, M., Cerreto, F. and Paolicelli, P., 2015. Infant Milk Formulas: Effect 
of Storage Conditions on the Stability of Powdered Products towards 
Autoxidation. Foods [online], 4 (3), 487-500. 
232 
Cesa, S., Paolicelli, P., Cerreto, F. and Casadei, M., 2012. Comparison between third 
derivative spectrophotometric method and HPLC-DAD method in detection of 
malondialdehyde in infant formulae, human and cow milks. J. Chem. Pharm 
Res [online], 4, 221-230. 
Chalon, S., Delion-Vancassel, S., Belzung, C., Guilloteau, D., Leguisquet, A. M., 
Besnard, J. C. and Durand, G., 1998. Dietary fish oil affects monoaminergic 
neurotransmission and behavior in rats. J Nutr [online], 128 (12), 2512-2519. 
Chan, J., Gill, G. and Chan, G., 2011. The effects of different thawing methods on the 
nutritional properties in human milk. Journal of Neonatal-Perinatal Medicine 
[online], 4 (4), 341-346. 
Chang, Y. C., Chen, C. H. and Lin, M. C., 2012. The macronutrients in human milk 
change after storage in various containers. Pediatr Neonatol [online], 53 (3), 
205-209. 
Chávez-Servín, J. L., 2009. Stability during storage of LC-PUFA-supplemented infant 
formula containing single cell oil or egg yolk. Food chemistry [online], v. 113 
(no. 2), pp. 484-492-2009 v.2113 no.2002. 
Chávez-Servín, J. L., Castellote, A. I. and López-Sabater, M. C., 2008. Volatile 
compounds and fatty acid profiles in commercial milk-based infant formulae by 
static headspace gas chromatography: Evolution after opening the packet. 
Food Chemistry [online], 107 (1), 558-569. 
Cheatham, C. L., Colombo, J. and Carlson, S. E., 2006. N-3 fatty acids and cognitive 
and visual acuity development: methodologic and conceptual considerations. 
Am J Clin Nutr [online], 83 (6 Suppl), 1458S-1466S. 
Cherian, G. and Sim, J. S., 1996. Changes in the breast milk fatty acids and plasma 
lipids of nursing mothers following consumption of n-3 polyunsaturated fatty 
acid enriched eggs. Nutrition [online], 12 (1), 8-12. 
Chessex, P., Harrison, A., Khashu, M. and Lavoie, J. C., 2007. In preterm neonates, is 
the risk of developing bronchopulmonary dysplasia influenced by the failure to 
protect total parenteral nutrition from exposure to ambient light? J Pediatr 
[online], 151 (2), 213-214. 
Cho, Y. I., Johnson, T. P. and Vangeest, J. B., 2013. Enhancing surveys of health care 
professionals: a meta-analysis of techniques to improve response. Eval Health 
Prof [online], 36 (3), 382-407. 
Choe, E. and Min, D. B., 2009. Mechanisms of Antioxidants in the Oxidation of Foods. 





Cindric, M., Cipak, A., Zapletal, E., Jaganjac, M., Milkovic, L., Waeg, G., Stolc, S., 
Zarkovic, N. and Suzana Borovic, S., 2013. Stobadine attenuates impairment of 
an intestinal barrier model caused by 4-hydroxynonenal. Toxicology in Vitro 
[online], 27 (1), 426-432. 
Clandinin, M. T., Chappell, J. E., Heim, T., Swyer, P. R. and Chance, G. W., 1981. 
Fatty acid utilization in perinatal de novo synthesis of tissues. Early Hum Dev 
[online], 5 (4), 355-366. 
Clandinin, M. T., Chappell, J. E., Leong, S., Heim, T., Swyer, P. R. and Chance, G. W., 
1980. Intrauterine fatty acid accretion rates in human brain: implications for fatty 
acid requirements. Early Hum Dev [online], 4 (2), 121-129. 
Clark, K. J., Makrides, M., Neumann, M. A. and Gibson, R. A., 1992. Determination of 
the optimal ratio of linoleic acid to α-linolenic acid in infant formulas. The 
Journal of Pediatrics [online], 120 (4, Part 2), S151-S158. 
Claud, E. C., 2009. Neonatal Necrotizing Enterocolitis -Inflammation and Intestinal 
Immaturity. Antiinflamm Antiallergy Agents Med Chem [online], 8 (3), 248-259. 
Cole, A., 2009. Neonatal care: time for action on the shortage of nurses. J Fam Health 
Care [online], 19 (2), 42-44. 
Collins, C. T., Makrides, M., McPhee, A. J., Sullivan, T. R., Davis, P. G., Thio, M., 
Simmer, K., Rajadurai, V. S., Travadi, J., Berry, M. J., Liley, H. G., Opie, G. F., 
Tan, K., Lui, K., Morris, S. A., Stack, J., Stark, M. J., Chua, M. C., Jayagobi, P. 
A., Holberton, J., Bolisetty, S., Callander, I. R., Harris, D. L. and Gibson, R. A., 
2017. Docosahexaenoic Acid and Bronchopulmonary Dysplasia in Preterm 
Infants. N Engl J Med, 376 (13), 1245-1255. 
Commission Delegated Regulation (EU) 2016/127 of 25 September 2015, 
supplementing Regulation (EU) 609/2013 of the European Parliament and of 
the Council as regards the specific compositional and infromation requirements 
for infant formula and follow-on formula and as regards requirements on 
information relating to infant and young children feeding [2016] OJ L25/1. 
Commission Delegated Regulation (EU) 2016/128 of  September 2015, supplementing 
Regulation (EU) 609/2013 of the European Parliament and of the Council as 
regards the specific compositional and information reequirements for food for 
special medical purposes [2016] OJ L25/30. 
Commission Directive 2006/141/EC of 22 December 2006, on infant formulae and 
follow-on formulae [2006] OJ L401/1. 
Comporti, M., Signorini, C., Leoncini, S., Buonocore, G., Rossi, V. and Ciccoli, L., 
2004. Plasma F2-isoprostanes are elevated in newborns and inversely 
correlated to gestational age. Free Radic Biol Med [online], 37 (5), 724-732. 
234 
Cook, J. V., Dickinson, H. O. and Eccles, M. P., 2009. Response rates in postal 
surveys of healthcare professionals between 1996 and 2005: an observational 
study. BMC Health Serv Res [online], 9, 160. 
Cooke, R. W. I., 2006. Preterm mortality and morbidity over 25 years. Arch Dis Child 
Fetal Neonatal Ed [online], 91 (4), F293-F294. 
Cormack, B. E. and Bloomfield, F. H., 2013. Increased protein intake decreases 
postnatal growth faltering in ELBW babies. Arch Dis Child Fetal Neonatal Ed 
[online], 98 (5), F399-404. 
Corpeleijn, W. E., de Waard, M., Christmann, V., van Goudoever, J. B., Jansen-van der 
Weide, M. C., Kooi, E. M., Koper, J. F., Kouwenhoven, S. M., Lafeber, H. N., 
Mank, E., van Toledo, L., Vermeulen, M. J., van Vliet, I. and van Zoeren-
Grobben, D., 2016. Effect of Donor Milk on Severe Infections and Mortality in 
Very Low-Birth-Weight Infants: The Early Nutrition Study Randomized Clinical 
Trial. JAMA Pediatr [online], 170 (7), 654-661. 
Cosgrove, J. P., Church, D. F. and Pryor, W. A., 1987. The kinetics of the autoxidation 
of polyunsaturated fatty acids. Lipids [online], 22 (5), 299-304. 
Cotman, C., Blank, M. L., Moehl, A. and Snyder, F., 1969. Lipid composition of synaptic 
plasma membranes isolated from rat brain by zonal centrifugation. Biochemistry 
[online], 8 (11), 4606-4612. 
Crawford, M., 2000. Placental delivery of arachidonic and docosahexaenoic acids: 
implications for the lipid nutrition of preterm infants. Am J Clin Nutr [online], 71 
(1 Suppl), 275S-284S. 
Crawford, M. A., 1993. The role of essential fatty acids in neural development: 
implications for perinatal nutrition. Am J Clin Nutr [online], 57 (5 Suppl), 703S-
709S; discussion 709S-710S. 
Crawford, M. A., Costeloe, K., Ghebremeskel, K. and Phylactos, A., 1998. The 
inadequacy of the essential fatty acid content of present preterm feeds. Eur J 
Pediatr [online], 157 Suppl 1, S23-27. 
Crawford, M. A., Costeloe, K., Ghebremeskel, K., Phylactos, A., Skirvin, L. and Stacey, 
F., 1997. Are deficits of arachidonic and docosahexaenoic acids responsible for 
the neural and vascular complications of preterm babies? Am J Clin Nutr 
[online], 66 (4 Suppl), 1032S-1041S. 
Crawford, M. A., Golfetto, I., Ghebremeskel, K., Min, Y., Moodley, T., Poston, L., 
Phylactos, A., Cunnane, S. and Schmidt, W., 2003. The potential role for 
arachidonic and docosahexaenoic acids in protection against some central 




Crawford, M. A., Hall, B., Laurance, B. M. and Munhambo, A., 1976a. Milk lipids and 
their variability. Current Medical Research and Opinion [online], 4 (sup1), 33-43. 
Crawford, M. A., Hassam, A. G. and Williams, G., 1976b. Essential fatty acids and fetal 
brain growth. Lancet [online], 1 (7957), 452-453. 
Crawford, M. A., Wang, Y., Forsyth, S. and Brenna, J. T., 2013. New European Food 
Safety Authority recommendation for infant formulae contradicts the physiology 
of human milk and infant development. Nutr Health [online], 22 (2), 81-87. 
Crawford, M. A., Wang, Y., Forsyth, S. and Brenna, J. T., 2015. The European Food 
Safety Authority recommendation for polyunsaturated fatty acid composition of 
infant formula overrules breast milk, puts infants at risk, and should be revised. 
Prostaglandins Leukot Essent Fatty Acids [online], 102-103, 1-3. 
Crawley, H., Westland, S. and Weston, S., 2019. Specialised Infant Milks in the UK: 
Infants 0-6 month. A Practical Guide for Health Professionals [online]. London: 
First Steps Nutrition Trust.  
Crean, D. and Godson, C., 2015. Specialised lipid mediators and their targets. Semin 
Immunol [online], 27 (3), 169-176. 
Cunnane, S. C., 2003. Problems with essential fatty acids: time for a new paradigm? 
Prog Lipid Res [online], 42 (6), 544-568. 
Cunnane, S. C., Francescutti, V., Brenna, J. T. and Crawford, M. A., 2000. Breast-fed 
infants achieve a higher rate of brain and whole body docosahexaenoate 
accumulation than formula-fed infants not consuming dietary 
docosahexaenoate. Lipids [online], 35 (1), 105-111. 
Czerska, M., Zielinski, M. and Gromadzinska, J., 2016. Isoprostanes - A novel major 
group of oxidative stress markers. Int J Occup Med Environ Health [online], 29 
(2), 179-190. 
Dammann, O., Allred, E. N., Fichorova, R. N., Kuban, K., O'Shea, T. M. and Leviton, 
A., 2016. Duration of Systemic Inflammation in the First Postnatal Month 
Among Infants Born Before the 28th Week of Gestation. Inflammation, 39 (2), 
672-677. 
Danone Nutricia Early Life Nutrition, 2017a. Cow & Gate Nutriprem 1 Low Birthweight 
Formula [online]. Trowbridge: Danone Nutricia Early Life Nutrition. Available 
from: www.eln.nutricia.co.uk/our-products/cow-gate-range/preterm/cow-gate-
nutriprem-1-low-birthweight-formula [Accessed 03/03/2017]. 
Danone Nutricia Early Life Nutrition, 2017b. Cow & Gate Nutriprem 2 Post Discharge 
Formula [online]. Trowbridge: Danone Nutricia Ealry Life Nutrition. Available 
236 
from: www.eln.nutricia.co.uk/our-products/cow-gate-range/preterm/cow-gate-
nutriprem-2-post-discharge-formula [Accessed 03/03/2017]. 
Danone Nutricia Early Life Nutrition, 2018. Cow & Gate First Infant Formula [online]. 
Trowbridge: Danone Nutricia Early Life Nutrition. Available from: 
https://www.cowandgatehcp.ie/product/first-infant-milk/ [Accessed 02/01/2020]. 
Danone Nutricia Early Life Nutrition, 2019. Cow & Gate Nutriprem Human Milk Fortifier 
[online]. Trowbridge: Danone Nutricia Early Life Nutrition. Available from: 
https://eln.nutricia.co.uk/our-products/cow-gate-range/preterm/cow-gate-
nutriprem-human-milk-fortifier [Accessed 15/10/2019]. 
Danone Nutricia Early Life Nutrition, 2020a. Nutriprem 1 preterm and low birthweight 
formula [online]. Towridge: Available from: https://eln.nutricia.co.uk/product-
info/cow-gate-nutriprem-1-low-birthweight-formula-2/ [Accessed 20/03/2020]. 
Danone Nutricia Early Life Nutrition, 2020b. Nutriprem 2 post discharge formula 
[online]. Towbridge: Available from: https://eln.nutricia.co.uk/product-info/cow-
gate-nutriprem-2-post-discharge-formula-2/ [Accessed 20/03/2020]. 
Das, U. N., 2006. Essential fatty acids: biochemistry, physiology and pathology. 
Biotechnology Journal [online], 1 (4), 420-439. 
Davis, J. M. and Auten, R. L., 2010. Maturation of the antioxidant system and the 
effects on preterm birth. Semin Fetal Neonatal Med [online], 15 (4), 191-195. 
De Rooy, L., Hamdallah, H. and Dyall, S. C., 2017. Extremely preterm infants receiving 
standard care receive very low levels of arachidonic and docosahexaenoic 
acids. Clin Nutr [online], 36 (6), 1593-1600. 
de Waard, M., Mank, E., van Dijk, K., Schoonderwoerd, A. and van Goudoever, J. B., 
2018. Holder-Pasteurized Human Donor Milk: How Long Can It Be Preserved? 
J Pediatr Gastroenterol Nutr [online], 66 (3), 479-483. 
Del Prado, M., Villalpando, S., Elizondo, A., Rodriguez, M., Demmelmair, H. and 
Koletzko, B., 2001. Contribution of dietary and newly formed arachidonic acid to 
human milk lipids in women eating a low-fat diet. Am J Clin Nutr [online], 74 (2), 
242-247. 
Del Rio, D., Stewart, A. J. and Pellegrini, N., 2005. A review of recent studies on 
malondialdehyde as toxic molecule and biological marker of oxidative stress. 
Nutr Metab Cardiovasc Dis [online], 15 (4), 316-328. 
Delgado, F. J., Cava, R., Delgado, J. and Ramírez, R., 2014. Tocopherols, fatty acids 
and cytokines content of holder pasteurised and high-pressure processed 




DeMarchis, A., Israel-Ballard, K., Mansen, K. A. and Engmann, C., 2017. Establishing 
an integrated human milk banking approach to strengthen newborn care. J 
Perinatol [online], 37 (5), 469-474. 
Demmelmair, H., Baumheuer, M., Koletzko, B., Dokoupil, K. and Kratl, G., 1998. 
Metabolism of U13C-labeled linoleic acid in lactating women. J Lipid Res 
[online], 39 (7), 1389-1396. 
Deshpande, G., Simmer, K., Deshmukh, M., Mori, T. A., Croft, K. D. and Kristensen, J., 
2014. Fish Oil (SMOFlipid) and olive oil lipid (Clinoleic) in very preterm 
neonates. J Pediatr Gastroenterol Nutr [online], 58 (2), 177-182. 
Devriendt, B., Stuyven, E., Verdonck, F., Goddeeris, B. M. and Cox, E., 2010. 
Enterotoxigenic Escherichia coli (K88) induce proinflammatory responses in 
porcine intestinal epithelial cells. Developmental & Comparative Immunology 
[online], 34 (11), 1175-1182. 
Devriese, S., Van den Bossche, L., Van Welden, S., Holvoet, T., Pinheiro, I., 
Hindryckx, P., De Vos, M. and Laukens, D., 2017. T84 monolayers are superior 
to Caco-2 as a model system of colonocytes. Histochem Cell Biol [online], 148 
(1), 85-93. 
Dill, C., Chen, C., Alford, E., Edwards, R., Richter, R. and Garza, C., 1983. Lipolytic 
Activity During Storage of Human Milk: Stability of the Bile Salt-Stimulated 
Lipase. Journal of Food Protection [online], 46 (11), 994-996. 
Dill, C. W., Chen, C. T., Alford, E. S., Edwards, R. L., Richter, R. L. and Garza, C., 
1984. Lipolytic Activity During Storage of Human Milk: Accumulation of Free 
Fatty Acids. Journal of Food Protection [online], 47 (9), 690-693. 
dit Trolli, S. E., Kermorvant-Duchemin, E., Huon, C., Bremond-Gignac, D. and 
Lapillonne, A., 2012. Early lipid supply and neurological development at one 
year in very low birth weight (VLBW) preterm infants. Early Hum Dev [online], 
88 Suppl 1, S25-29. 
Drexler, H., G, Dirks, W., MacLeod, R., A, F , Quentmeier, H., Streube, K., G  and 
Uphoff, C. e., 2017. DSMZ Catalogue of Human and Animal Cell Lines (Vol. 
2017). Braunschweig. 
Dror, D. K. and Allen, L. H., 2008. Effect of vitamin B12 deficiency on 
neurodevelopment in infants: current knowledge and possible mechanisms. 
Nutr Rev [online], 66 (5), 250-255. 
Drury, J. A., Nycyk, J. A. and Cooke, R. W., 1997. Comparison of urinary and plasma 
malondialdehyde in preterm infants. Clin Chim Acta [online], 263 (2), 177-185. 
238 
Dunstan, J. A., Mitoulas, L. R., Dixon, G., Doherty, D. A., Hartmann, P. E., Simmer, K. 
and Prescott, S. L., 2007. The effects of fish oil supplementation in pregnancy 
on breast milk fatty acid composition over the course of lactation: a randomized 
controlled trial. Pediatr Res [online], 62 (6), 689-694. 
Duval, V. and Karlsson, M. O., 2002. Impact of Omission or Replacement of Data 
Below the Limit of Quantification on Parameter Estimates in a Two-
Compartment Model. Pharm Res [online], 19 (12), 1835-1840. 
Dyall, S. C., 2011. Methodological issues and inconsistencies in the field of omega-3 
fatty acids research. Prostaglandins Leukot Essent Fatty Acids [online], 85 (5), 
281-285. 
Dyall, S. C., 2015. Long-chain omega-3 fatty acids and the brain: a review of the 
independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci 
[online], 7, 52. 
Dyall, S. C., 2017. Interplay Between n-3 and n-6 Long-Chain Polyunsaturated Fatty 
Acids and the Endocannabinoid System in Brain Protection and Repair. Lipids 
[online], 52 (11), 885-900. 
Dyall, S. C., Mandhair, H. K., Fincham, R. E. A., Kerr, D. M., Roche, M. and Molina-
Holgado, F., 2016. Distinctive effects of eicosapentaenoic and 
docosahexaenoic acids in regulating neural stem cell fate are mediated via 
endocannabinoid signalling pathways. Neuropharmacology [online], 107, 387-
395. 
Dyall, S. C. and Michael-Titus, A. T., 2008. Neurological benefits of omega-3 fatty 
acids. Neuromolecular Med [online], 10 (4), 219-235. 
Eckl, P. M., Ortner, A. and Esterbauer, H., 1993. Genotoxic properties of 4-
hydroxyalkenals and analogous aldehydes. Mutation Research/Fundamental 
and Molecular Mechanisms of Mutagenesis [online], 290 (2), 183-192. 
Edwards, M., 2017. The Barker Hypothesis. In: Preedy, V. and Patel, V. B., eds. 
Handbook of Famine, Starvation, and Nutrient Deprivation: From Biology to 
Policy.  Cham: Springer International Publishing, 1-21. 
EFSA Panel on Dietetic Products, N. and Allergies, 2014. Scientific Opinion on the 
essential composition of infant and follow-on formulae. EFSA Journal [online], 
12 (7), 3760-n/a. 
Ehrenkranz, R. A., Dusick, A. M., Vohr, B. R., Wright, L. L., Wrage, L. A. and Poole, W. 
K., 2006. Growth in the neonatal intensive care unit influences 
neurodevelopmental and growth outcomes of extremely low birth weight infants. 




Elisia, I. and Kitts, D. D., 2011. Quantification of hexanal as an index of lipid oxidation 
in human milk and association with antioxidant components. J Clin Biochem 
Nutr [online], 49 (3), 147-152. 
Elremaly, W., Rouleau, T. and Lavoie, J. C., 2012. Inhibition of hepatic methionine 
adenosyltransferase by peroxides contaminating parenteral nutrition leads to a 
lower level of glutathione in newborn Guinea pigs. Free Radic Biol Med [online], 
53 (12), 2250-2255. 
Ermis, B., Yildirim, A., Örs, R., Tastekin, A., Özkan, B. and Akcay, F., 2005. Influence 
of Smoking on Serum and Milk Malondialdehyde, Superoxide Dismutase, 
Glutathione Peroxidase, and Antioxidant Potential Levels in Mothers at the 
Postpartum Seventh Day. Biological trace element research [online], 105, 27-
36. 
ESPGHAN Committee on Nutrition, Agostoni, C., Braegger, C., Decsi, T., Kolacek, S., 
Koletzko, B., Michaelsen, K. F., Mihatsch, W., Moreno, L. A., Puntis, J., Shamir, 
R., Szajewska, H., Turck, D. and van Goudoever, J., 2009. Breast-feeding: A 
commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol 
Nutr, 49 (1), 112-125. 
Esterbauer, H., 1993. Cytotoxicity and genotoxicity of lipid-oxidation products. Am J 
Clin Nutr [online], 57 (5 Suppl), 779S-785S; discussion 785S-786S. 
Esterbauer, H., Eckl, P. and Ortner, A., 1990. Possible mutagens derived from lipids 
and lipid precursors. Mutat Res [online], 238 (3), 223-233. 
Esterbauer, H., Schaur, R. J. and Zollner, H., 1991. Chemistry and biochemistry of 4-
hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 
[online], 11 (1), 81-128. 
Ezaki, S., Suzuki, K., Kurishima, C., Miura, M., Weilin, W., Hoshi, R., Tanitsu, S., 
Tomita, Y., Takayama, C., Wada, M., Kondo, T. and Tamura, M., 2009. 
Resuscitation of preterm infants with reduced oxygen results in less oxidative 
stress than resuscitation with 100% oxygen. J Clin Biochem Nutr [online], 44 
(1), 111-118. 
Ezz El Din, Z. M., Abd El Ghaffar, S., El Gabry, E. K., Fahmi, W. A. and Bedair, R. F., 
2004. Is stored expressed breast milk an alternative for working Egyptian 
mothers? East Mediterr Health J [online], 10 (6), 815-821. 
FAO/WHO, 2016. Codex Alimentarius: Standard for infant formula and formulas for 
special medical purposes intended for infants CODEX STAN 72-1981. 
FAO/WHO.  
Fares, S., Sethom, M. M., Hammami, M. B., Cheour, M., Feki, M., Hadj-Taieb, S. and 
Kacem, S., 2017. Postnatal RBC arachidonic and docosahexaenoic acids 
deficiencies are associated with higher risk of neonatal morbidities and mortality 
240 
in preterm infants. Prostaglandins Leukot Essent Fatty Acids [online], 126, 112-
116. 
Farina, M., Rocha, J. B. and Aschner, M., 2011. Mechanisms of methylmercury-
induced neurotoxicity: evidence from experimental studies. Life Sci [online], 89 
(15-16), 555-563. 
Farquharson, J., Cockburn, F., Patrick, W. A., Jamieson, E. C. and Logan, R. W., 1993. 
Effect of diet on infant subcutaneous tissue triglyceride fatty acids. Arch Dis 
Child [online], 69 (5), 589-593. 
Fenaille, F., Mottier, P., Turesky, R. J., Ali, S. and Guy, P. A., 2001. Comparison of 
analytical techniques to quantify malondialdehyde in milk powders. J 
Chromatogr A [online], 921 (2), 237-245. 
Fenaille, F., Parisod, V., Visani, P., Populaire, S., Tabet, J.-C. and Guy, P. A., 2006. 
Modifications of milk constituents during processing: A preliminary 
benchmarking study. International Dairy Journal [online], 16 (7), 728-739. 
Fernandez, D. R., Vanderjagt, D. J., Williams, M., Huang, Y. S., Chuang, L.-T., Millson, 
M., Andrews, R., Pastuszyn, A. and Glew, R. H., 2002. Fatty acid, amino acid, 
and trace mineral analyses of five weaning foods from Jos, Nigeria. Plant Foods 
for Human Nutrition [online], 57 (3), 257-274. 
Fessel, J. P., Porter, N. A., Moore, K. P., Sheller, J. R. and Roberts, L. J., 2nd, 2002. 
Discovery of lipid peroxidation products formed in vivo with a substituted 
tetrahydrofuran ring (isofurans) that are favored by increased oxygen tension. 
Proc Natl Acad Sci U S A [online], 99 (26), 16713-16718. 
Fidler, N., Sauerwald, T., Pohl, A., Demmelmair, H. and Koletzko, B., 2000. 
Docosahexaenoic acid transfer into human milk after dietary supplementation: a 
randomized clinical trial. J Lipid Res [online], 41 (9), 1376-1383. 
Fidler, N., Sauerwald, T. U., Demmelmair, H. and Koletzko, B., 2001. Fat content and 
fatty acid composition of fresh, pasteurized, or sterilized human milk. Adv Exp 
Med Biol [online], 501, 485-495. 
Field, C. J., Thomson, C. A., Van Aerde, J. E., Parrott, A., Euler, A., Lien, E. and 
Clandinin, M. T., 2000. Lower proportion of CD45R0+ cells and deficient 
interleukin-10 production by formula-fed infants, compared with human-fed, is 
corrected with supplementation of long-chain polyunsaturated fatty acids. J 
Pediatr Gastroenterol Nutr [online], 31 (3), 291-299. 
Fink, N. H., Collins, C. T., Gibson, R. A., Makrides, M. and Penttila, I. A., 2016. 
Targeting inflammation in the preterm infant: The role of the omega-3 fatty acid 





Fitzgibbons, S. C., Ching, Y., Yu, D., Carpenter, J., Kenny, M., Weldon, C., Lillehei, C., 
Valim, C., Horbar, J. D. and Jaksic, T., 2009. Mortality of necrotizing 
enterocolitis expressed by birth weight categories. J Pediatr Surg [online], 44 
(6), 1072-1075; discussion 1075-1076. 
Forsyth, J. S., Willatts, P., Agostoni, C., Bissenden, J., Casaer, P. and Boehm, G., 
2003. Long chain polyunsaturated fatty acid supplementation in infant formula 
and blood pressure in later childhood: follow up of a randomised controlled trial. 
BMJ [online], 326 (7396), 953. 
Francois, C. A., Connor, S. L., Bolewicz, L. C. and Connor, W. E., 2003. 
Supplementing lactating women with flaxseed oil does not increase 
docosahexaenoic acid in their milk. Am J Clin Nutr [online], 77 (1), 226-233. 
Franz, A. R., Pohlandt, F., Bode, H., Mihatsch, W. A., Sander, S., Kron, M. and 
Steinmacher, J., 2009. Intrauterine, early neonatal, and postdischarge growth 
and neurodevelopmental outcome at 5.4 years in extremely preterm infants 
after intensive neonatal nutritional support. Pediatrics [online], 123 (1), e101-
109. 
Fride, E., 2004. The endocannabinoid-CB(1) receptor system in pre- and postnatal life. 
Eur J Pharmacol [online], 500 (1-3), 289-297. 
Fride, E., Ginzburg, Y., Breuer, A., Bisogno, T., Di Marzo, V. and Mechoulam, R., 2001. 
Critical role of the endogenous cannabinoid system in mouse pup suckling and 
growth. European Journal of Pharmacology [online], 419 (2), 207-214. 
Friedman, Z., Danon, A., Stahlman, M. T. and Oates, J. A., 1976. Rapid onset of 
essential fatty acid deficiency in the newborn. Pediatrics [online], 58 (5), 640-
649. 
Friend, B. A., Shahani, K. M., Long, C. A. and Agel, E. N., 1983a. Evaluation of Freeze-
Drying, Pasteurization, High-Temperature Heating and Storage on Selected 
Enzymes, B-Vitamins and Lipids of Mature Human Milk. J Food Prot [online], 46 
(4), 330-334. 
Friend, B. A., Shahani, K. M., Long, C. A. and Vaughn, L. A., 1983b. The effect of 
processing and storage on key enzymes, B vitamins, and lipids of mature 
human milk. I. Evaluation of fresh samples and effects of freezing and frozen 
storage. Pediatr Res [online], 17 (1), 61-64. 
Fu, Y., Liu, X., Zhou, B., Jiang, A. C. and Chai, L., 2016. An updated review of 
worldwide levels of docosahexaenoic and arachidonic acid in human breast 
milk by region. Public Health Nutr [online], 1-13. 
Gao, C., Miller, J., Middleton, P. F., Huang, Y.-C., McPhee, A. J. and Gibson, R. A., 
2019. Changes to breast milk fatty acid composition during storage, handling 
242 
and processing: a systematic review. Prostaglandins, Leukotrienes and 
Essential Fatty Acids [online]. 
Garcia-Lara, N. R., Escuder-Vieco, D., Garcia-Algar, O., De la Cruz, J., Lora, D. and 
Pallas-Alonso, C., 2012. Effect of freezing time on macronutrients and energy 
content of breastmilk. Breastfeed Med [online], 7, 295-301. 
Garcia-Lara, N. R., Vieco, D. E., De la Cruz-Bertolo, J., Lora-Pablos, D., Velasco, N. U. 
and Pallas-Alonso, C. R., 2013. Effect of Holder pasteurization and frozen 
storage on macronutrients and energy content of breast milk. J Pediatr 
Gastroenterol Nutr [online], 57 (3), 377-382. 
Garcia-Ravelo, S., Diaz-Gomez, N. M., Martin, M. V., Dorta-Guerra, R., Murray, M., 
Escuder, D. and Rodriguez, C., 2018. Fatty Acid Composition and Eicosanoid 
Levels (LTE4 and PGE2) of Human Milk from Normal Weight and Overweight 
Mothers. Breastfeed Med [online]. 
García‐Martínez, C., Holgado, F., Velasco, J. and Márquez‐Ruiz, G., 2012. Effect of 
classic sterilization on lipid oxidation in model liquid milk‐based infant and 
follow‐on formulas. European Journal of Lipid Science and Technology [online], 
114 (12), 1373-1380. 
Garelli, A., Rotstein, N. P. and Politi, L. E., 2006. Docosahexaenoic acid promotes 
photoreceptor differentiation without altering Crx expression. Invest Ophthalmol 
Vis Sci [online], 47 (7), 3017-3027. 
Garg, U., Jain, A., Singla, P., Beri, S., Garg, R. and Saili, A., 2012. Free radical status 
in retinopathy of prematurity. Indian J Clin Biochem [online], 27 (2), 196-199. 
Garza, C., Johnson, C. A., Harrist, R. and Nichols, B. L., 1982. Effects of methods of 
collection and storage on nutrients in human milk. Early Hum Dev [online], 6 (3), 
295-303. 
GBD 2015 Mortality and Causes of Death Collaborators, 2016. Global, regional, and 
national life expectancy, all-cause mortality, and cause-specific mortality for 249 
causes of death, 1980-2015: a systematic analysis for the Global Burden of 
Disease Study 2015. Lancet [online], 388 (10053), 1459-1544. 
Geens, M. M. and Niewold, T. A., 2011. Optimizing culture conditions of a porcine 
epithelial cell line IPEC-J2 through a histological and physiological 
characterization. Cytotechnology [online], 63 (4), 415-423. 
Genzel-Boroviczeny, O., Wahle, J. and Koletzko, B., 1997. Fatty acid composition of 
human milk during the 1st month after term and preterm delivery. Eur J Pediatr 




Georgeson, G. D., Szony, B. J., Streitman, K., Varga, I. S., Kovacs, A., Kovacs, L. and 
Laszlo, A., 2002. Antioxidant enzyme activities are decreased in preterm infants 
and in neonates born via caesarean section. Eur J Obstet Gynecol Reprod Biol 
[online], 103 (2), 136-139. 
Georgieff, M. K., 2007. Nutrition and the developing brain: nutrient priorities and 
measurement. Am J Clin Nutr [online], 85 (2), 614S-620S. 
Georgieff, M. K., 2008. The role of iron in neurodevelopment: fetal iron deficiency and 
the developing hippocampus. Biochem Soc Trans [online], 36 (Pt 6), 1267-
1271. 
Georgieff, M. K. and Innis, S. M., 2005. Controversial nutrients that potentially affect 
preterm neurodevelopment: essential fatty acids and iron. Pediatr Res [online], 
57 (5 Pt 2), 99R-103R. 
Ghazal, Z., Dima Al, D. and Ayat, A., 2016. Determination of protein and fat oxidation 
levels in imported infant formula available in Syria. International Journal of 
Pharmacy and Pharmaceutical Sciences [online], 8 (2). 
Ghebremeskel, K., Leighfield, M., Ashwell, M., Sanders, T. A. B. and Reddy, S., 1992. 
Infant brain lipids and diet. The Lancet [online], 340 (8827), 1093-1094. 
Ghiselli, A., Serafini, M., Natella, F. and Scaccini, C., 2000. Total antioxidant capacity 
as a tool to assess redox status: critical view and experimental data. Free Radic 
Biol Med [online], 29 (11), 1106-1114. 
Gibson, A., Carney, S. and Wales, J. K., 2006. Growth and the premature baby. Horm 
Res [online], 65 Suppl 3, 75-81. 
Gibson, R. A., Muhlhausler, B. and Makrides, M., 2011. Conversion of linoleic acid and 
alpha-linolenic acid to long-chain polyunsaturated fatty acids (LCPUFAs), with a 
focus on pregnancy, lactation and the first 2 years of life. Matern Child Nutr 
[online], 7 Suppl 2, 17-26. 
Gibson, R. A., Neumann, M. A., Lien, E. L., Boyd, K. A. and Tu, W. C., 2013. 
Docosahexaenoic acid synthesis from alpha-linolenic acid is inhibited by diets 
high in polyunsaturated fatty acids. Prostaglandins Leukot Essent Fatty Acids 
[online], 88 (1), 139-146. 
Gidrewicz, D. A. and Fenton, T. R., 2014. A systematic review and meta-analysis of the 
nutrient content of preterm and term breast milk. BMC Pediatr [online], 14, 216. 
Glass, H. C., Costarino, A. T., Stayer, S. A., Brett, C. M., Cladis, F. and Davis, P. J., 
2015. Outcomes for extremely premature infants. Anesth Analg [online], 120 
(6), 1337-1351. 
244 
Goes, H. C., Torres, A. G., Donangelo, C. M. and Trugo, N. M., 2002. Nutrient 
composition of banked human milk in Brazil and influence of processing on zinc 
distribution in milk fractions. Nutrition [online], 18 (7-8), 590-594. 
Goicoechea, E., Brandon, E. F., Blokland, M. H. and Guillen, M. D., 2011. Fate in 
digestion in vitro of several food components, including some toxic compounds 
coming from omega-3 and omega-6 lipids. Food Chem Toxicol [online], 49 (1), 
115-124. 
Goldring, C., Casini, A. F., Maellaro, E., Del Bello, B. and Comporti, M., 1993. 
Determination of 4-hydroxynonenal by high-performance liquid chromatography 
with electrochemical detection. Lipids [online], 28 (2), 141-145. 
Goldsmith, S. J., Eitenmiller, R. R., Toledo, R. T. and Barnhart, H. M., 1983. Effects of 
Processing and Storage on the Water-Soluble Vitamin Content of Human Milk. 
Journal of Food Science [online], 48 (3), 994-995. 
Gottrand, F., 2008. Long-chain polyunsaturated fatty acids influence the immune 
system of infants. J Nutr [online], 138 (9), 1807S-1812S. 
Gouveia-Figueira, S. and Nording, M. L., 2014. Development and validation of a 
sensitive UPLC-ESI-MS/MS method for the simultaneous quantification of 15 
endocannabinoids and related compounds in milk and other biofluids. Analytical 
Chemistry [online], 86 (2), 1186-1195. 
Green, P., Glozman, S. and Yavin, E., 2001. Ethyl docosahexaenoate-associated 
decrease in fetal brain lipid peroxide production is mediated by activation of 
prostanoid and nitric oxide pathways. Biochimica et Biophysica Acta, 1531, 
156-164. 
Greenhalgh, T. and Peacock, R., 2005. Effectiveness and efficiency of search methods 
in systematic reviews of complex evidence: audit of primary sources. BMJ 
[online], 331 (7524), 1064-1065. 
Grune, T., Siems, W., Kowalewski, J., Zollner, H. and Esterbauer, H., 1991. 
Identification of metabolic pathways of the lipid peroxidation product 4-
hydroxynonenal by enterocytes of rat small intestine. Biochem Int [online], 25 
(5), 963-971. 
Guest, G., Mac Queen, K. M. and Namey, E. E., 2012. Applied Thematic Analysis.  
2018/06/25.  Thousand Oaks, California. 
Guichardant, M., Bacot, S., Moliere, P. and Lagarde, M., 2006. Hydroxy-alkenals from 
the peroxidation of n-3 and n-6 fatty acids and urinary metabolites. 




Guichardant, M., Chantegrel, B., Deshayes, C., Doutheau, A., Moliere, P. and Lagarde, 
M., 2004. Specific markers of lipid peroxidation issued from n-3 and n-6 fatty 
acids. Biochem Soc Trans [online], 32 (Pt 1), 139-140. 
Gurnida, D. A., Rowan, A. M., Idjradinata, P., Muchtadi, D. and Sekarwana, N., 2012. 
Association of complex lipids containing gangliosides with cognitive 
development of 6-month-old infants. Early Human Development [online], 88 (8), 
595-601. 
Gutierrez, D. and de Almeida, J. A., 1998. Human milk banks in Brazil. J Hum Lact 
[online], 14 (4), 333-335. 
Gutteridge, J. M., 1995. Lipid peroxidation and antioxidants as biomarkers of tissue 
damage. Clin Chem [online], 41 (12 Pt 2), 1819-1828. 
Hackam, D. J. and Sodhi, C. P., 2018. Toll-Like Receptor-Mediated Intestinal 
Inflammatory Imbalance in the Pathogenesis of Necrotizing Enterocolitis. Cell 
Mol Gastroenterol Hepatol [online], 6 (2), 229-238 e221. 
Hadley, K. B., Ryan, A. S., Forsyth, S., Gautier, S. and Salem, N., 2016. The 
Essentiality of Arachidonic Acid in Infant Development. Nutrients [online], 8 (4). 
Haggarty, P., Ashton, J., Joynson, M., Abramovich, D. R. and Page, K., 1999. Effect of 
maternal polyunsaturated fatty acid concentration on transport by the human 
placenta. Biol Neonate [online], 75 (6), 350-359. 
Hair, A. B., Bergner, E. M., Lee, M. L., Moreira, A. G., Hawthorne, K. M., Rechtman, D. 
J., Abrams, S. A. and Blanco, C. L., 2016a. Premature Infants 750-1,250 g Birth 
Weight Supplemented with a Novel Human Milk-Derived Cream Are Discharged 
Sooner. Breastfeed Med [online], 11, 133-137. 
Hair, A. B., Peluso, A. M., Hawthorne, K. M., Perez, J., Smith, D. P., Khan, J. Y., 
O'Donnell, A., Powers, R. J., Lee, M. L. and Abrams, S. A., 2016b. Beyond 
Necrotizing Enterocolitis Prevention: Improving Outcomes with an Exclusive 
Human Milk-Based Diet. Breastfeed Med [online], 11 (2), 70-74. 
Hakeem, A. H., Mohamed, G. B. and Othman, M. F., 2012. Retinopathy of prematurity: 
a study of prevalence and risk factors. Middle East Afr J Ophthalmol [online], 19 
(3), 289-294. 
Halpern, M. D. and Denning, P. W., 2015. The role of intestinal epithelial barrier 
function in the development of NEC. Tissue Barriers [online], 3 (1-2), e1000707. 
Hamprecht, K., Maschmann, J., Muller, D., Dietz, K., Besenthal, I., Goelz, R., 
Middeldorp, J. M., Speer, C. P. and Jahn, G., 2004. Cytomegalovirus (CMV) 
inactivation in breast milk: reassessment of pasteurization and freeze-thawing. 
Pediatr Res [online], 56 (4), 529-535. 
246 
Handa, D., Ahrabi, A. F., Codipilly, C. N., Shah, S., Ruff, S., Potak, D., Williams, J. E., 
McGuire, M. A. and Schanler, R. J., 2014. Do thawing and warming affect the 
integrity of human milk? J Perinatol [online], 34 (11), 863-866. 
Hanna, N., Ahmed, K., Anwar, M., Petrova, A., Hiatt, M. and Hegyi, T., 2004. Effect of 
storage on breast milk antioxidant activity. Arch Dis Child Fetal Neonatal Ed 
[online], 89 (6), F518-520. 
Hanson, C., Lyden, E., Furtado, J., Van Ormer, M. and Anderson-Berry, A., 2016. A 
Comparison of Nutritional Antioxidant Content in Breast Milk, Donor Milk, and 
Infant Formulas. Nutrients [online], 8 (11). 
Harris, W. S. and Baack, M. L., 2015. Beyond building better brains: bridging the 
docosahexaenoic acid (DHA) gap of prematurity. J Perinatol [online], 35 (1), 1-
7. 
Hartley, D. P., Ruth, J. A. and Petersen, D. R., 1995. The hepatocellular metabolism of 
4-hydroxynonenal by alcohol dehydrogenase, aldehyde dehydrogenase, and 
glutathione S-transferase. Arch Biochem Biophys [online], 316 (1), 197-205. 
Hartmann, B. T., Pang, W. W., Keil, A. D., Hartmann, P. E. and Simmer, K., 2007. Best 
practice guidelines for the operation of a donor human milk bank in an 
Australian NICU. Early Hum Dev [online], 83 (10), 667-673. 
Hay, W. W. and Thureen, P., 2010. Protein for Preterm Infants: How Much is Needed? 
How Much is Enough? How Much is Too Much? Pediatrics & Neonatology 
[online], 51 (4), 198-207. 
Henderson, T. R., Fay, T. N. and Hamosh, M., 1998. Effect of pasteurization on long 
chain polyunsaturated fatty acid levels and enzyme activities of human milk. J 
Pediatr [online], 132 (5), 876-878. 
Henriksen, C., Haugholt, K., Lindgren, M., Aurvag, A. K., Ronnestad, A., Gronn, M., 
Solberg, R., Moen, A., Nakstad, B., Berge, R. K., Smith, L., Iversen, P. O. and 
Drevon, C. A., 2008. Improved cognitive development among preterm infants 
attributable to early supplementation of human milk with docosahexaenoic acid 
and arachidonic acid. Pediatrics [online], 121 (6), 1137-1145. 
Hernell, O., 1975. Human milk lipases. III. Physiological implications of the bile salt-
stimulated lipase. Eur J Clin Invest [online], 5 (3), 267-272. 
Hibbeln, J. R., Davis, J. M., Steer, C., Emmett, P., Rogers, I., Williams, C. and Golding, 
J., 2007. Maternal seafood consumption in pregnancy and neurodevelopmental 
outcomes in childhood (ALSPAC study): an observational cohort study. Lancet 




Hibbeln, J. R., Spiller, P., Brenna, J. T., Golding, J., Holub, B. J., Harris, W. S., Kris-
Etherton, P., Lands, B., Connor, S. L., Myers, G., Strain, J. J., Crawford, M. A. 
and Carlson, S. E., 2019. Relationships between seafood consumption during 
pregnancy and childhood and neurocognitive development: Two systematic 
reviews. Prostaglandins Leukot Essent Fatty Acids [online], 151, 14-36. 
Hicks, S. W. and Machamer, C. E., 2005. Golgi structure in stress sensing and 
apoptosis. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 
[online], 1744 (3), 406-414. 
Hidalgo, I. J., 1996. Cultured Intestinal Epithelial Cell Models. In: Borchardt, R. T., 
Smith, P. L. and Wilson, G., eds. 1996//. Models for Assessing Drug Absorption 
and Metabolism [online].  Boston, MA: Springer US, 35-50. 
Hill, P. D., Aldag, J. C., Chatterton, R. T. and Zinaman, M., 2005. Comparison of milk 
output between mothers of preterm and term infants: the first 6 weeks after 
birth. J Hum Lact [online], 21 (1), 22-30. 
Hill, S., Lamberson, C. R., Xu, L., To, R., Tsui, H. S., Shmanai, V. V., Bekish, A. V., 
Awad, A. M., Marbois, B. N., Cantor, C. R., Porter, N. A., Clarke, C. F. and 
Shchepinov, M. S., 2012. Small amounts of isotope-reinforced polyunsaturated 
fatty acids suppress lipid autoxidation. Free Radic Biol Med [online], 53 (4), 
893-906. 
Hodson, L., Skeaff, C. M. and Fielding, B. A., 2008. Fatty acid composition of adipose 
tissue and blood in humans and its use as a biomarker of dietary intake. Prog 
Lipid Res [online], 47 (5), 348-380. 
Hoffman, D. R., Theuer, R. C., Castañeda, Y. S., Wheaton, D. H., Bosworth, R. G., 
O'Connor, A. R., Morale, S. E., Wiedemann, L. E. and Birch, E. E., 2004. 
Maturation of Visual Acuity Is Accelerated in Breast-Fed Term Infants Fed Baby 
Food Containing DHA-Enriched Egg Yolk. The Journal of Nutrition [online], 134 
(9), 2307-2313. 
Hojo, Y., 1986. Sequential study on glutathione peroxidase and selenium contents of 
human milk. Science of The Total Environment [online], 52 (1), 83-91. 
Holman, R. T. and Elmer, O. C., 1947. The rates of oxidation of unsaturated fatty acids 
and esters. Journal of the American Oil Chemists Society [online], 24 (4), 127-
129. 
Howard, M., 2010. Toolkit for High-quality Neonatal Services. Infant [online], 6 (2), 48. 
Huertas, J. R., Palomino, N., Ochoa, J. J., Quiles, J. L., Ramirez-Tortosa, M. C., 
Battino, M., Robles, R. and Mataix, J., 1998. Lipid peroxidation and antioxidants 
in erythrocyte membranes of full-term and preterm newborns. Biofactors 
[online], 8 (1-2), 133-137. 
248 
Ianiro, G., Franceschi, F., Bibbo, S. and Gasbarrini, A., 2014. Omega-3 fatty acids: a 
novel resort against gastrointestinal injury. Eur Rev Med Pharmacol Sci [online], 
18 (20), 3086-3090. 
Inder, T. E., Darlow, B. A., Sluis, K. B., Winterbourn, C. C., Graham, P., Sanderson, K. 
J. and Taylor, B. J., 1996. The correlation of elevated levels of an index of lipid 
peroxidation (MDA-TBA) with adverse outcome in the very low birthweight 
infant. Acta Paediatr [online], 85 (9), 1116-1122. 
Infant and Young Child Feeding Subspecialty Chapter, 2013. Guidelines for the 
establishement & operation of human milk banks. Udaipur: Indian Academy of 
Pediatrics.  
Institute of Medicine (US) Committee on Understanding Premature Birth and Assuring 
Healthy Outcomes; Behrman RE, B. A., editors, 2007. Premature Birth: Causes, 
Consequences, and Prevention. 
ISSFAL, 2004. Recommendations for intake of polyunsaturated fatty acids in healthy 
adults. Washington: ISSFAL.  
Izaki, Y., Yoshikawa, S. and Uchiyama, M., 1984. Effect of ingestion of thermally 
oxidized frying oil on peroxidative criteria in rats. Lipids [online], 19 (5), 324-331. 
Jain, A., Mehta, T., Auld, P. A., Rodrigues, J., Ward, R. F., Schwartz, M. K. and 
Martensson, J., 1995. Glutathione metabolism in newborns: evidence for 
glutathione deficiency in plasma, bronchoalveolar lavage fluid, and lymphocytes 
in prematures. Pediatr Pulmonol [online], 20 (3), 160-166. 
Janjindamai, W., Thatrimontrichai, A., Maneenil, G. and Puwanant, M., 2013. Soft 
plastic bag instead of hard plastic container for long-term storage of breast milk. 
Indian J Pediatr [online], 80 (10), 809-813. 
Jensen, C. L., Maude, M., Anderson, R. E. and Heird, W. C., 2000. Effect of 
docosahexaenoic acid supplementation of lactating women on the fatty acid 
composition of breast milk lipids and maternal and infant plasma phospholipids. 
Am J Clin Nutr [online], 71 (1 Suppl), 292S-299S. 
Jensen, R. G. and Jensen, G. L., 1992. Specialty lipids for infant nutrition. I. Milks and 
formulas. J Pediatr Gastroenterol Nutr [online], 15 (3), 232-245. 
Jo, H. Y., Kim, Y., Park, H. W., Moon, H. E., Bae, S., Kim, J., Kim, D. G. and Paek, S. 
H., 2015. The Unreliability of MTT Assay in the Cytotoxic Test of Primary 
Cultured Glioblastoma Cells. Exp Neurobiol [online], 24 (3), 235-245. 
Joffe, N., Webster, F. and Shenker, N., 2019. Support for breastfeeding is an 




Jones, E. and Spencer, S. A., 2005. Why is preterm milk expression so difficult. Infant 
[online], 1 (3), 77-80. 
Jones, F. R. N., 2011. Best practices for expressing, storing, and handling human milk 
in hospitals, homes, and child care settings [Bibliographies 
Non-fiction]. Fort Worth, TX : Human Milk Banking Association of North America, 3rd 
ed. 
Juber, B. A., Jackson, K. H., Johnson, K. B., Harris, W. S. and Baack, M. L., 2016. 
Breast milk DHA levels may increase after informing women: a community-
based cohort study from South Dakota USA. Int Breastfeed J [online], 12, 7. 
Julious, S. A., 2005. Sample size of 12 per group rule of thumb for a pilot study. Pharm 
Stat [online], 4 (4), 287-291. 
Jun, B., Mukherjee, P. K., Asatryan, A., Kautzmann, M. A., Heap, J., Gordon, W. C., 
Bhattacharjee, S., Yang, R., Petasis, N. A. and Bazan, N. G., 2017. Elovanoids 
are novel cell-specific lipid mediators necessary for neuroprotective signaling 
for photoreceptor cell integrity. Sci Rep [online], 7 (1), 5279. 
Kamal-Eldin, A. and Appelqvist, L. A., 1996. The chemistry and antioxidant properties 
of tocopherols and tocotrienols. Lipids [online], 31 (7), 671-701. 
Kaplan, M. J. and Radic, M., 2012. Neutrophil extracellular traps: double-edged swords 
of innate immunity. Journal of immunology (Baltimore, Md. : 1950) [online], 189 
(6), 2689-2695. 
Katakura, M., Hashimoto, M., Shahdat, H. M., Gamoh, S., Okui, T., Matsuzaki, K. and 
Shido, O., 2009. Docosahexaenoic acid promotes neuronal differentiation by 
regulating basic helix-loop-helix transcription factors and cell cycle in neural 
stem cells. Neuroscience, 160 (3), 651-660. 
Kelly, F. J., 1993. Free radical disorders of preterm infants. Br Med Bull, 49 (3), 668-
678. 
Khashu, M., Harrison, A., Lalari, V., Lavoie, J. C. and Chessex, P., 2009. Impact of 
shielding parenteral nutrition from light on routine monitoring of blood glucose 
and triglyceride levels in preterm neonates. Arch Dis Child Fetal Neonatal Ed, 
94 (2), F111-115. 
Kilari, A. S., Mehendale, S. S., Dangat, K. D., Yadav, H. R., Kulakarni, A. V., Dhobale, 
M. V., Taralekar, V. S. and Joshi, S. R., 2009. Long chain polyunsaturated fatty 
acids in mothers and term babies. J Perinat Med [online], 37 (5), 513-518. 
Kim, S. W., Schifano, M., Oleksyn, D., Jordan, C. T., Ryan, D., Insel, R., Zhao, J. and 
Chen, L., 2014. Protein kinase C-associated kinase regulates NF-kappaB 
250 
activation through inducing IKK activation. Int J Oncol [online], 45 (4), 1707-
1714. 
Kim, Y. D. and Morr, C. V., 1996. Dynamic headspace analysis of light activated flavor 
in milk. International Dairy Journal [online], 6 (2), 185-193. 
Kirtland, S. J., 1988. Prostaglandin E1: A review. Prostaglandins, Leukotrienes and 
Essential Fatty Acids (PLEFA) [online], 32 (3), 165-174. 
Kleiveland, C. R., 2015. Co-cultivation of Caco-2 and HT-29MTX. In: Verhoeckx, K., 
Cotter, P., López-Expósito, I., Kleiveland, C., Lea, T., Mackie, A., Requena, T., 
Swiatecka, D. and Wichers, H., eds. 2015//. The Impact of Food Bioactives on 
Health: in vitro and ex vivo models [online].  Cham: Springer International 
Publishing, 135-140. 
Klingenberg, C., Embleton, N. D., Jacobs, S. E., O'Connell, L. A. and Kuschel, C. A., 
2012. Enteral feeding practices in very preterm infants: an international survey. 
Arch Dis Child Fetal Neonatal Ed [online], 97 (1), F56-61. 
Knoop, K. A. and Newberry, R. D., 2018. Goblet cells: multifaceted players in immunity 
at mucosal surfaces. Mucosal Immunology [online], 11 (6), 1551-1557. 
Koletzko, B., 2016. Human Milk Lipids. Ann Nutr Metab [online], 69 Suppl 2, 28-40. 
Koletzko, B., Agostoni, C., Carlson, S. E., Clandinin, T., Hornstra, G., Neuringer, M., 
Uauy, R., Yamashiro, Y. and Willatts, P., 2001. Long chain polyunsaturated 
fatty acids (LC-PUFA) and perinatal development. Acta Paediatr [online], 90 (4), 
460-464. 
Koletzko, B., Carlson, S. E. and van Goudoever, J. B., 2015. Should Infant Formula 
Provide Both Omega-3 DHA and Omega-6 Arachidonic Acid? Ann Nutr Metab 
[online], 66 (2-3), 137-138. 
Koletzko, B., Poindexter, B. and Uauy, R., 2014. Recommended nutrient intake levels 
for stable, fully enterally fed very low birth weight infants. World Rev Nutr Diet 
[online], 110, 297-299. 
Kuban, K. C., Joseph, R. M., O'Shea, T. M., Heeren, T., Fichorova, R. N., Douglass, L., 
Jara, H., Frazier, J. A., Hirtz, D., Rollins, J. V., Paneth, N. and Extremely Low 
Gestational Age Newborn Study, I., 2017. Circulating Inflammatory-Associated 
Proteins in the First Month of Life and Cognitive Impairment at Age 10 Years in 
Children Born Extremely Preterm. J Pediatr [online], 180, 116-123 e111. 
Kuban, K. C., O'Shea, T. M., Allred, E. N., Fichorova, R. N., Heeren, T., Paneth, N., 
Hirtz, D., Dammann, O. and Leviton, A., 2015. The breadth and type of 
systemic inflammation and the risk of adverse neurological outcomes in 




Kuipers, R. S., Luxwolda, M. F., Janneke Dijck-Brouwer, D. A., Eaton, S. B., Crawford, 
M. A., Cordain, L. and Muskiet, F. A. J., 2010. Estimated macronutrient and 
fatty acid intakes from an East African Paleolithic diet. British Journal of 
Nutrition [online], 104 (11), 1666-1687. 
Kuipers, R. S., Luxwolda, M. F., Offringa, P. J., Boersma, E. R., Dijck-Brouwer, D. A. 
and Muskiet, F. A., 2012. Fetal intrauterine whole body linoleic, arachidonic and 
docosahexaenoic acid contents and accretion rates. Prostaglandins Leukot 
Essent Fatty Acids [online], 86 (1-2), 13-20. 
Kuligowski, J., Aguar, M., Rook, D., Lliso, I., Torres-Cuevas, I., Escobar, J., Quintas, 
G., Brugada, M., Sanchez-Illana, A., van Goudoever, J. B. and Vento, M., 2015. 
Urinary Lipid Peroxidation Byproducts: Are They Relevant for Predicting 
Neonatal Morbidity in Preterm Infants? Antioxid Redox Signal [online], 23 (2), 
178-184. 
Kuligowski, J., Escobar, J., Quintas, G., Lliso, I., Torres-Cuevas, I., Nunez, A., Cubells, 
E., Rook, D., van Goudoever, J. B. and Vento, M., 2014. Analysis of lipid 
peroxidation biomarkers in extremely low gestational age neonate urines by 
UPLC-MS/MS. Anal Bioanal Chem [online], 406 (18), 4345-4356. 
Kus-Yamashita, M. M. M., Aued-Pimentel, S. and Mancini Filho, J., 2016. Lipid and 
polyunsaturated fatty acid contents in infant formulas in reference to the Codex 
Alimentarius. Vigilância Sanitária em Debate: Sociedade, Ciência & Tecnologia 
[online], 4 (1), 78-82. 
L'Abbe, M. R. and Friel, J. K., 2000. Superoxide dismutase and glutathione peroxidase 
content of human milk from mothers of premature and full-term infants during 
the first 3 months of lactation. J Pediatr Gastroenterol Nutr [online], 31 (3), 270-
274. 
Laborie, S., Lavoie, J. C., Rouleau, T. and Chessex, P., 2002. Multivitamin solutions for 
enteral supplementation: a source of peroxides. Nutrition [online], 18 (6), 470-
473. 
Lacomba, R., Cilla, A., Alegría, A., Barberá, R., Silvestre, D. and Lagarda, M. J., 2012. 
Stability of fatty acids and tocopherols during cold storage of human milk. 
International Dairy Journal [online], 27 (1-2), 22-26. 
Laiho, K., Lampi, A. M., Hamalainen, M., Moilanen, E., Piironen, V., Arvola, T., 
Syrjanen, S. and Isolauri, E., 2003. Breast milk fatty acids, eicosanoids, and 
cytokines in mothers with and without allergic disease. Pediatr Res [online], 53 
(4), 642-647. 
Lammi-Keefe, C. J. and Jensen, R. G., 1984. Lipids in human milk: a review. 2: 
Composition and fat-soluble vitamins. J Pediatr Gastroenterol Nutr [online], 3 
(2), 172-198. 
252 
Landers, S. and Updegrove, K., 2010. Bacteriological screening of donor human milk 
before and after Holder pasteurization. Breastfeed Med [online], 5 (3), 117-121. 
Lapillonne, A., Eleni dit Trolli, S. and Kermorvant-Duchemin, E., 2010. Postnatal 
docosahexaenoic acid deficiency is an inevitable consequence of current 
recommendations and practice in preterm infants. Neonatology [online], 98 (4), 
397-403. 
Lapillonne, A., Groh-Wargo, S., Gonzalez, C. H. and Uauy, R., 2013. Lipid needs of 
preterm infants: updated recommendations. J Pediatr [online], 162 (3 Suppl), 
S37-47. 
Lapillonne, A. and Jensen, C. L., 2009. Reevaluation of the DHA requirement for the 
premature infant. Prostaglandins Leukot Essent Fatty Acids [online], 81 (2-3), 
143-150. 
Lapillonne, A. and Moltu, S. J., 2016. Long-Chain Polyunsaturated Fatty Acids and 
Clinical Outcomes of Preterm Infants. Ann Nutr Metab [online], 69 Suppl 1, 35-
44. 
Lau, C., Smith, E. O. and Schanler, R. J., 2003. Coordination of suck-swallow and 
swallow respiration in preterm infants. Acta Paediatr [online], 92 (6), 721-727. 
Lauritzen, L., Brambilla, P., Mazzocchi, A., Harslof, L. B., Ciappolino, V. and Agostoni, 
C., 2016. DHA Effects in Brain Development and Function. Nutrients [online], 8 
(1). 
Lavine, M. and Clark, R. M., 1987. Changing patterns of free fatty acids in breast milk 
during storage. J Pediatr Gastroenterol Nutr [online], 6 (5), 769-774. 
Lavine, M. and Clark, R. M., 1989. The effect of short-term refrigeration of milk and 
addition of breast milk fortifier on the delivery of lipids during tube feeding. J 
Pediatr Gastroenterol Nutr [online], 8 (4), 496-499. 
Lavoie, P. M., Lavoie, J. C., Watson, C., Rouleau, T., Chang, B. A. and Chessex, P., 
2010. Inflammatory response in preterm infants is induced early in life by 
oxygen and modulated by total parenteral nutrition. Pediatr Res [online], 68 (3), 
248-251. 
Lea, T., 2015a. Caco-2 Cell Line. In: Verhoeckx, K., Cotter, P., Lopez-Exposito, I., 
Kleiveland, C., Lea, T., Mackie, A., Requena, T., Swiatecka, D. and Wichers, 
H., eds.  The Impact of Food Bioactives on Health: in vitro and ex vivo models 
[online].  Cham (CH), 103-113. 
Lea, T., 2015b. Epithelial Cell Models; General Introduction. In: Verhoeckx, K., Cotter, 




Swiatecka, D. and Wichers, H., eds.  The Impact of Food Bioactives on Health: 
in vitro and ex vivo models [online].  Cham (CH), 95-102. 
Leaf, A. A., Leighfield, M. J., Costeloe, K. L. and Crawford, M. A., 1992a. Factors 
Affecting Long-Chain Polyunsaturated Fatty Acid Composition of Plasma 
Choline Phosphoglycerides in Preterm Infants. Journal of Pediatric 
Gastroenterology and Nutrition [online], 14 (3). 
Leaf, A. A., Leighfield, M. J., Costeloe, K. L. and Crawford, M. A., 1992b. Long chain 
polyunsaturated fatty acids and fetal growth. Early Human Development 
[online], 30 (3), 183-191. 
Lee, Y. S. and Chou, Y. H., 2005. Antioxidant profiles in full term and preterm 
neonates. Chang Gung Med J, 28 (12), 846-851. 
Léké, A., Grognet, S., Deforceville, M., Goudjil, S., Chazal, C., Kongolo, G., Dzon, B. E. 
and Biendo, M., 2019. Macronutrient composition in human milk from mothers 
of preterm and term neonates is highly variable during the lactation period. 
Clinical Nutrition Experimental [online], 26, 59-72. 
Lepri, L., Del Bubba, M., Maggini, R., Donzelli, G. P. and Galvan, P., 1997. Effect of 
pasteurization and storage on some components of pooled human milk. J 
Chromatogr B Biomed Sci Appl [online], 704 (1-2), 1-10. 
Lev, H. M., Ovental, A., Mandel, D., Mimouni, F. B., Marom, R. and Lubetzky, R., 2014. 
Major losses of fat, carbohydrates and energy content of preterm human milk 
frozen at -80 degrees C. J Perinatol [online], 34 (5), 396-398. 
Lewinska, A., Wnuk, M., Slota, E. and Bartosz, G., 2007. Total anti-oxidant capacity of 
cell culture media. Clin Exp Pharmacol Physiol [online], 34 (8), 781-786. 
Ley, S. H., Hanley, A. J., Stone, D. and O'Connor, D. L., 2011. Effects of pasteurization 
on adiponectin and insulin concentrations in donor human milk. Pediatr Res 
[online], 70 (3), 278-281. 
Li, T., Zhang, Z., Li, X., Dong, G., Zhang, M., Xu, Z. and Yang, J., 2020. Neutrophil 
Extracellular Traps: Signaling Properties and Disease Relevance. Mediators of 
Inflammation [online], 2020, 9254087. 
Liang, C. C., Park, A. Y. and Guan, J. L., 2007. In vitro scratch assay: a convenient and 
inexpensive method for analysis of cell migration in vitro. Nat Protoc [online], 2 
(2), 329-333. 
Libuda, L., Mesch, C. M., Stimming, M., Demmelmair, H., Koletzko, B., Warschburger, 
P., Blanke, K., Reischl, E., Kalhoff, H. and Kersting, M., 2016. Fatty acid supply 
with complementary foods and LC-PUFA status in healthy infants: results of a 
254 
randomised controlled trial. European Journal of Nutrition [online], 55 (4), 1633-
1644. 
Liu, L., Johnson, H. L., Cousens, S., Perin, J., Scott, S., Lawn, J. E., Rudan, I., 
Campbell, H., Cibulskis, R., Li, M., Mathers, C. and Black, R. E., 2012. Global, 
regional, and national causes of child mortality: an updated systematic analysis 
for 2010 with time trends since 2000. Lancet [online], 379 (9832), 2151-2161. 
Liu, M., Wallin, R., Wallmon, A. and Saldeen, T., 2002. Mixed tocopherols have a 
stronger inhibitory effect on lipid peroxidation than alpha-tocopherol alone. J 
Cardiovasc Pharmacol [online], 39 (5), 714-721. 
Loughrill, E. and Zand, N., 2016. An investigation into the fatty acid content of selected 
fish-based commercial infant foods in the UK and the impact of commonly 
practiced re-heating treatments used by parents for the preparation of infant 
formula milks. Food Chem [online], 197 (Pt A), 783-789. 
Lucas, A. and Mitchell, M. D., 1980. Prostaglandins in human milk. Arch Dis Child 
[online], 55 (12), 950-952. 
Lueschow, S. R. and McElroy, S. J., 2020. The Paneth Cell: The Curator and Defender 
of the Immature Small Intestine. Frontiers in Immunology [online], 11 (587). 
MacDonald, T. T., Monteleone, I., Fantini, M. C. and Monteleone, G., 2011. Regulation 
of homeostasis and inflammation in the intestine. Gastroenterology [online], 140 
(6), 1768-1775. 
Maghdessian, R., Cote, F., Rouleau, T., Ben Djoudi Ouadda, A., Levy, E. and Lavoie, 
J. C., 2010. Ascorbylperoxide contaminating parenteral nutrition perturbs the 
lipid metabolism in newborn guinea pig. J Pharmacol Exp Ther [online], 334 (1), 
278-284. 
Mahdavi, R., Nikniaz, L., Ostadrahimi, A., Nikniaz, Z. and Khamnian, Z., 2017. 
Lactobacillus intake for 60 days favors antioxidant status of human breast milk: 
an RCT. Asia Pac J Clin Nutr [online], 26 (4), 619-623. 
Mahon, J., Claxton, L. and Wood, H., 2016. Modelling the cost-effectiveness of human 
milk and breastfeeding in preterm infants in the United Kingdom. Health Econ 
Rev [online], 6 (1), 54. 
Makrides, M., Gibson, R. A., McPhee, A. J., Collins, C. T., Davis, P. G., Doyle, L. W., 
Simmer, K., Colditz, P. B., Morris, S., Smithers, L. G., Willson, K. and Ryan, P., 
2009. Neurodevelopmental outcomes of preterm infants fed high-dose 





Makrides, M., Neumann, M., Simmer, K., Pater, J. and Gibson, R., 1995a. Are Long-
Chain Polyunsaturated Fatty-Acids Essential Nutrients in Infancy. Lancet, 345 
(8963), 1463-1468. 
Makrides, M., Neumann, M. A., Byard, R. W., Simmer, K. and Gibson, R. A., 1994. 
Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-
fed infants. Am J Clin Nutr [online], 60 (2), 189-194. 
Makrides, M., Neumann, M. A. and Gibson, R. A., 1996. Effect of maternal 
docosahexaenoic acid (DHA) supplementation on breast milk composition. Eur 
J Clin Nutr [online], 50 (6), 352-357. 
Makrides, M., Neumann, M. A., Simmer, K. and Gibson, R. A., 1995b. Erythrocyte fatty 
acids of term infants fed either breast milk, standard formula, or formula 
supplemented with long-chain polyunsaturates. Lipids [online], 30 (10), 941-
948. 
Makrides, M., Simmer, K., Neumann, M. and Gibson, R., 1995c. Changes in the 
polyunsaturated fatty acids of breast milk from mothers of full-term infants over 
30 wk of lactation. Am J Clin Nutr [online], 61 (6), 1231-1233. 
Makrides, M. and Uauy, R., 2014. LCPUFAs as conditionally essential nutrients for 
very low birth weight and low birth weight infants: metabolic, functional, and 
clinical outcomes-how much is enough? Clinics in Perinatology [online], 41 (2), 
451-461. 
Mangham, L. J., Petrou, S., Doyle, L. W., Draper, E. S. and Marlow, N., 2009. The cost 
of preterm birth throughout childhood in England and Wales. Pediatrics, 123 (2), 
e312-327. 
Manglano, P., Lagarda, M. J., Silvestre, M. D., Vidal, C., Clemente, G. and Farré, R., 
2005. Stability of the lipid fraction of milk‐based infant formulas during storage. 
European Journal of Lipid Science and Technology [online], 107 (11), 815-823. 
Manley, B. J., Makrides, M., Collins, C. T., McPhee, A. J., Gibson, R. A., Ryan, P., 
Sullivan, T. R., Davis, P. G. and Committee, D. S., 2011. High-dose 
docosahexaenoic acid supplementation of preterm infants: respiratory and 
allergy outcomes. Pediatrics [online], 128 (1), e71-77. 
March of Dimes PMNCH Save the Children WHO, 2012. Born too soon: The Global 
Action Report on Preterm Birth. [online]. Geneva: World Health Organization. 
Marinkovic, V., Rankovic-Janevski, M., Spasic, S., Nikolic-Kokic, A., Lugonja, N., 
Djurovic, D., Miletic, S., Vrvic, M. M. and Spasojevic, I., 2016. Antioxidative 
Activity of Colostrum and Human Milk: Effects of Pasteurization and Storage. J 
Pediatr Gastroenterol Nutr [online], 62 (6), 901-906. 
256 
Marshall, T. A. and Roberts, R. J., 1990. In vitro and in vivo assessment of lipid 
peroxidation of infant nutrient preparations: effect of nutrition on oxygen toxicity. 
J Am Coll Nutr [online], 9 (3), 190-199. 
Marsili, R. T., 1999. Comparison of solid-phase microextraction and dynamic 
headspace methods for the gas chromatographic-mass spectrometric analysis 
of light-induced lipid oxidation products in milk. J Chromatogr Sci [online], 37 
(1), 17-23. 
Martin, C. R., Dasilva, D. A., Cluette-Brown, J. E., Dimonda, C., Hamill, A., Bhutta, A. 
Q., Coronel, E., Wilschanski, M., Stephens, A. J., Driscoll, D. F., Bistrian, B. R., 
Ware, J. H., Zaman, M. M. and Freedman, S. D., 2011. Decreased postnatal 
docosahexaenoic and arachidonic acid blood levels in premature infants are 
associated with neonatal morbidities. J Pediatr [online], 159 (5), 743-749 e741-
742. 
Martinez-Maqueda, D., Miralles, B. and Recio, I., 2015. HT29 Cell Line. In: Verhoeckx, 
K., Cotter, P., Lopez-Exposito, I., Kleiveland, C., Lea, T., Mackie, A., Requena, 
T., Swiatecka, D. and Wichers, H., eds.  The Impact of Food Bioactives on 
Health: in vitro and ex vivo models [online].  Cham (CH), 113-124. 
Martinez, M., 1992. Tissue levels of polyunsaturated fatty acids during early human 
development. J Pediatr [online], 120 (4 Pt 2), S129-138. 
Martínez, M. and Mougan, I., 1998. Fatty Acid Composition of Human Brain 
Phospholipids During Normal Development. Journal of Neurochemistry [online], 
71 (6), 2528-2533. 
Martysiak-Żurowska, D., Puta, M., Barczak, N., Dąbrowska, J., Malinowska-Pańczyk, 
E., Kiełbratowska, B. and Kołodziejska, I., 2017. Effect of High Pressure and 
Sub-Zero Temperature on Total Antioxidant Capacity and the Content of 
Vitamin C, Fatty Acids and Secondary Products of Lipid Oxidation in Human 
Milk. Polish Journal of Food and Nutrition Sciences [online], 67 (2), 117. 
Martysiak-Zurowska, D. and Stolyhwo, A., 2006. Content of Malondialdehyde (MDA) in 
Infant Formulae and Follow-on Formulae. Polish Journal of Food and Nutrition 
Sciences [online], 15 (56), 323-3238. 
Massey, K. A. and Nicolaou, A., 2011. Lipidomics of polyunsaturated-fatty-acid-derived 
oxygenated metabolites. Biochem Soc Trans [online], 39 (5), 1240-1246. 
McAndrew, F., Thompson, J., Fellows, L., Large, A., Speed, M. and Renfrew, M. J., 
2012. Infant feeding survey 2010 [online]. Leeds: Health and Social Care 
Information Centre.  
McCallie, K. R., Lee, H. C., Mayer, O., Cohen, R. S., Hintz, S. R. and Rhine, W. D., 
2011. Improved outcomes with a standardized feeding protocol for very low 




McMurchie, E. J., Rinaldi, J. A., Burnard, S. L., Patten, G. S., Neumann, M., McIntosh, 
G. H., Abbey, M. and Gibson, R. A., 1990. Incorporation and effects of dietary 
eicosapentaenoate (20 : 5(n − 3)) on plasma and erythrocyte lipids of the 
marmoset following dietary supplementation with differing levels of linoleic acid. 
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism [online], 
1045 (2), 164-173. 
Mehta, N. R., Jones, J. B. and Hamosh, M., 1982. Lipases in preterm human milk: 
ontogeny and physiologic significance. J Pediatr Gastroenterol Nutr [online], 1 
(3), 317-326. 
Mennella, J. A., Griffin, C. E. and Beauchamp, G. K., 2004. Flavor programming during 
infancy. Pediatrics [online], 113 (4), 840-845. 
Mertsch, K., Blasig, I. and Grune, T., 2001. 4-Hydroxynonenal impairs the permeability 
of an in vitro rat blood–brain barrier. Neuroscience Letters, 314 (3), 135-138. 
Meyer, B. J., Mann, N. J., Lewis, J. L., Milligan, G. C., Sinclair, A. J. and Howe, P. R., 
2003. Dietary intakes and food sources of omega-6 and omega-3 
polyunsaturated fatty acids. Lipids [online], 38 (4), 391-398. 
Michalski, M. C., Calzada, C., Makino, A., Michaud, S. and Guichardant, M., 2008. 
Oxidation products of polyunsaturated fatty acids in infant formulas compared to 
human milk--a preliminary study. Mol Nutr Food Res [online], 52 (12), 1478-
1485. 
Michiels, C. and Remacle, J., 1991. Cytotoxicity of linoleic acid peroxide, 
malondialdehyde and 4-hydroxynonenal towards human fibroblasts. Toxicology 
[online], 66 (2), 225-234. 
Middleton, P., Gomersall, J. C., Gould, J. F., Shepherd, E., Olsen, S. F. and Makrides, 
M., 2018. Omega-3 fatty acid addition during pregnancy. Cochrane Database 
Syst Rev [online], 11, CD003402. 
Miloudi, K., Comte, B., Rouleau, T., Montoudis, A., Levy, E. and Lavoie, J. C., 2012. 
The mode of administration of total parenteral nutrition and nature of lipid 
content influence the generation of peroxides and aldehydes. Clin Nutr [online], 
31 (4), 526-534. 
Miranda, M., Muriach, M., Almansa, I., Jareno, E., Bosch-Morell, F., Romero, F. J. and 
Silvestre, D., 2004. Oxidative status of human milk and its variations during cold 
storage. Biofactors [online], 20 (3), 129-137. 
Mitchell, D. C., Niu, S.-L. and Litman, B. J., 2003. DHA-Rich phospholipids optimize G-
Protein–coupled signaling. The Journal of Pediatrics [online], 143 (4, 
Supplement), 80-86. 
258 
Mitoulas, L. R., Gurrin, L. C., Doherty, D. A., Sherriff, J. L. and Hartmann, P. E., 2003. 
Infant intake of fatty acids from human milk over the first year of lactation. Br J 
Nutr [online], 90 (5), 979-986. 
Mizuno, K., Nishida, Y., Taki, M., Murase, M., Mukai, Y., Itabashi, K., Debari, K. and 
Iiyama, A., 2009. Is increased fat content of hindmilk due to the size or the 
number of milk fat globules? Int Breastfeed J, 4, 7. 
Moffatt, P. A., Lammi-Keefe, C. J., Ferris, A. M. and Jensen, R. G., 1987. Alpha and 
gamma tocopherols in pooled mature human milk after storage. J Pediatr 
Gastroenterol Nutr [online], 6 (2), 225-227. 
Moltó-Puigmartí, C., Permanyer, M., Castellote, A. I. and López-Sabater, M. C., 2011. 
Effects of pasteurisation and high-pressure processing on vitamin C, 
tocopherols and fatty acids in mature human milk. Food Chemistry [online], 124 
(3), 697-702. 
Montuschi, P., Barnes, P. J. and Roberts, L. J., 2nd, 2004. Isoprostanes: markers and 
mediators of oxidative stress. Faseb Journal [online], 18 (15), 1791-1800. 
Moon, K., Rao, S. C., Schulzke, S. M., Patole, S. K. and Simmer, K., 2016. Longchain 
polyunsaturated fatty acid supplementation in preterm infants. Cochrane 
Database Syst Rev [online], 12, CD000375. 
Moore, S. A., Nighot, P., Reyes, C., Rawat, M., McKee, J., Lemon, D., Hanson, J. and 
Ma, T. Y., 2016. Intestinal barrier dysfunction in human necrotizing enterocolitis. 
Journal of pediatric surgery [online], 51 (12), 1907-1913. 
Moore, T., Hennessy, E. M., Myles, J., Johnson, S. J., Draper, E. S., Costeloe, K. L. 
and Marlow, N., 2012. Neurological and developmental outcome in extremely 
preterm children born in England in 1995 and 2006: the EPICure studies. BMJ 
[online], 345, e7961. 
Morera Pons, S., Castellote Bargallo, A. I. and Lopez Sabater, M. C., 1998. Evaluation 
by high-performance liquid chromatography of the hydrolysis of human milk 
triacylglycerides during storage at low temperatures. J Chromatogr A [online], 
823 (1-2), 467-474. 
Mori, T. A., Croft, K. D., Puddey, I. B. and Beilin, L. J., 1999. An improved method for 
the measurement of urinary and plasma F2-isoprostanes using gas 
chromatography-mass spectrometry. Anal Biochem [online], 268 (1), 117-125. 
Morrison, W. R. and Smith, L. M., 1964. Preparation of Fatty Acid Methyl Esters and 





Morrow, J. D., Awad, J. A., Boss, H. J., Blair, I. A. and Roberts, L. J., 2nd, 1992. Non-
cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on 
phospholipids. Proc Natl Acad Sci U S A [online], 89 (22), 10721-10725. 
Morrow, J. D., Awad, J. A., Wu, A., Zackert, W. E., Daniel, V. C. and Roberts, L. J., 
2nd, 1996. Nonenzymatic free radical-catalyzed generation of thromboxane-like 
compounds (isothromboxanes) in vivo. J Biol Chem [online], 271 (38), 23185-
23190. 
Mukherjee, D., Nissen, S. E. and Topol, E. J., 2001. Risk of cardiovascular events 
associated with selective COX-2 inhibitors. JAMA [online], 286 (8), 954-959. 
Mun, S. E., Sim, B. W., Yoon, S. B., Jeong, P. S., Yang, H. J., Choi, S. A., Park, Y. H., 
Kim, Y. H., Kang, P., Jeong, K. J., Lee, Y., Jin, Y. B., Song, B. S., Kim, J. S., 
Huh, J. W., Lee, S. R., Choo, Y. K., Kim, S. U. and Chang, K. T., 2017. Dual 
effect of fetal bovine serum on early development depends on stage-specific 
reactive oxygen species demands in pigs. PLoS One [online], 12 (4), e0175427. 
Nakamura, M. T. and Nara, T. Y., 2004. STRUCTURE, FUNCTION, AND DIETARY 
REGULATION OF Δ6, Δ5, AND Δ9 DESATURASES. Annual Review of 
Nutrition [online], 24 (1), 345-376. 
Namdev, S., Bhat, V., Adhisivam, B. and Zachariah, B., 2014. Oxidative stress and 
antioxidant status among neonates born to mothers with pre-eclampsia and 
their early outcome. J Matern Fetal Neonatal Med [online], 27 (14), 1481-1484. 
National Institute for Health and Clinical Excellence, 2010. Donor breast milk banks: 
the operation of donor breast milk bank services [online]. London: National 
Institute for Health and Clinical Excellence.  
Negi, R., Pande, D., Kumar, A., Khanna, R. S. and Khanna, H. D., 2012. Evaluation of 
biomarkers of oxidative stress and antioxidant capacity in the cord blood of 
preterm low birth weight neonates. J Matern Fetal Neonatal Med [online], 25 
(8), 1338-1341. 
Nessel, I., De Rooy, L., Khashu, M., Murphy, J. L. and Dyall, S. C., 2020. Long-Chain 
Polyunsaturated Fatty Acids and Lipid Peroxidation Products in Donor Human 
Milk in the United Kingdom: Results from the LIMIT 2-Centre Cross-Sectional 
Study. Journal of Parenteral and Enteral Nutrition [online], 44 (ahead of print). 
Nessel, I., Khashu, M. and Dyall, S. C., 2019. The effects of storage conditions on 
long-chain polyunsaturated fatty acids, lipid mediators, and antioxidants in 
donor human milk - A review. Prostaglandins, Leukotrienes and Essential Fatty 
Acids, 149, 8-17. 
Neu, J., 2007. Gastrointestinal development and meeting the nutritional needs of 
premature infants. Am J Clin Nutr [online], 85 (2), 629s-634s. 
260 
Neuzil, J., Darlow, B. A., Inder, T. E., Sluis, K. B., Winterbourn, C. C. and Stocker, R., 
1995. Oxidation of parenteral lipid emulsion by ambient and phototherapy lights: 
potential toxicity of routine parenteral feeding. The Journal of pediatrics [online], 
126 (5), 785-790. 
Niedernhofer, L. J., Daniels, J. S., Rouzer, C. A., Greene, R. E. and Marnett, L. J., 
2003. Malondialdehyde, a product of lipid peroxidation, is mutagenic in human 
cells. J Biol Chem [online], 278 (33), 31426-31433. 
Niki, E., 1987. Antioxidants in relation to lipid peroxidation. Chem Phys Lipids [online], 
44 (2-4), 227-253. 
Nilsson, A. K., Lofqvist, C., Najm, S., Hellgren, G., Savman, K., Andersson, M. X., 
Smith, L. E. H. and Hellstrom, A., 2018. Long-chain polyunsaturated fatty acids 
decline rapidly in milk from mothers delivering extremely preterm indicating the 
need for supplementation. Acta Paediatr [online], 107 (6), 1020-1027. 
Niu, S. L., Mitchell, D. C., Lim, S. Y., Wen, Z. M., Kim, H. Y., Salem, N., Jr. and Litman, 
B. J., 2004. Reduced G protein-coupled signaling efficiency in retinal rod outer 
segments in response to n-3 fatty acid deficiency. J Biol Chem [online], 279 
(30), 31098-31104. 
Ntoumani, E., Strandvik, B. and Sabel, K. G., 2013. Nervonic acid is much lower in 
donor milk than in milk from mothers delivering premature infants—Of 
neglected importance? Prostaglandins, Leukotrienes and Essential Fatty Acids 
[online], 89 (4), 241-244. 
O'Connor, D. L., Gibbins, S., Kiss, A., Bando, N., Brennan-Donnan, J., Ng, E., 
Campbell, D. M., Vaz, S., Fusch, C., Asztalos, E., Church, P., Kelly, E., Ly, L., 
Daneman, A. and Unger, S., 2016. Effect of Supplemental Donor Human Milk 
Compared With Preterm Formula on Neurodevelopment of Very Low-Birth-
Weight Infants at 18 Months: A Randomized Clinical Trial. JAMA [online], 316 
(18), 1897-1905. 
O'Donovan, D. J. and Fernandes, C. J., 2004. Free radicals and diseases in premature 
infants. Antioxid Redox Signal [online], 6 (1), 169-176. 
O'Hare, E. M., Wood, A. and Fiske, E., 2013. Human milk banking. Neonatal Network 
[online], 32 (3), 175-183. 
O'Shea, T. M., Allred, E. N., Dammann, O., Hirtz, D., Kuban, K. C., Paneth, N. and 
Leviton, A., 2009. The ELGAN study of the brain and related disorders in 
extremely low gestational age newborns. Early Hum Dev, 85 (11), 719-725. 
Office for National Statistics, 2014. Gestation-specific Infant Mortality in England and 




Office for National Statistics, 2019. Birth Characteristics Dataset 2017 [online]. 




Office for National Statistics, 2020. Child and infant mortality in England and Wales: 
2018. Newport: Office for National Statistics.  
Ogundele, M. O., 1999. Cytotoxicity by stored human breast-milk: possible contribution 
of complement system. Cell Biol Int [online], 23 (8), 585-588. 
Ogundipe, E., Johnson, M. R., Wang, Y. and Crawford, M. A., 2016. Peri-conception 
maternal lipid profiles predict pregnancy outcomes. Prostaglandins Leukot 
Essent Fatty Acids [online], 114, 35-43. 
Olegard, R. and Svennerholm, L., 1970. FATTY ACID COMPOSITION OF PLASMA 
AND RED CELL PHOSPHOGLYCERIDES IN FULL TERM INFANTS AND 
THEIR MOTHERS1. Acta Paediatrica [online], 59 (6), 637-647. 
Orbach, R., Mandel, D., Mangel, L., Marom, R. and Lubetzky, R., 2019. The Effect of 
Deep Freezing on Human Milk Macronutrients Content. Breastfeed Med 
[online], 14 (3), 172-176. 
Orloff, S. L., Wallingford, J. C. and McDougal, J. S., 1993. Inactivation of human 
immunodeficiency virus type I in human milk: effects of intrinsic factors in 
human milk and of pasteurization. J Hum Lact [online], 9 (1), 13-17. 
Ozsurekci, Y. and Aykac, K., 2016. Oxidative Stress Related Diseases in Newborns. 
Oxid Med Cell Longev [online], 2016, 2768365. 
Paduraru, L., Dimitriu, D. C., Avasiloaiei, A. L., Moscalu, M., Zonda, G. I. and Stamatin, 
M., 2018. Total antioxidant status in fresh and stored human milk from mothers 
of term and preterm neonates. Pediatr Neonatol [online]. 
Pardou, A., Serruys, E., Mascart-Lemone, F., Dramaix, M. and Vis, H. L., 1994. Human 
milk banking: influence of storage processes and of bacterial contamination on 
some milk constituents. Biol Neonate [online], 65 (5), 302-309. 
Park, H. G., Park, W. J., Kothapalli, K. S. and Brenna, J. T., 2015. The fatty acid 
desaturase 2 (FADS2) gene product catalyzes Delta4 desaturation to yield n-3 
docosahexaenoic acid and n-6 docosapentaenoic acid in human cells. Faseb 
Journal [online], 29 (9), 3911-3919. 
Park, W. J., Kothapalli, K. S., Lawrence, P., Tyburczy, C. and Brenna, J. T., 2009. An 
alternate pathway to long-chain polyunsaturates: the FADS2 gene product 
Delta8-desaturates 20:2n-6 and 20:3n-3. J Lipid Res, 50 (6), 1195-1202. 
262 
Parra-Llorca, A., Gormaz, M., Alcántara, C., Cernada, M., Nuñez-Ramiro, A., Vento, M. 
and Collado, M. C., 2018. Preterm Gut Microbiome Depending on Feeding 
Type: Significance of Donor Human Milk. Frontiers in Microbiology, 9 (1376). 
Paszti-Gere, E., Csibrik-Nemeth, E., Szeker, K., Csizinszky, R., Jakab, C. and Galfi, P., 
2012. Acute oxidative stress affects IL-8 and TNF-alpha expression in IPEC-J2 
porcine epithelial cells. Inflammation [online], 35 (3), 994-1004. 
Pathmakanthan, S. and Hawkey, C. J., 2000. A lay doctor's guide to the inflammatory 
process in the gastrointestinal tract. Postgrad Med J [online], 76 (900), 611-617. 
Pawlik, D., Lauterbach, R., Walczak, M., Hurkala, J. and Sherman, M. P., 2014. Fish-oil 
fat emulsion supplementation reduces the risk of retinopathy in very low birth 
weight infants: a prospective, randomized study. JPEN J Parenter Enteral Nutr 
[online], 38 (6), 711-716. 
Pawlosky, R. J., Hibbeln, J. R., Novotny, J. A. and Salem, N., Jr., 2001. Physiological 
compartmental analysis of alpha-linolenic acid metabolism in adult humans. J 
Lipid Res [online], 42 (8), 1257-1265. 
Peila, C., Emmerik, N. E., Giribaldi, M., Stahl, B., Ruitenberg, J. E., van Elburg, R. M., 
Moro, G. E., Bertino, E., Coscia, A. and Cavallarin, L., 2017. Human Milk 
Processing: A Systematic Review of Innovative Techniques to Ensure the 
Safety and Quality of Donor Milk. J Pediatr Gastroenterol Nutr [online], 64 (3), 
353-361. 
Peila, C., Moro, G. E., Bertino, E., Cavallarin, L., Giribaldi, M., Giuliani, F., Cresi, F. and 
Coscia, A., 2016. The Effect of Holder Pasteurization on Nutrients and 
Biologically-Active Components in Donor Human Milk: A Review. Nutrients 
[online], 8 (8). 
Perrin, M. T., Fogleman, A. D., Newburg, D. S. and Allen, J. C., 2016. A longitudinal 
study of human milk composition in the second year postpartum: implications 
for human milk banking. Matern Child Nutr [online]. 
Petrou, S., Eddama, O. and Mangham, L., 2011. A structured review of the recent 
literature on the economic consequences of preterm birth. Arch Dis Child Fetal 
Neonatal Ed [online], 96 (3), F225-232. 
Picciano, M. F., 2001. Nutrient composition of human milk. Pediatr Clin North Am 
[online], 48 (1), 53-67. 





Pillay, T., Nightingale, P., Owen, S., Kirby, D. and Spencer, A., 2012. Neonatal nurse 
staffing and delivery of clinical care in the SSBC Newborn Network. Arch Dis 
Child Fetal Neonatal Ed [online], 97 (3), F174-178. 
Pitino, M. A., Alashmali, S. M., Hopperton, K. E., Unger, S., Pouliot, Y., Doyen, A., 
O'Connor, D. L. and Bazinet, R. P., 2019. Oxylipin concentration, but not fatty 
acid composition, is altered in human donor milk pasteurised using both thermal 
and non-thermal techniques. Br J Nutr [online], 122 (1), 47-55. 
Platt, M. J., 2014. Outcomes in preterm infants. Public Health [online], 128 (5), 399-
403. 
Plourde, M. and Cunnane, S. C., 2007. Extremely limited synthesis of long chain 
polyunsaturates in adults: implications for their dietary essentiality and use as 
supplements. Appl Physiol Nutr Metab [online], 32 (4), 619-634. 
Poindexter, B., 2014. Approaches to growth faltering. World Rev Nutr Diet [online], 110, 
228-238. 
Polberger, S., Cederholm, U., Hjort, C., Ewald, U., Nilsson, D., Stigson, L., Vanpee, M., 
Oehlund, I. and Hedin, G., 2016. Guidelines for use of human milk and milk 
handling in Sweden. Lund: Swedish Milknet.  
Prolacta Bioscience Inc, 2017. Prolact+ H2MF Human Milk-Based Liquid Human Milk 
Fortifier [online]. City of Industry: Prolacta Bioscience Inc. Available from: 
http://www.prolacta.com/human-milk-fortifier [Accessed 17/03/2017]. 
Prolacta Bioscience Inc, 2020. Quality and product safety [online]. Prolacta Bioscience 
Inc. Available from: http://www.prolacta.uk/product/quality-safety [Accessed 
23012020]. 
Public Health England, 2016. National Diet and Nutrition Survey Results form Years 5 
and 6 (combined) of the Rolling Programme (2012/2013 - 2013/2014). London: 
Public Health England.  
Qanungo, S. and Mukherjea, M., 2000. Ontogenic profile of some antioxidants and lipid 
peroxidation in human placental and fetal tissues. Mol Cell Biochem [online], 
215 (1-2), 11-19. 
Qi, C., Sun, J., Xia, Y., Yu, R., Wei, W., Xiang, J., Jin, Q., Xiao, H. and Wang, X., 2018. 
Fatty Acid Profile and the sn-2 Position Distribution in Triacylglycerols of Breast 
Milk during Different Lactation Stages. Journal of Agricultural and Food 
Chemistry [online], 66 (12), 3118-3126. 
Quigley, M. and McGuire, W., 2014. Formula versus donor breast milk for feeding 
preterm or low birth weight infants. Cochrane Database Syst Rev [online], 4, 
CD002971. 
264 
R&D Systems, 2018. Flow Cytometry Protocol for Analysis of Cell Viability using 
Propidium Iodide [online]. Minneapolis: R&D Systems, Inc. Available from: 
https://www.rndsystems.com/resources/protocols/flow-cytometry-protocol-
analysis-cell-viability-using-propidium-iodide [Accessed 10/10/2018]. 
Raghuveer, T. S., McGuire, E. M., Martin, S. M., Wagner, B. A., Rebouche, C. J., 
Buettner, G. R. and Widness, J. A., 2002. Lactoferrin in the preterm infants' diet 
attenuates iron-induced oxidation products. Pediatr Res [online], 52 (6), 964-
972. 
Rajalakshmi, K. and Srikantia, S. G., 1980. Copper, zinc, and magnesium content of 
breast milk of Indian women. Am J Clin Nutr [online], 33 (3), 664-669. 
Ramana, K. V., Bhatnagar, A., Srivastava, S., Yadav, U. C., Awasthi, S., Awasthi, Y. C. 
and Srivastava, S. K., 2006. Mitogenic responses of vascular smooth muscle 
cells to lipid peroxidation-derived aldehyde 4-hydroxy-trans-2-nonenal (HNE): 
role of aldose reductase-catalyzed reduction of the HNE-glutathione conjugates 
in regulating cell growth. J Biol Chem [online], 281 (26), 17652-17660. 
Rasmussen, S. O., Martin, L., Ostergaard, M. V., Rudloff, S., Roggenbuck, M., Nguyen, 
D. N., Sangild, P. T. and Bering, S. B., 2017. Human milk oligosaccharide 
effects on intestinal function and inflammation after preterm birth in pigs. J Nutr 
Biochem [online], 40, 141-154. 
Rechtman, D. J., Lee, M. L. and Berg, H., 2006. Effect of environmental conditions on 
unpasteurized donor human milk. Breastfeed Med [online], 1 (1), 24-26. 
Regulation (EU) 609/2013 of the European Parliament and of the Council of 12 June 
2013, on food intended for infants and young children, food for special medical 
purposes, and total diet replacement for weight control [2013] OJ L181/35. 
Riahi, Y., Cohen, G., Shamni, O. and Sasson, S., 2010. Signaling and cytotoxic 
functions of 4-hydroxyalkenals. Am J Physiol Endocrinol Metab [online], 299 (6), 
E879-886. 
Ricciotti, E. and FitzGerald, G. A., 2011. Prostaglandins and inflammation. Arterioscler 
Thromb Vasc Biol [online], 31 (5), 986-1000. 
Roberts, L. J., 2nd, Fessel, J. P. and Davies, S. S., 2005. The biochemistry of the 
isoprostane, neuroprostane, and isofuran Pathways of lipid peroxidation. Brain 
Pathol [online], 15 (2), 143-148. 
Robles, R., Palomino, N. and Robles, A., 2001. Oxidative stress in the neonate. Early 
Hum Dev [online], 65 Suppl, S75-81. 
Rodriguez-Alcala, L. M., Alonso, L. and Fontecha, J., 2014. Stability of fatty acid 




milk as affected by polyunsaturated fatty acid concentration. J Dairy Sci [online], 
97 (12), 7307-7315. 
Romeu-Nadal, M., Castellote, A. I., Gayà, A. and López-Sabater, M. C., 2008a. Effect 
of pasteurisation on ascorbic acid, dehydroascorbic acid, tocopherols and fatty 
acids in pooled mature human milk. Food Chemistry [online], 107 (1), 434-438. 
Romeu-Nadal, M., Castellote, A. I. and Lopez-Sabater, M. C., 2004. Headspace gas 
chromatographic method for determining volatile compounds in infant formulas. 
J Chromatogr A [online], 1046 (1-2), 235-239. 
Romeu-Nadal, M., Castellote, A. I. and López-Sabater, M. C., 2008b. Effect of cold 
storage on vitamins C and E and fatty acids in human milk. Food Chemistry 
[online], 106 (1), 65-70. 
Romeu-Nadal, M., Chavez-Servin, J., Castellote, A., Rivero, M. and Lopez-Sabater, M., 
2007. Oxidation stability of the lipid fraction in milk powder formulas. Food 
Chemistry [online], 100 (2), 756-763. 
Rouzer, C. A., Ghebreselasie, K. and Marnett, L. J., 2002. Chemical stability of 2-
arachidonylglycerol under biological conditions. Chemistry and Physics of Lipids 
[online], 119 (1), 69-82. 
Rufian-Henares, J. A., Guerra-Hernandez, E. and Garcia-Villanova, B., 2005. Evolution 
of fatty acid profile and lipid oxidation during enteral formula storage. JPEN J 
Parenter Enteral Nutr [online], 29 (3), 204-211. 
Rump, P., Mensink, R. P., Kester, A. D. and Hornstra, G., 2001. Essential fatty acid 
composition of plasma phospholipids and birth weight: a study in term 
neonates. Am J Clin Nutr [online], 73 (4), 797-806. 
Sakaguchi, M., Tomomasa, T. and Kuroume, T., 1995. Cytolytic action of stored human 
milk on blood cells in vitro. J Perinat Med [online], 23 (4), 293-300. 
Salimetrics Inc, 2017. Inter- and Intra-Assay Coefficients of Variability [online]. 
Carlsbad: Salimetrics Inc,. Available from: 
https://www.salimetrics.com/assets/documents/Spit_Tips_-
_Inter__Intra_Assay_Coefficients_of_Variability.pdf [Accessed 01/06/2017]. 
Samiec, P. S., Dahm, L. J. and Jones, D. P., 2000. Glutathione S-transferase in mucus 
of rat small intestine. Toxicol Sci [online], 54 (1), 52-59. 
Sanders, T. A., 2000. Polyunsaturated fatty acids in the food chain in Europe. The 
American Journal of Clinical Nutrition [online], 71 (1), 176s-178s. 
266 
Sanders, T. A., 2009. DHA status of vegetarians. Prostaglandins Leukot Essent Fatty 
Acids [online], 81 (2-3), 137-141. 
Sanders, T. A. and Reddy, S., 1992. The influence of a vegetarian diet on the fatty acid 
composition of human milk and the essential fatty acid status of the infant. J 
Pediatr [online], 120 (4 Pt 2), S71-77. 
SanGiovanni, J. P., Parra-Cabrera, S., Colditz, G. A., Berkey, C. S. and Dwyer, J. T., 
2000. Meta-analysis of dietary essential fatty acids and long-chain 
polyunsaturated fatty acids as they relate to visual resolution acuity in healthy 
preterm infants. Pediatrics [online], 105 (6), 1292-1298. 
Santaolalla, R., Fukata, M. and Abreu, M. T., 2011. Innate immunity in the small 
intestine. Current opinion in gastroenterology [online], 27 (2), 125-131. 
Sari, F. N., Akdag, A., Dizdar, E. A., Uras, N., Erdeve, O., Erel, O. and Dilmen, U., 
2012. Antioxidant capacity of fresh and stored breast milk: is -80 degrees C 
optimal temperature for freeze storage? J Matern Fetal Neonatal Med [online], 
25 (6), 777-782. 
Sastry, P. S., 1985. Lipids of nervous tissue: Composition and metabolism. Progress in 
Lipid Research [online], 24 (2), 69-176. 
Saugstad, O. D., 1988. Hypoxanthine as an indicator of hypoxia: its role in health and 
disease through free radical production. Pediatr Res, 23 (2), 143-150. 
Saugstad, O. D., 1990. Oxygen toxicity in the neonatal period. Acta Paediatr Scand 
[online], 79 (10), 881-892. 
Saugstad, O. D., 2001. Update on oxygen radical disease in neonatology. Curr Opin 
Obstet Gynecol, 13 (2), 147-153. 
Saugstad, O. D., 2003. Bronchopulmonary dysplasia—oxidative stress and 
antioxidants. Seminars in Neonatology [online], 8 (1), 39-49. 
Saugstad, O. D., 2005. Oxidative stress in the newborn-a 30-year perspective. Biol 
Neonate [online], 88 (3), 228-236. 
Saxby, M. J., 1996. Food Taints and Off-Flavours. Springer US. 
Scheuplein, R., Charnley, G. and Dourson, M., 2002. Differential sensitivity of children 





Schierack, P., Nordhoff, M., Pollmann, M., Weyrauch, K. D., Amasheh, S., Lodemann, 
U., Jores, J., Tachu, B., Kleta, S., Blikslager, A., Tedin, K. and Wieler, L. H., 
2006. Characterization of a porcine intestinal epithelial cell line for in vitro 
studies of microbial pathogenesis in swine. Histochem Cell Biol [online], 125 
(3), 293-305. 
Schlenzig, J. S., Bervoets, K., von Loewenich, V. and Bohles, H., 1993. Urinary 
malondialdehyde concentration in preterm neonates: is there a relationship to 
disease entities of neonatal intensive care? Acta Paediatr [online], 82 (2), 202-
205. 
Schmidt, H., Grune, T., Müller, R., Siems, W. G. and Wauer, R. R., 1996. Increased 
Levels of Lipid Peroxidation Products Malondialdehyde and 4-Hydroxynonenal 
after Perinatal Hypoxia. Pediatric Research [online], 40 (1), 15-20. 
Scientific Advisory Committee on Nutrition, 2004. Advice on fish consumption: benefits 
& risks. London: The Stationery Office  
Scott, P. H., Berger, H. M., Kenward, C., Scott, P. and Wharton, B. A., 1975. Effect of 
gestational age and intrauterine nutrition on plasma transferrin and iron in the 
newborn. Arch Dis Child [online], 50 (10), 796-798. 
Selley, M. L., 1997. Determination of the lipid peroxidation product (E)-4-hydroxy-2-
nonenal in clinical samples by gas chromatography-negative-ion chemical 
ionisation mass spectrometry of the O-pnetafluorobenzyl oxime. Journal of 
Chromatography B: Biomedical Sciences and Applications [online], 691 (2), 
263-268. 
Selley, M. L., Bartlett, M. R., McGuiness, J. A., Hapel, A. J., Ardlie, N. G. and Lacey, M. 
J., 1989. Determination of the lipid peroxidation product trans-4-hydroxy-2-
nonenal in biological samples by high-performance liquid chromatography and 
combined capillary column gas chromatography—negative-ion chemical 
ionisation mass spectrometry. Journal of Chromatography B: Biomedical 
Sciences and Applications [online], 488 (2), 329-340. 
Serhan, C. N., Chiang, N. and Van Dyke, T. E., 2008. Resolving inflammation: dual 
anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol [online], 
8 (5), 349-361. 
Serhan, C. N. and Levy, B. D., 2018. Resolvins in inflammation: emergence of the pro-
resolving superfamily of mediators. J Clin Invest [online], 128 (7), 2657-2669. 
Shahidi, F. and Zhong, Y., 2010. Lipid oxidation and improving the oxidative stability. 
Chem Soc Rev [online], 39 (11), 4067-4079. 
Shanklin, J., Guy, J. E., Mishra, G. and Lindqvist, Y., 2009. Desaturases: emerging 
models for understanding functional diversification of diiron-containing 
enzymes. J Biol Chem [online], 284 (28), 18559-18563. 
268 
Sies, H., 2017. Hydrogen peroxide as a central redox signaling molecule in 
physiological oxidative stress: Oxidative eustress. Redox Biol [online], 11, 613-
619. 
Siggers, J., Ostergaard, M. V., Siggers, R. H., Skovgaard, K., Molbak, L., Thymann, T., 
Schmidt, M., Moller, H. K., Purup, S., Fink, L. N., Frokiaer, H., Boye, M., 
Sangild, P. T. and Bering, S. B., 2013. Postnatal amniotic fluid intake reduces 
gut inflammatory responses and necrotizing enterocolitis in preterm neonates. 
Am J Physiol Gastrointest Liver Physiol [online], 304 (10), G864-875. 
Sigma-Aldrich Co, 1998. Solid Phase Microextraction: Theory and Optimization of 
Conditions [online]. St.English Louis: Sigma-Aldrich Co.  
Sigma-Aldrich Co, 2017. MTT Product No M5655. Saint Louis.  
Siimes, M. A., Vuori, E. and Kuitunen, P., 1979. Breast milk iron--a declining 
concentration during the course of lactation. Acta Paediatr Scand [online], 68 
(1), 29-31. 
Silvers, K. M., Sluis, K. B., Darlow, B. A., McGill, F., Stocker, R. and Winterbourn, C. 
C., 2001. Limiting light-induced lipid peroxidation and vitamin loss in infant 
parenteral nutrition by adding multivitamin preparations to Intralipid. Acta 
Paediatr [online], 90 (3), 242-249. 
Silvestre, D., Fraga, M., Gormaz, M., Torres, E. and Vento, M., 2014. Comparison of 
mid-infrared transmission spectroscopy with biochemical methods for the 
determination of macronutrients in human milk. Matern Child Nutr [online], 10 
(3), 373-382. 
Silvestre, D., Miranda, M., Muriach, M., Almansa, I., Jareno, E. and Romero, F. J., 
2008. Antioxidant capacity of human milk: effect of thermal conditions for the 
pasteurization. Acta Paediatr [online], 97 (8), 1070-1074. 
Silvestre, D., Miranda, M., Muriach, M., Almansa, I., Jareno, E. and Romero, F. J., 
2010. Frozen breast milk at -20 degrees C and -80 degrees C: a longitudinal 
study of glutathione peroxidase activity and malondialdehyde concentration. J 
Hum Lact [online], 26 (1), 35-41. 
Simmer, K. and Hartmann, B., 2009. The knowns and unknowns of human milk 
banking. Early Hum Dev [online], 85 (11), 701-704. 
Simopoulos, A. P., 2002. The importance of the ratio of omega-6/omega-3 essential 
fatty acids. Biomedicine & Pharmacotherapy [online], 56 (8), 365-379. 
Singhal, A., Cole, T. J., Fewtrell, M. and Lucas, A., 2004. Breastmilk feeding and 
lipoprotein profile in adolescents born preterm: follow-up of a prospective 




Singhal, A., Cole, T. J. and Lucas, A., 2001. Early nutrition in preterm infants and later 
blood pressure: two cohorts after randomised trials. Lancet [online], 357 (9254), 
413-419. 
Siu, G. M., Draper, H. H. and Valli, V. E., 1983. Oral toxicity of malonaldehyde: a 90-
day study on mice. J Toxicol Environ Health [online], 11 (1), 105-119. 
Skouroliakou, M., Konstantinou, D., Koutri, K., Kakavelaki, C., Stathopoulou, M., 
Antoniadi, M., Xemelidis, N., Kona, V. and Markantonis, S., 2010. A double-
blind, randomized clinical trial of the effect of omega-3 fatty acids on the 
oxidative stress of preterm neonates fed through parenteral nutrition. Eur J Clin 
Nutr [online], 64 (9), 940-947. 
Slutzah, M., Codipilly, C. N., Potak, D., Clark, R. M. and Schanler, R. J., 2010. 
Refrigerator storage of expressed human milk in the neonatal intensive care 
unit. J Pediatr [online], 156 (1), 26-28. 
SMA Nutrition, 2017a. New SMA Pro Gold Prem 2 [online]. Gatwick: SMA Nutrition. 
Available from: www.smahcp.co.uk/content/sma-nutrition-range/products/sma-
pro-gold-prem-2/ [Accessed 03/03/2017]. 
SMA Nutrition, 2017b. SMA Pro Gold Prem 1 [online]. Gatwick: SMA Nutrition. 
Available from: www.smahcp.co.uk/content/sma-nutrition-range/products/sma-
pro-gold-prem-1/ [Accessed 03/03/2017]. 
SMA Nutrition, 2018. SMA Pro First Infant Milk [online]. Gatwick: SMA Nutrition. 
Available from: https://www.smahcp.co.uk/formula-milk/pro-first-infant-milk 
[Accessed 02/01/2020]. 
SMA Nutrition, 2019. New SMA Pro Breast Milk Fortifier [online]. Gatwick: SMA 
Nutrition. Available from: https://www.smahcp.co.uk/content/sma-nutrition-
range/products/sma-pro-breast-milk-fortifier/ [Accessed 15/10/2019]. 
SMA Nutrition, 2020a. SMA Gold Prem 1 [online]. Gatwick: SMA Nutrition. Available 
from: https://www.smahcp.co.uk/formula-milk/gold-prem-1 [Accessed 
20/03/2020]. 
SMA Nutrition, 2020b. SMA Gold Prem 2 [online]. Gatwick: SMA Nutrition. Available 
from: https://www.smahcp.co.uk/formula-milk/gold-prem-2 [Accessed 
20/03/2020]. 
Smith, S. L. and Rouse, C. A., 2017. Docosahexaenoic acid and the preterm infant. 
Matern Health Neonatol Perinatol [online], 3, 22. 
Smithers, L. G., Gibson, R. A., McPhee, A. and Makrides, M., 2008. Effect of two doses 
of docosahexaenoic acid (DHA) in the diet of preterm infants on infant fatty acid 
270 
status: results from the DINO trial. Prostaglandins Leukot Essent Fatty Acids 
[online], 79 (3-5), 141-146. 
Specker, B. L., Black, A., Allen, L. and Morrow, F., 1990. Vitamin B-12: low milk 
concentrations are related to low serum concentrations in vegetarian women 
and to methylmalonic aciduria in their infants. Am J Clin Nutr [online], 52 (6), 
1073-1076. 
Spiller, P., Hibbeln, J. R., Myers, G., Vannice, G., Golding, J., Crawford, M. A., Strain, 
J. J., Connor, S. L., Brenna, J. T., Kris-Etherton, P., Holub, B. J., Harris, W. S., 
Lands, B., McNamara, R. K., Tlusty, M. F., Salem, N., Jr. and Carlson, S. E., 
2019. An abundance of seafood consumption studies presents new 
opportunities to evaluate effects on neurocognitive development. 
Prostaglandins Leukot Essent Fatty Acids [online], 151, 8-13. 
Sprecher, H., Luthria, D. L., Mohammed, B. S. and Baykousheva, S. P., 1995. 
Reevaluation of the pathways for the biosynthesis of polyunsaturated fatty 
acids. J Lipid Res [online], 36 (12), 2471-2477. 
Srinivasan, B., Kolli, A. R., Esch, M. B., Abaci, H. E., Shuler, M. L. and Hickman, J. J., 
2015. TEER measurement techniques for in vitro barrier model systems. 
Journal of laboratory automation [online], 20 (2), 107-126. 
Staprans, I., Rapp, J. H., Pan, X. M., Kim, K. Y. and Feingold, K. R., 1994. Oxidized 
lipids in the diet are a source of oxidized lipid in chylomicrons of human serum. 
Arterioscler Thromb [online], 14 (12), 1900-1905. 
Steele, C., 2018. Best Practices for Handling and Administration of Expressed Human 
Milk and Donor Human Milk for Hospitalized Preterm Infants. Front Nutr 
[online], 5, 76. 
Steghens, J. P., van Kappel, A. L., Denis, I. and Collombel, C., 2001. 
Diaminonaphtalene, a new highly specific reagent for HPLC-UV measurement 
of total and free malondialdehyde in human plasma or serum. Free Radic Biol 
Med [online], 31 (2), 242-249. 
Stengel, D. B., Connan, S. and Popper, Z. A., 2011. Algal chemodiversity and 
bioactivity: Sources of natural variability and implications for commercial 
application. Biotechnology Advances [online], 29 (5), 483-501. 
Stephens, B. E., Walden, R. V., Gargus, R. A., Tucker, R., McKinley, L., Mance, M., 
Nye, J. and Vohr, B. R., 2009. First-week protein and energy intakes are 
associated with 18-month developmental outcomes in extremely low birth 
weight infants. Pediatrics [online], 123 (5), 1337-1343. 
Stevens, E. E., Patrick, T. E. and Pickler, R., 2009. A history of infant feeding. J Perinat 




Stoy, A. C., Molbak, L., Delegue, C. L., Thymann, T., Sangild, P. T., Heegaard, P. M., 
Manurung, S. and Skovgaard, K., 2015. Necrotizing Enterocolitis in Preterm 
Pigs Is Associated with Increased Density of Intestinal Mucosa-Associated 
Bacteria Including Clostridium perfringens. Neonatology [online], 108 (3), 188-
195. 
Stoy, A. C. F., Heegaard, P. M. H., Sangild, P. T., Ostergaard, M. V. and Skovgaard, 
K., 2013. Gene Expression Analysis of the IPEC-J2 Cell Line: A Simple Model 
for the Inflammation-Sensitive Preterm Intestine. Isrn Genomics [online], 2013, 
7. 
Strober, W., 2015. Trypan Blue Exclusion Test of Cell Viability. Curr Protoc Immunol, 
111, A3 B 1-3. 
Su, H. M., Bernardo, L., Mirmiran, M., Ma, X. H., Nathanielsz, P. W. and Brenna, J. T., 
1999. Dietary 18:3n-3 and 22:6n-3 as sources of 22:6n-3 accretion in neonatal 
baboon brain and associated organs. Lipids [online], 34 Suppl, S347-350. 
Surh, J. and Kwon, H., 2005. Estimation of daily exposure to 4-hydroxy-2-alkenals in 
Korean foods containing n-3 and n-6 polyunsaturated fatty acids. Food Addit 
Contam [online], 22 (8), 701-708. 
Surh, J., Lee, S. and Kwon, H., 2007. 4-hydroxy-2-alkenals in polyunsaturated fatty 
acids-fortified infant formulas and other commercial food products. Food Addit 
Contam [online], 24 (11), 1209-1218. 
Szlagatys-Sidorkiewicz, A., Zagierski, M., Jankowska, A., Luczak, G., Macur, K., 
Baczek, T., Korzon, M., Krzykowski, G., Martysiak-Zurowska, D. and Kaminska, 
B., 2012. Longitudinal study of vitamins A, E and lipid oxidative damage in 
human milk throughout lactation. Early Hum Dev [online], 88 (6), 421-424. 
Tacken, K. J., Vogelsang, A., van Lingen, R. A., Slootstra, J., Dikkeschei, B. D. and 
van Zoeren-Grobben, D., 2009. Loss of triglycerides and carotenoids in human 
milk after processing. Arch Dis Child Fetal Neonatal Ed [online], 94 (6), F447-
450. 
Tamura, T., Goldenberg, R. L., Hou, J., Johnston, K. E., Cliver, S. P., Ramey, S. L. and 
Nelson, K. G., 2002. Cord serum ferritin concentrations and mental and 
psychomotor development of children at five years of age. J Pediatr [online], 
140 (2), 165-170. 
Thakkar, S. K., De Castro, C. A., Beauport, L., Tolsa, J. F., Fischer Fumeaux, C. J., 
Affolter, M. and Giuffrida, F., 2019. Temporal Progression of Fatty Acids in 
Preterm and Term Human Milk of Mothers from Switzerland. Nutrients [online], 
11 (1). 
272 
Thatrimontrichai, A., Janjindamai, W. and Puwanant, M., 2012. Fat loss in thawed 
breast milk: comparison between refrigerator and warm water. Indian Pediatr 
[online], 49 (11), 877-880. 
Thermo Fisher Scientific Inc., 2016. Cell Culture Basics Handbook [online]. Waltham 
Tijerina-Saenz, A., Innis, S. M. and Kitts, D. D., 2009. Antioxidant capacity of human 
milk and its association with vitamins A and E and fatty acid composition. Acta 
Paediatr [online], 98 (11), 1793-1798. 
Timby, N., Domellof, E., Hernell, O., Lonnerdal, B. and Domellof, M., 2014. 
Neurodevelopment, nutrition, and growth until 12 mo of age in infants fed a low-
energy, low-protein formula supplemented with bovine milk fat globule 
membranes: a randomized controlled trial. Am J Clin Nutr [online], 99 (4), 860-
868. 
Tin, W. and Gupta, S., 2007. Optimum oxygen therapy in preterm babies. Arch Dis 
Child Fetal Neonatal Ed [online], 92 (2), F143-147. 
Tomsits, E., Pataki, M., Tolgyesi, A., Fekete, G., Rischak, K. and Szollar, L., 2010. 
Safety and efficacy of a lipid emulsion containing a mixture of soybean oil, 
medium-chain triglycerides, olive oil, and fish oil: a randomised, double-blind 
clinical trial in premature infants requiring parenteral nutrition. J Pediatr 
Gastroenterol Nutr [online], 51 (4), 514-521. 
Trapecar, M., Goropevsek, A., Gorenjak, M., Gradisnik, L. and Slak Rupnik, M., 2014. 
A co-culture model of the developing small intestine offers new insight in the 
early immunomodulation of enterocytes and macrophages by Lactobacillus spp. 
through STAT1 and NF-kB p65 translocation. PLoS One [online], 9 (1), e86297. 
Tripathi, M., 2014. Effect of nutrition on production, composition, fatty acids and 
nutraceutical properties of milk. J Adv Dairy Res, 2 (2), 115-125. 
Turhan, A. H., Atici, A. and Muslu, N., 2011. Antioxidant capacity of breast milk of 
mothers who delivered prematurely is higher than that of mothers who delivered 
at term. Int J Vitam Nutr Res [online], 81 (6), 368-371. 
Turoli, D., Testolin, G., Zanini, R. and Bellu, R., 2004. Determination of oxidative status 
in breast and formula milk. Acta paediatrica [online], 93 (12), 1569-1574. 
Twilhaar, E. S., Wade, R. M., de Kieviet, J. F., van Goudoever, J. B., van Elburg, R. M. 
and Oosterlaan, J., 2018. Cognitive Outcomes of Children Born Extremely or 
Very Preterm Since the 1990s and Associated Risk Factors: A Meta-analysis 




Uauy, R., Mena, P., Wegher, B., Nieto, S. and Salem, N., Jr., 2000. Long chain 
polyunsaturated fatty acid formation in neonates: effect of gestational age and 
intrauterine growth. Pediatr Res [online], 47 (1), 127-135. 
UKAMB, 2017. What we do [online]. UKAMB. Available from: 
http://www.ukamb.org/what-we-do/ [Accessed 07/02/2017]. 
Unal, S., Demirel, N., Yaprak Sul, D., Ulubas Isik, D., Erol, S., Neselioglu, S., Erel, O. 
and Bas, A. Y., 2019. The consequence of phototherapy exposure on oxidative 
stress status of expressed human milk. The Journal of Maternal-Fetal & 
Neonatal Medicine [online], 32 (1), 46-50. 
Unger, S., Gibbins, S., Zupancic, J. and O'Connor, D. L., 2014. DoMINO: Donor milk 
for improved neurodevelopmental outcomes. BMC Pediatr [online], 14, 123. 
Urwin, H. J., Miles, E. A., Noakes, P. S., Kremmyda, L. S., Vlachava, M., Diaper, N. D., 
Perez-Cano, F. J., Godfrey, K. M., Calder, P. C. and Yaqoob, P., 2012. Salmon 
consumption during pregnancy alters fatty acid composition and secretory IgA 
concentration in human breast milk. J Nutr [online], 142 (8), 1603-1610. 
Usatyuk, P. V. and Natarajan, V., 2004. Role of mitogen-activated protein kinases in 4-
hydroxy-2-nonenal-induced actin remodeling and barrier function in endothelial 
cells. J Biol Chem [online], 279 (12), 11789-11797. 
Usatyuk, P. V., Parinandi, N. L. and Natarajan, V., 2006. Redox regulation of 4-
hydroxy-2-nonenal-mediated endothelial barrier dysfunction by focal adhesion, 
adherens, and tight junction proteins. J Biol Chem [online], 281 (46), 35554-
35566. 
Utrera Torres, M. I., Medina Lopez, C., Vazquez Roman, S., Alonso Diaz, C., Cruz-
Rojo, J., Fernandez Cooke, E. and Pallas Alonso, C. R., 2010. Does opening a 
milk bank in a neonatal unit change infant feeding practices? A before and after 
study. Int Breastfeed J [online], 5, 4. 
Valentine, C. J., Morrow, G., Fernandez, S., Gulati, P., Bartholomew, D., Long, D., 
Welty, S. E., Morrow, A. L. and Rogers, L. K., 2010. Docosahexaenoic Acid and 
Amino Acid Contents in Pasteurized Donor Milk are Low for Preterm Infants. J 
Pediatr [online], 157 (6), 906-910. 
Valentine, C. J., Morrow, G., Pennell, M., Morrow, A. L., Hodge, A., Haban-Bartz, A., 
Collins, K. and Rogers, L. K., 2013. Randomized controlled trial of 
docosahexaenoic acid supplementation in midwestern U.S. human milk donors. 
Breastfeed Med [online], 8 (1), 86-91. 
Van Den Driessche, M., Peeters, K., Marien, P., Ghoos, Y., Devlieger, H. and 
Veereman-Wauters, G., 1999. Gastric emptying in formula-fed and breast-fed 
infants measured with the 13C-octanoic acid breath test. J Pediatr 
Gastroenterol Nutr [online], 29 (1), 46-51. 
274 
Van Gysel, M., Cossey, V., Fieuws, S. and Schuermans, A., 2012. Impact of 
pasteurization on the antibacterial properties of human milk. Eur J Pediatr 
[online], 171 (8), 1231-1237. 
Van Kuijk, F. J., Holte, L. L. and Dratz, E. A., 1990. 4-Hydroxyhexenal: a lipid 
peroxidation product derived from oxidized docosahexaenoic acid. Biochim 
Biophys Acta [online], 1043 (1), 116-118. 
van Staveren, W. A., Deurenberg, P., Katan, M. B., Burema, J., de Groot, L. C. and 
Hoffmans, M. D., 1986. Validity of the fatty acid composition of subcutaneous 
fat tissue microbiopsies as an estimate of the long-term average fatty acid 
composition of the diet of separate individuals. American Journal of 
Epidemiology [online], 123 (3), 455-463. 
van Teijlingen, E. R., Douglas, F. and Torrance, N., 2008. Clinical governance and 
research ethics as barriers to UK low-risk population-based health research? 
BMC Public Health [online], 8, 396. 
Van Zoeren-Grobben, D., Moison, R., Ester, W. and Berger, H., 1993. Lipid 
peroxidation in human milk and infant formula: effect of storage, tube feeding 
and exposure to phototherapy. Acta Paediatrica [online], 82 (8), 645-649. 
Van Zoeren-Grobben, D., Schrijver, J., Van den Berg, H. and Berger, H. M., 1987. 
Human milk vitamin content after pasteurisation, storage, or tube feeding. Arch 
Dis Child [online], 62 (2), 161-165. 
VanderVeen, L. A., Hashim, M. F., Shyr, Y. and Marnett, L. J., 2003. Induction of 
frameshift and base pair substitution mutations by the major DNA adduct of the 
endogenous carcinogen malondialdehyde. Proc Natl Acad Sci U S A [online], 
100 (24), 14247-14252. 
VanGeest, J. B., Johnson, T. P. and Welch, V. L., 2007. Methodologies for improving 
response rates in surveys of physicians: a systematic review. Eval Health Prof 
[online], 30 (4), 303-321. 
Vangnai, K., Phamornsuwana, T., Puhin, K., Sribunsua, R. and Rathanachai, S., 2017. 
Oxidative stability of human breast milk during freeze-storage. Italian Journal of 
Food Science [online], 120-125. 
Vaughan, L. A., Weber, C. W. and Kemberling, S. R., 1979. Longitudinal changes in 
the mineral content of human milk. Am J Clin Nutr [online], 32 (11), 2301-2306. 
Vergauwen, H., 2015. The IPEC-J2 Cell Line. In: Verhoeckx, K., Cotter, P., Lopez-
Exposito, I., Kleiveland, C., Lea, T., Mackie, A., Requena, T., Swiatecka, D. and 
Wichers, H., eds.  The Impact of Food Bioactives on Health: in vitro and ex vivo 




Vergauwen, H., Tambuyzer, B., Jennes, K., Degroote, J., Wang, W., De Smet, S., 
Michiels, J. and Van Ginneken, C., 2015. Trolox and ascorbic acid reduce direct 
and indirect oxidative stress in the IPEC-J2 cells, an in vitro model for the 
porcine gastrointestinal tract. PLoS One [online], 10 (3), e0120485. 
Verma, S. P. and Das, P., 2018. Monensin induces cell death by autophagy and 
inhibits matrix metalloproteinase 7 (MMP7) in UOK146 renal cell carcinoma cell 
line. In Vitro Cell Dev Biol Anim [online], 54 (10), 736-742. 
Vieira, A. A., Soares, F. V., Pimenta, H. P., Abranches, A. D. and Moreira, M. E., 2011. 
Analysis of the influence of pasteurization, freezing/thawing, and offer 
processes on human milk's macronutrient concentrations. Early Hum Dev 
[online], 87 (8), 577-580. 
Villamor-Martinez, E., Pierro, M., Cavallaro, G., Mosca, F., Kramer, B. W. and Villamor, 
E., 2018. Donor Human Milk Protects against Bronchopulmonary Dysplasia: A 
Systematic Review and Meta-Analysis. Nutrients, 10 (2). 
Voitkun, V. and Zhitkovich, A., 1999. Analysis of DNA-protein crosslinking activity of 
malondialdehyde in vitro. Mutat Res [online], 424 (1-2), 97-106. 
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gotzsche, P. C. and 
Vandenbroucke, J. P., 2014. The Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) Statement: guidelines for reporting 
observational studies. Int J Surg [online], 12 (12), 1495-1499. 
Wang, Y., Wang, W., Yang, H., Shao, D., Zhao, X. and Zhang, G., 2019. 
Intraperitoneal injection of 4-hydroxynonenal (4-HNE), a lipid peroxidation 
product, exacerbates colonic inflammation through activation of Toll-like 
receptor 4 signaling. Free Radic Biol Med [online], 131, 237-242. 
Wardell, J. M., Hill, C. M. and D'Souza, S. W., 1981. Effect of pasteurization and of 
freezing and thawing human milk on its triglyceride content. Acta Paediatr 
Scand [online], 70 (4), 467-471. 
Wardle, S. P., Drury, J., Garr, R. and Weindling, A. M., 2002. Effect of blood 
transfusion on lipid peroxidation in preterm infants. Arch Dis Child Fetal 
Neonatal Ed [online], 86 (1), F46-48. 
Watkins, J. B., 1985. Lipid Digestion and Absorption. Pediatrics [online], 75 (1), 151-
156. 
Weaver, G., Bertino, E., Gebauer, C., Grovslien, A., Mileusnic-Milenovic, R., 
Arslanoglu, S., Barnett, D., Boquien, C. Y., Buffin, R., Gaya, A., Moro, G. E., 
Wesolowska, A. and Picaud, J. C., 2019. Recommendations for the 
Establishment and Operation of Human Milk Banks in Europe: A Consensus 
Statement From the European Milk Bank Association (EMBA). Front Pediatr 
[online], 7, 53. 
276 
Wei, W., Jin, Q. and Wang, X., 2019a. Human milk fat substitutes: Past achievements 
and current trends. Prog Lipid Res [online], 74, 69-86. 
Wei, W., Yang, J., Xia, Y., Chang, C., Sun, C., Yu, R., Zhou, Q., Qi, C., Jin, Q. and 
Wang, X., 2018. Tocopherols in human milk: Change during lactation, stability 
during frozen storage, and impact of maternal diet. International Dairy Journal 
[online], 84, 1-5. 
Wei, W., Yang, J., Yang, D., Wang, X., Yang, Z., Jin, Q., Wang, M., Lai, J. and Wang, 
X., 2019b. Phospholipid Composition and Fat Globule Structure I: Comparison 
of Human Milk Fat from Different Gestational Ages, Lactation Stages, and Infant 
Formulas. Journal of Agricultural and Food Chemistry [online], 67 (50), 13922-
13928. 
Weinberger, B., Anwar, M., Henien, S., Sosnovsky, A., Hiatt, M., Jochnowitz, N., Witz, 
G. and Hegyi, T., 2004. Association of lipid peroxidation with antenatal 
betamethasone and oxygen radial disorders in preterm infants. Biol Neonate 
[online], 85 (2), 121-127. 
Wells, W. W., Xu, D. P. and Washburn, M. P., 1995. Glutathione: dehydroascorbate 
oxidoreductases. Methods Enzymol [online], 252, 30-38. 
Wesolowska, A., Sinkiewicz-Darol, E., Barbarska, O., Strom, K., Rutkowska, M., 
Karzel, K., Rosiak, E., Oledzka, G., Orczyk-Pawiłowicz, M., Rzoska, S. and 
Borszewska-Kornacka, M. K., 2018. New Achievements in High-Pressure 
Processing to Preserve Human Milk Bioactivity. Front Pediatr [online], 6, 323-
323. 
Westerberg, A. C., Schei, R., Henriksen, C., Smith, L., Veierod, M. B., Drevon, C. A. 
and Iversen, P. O., 2011. Attention among very low birth weight infants 
following early supplementation with docosahexaenoic and arachidonic acid. 
Acta Paediatrica [online], 100 (1), 47-52. 
WHO, 2003. Global Strategy for Infant and Young Child Feeding [online]. Geneva: 
WHO.  
WHO and FAO, 2007. Safe preperation, storage and handling of powdered infant 
formula Guidelines [online]. Geneva: WHO.  
Wight, N. E., 2001. Donor human milk for preterm infants. J Perinatol [online], 21 (4), 
249-254. 
Wijendran, V., Lawrence, P., Diau, G. Y., Boehm, G., Nathanielsz, P. W. and Brenna, 
J. T., 2002. Significant utilization of dietary arachidonic acid is for brain adrenic 




Worthington, J. J., Reimann, F. and Gribble, F. M., 2018. Enteroendocrine cells-
sensory sentinels of the intestinal environment and orchestrators of mucosal 
immunity. Mucosal Immunology [online], 11 (1), 3-20. 
Wren, J. J. and Szczepanowska, A. D., 1964. Chromatography of Lipids in Presence of 
Antioxidant 4-Methyl-2,6-Di-Tert-Butylphenol. Journal of Chromatography 
[online], 14 (3), 405-+. 
Wu, J., Gouveia-Figueira, S., Domellof, M., Zivkovic, A. M. and Nording, M. L., 2016. 
Oxylipins, endocannabinoids, and related compounds in human milk: Levels 
and effects of storage conditions. Prostaglandins Other Lipid Mediat [online], 
122, 28-36. 
Xavier, A. M., Rai, K. and Hegde, A. M., 2011. Total Antioxidant Concentrations of 
Breastmilk—An Eye-opener to the Negligent. Journal of Health, Population, and 
Nutrition [online], 29 (6), 605-611. 
Yadav, U. C. and Ramana, K. V., 2013. Regulation of NF-kappaB-induced 
inflammatory signaling by lipid peroxidation-derived aldehydes. Oxid Med Cell 
Longev [online], 2013, 690545. 
Yadav, U. C. S., Ramana, K. V., Awasthi, Y. C. and Srivastava, S. K., 2008. 
Glutathione level regulates HNE-induced genotoxicity in human 
erythroleukemia cells. Toxicology and Applied Pharmacology [online], 227 (2), 
257-264. 
Yalcin, S. S., Yalcin, S. and Gucus, A. I., 2015. Zinc and Copper Concentrations in 
Breast Milk During the First Nine Months of Lactation: A Longitudinal Study. 
Pediatrics [online], 135 (Supplement 1), S13-S14. 
Yan, Z., Mas, E., Mori, T. A., Croft, K. D. and Barden, A. E., 2010. A significant 
proportion of F2-isoprostanes in human urine are excreted as glucuronide 
conjugates. Anal Biochem [online], 403 (1-2), 126-128. 
Yao, M., Lien, E. L., Capeding, M. R., Fitzgerald, M., Ramanujam, K., Yuhas, R., 
Northington, R., Lebumfacil, J., Wang, L. and DeRusso, P. A., 2014. Effects of 
term infant formulas containing high sn-2 palmitate with and without 
oligofructose on stool composition, stool characteristics, and bifidogenicity. J 
Pediatr Gastroenterol Nutr [online], 59 (4), 440-448. 
Yokoyama, W. M., Thompson, M. L. and Ehrhardt, R. O., 2012. Cryopreservation and 
thawing of cells. Curr Protoc Immunol, Appendix 3, 3G. 
Yuen, J. W., Loke, A. Y. and Gohel, M. D., 2012. Nutritional and immunological 
characteristics of fresh and refrigerated stored human milk in Hong Kong: a pilot 
study. Clin Chim Acta [online], 413 (19-20), 1549-1554. 
278 
Yuhas, R., Pramuk, K. and Lien, E. L., 2006. Human milk fatty acid composition from 
nine countries varies most in DHA. Lipids [online], 41 (9), 851-858. 
Zakrzewski, S. S., Richter, J. F., Krug, S. M., Jebautzke, B., Lee, I. F., Rieger, J., 
Sachtleben, M., Bondzio, A., Schulzke, J. D., Fromm, M. and Gunzel, D., 2013. 
Improved cell line IPEC-J2, characterized as a model for porcine jejunal 
epithelium. PLoS One [online], 8 (11), e79643. 
Zarban, A., Toroghi, M. M., Asli, M., Jafari, M., Vejdan, M. and Sharifzadeh, G., 2015. 
Effect of vitamin C and E supplementation on total antioxidant content of human 
breastmilk and infant urine. Breastfeed Med [online], 10 (4), 214-217. 
Zarkovic, N., Cipak, A., Jaganjac, M., Borovic, S. and Zarkovic, K., 2013. 
Pathophysiological relevance of aldehydic protein modifications. J Proteomics 
[online], 92, 239-247. 
Zarkovic, N., Ilic, Z., Jurin, M., Schaur, R. J., Puhl, H. and Esterbauer, H., 1993. 
Stimulation of HeLa cell growth by physiological concentrations of 4-
hydroxynonenal. Cell Biochem Funct [online], 11 (4), 279-286. 
Zesiewicz, T., Heerinckx, F., De Jager, R., Omidvar, O., Kilpatrick, M., Shaw, J. and 
Shchepinov, M. S., 2018. Randomized, clinical trial of RT001: Early signals of 
efficacy in Friedreich's ataxia. Mov Disord [online], 33 (6), 1000-1005. 
Zhang, P., Lavoie, P. M., Lacaze-Masmonteil, T., Rhainds, M. and Marc, I., 2014. 
Omega-3 long-chain polyunsaturated fatty acids for extremely preterm infants: a 
systematic review. Pediatrics [online], 134 (1), 120-134. 
Zhu, M., Yang, Z., Ren, Y., Duan, Y., Gao, H., Liu, B., Ye, W., Wang, J. and Yin, S., 
2017. Comparison of macronutrient contents in human milk measured using 
mid-infrared human milk analyser in a field study vs. chemical reference 
methods. Matern Child Nutr [online], 13 (1). 
Zipitis, C. S., Ward, J. and Bajaj, R., 2015. Use of donor breast milk in neonatal units in 
the UK. Arch Dis Child Fetal Neonatal Ed [online], 100 (3), F279-281. 
Zoeren‐Grobben, D., Moison, R., Ester, W. and Berger, H., 1993. Lipid peroxidation in 
human milk and infant formula: effect of storage, tube feeding and exposure to 
phototherapy. Acta Paediatrica [online], 82 (8), 645-649. 
Zou, L. and Akoh, C. C., 2015. Oxidative stability of structured lipid-based infant 
formula emulsion: effect of antioxidants. Food Chem [online], 178, 1-9. 
Zou, L., Pande, G. and Akoh, C. C., 2016. Infant Formula Fat Analogs and Human Milk 
Fat: New Focus on Infant Developmental Needs. Annu Rev Food Sci Technol 




Zunin, P., Boggia, R., Turrini, F. and Leardi, R., 2015. Total and "free" lipids in 
commercial infant formulas: fatty acid composition and their stability to 
oxidation. Food Chem [online], 173, 332-338. 
280 
9 Appendices 

















































Appendix III.I: Bournemouth University Research Ethics approval – 















































Appendix IV.III: Research Gateway (Northern Ireland) approval letter 




Appendix IV.IV: Bournemouth University’s Research Ethics 






















































































Appendix IV.VII: Coding and themes emerged from the open 
questions 
HMB Meaning Unit Condensed Meaning 
Unit 
Code Sub-theme Theme 
2 “My staff are really hard 
working, and work 
beyond the hours that 
they have to.” 
Staff is working over 
hours, since there is 
too much work to do 
Time Lack of time Limited 
resources  
2 “I have to see breast 
feeders in difficulty, do 
breast feeding support 
groups and provide the 
training for both our staff 
and peer support 
mothers for UNICEF 
baby friendly. At present I 
am auditing this too. I 
really feel that a milk 
bank manager should 
have one sole role.” 
Too many roles, lack of 
time for HMB 
Time Lack of time Limited 
resources  
3 “More dedicated time for 
milk bank. Milk bank 
away from neonatal unit.” 
Not enough time for 
HMB 
Time Lack of time Limited 
resources  
10 “Only in post for last 6 
month on part time basis 
- still reviewing.” 
Only part time role, not 
enough time for HMB 
Time Lack of time Limited 
resources  
8 “Would like to be able to 
pasteurise on more 
days.” 
Not enough time to 
pasteurise more often 
Time Lack of time Limited 
resources  
7 “Staff knowledge could 
be furthered but our 
contracts limit us to focus 
on the day to day running 
of the milk bank and 
providing as good a 
service as possible to our 
donor mums.” 












15 “We would like more 
experienced staff in order 











2 “We are desperately 
short of space as we 
issue 4 x the quantity of 
milk every year that we 
did when we moved here, 
we are hoping to have 
better premises soon.” 






3 “Milk bank away from 
neonatal unit.” 








3 “Dedicated telephone 
line/answer machine” 






2 “We have 1 computer, so 
this has to be answered 
out of work time.” 






14 “It would be lovely to 
have an up to date new 
pasteuriser so we could 
pasteurise more often 
with smaller amounts.” 








4 “Service could be 
improved with a bar 
coding system to 
eliminate human error 
with batch numbers lots 
of time spent checking 










dix IV.VIII: Calculated absolute DHA and ARA levels in a daily BM 
feed during the first year of lactation 
DHA and ARA concentration received from BM at different time-points of lactation 
during the first year were calculated for a preterm baby (28 weeks gestational age, 
1000 g), receiving full enteral feeding (150 mg per kg bodyweight per day) using the 
relative fatty acid concentrations and absolute fat content of BM reported by Mitoulas et 
al. (2003) (Table 9-1). 
 














 DHA (mg/150 mL) ARA (mg/150mL) 
1 month 11.85 22.51 
2 months 7.95 16.67 
4 months 8.45 17.73 
6 months 10.58 17.81 
9 months 11.51 22.23 





































































































Appendix VI.VII: St George’s University Hospitals – Confirmation of 

















































































Appendix VII: Conference presentations  
Oral presentations:  
9th Annual Postgraduate Conference Bournemouth University, Bournemouth, U.K. - 
8/03/2017 
Lipid Peroxidation Products in Preterm Formula Milk 
Isabell Nessel1, Minesh Khashu1,2, Simon C. Dyall1 
1
 Centre for Midwifery, Maternal and Perinatal Health, Bournemouth University, Bournemouth 
2
 Neonatal Unit, Poole Hospital NHS Foundation Trust, Poole  
Lipid peroxidation products are linked to several morbidities of prematurity eg 
bronchopulmonary dysplasia, retinopathy of prematurity and necrotising 
enterocolitis. Preterm formulas contain important omega-3 and omega-6 
polyunsaturated fatty acids (PUFAs), which due to their high number of double 
bonds are particularly prone to peroxidation. Consequently, preterm formula 
may be a potential dietary source of oxidants. Furthermore, omega-3 and 
omega-6 PUFAs levels may also concomitantly decrease over time. 
The aims of the study were to measure lipid peroxidation products and PUFA 
levels from both liquid and powdered preterm formulas. Liquid formulas were 
measured at opening and after 4 h storage at 4°C, whereas the powdered 
form was made-up and measured on days 0, 6, 14, 30 and 37, at time-points 0 
h, 4 h and 24 h each day. The non-specific lipid peroxidation product 
malondialdehyde was measured colorimetrically; PUFA levels by gas 





13th Congress Of The International Society For The Study Of Fatty Acids And Lipids 
(ISSFAL), Las Vegas, USA – 27-31/05/2018  
Optimising long-chain polyunsaturated fatty acid content of donor human 
milk: a review of current milk banking practices and recommendations for 
improvement 
Isabell Nessel1, Gillian Weaver2, Minesh Khashu1,3, Simon C. Dyall1  
1
Faculty of Health and Social Sciences, Bournemouth University, United Kingdom 
2
 Hearts Milk Bank, United Kingdom 
3
 Neonatal Unit, Poole Hospital NHS Foundation Trust, United Kingdom 
Extremely preterm infants have been shown to receive very low levels of 
docosahexaenoic acid and arachidonic acid, two long-chain polyunsaturated 
fatty acids (LCPUFAs) needed for optimal brain and visual development and 
immune system function (De Rooy et al. 2017). Donor human milk may be an 
important dietary source of LCPUFAs for many of these infants; however, 
processes involved in human milk banking, such as storage time and 
temperature, may negatively affect LCPUFA content of donor human milk. 
To identify current milk banking practices and to develop best practice 
recommendations, a mixed-methods questionnaire was sent out electronically 
to all human milk banks in the U.K. between December 2016 and May 2017. 
The questionnaire covered donor selection, nutrition, and transportation, 
storage and handling of donor human milk.  
The overall response rate was 81% (13 out of 16 human milk banks). This first 
national survey of human milk banking practices in the U.K. with respect to 
LCPUFAs, identified considerable variations in practice across all areas, 
including nutritional advice given to donors, maximum duration of milk 
donations, pooling of milk over 24 hours at 4C, and same day pasteurisation of 
thawed samples.  
Small changes in practices such as the provision of nutritional information to 
donors, direct freezing of expressed breast milk, reduced pre-pasteurisation 
storage time and direct pasteurisation after pooling could help to maintain or 
protect the LCPUFA content in donor human milk and may help to increase the 
LCPUFA intake of preterm infants. This analysis of human milk banking 
practices is currently being extended to Europe, North America and Australasia 
to identify if the recommendations would benefit other countries.  
346 
Poster presentations:  
4th International European Milk Bank Association Congress, Glasgow, U.K. – 5 and 
6/10/2017 and  
10th Annual Postgraduate Conference Bournemouth University, Bournemouth, U.K. – 
7/03/2018 
Human Milk Banking Practices in the U.K.: Optimising LCPUFA content 
Isabell Nessel1, Gillian Weaver2, Minesh Khashu1,3, Simon C. Dyall1  
1
 Centre for Midwifery, Maternal and Perinatal Health, Bournemouth University, Bournemouth 
2
 Hearts Milk Bank, Herts 
3 
Neonatal Unit, Poole Hospital NHS Foundation Trust, Poole  
Fat intake for preterm infants comes from diverse sources, including maternal 
expressed breast milk, donor human milk, formula milk, and parenteral nutrition. 
We have previously shown that extremely preterm infants receive very low 
levels of omega-3 and omega-6 long-chain polyunsaturated fatty acids 
(LCPUFAs), which are essential for optimal brain and visual development and 
immune system function (De Rooy et al. 2017). Levels significantly below 
European Society for Paediatric Gastroenterology Hepatology and Nutrition 
guidelines and estimated in utero accretion rates were noted.  
Previous research indicates that the processes involved in human milk banking, 
e.g. storage time and temperature, may negatively affect LCPUFA levels. 
Although operation of Human Milk Banks (HMBs) is covered by NICE Clinical 
guideline 93, this does not explicitly consider implications on LCPUFA content. 
Therefore, to identify the effects of current practices on LCPUFAs, an audit was 
conducted of all HMBs in the U.K. using a mixed-methods questionnaire, 
covering donor selection, nutrition, transportation, storage and handling. 
Questionnaires were distributed electronically between December 2016 and 
May 2017.  
The overall responses rate was 86% (12 out of 14 HMBs). Considerable 
variations were identified across all areas of practice. Differences were 
observed in key practices such as nutritional advice given to donors, maximum 
duration of milk donations, pooling of milk over 24 hours at 4C, and same day 
pasteurisation of thawed samples. The information gathered in this audit will be 
used to develop guidance for HMBs with specific regard to the optimisation of 












13th Congress Of The International Society For The Study Of Fatty Acids And Lipids 
(ISSFAL), Las Vegas, USA – 27-31/05/2018  
Current storage practices of preterm infant formula milk do not increase 
lipid peroxidation as assessed by thiobarbitruic acid reactive substance 
levels 
Isabell Nessel1, Minesh Khashu1,2, Simon C. Dyall1 
1
 Faculty of Health and Social Sciences, Bournemouth University, United Kingdom 
2
 Neonatal Unit, Poole Hospital NHS Foundation Trust, United Kingdom 
 
Lipid peroxidation products are linked to morbidities of prematurity, such as 
bronchopulmonary dysplasia, retinopathy of prematurity, and necrotising 
enterocolitis. Docosahexaenoic and arachidonic acid, long-chain 
polyunsaturated fatty acids supplemented in preterm formula milk, are prone to 
lipid peroxidation due to their highly unsaturated nature. It is current practice in 
many neonatal units in the U.K. to pre-make powdered preterm formula milk 
and open liquid preterm formula milk and store it at 4°C for up to 24 and 12 
hours, respectively.  
To investigate whether these storage conditions increase the oxidative load of 
preterm infants, thiobarbituric acid reactive substances (TBARS) were 
measured at different time-points using a colourimetric assay. Preterm formula 
milk powder was opened and stirred 3 times per day and milk was prepared 
fresh at day 0, 7, 14, 21, and 28 and stored for 0, 4, or 24 hours at 4°C before 
analysis (n=3). Preterm liquid formula and preterm liquid post-discharge formula 
were analysed after opening and storing for 0, 4, or 10 hours at 4°C (n=5). 
The TBARS concentration was 8.65 ± 0.48 µM at opening of the powder box 
and no significant changes were detected at subsequent time-points tested. 
Furthermore, no changes in TBARS concentration occurred after storage for 4 
and 24 hours at 4°C. TBARS concentration in preterm liquid formula milk and 
preterm liquid post-discharge formula milk were 7.26 ± 0.6 µM and 9.86 ± 0.79 
µM, respectively, with no changes occurring after storage. Nevertheless, these 
values are considerably higher than TBARS concentrations found in fresh 
human milk (Turoli et al. 2004). 
For the first time, this work tested the effect of preterm formula milk storage 
conditions, as currently used in neonatal units, and demonstrated no effects on 
TBARS concentrations. However, further work is exploring the effects on other 













13th Congress Of The International Society For The Study Of Fatty Acids And Lipids 
(ISSFAL), Las Vegas, USA – 27-31/05/2018  
and  
Postgraduate Research Live Exhibition 2018, Bournemouth, U.K. – 5/12/2018 
Effects of docosahexaenoic acid and arachidonic acid–derived lipid 
peroxidation products on porcine neonatal intestinal cells in vitro 
Isabell Nessel1, Caroline E. Childs2, Minesh Khashu1,3, Simon C. Dyall1 
1
 Faculty of Health and Social Sciences, Bournemouth University, United Kingdom 
2
 Faculty of Medicine, University of Southampton, United Kingdom 
3 
Neonatal Unit, Poole Hospital NHS Foundation Trust, United Kingdom 
 
Long-chain omega-3 and omega-6 polyunsaturated fatty acids (LCPUFAs) are 
essential for optimal brain and visual development and immune system 
function. Therefore, preterm formula milk is currently supplemented with 
docosahexaenoic and arachidonic acids; however, these LCPUFAs are highly 
prone to lipid peroxidation and can give rise to the specific lipid peroxidation 
products 4-hydroxy-2-hexenal (4HHE) and 4-hydroxy-2-nonenal (4HNE), 
respectively. High concentrations of 4HHE and 4HNE can activate inflammatory 
pathways and exhibit cytotoxic effects. Such inflammatory cascades have been 
implicated in the development of necrotising enterocolitis, a severe 
gastrointestinal disease, mainly occurring in preterm infants. However, safe and 
toxic intake levels of 4HHE and 4HNE from preterm formula milk have not yet 
been established. 
To investigate the effect of ingested 4HHE and 4HNE on the inflammation-
sensitive preterm gut, IPEC-J2 cells were incubated in triplicates with 4HHE 
(0.01, 0.1, 0.25, 0.5 µM) and 4HNE (0.005, 0.05, 0.5, 1 µM) for 2 hours after 10 
days of differentiation. Single exposure to 4HHE and 4HNE did not affect cell 
viability (98.5% ± 0.1% control vs 98.3% ±0.1 % 0.5 µM 4HHE vs 98.1% ± 0.5% 
1 µM 4HNE) or cell cycle, measured by flow cytometry. Furthermore, cell 
migration was not affected in a wound healing assay and the metabolic activity 
did not differ significantly in a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay.  
These preliminary in vitro results reveal no detrimental effects of 4HHE and 
4HNE on intestinal cells at concentrations found in preterm formula milk after 
single short exposure. Further work will investigate the effects of repeated 
exposures and explore effects on inflammatory and oxidative stress-related 
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And Lipids (ISSFAL), University of Roehampton, London, U.K. – 17-19/06/2019  
  
